<SEC-DOCUMENT>0001628280-22-008159.txt : 20220401
<SEC-HEADER>0001628280-22-008159.hdr.sgml : 20220401
<ACCEPTANCE-DATETIME>20220401160951
ACCESSION NUMBER:		0001628280-22-008159
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20220524
FILED AS OF DATE:		20220401
DATE AS OF CHANGE:		20220401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		22798303

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>sgmo_proxyx2022xdef.htm
<DESCRIPTION>DEF 14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i89eaa63eb2fa4775974405ea28334ee8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SCHEDULE 14A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proxy Statement Pursuant to Section 14(a) of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amendment No. &#160;&#160;&#160;&#160;)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed by the Registrant&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">x</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Filed by a party other than the Registrant&#160;&#160;&#9744;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary Proxy Statement</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">x</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definitive Proxy Statement</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definitive Additional Materials</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting Material Pursuant to &#167;240.14a-12</font></td></tr></table></div><div style="margin-top:1pt;text-align:center"><font><br></font></div><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Name of Registrant as Specified In Its Charter)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of Filing Fee (Check all boxes that apply)&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">x</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No fee required</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee paid previously with preliminary materials</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_1752"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To Be Held May&#160;24, 2022 </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders of Sangamo Therapeutics, Inc.&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You are cordially invited to attend the 2022 Annual Meeting of Stockholders, or the Annual Meeting, of Sangamo Therapeutics, Inc., a Delaware corporation (referred to herein as the Company, Sangamo, we or us). In light of public health concerns regarding the ongoing COVID-19 pandemic, and to protect the health and safety of our stockholders and employees, and to facilitate stockholder participation in the Annual Meeting, the Annual Meeting will be held in an online-only format through a live webcast at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">meetnow.global&#47;MRUK4ZH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on Tuesday, May&#160;24, 2022, at 8&#58;30&#160;a.m. Pacific Time. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You will not be able to attend the meeting in person.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Annual Meeting will be held for the following purposes&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">to elect the seven nominees for director named in the accompanying proxy statement, or the Proxy Statement, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2023 and until their successors are duly elected and qualified&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">to approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as described in the accompanying Proxy Statement&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">to approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 7,900,000 shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">to ratify the appointment of Ernst&#160;&#38; Young LLP as our independent registered public accounting firm for the year ending December&#160;31, 2022&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">to transact such other business as may properly come before the meeting.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These items of business are more fully described in the Proxy Statement accompanying this Notice.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The record date for the Annual Meeting is March&#160;30, 2022. Only stockholders of record at the close of business on that date may vote at the Annual Meeting or any adjournment or postponement thereof. At the time and date of the Annual Meeting, stockholders will be able to inspect a list of stockholders of record in the meeting center at meetnow.global&#47;MRUK4ZH for any purpose germane to the Annual Meeting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">May&#160;24, 2022 at 8&#58;30 a.m. Pacific Time</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">via Live Webcast through the meeting center at meetnow.global&#47;MRUK4ZH</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Proxy Statement, Proxy Card and Annual Report on Form 10-K for 2021 are available at&#58;</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">www.envisionreports.com&#47;SGMO</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely,</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"><div style="text-align:center"><img alt="macraesignaturea02.jpg" src="macraesignaturea02.jpg" style="height:32px;margin-bottom:5pt;vertical-align:text-bottom;width:94px"></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alexander D. Macrae</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brisbane, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2022</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YOUR VOTE IS VERY IMPORTANT</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You are cordially invited to attend the Annual Meeting through the live webcast. Whether or not you expect to access the live webcast of the Annual Meeting, please vote over the telephone or the Internet, or, if you receive a paper proxy card by mail, by completing, dating, signing and returning the proxy mailed to you, as promptly as possible in order to ensure your representation at the Annual Meeting. Even if you have voted by proxy, you may still vote your shares online at the Annual Meeting by clicking on the &#8220;Cast Your Vote&#8221; link in the meeting center. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING</a></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_10" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">PROPOSAL NO. 1&#58; ELECTION OF DIRECTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_10" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_13" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">General</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_13" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Nominees</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Recommendation of the Board of Directors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Stockholder Engagement and Responsiveness</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Board Independence</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_28" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Board Committees and Meetings</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_28" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Leadership Structure of the Board</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Oversight of Risk Management by the Board</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Meeting Attendance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Communications with the Board of Directors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Code of Business Conduct and Ethics</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibitions on Hedging, Pledging and Speculative Transactions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Director Compensation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">PROPOSAL NO. 2&#58; ADVISORY VOTE ON EXECUTIVE COMPENSATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">General</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Resolution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Recommendation of the Board of Directors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_1744" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">PROPOSAL NO. 3&#58; AMENDMENT AND RESTATEMENT OF THE 2018 EQUITY INCENTIVE PLAN</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_1744" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">18</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">PROPOSAL NO. </a><a href="#i89eaa63eb2fa4775974405ea28334ee8_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">4</a><a href="#i89eaa63eb2fa4775974405ea28334ee8_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#58; RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Principal Accounting Fees and Services</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_112" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Recommendation of the Board of Directors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_112" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EXECUTIVE OFFICERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_118" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_118" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">34</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_121" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">DELINQUENT SECTION 16(a) REPORTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_121" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EXECUTIVE COMPENSATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Discussion and Analysis</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_130" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Executive Summary</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_130" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_133" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">How We Determine Executive Compensation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_133" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_136" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Design of the Executive Compensation Program and Key Components</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_136" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">202</a><a href="#i89eaa63eb2fa4775974405ea28334ee8_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">1</a><a href="#i89eaa63eb2fa4775974405ea28334ee8_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"> Compensation Decisions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Compensation Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Summary Compensation Table</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">50</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_148" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Grants of Plan-Based Awards</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_148" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">51</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreements and Compensation Arrangements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_154" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Outstanding Equity Awards at Fiscal Year-End</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_154" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">54</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_157" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Option Exercises and Stock Vested</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_157" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">55</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_160" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Pension Benefits</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_160" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">55</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_163" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Nonqualified Deferred Compensation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_163" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">55</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_166" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Risk Assessment of Compensation Policies and Practices</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_166" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">55</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Contracts and Separation and Change in Control Arrangements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">56</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">CEO Pay Ratio Disclosure</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_193" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">COMPENSATION COMMITTEE REPORT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_193" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EQUITY COMPENSATION PLAN INFORMATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_199" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_199" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">CERTAIN RELATIONSHIPS AND RELATED </a><a href="#i89eaa63eb2fa4775974405ea28334ee8_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">PARTY </a><a href="#i89eaa63eb2fa4775974405ea28334ee8_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">TRANSACTIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">64</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">65</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">HOUSEHOLDING OF PROXY MATERIALS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">65</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_211" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER MATTERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_211" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">66</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_1758" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX A&#58; AMENDED AND RESTATED 2018 </a><a href="#i89eaa63eb2fa4775974405ea28334ee8_1758" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EQUITY </a><a href="#i89eaa63eb2fa4775974405ea28334ee8_1758" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">INCENTIVE PLAN</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A-</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_1758" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7000 Marina Boulevard</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brisbane, California 94005</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROXY STATEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE ANNUAL MEETING OF STOCKHOLDERS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To Be Held On May&#160;24, 2022</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Why am I receiving these materials&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors (referred to herein as the Board of Directors or the Board) is soliciting your proxy to vote at the Annual Meeting including at any adjournments or postponements of the Annual Meeting. This Proxy Statement contains important information regarding the Annual Meeting, the proposals on which you are being asked to vote, information you may find useful in determining how to vote and voting procedures. You are invited to attend the Annual Meeting online to vote on the proposals described in this Proxy Statement. However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions found below to submit your proxy over the telephone or through the Internet.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Why did I receive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a notice regarding the availability of proxy materials on the Internet&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to rules adopted by the Securities and Exchange Commission, or SEC, we have elected to provide access to our proxy materials over the Internet. Most of our stockholders holding their shares in &#8220;street name&#8221; will not receive paper copies of our proxy materials (unless requested) and will instead be sent a Notice of Internet Availability of Proxy Materials, or Notice, from the brokerage firms, banks or other agents holding their accounts. All &#8220;street name&#8221; stockholders receiving a Notice will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the Internet or to request a printed copy may be found in the Notice.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Why did I receive a full set of proxy materials in the mail instead of a notice regarding the Internet availability of proxy materials&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing stockholders of record who hold shares in their own name and stockholders who have previously requested a printed set of our proxy materials with paper copies of our proxy materials instead of a Notice. We intend to mail a full set of proxy materials to our stockholders of record on or about April&#160;11, 2022.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How do I attend and vote at the Annual Meeting as a stockholder of record&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of public health concerns regarding the ongoing COVID-19 pandemic, and to protect the health and safety of our stockholders and employees, and to facilitate stockholder participation in the Annual Meeting, the Annual Meeting will be held through a live webcast at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">meetnow.global&#47;MRUK4ZH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on Tuesday, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">May&#160;24, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at 8&#58;30 a.m. Pacific Time. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You will not be able to attend the Annual Meeting in person.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the time and date of the Annual Meeting, Sangamo stockholders of record as of March&#160;30, 2022 can attend and vote by accessing the meeting center at meetnow.global&#47;MRUK4ZH and entering the 15-digit control number on the proxy card or Notice. Stockholders of record can vote their shares by clicking on the &#8220;Cast Your Vote&#8221; link in the meeting center.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How do I register to attend and vote at the Annual Meeting as a beneficial owner&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficial stockholders as of March&#160;30, 2022 (i.e., shares held in &#8220;street name&#8221; through an intermediary, such as a bank or broker) must register in advance to attend and vote online at the Annual Meeting. To register, stockholders must obtain a legal proxy from the holder of record and submit proof of legal proxy reflecting the number of shares of Sangamo common stock held as of March&#160;30, 2022, along with name and email address, to Computershare at legalproxy&#64;computershare.com. Requests for registration must be labeled as &#8220;Legal Proxy&#8221; and must be received no later than Thursday, May&#160;19, 2021, 2&#58;00&#160;p.m. Pacific Time. Stockholders will then receive a confirmation of registration with a control number by email from Computershare. At the time and date of the Annual Meeting, registered beneficial stockholders can attend by accessing the meeting center at meetnow.global&#47;MRUK4ZH and entering the 15-digit control number on the proxy card or Notice. Registered beneficial owners can vote their shares by clicking on the &#8220;Cast Your Vote&#8221; link in the meeting center.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What if I cannot find my control number&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are a stockholder of record, you will find your control number in the shaded bar or below the voting instructions on the front of the proxy card or Notice you received. Please enter the control number without any spaces. If you are a beneficial owner (that is, you hold your shares in an account at a bank, broker or other holder of record), in order to obtain a control number, you will need to obtain a legal proxy from the holder of record and submit proof of legal proxy in accordance with the instructions in the preceding question above. If you are not able to find your control number or obtain a control number, you may attend the Annual Meeting as a guest, but you will not be able to vote your shares or ask questions during the Annual Meeting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How do I attend the Annual Meeting as a guest&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time and date of the Annual Meeting, guests can attend by accessing the meeting center at meetnow.global&#47;MRUK4ZH, clicking on the &#8220;I am a Guest&#8221; button and entering the information requested on the following screen. If you login as a guest, you will not be able to vote your shares or ask questions during the Annual Meeting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How do I ask questions at the Annual Meeting&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders of record or registered beneficial owners will be allowed to submit questions and comments before and during the Annual Meeting. You may submit questions before the Annual Meeting at meetnow.global&#47;MRUK4ZH. During the Annual Meeting, you may only submit questions online to Sangamo&#8217;s representatives in the question box provided at meetnow.global&#47;MRUK4ZH. In both cases, stockholders must have available their 15-digit control number provided in the Notice or your proxy card (if you received a printed copy of the proxy materials). We will respond to as many inquiries at the Annual Meeting as time allows.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What if during the check-in time or during the Annual Meeting I have technical difficulties or trouble accessing the meeting center&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will have technicians ready to assist you with any technical difficulties you may have accessing the meeting center at meetnow.global&#47;MRUK4ZH. If you encounter any difficulties accessing the Annual Meeting during the check-in or meeting time, please call the technical support number that will be posted on the Annual Meeting website log-in page.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How can I access the list of stockholders of record&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time and date of the Annual Meeting, stockholders will be able to inspect a list of stockholders of record in the meeting center at meetnow.global&#47;MRUK4ZH for any purpose germane to the Annual Meeting. During the 10&#160;days prior to the Annual Meeting, stockholders may also request to view a list of stockholders of record by sending an email to investor&#64;sangamo.com.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What am I voting on&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are four matters scheduled for a vote at the Annual Meeting&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">election of the seven nominees for director (Proposal No.&#160;1)&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advisory approval of the compensation of our NEOs as disclosed in this Proxy Statement in accordance with SEC rules (Proposal No.&#160;2)&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of the amendment and restatement of the 2018 Plan to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 7,900,000 shares (Proposal No.&#160;3)&#59; and</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ratification of the appointment of Ernst&#160;&#38; Young LLP as our independent registered public accounting firm for our fiscal year ending December&#160;31, 2022 (Proposal No.&#160;4).</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What if another matter is properly brought before the Annual Meeting&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How do I vote&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the other matters to be voted on at the Annual Meeting, including each nominee for director, you may vote &#8220;For&#8221; or &#8220;Against&#8221; or abstain from voting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The procedures for voting are fairly simple&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholder of Record&#58; Shares Registered in Your Name</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are a stockholder of record, you may vote online at the Annual Meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using the enclosed proxy card. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend and vote online at the Annual Meeting even if you have already voted by proxy.</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To vote at the Annual Meeting, click on the &#8220;Cast Your Vote&#8221; link in the meeting center at meetnow.global&#47;MRUK4ZH.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To vote over the telephone, dial toll-free 1-800-652-VOTE (8683) within the United States, U.S. territories and Canada using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the enclosed proxy card. Your telephone vote must be received by 1&#58;00 a.m. Eastern Time on May&#160;24, 2022 to be counted.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To vote through the Internet, go to http&#58;&#47;&#47;www.envisionreports.com&#47;SGMO to complete an electronic proxy card. You will be asked to provide the company number and control number from the enclosed proxy card. Your Internet vote must be received by 1&#58;00 a.m. Eastern Time on May&#160;24, 2022 to be counted.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beneficial Owner&#58; Shares Registered in the Name of Broker or Bank</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a Notice containing voting instructions from that organization rather than from us. To vote </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prior to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Annual Meeting, simply follow the voting instructions in the Notice to ensure that your vote is counted. Alternatively, you may vote by telephone or over the Internet as instructed by your broker or bank. To vote online at the Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact that organization to request a proxy form.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internet proxy voting may be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</font></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How many votes do I have&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each matter to be voted upon, you have one vote for each share of common stock you owned as of March&#160;30, 2022.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If I am a stockholder of record and I do not vote, or if I return a proxy card or otherwise vote without giving specific voting instructions, what happens&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are a stockholder of record and do not vote through the Internet, by telephone, by completing your proxy card or online at the Annual Meeting, your shares will not be voted.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted &#8220;For&#8221; each of the proposals, including for each nominee for director. If any other matter is properly presented at the Annual Meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion. In this regard, under the rules of the New York Stock Exchange, or NYSE, brokers, banks and other securities intermediaries that are subject to NYSE rules may use their discretion to vote your &#8220;uninstructed&#8221; shares with respect to matters considered to be &#8220;routine&#8221; under NYSE rules, but not with respect to &#8220;non-routine&#8221; matters. Proposal Nos.&#160;1,&#160;2 and&#160;3 are considered to be &#8220;non-routine&#8221; under NYSE rules meaning that your broker may not vote your shares on those proposals in the absence of your voting instructions. Proposal No.&#160;4 is considered a &#8220;routine&#8221; matter under NYSE rules, meaning that if you do not return voting instructions to your broker by its deadline, your shares may be voted by your broker in its discretion on such proposal.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If you are a beneficial owner of shares held in street name, to ensure your shares are voted in the way you would prefer, you</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">must</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Who is paying for this proxy solicitation&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What does it mean if I receive more than one set of proxy materials, or more than one Notice, or combination thereof&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you receive more than one set of proxy materials, or more than one Notice, or combination thereof, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on each set of proxy materials or Notices to ensure that all of your shares are voted.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Can I change my vote after submitting my proxy&#63;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholder of Record&#58; Shares Registered in Your Name</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You may grant a subsequent proxy by telephone or through the Internet.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You may submit another properly completed proxy card with a later date.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You may send a timely written notice that you are revoking your proxy to P.O. Box 505000, Louisville, KY 40233-5000. Such notice will be considered timely if it is received at the indicated address by the close of business on Monday, May&#160;23, 2022.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You may attend the Annual Meeting via the live webcast and vote your shares online by clicking on the &#8220;Cast Your Vote&#8221; link in the meeting center at meetnow.global&#47;MRUK4ZH. Simply attending the Annual Meeting via the live webcast will not, by itself, revoke your proxy.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your most current proxy card or telephone or Internet proxy is the one that is counted.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beneficial Owner&#58; Shares Registered in the Name of Broker or Bank</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If your shares are held by your broker, bank or other agent, you should follow the instructions provided by your broker, bank or other agent.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How are votes counted&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count votes &#8220;For&#8221; and &#8220;Against,&#8221; abstentions and, if applicable, broker non-votes.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What are &#8220;broker non-votes&#63;&#8221;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, when a beneficial owner of shares held in street name does not give voting instructions to his or her broker, bank or other securities intermediary holding his or her shares as to how to vote on matters deemed to be &#8220;non-routine&#8221; under NYSE rules, the broker, bank or other such agent cannot vote the shares. These un-voted shares are counted as &#8220;broker non-votes.&#8221; Proposal Nos.&#160;1,&#160;2 and&#160;3 are considered to be &#8220;non-routine&#8221; under NYSE rules and we therefore expect broker non-votes to exist in connection with those proposals.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a reminder, if you are a beneficial owner of shares held in street name, to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How many votes are needed to approve each proposal&#63; How are abstentions and broker non-votes treated&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Proposal<br>Number</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Proposal Description</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vote&#160;Required&#160;for&#160;Approval</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br>Abstentions</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br>Broker&#160;Non-<br>Votes</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Election of directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As this is an uncontested election, each director nominee must receive &#8220;For&#8221; votes from the majority of the votes cast on his or her election (i.e., the number of votes cast &#8220;For&#8221; a nominee&#8217;s election must exceed the number of votes cast &#8220;Against&#8221; that nominee&#8217;s election). Pursuant to our Fourth Amended and Restated Bylaws, or our Bylaws, any incumbent director who does not receive the required majority votes at the Annual Meeting will promptly tender his or her resignation to the Board, and the Board, after considering the recommendation of the Nominating and Corporate Governance Committee regarding such resignation, will determine whether to accept or reject the resignation. For a more detailed description of the majority voting process, see &#8220;Proposal No.&#160;1&#58; Election of Directors&#8212;General&#8221; below.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No effect</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No effect</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advisory approval of the compensation of our named executive officers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;For&#8221; votes from holders of a majority in voting power of the shares present online or represented by proxy at the Annual Meeting and entitled to vote on this proposal.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Against</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No effect</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approval of the amendment and restatement of the 2018 Plan to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 7,900,000 shares</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;For&#8221; votes from holders of a majority in voting power of the shares present online or represented by proxy at the Annual Meeting and entitled to vote on this proposal.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Against</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No effect</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ratification of the appointment of Ernst&#160;&#38; Young LLP as our independent registered public accounting firm for the year ending December&#160;31, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;For&#8221; votes from holders of a majority in voting power of the shares present online or represented by proxy at the Annual Meeting and entitled to vote on this proposal.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Against</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brokers have discretion to vote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This proposal is considered a &#8220;routine&#8221; matter under NYSE rules. Accordingly, if you hold your shares in street name and do not provide voting instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority under NYSE rules to vote your shares on this proposal. For more information, see &#8220;If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with my voting instructions, what happens&#63;&#8221; and &#8220;What are &#8216;broker non-votes&#63;&#8217;&#8221; above. As a reminder, if you are a beneficial owner of shares held in street name, to ensure your shares are voted in the way you would prefer, you</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">must</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What is the quorum requirement&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority in voting power of the outstanding shares entitled to vote are present online or represented by proxy at the Annual Meeting. On the record date, there were 146,664,760&#160;shares of common stock outstanding and entitled to vote.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote online at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, either the Chair of the Board, without a stockholder vote, or the stockholders so present, by a majority in voting power thereof, may adjourn the meeting to another date.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How can I find out the results of the voting at the Annual Meeting&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form&#160;8-K within four business days after the meeting, we intend to file a Form&#160;8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form&#160;8-K to publish the final results.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">When are stockholder proposals and director nominations due for next year&#8217;s Annual Meeting&#63;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be considered for inclusion in next year&#8217;s proxy materials, your proposal must be submitted in writing by December&#160;12, 2022, to our Corporate Secretary at 7000 Marina Boulevard, Brisbane, California 94005, and you must comply with all applicable requirements of Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended, or the Exchange Act. However, if our 2023 Annual Meeting of Stockholders is not held between April&#160;24, 2023 and June&#160;23, 2023, then the deadline will be a reasonable time prior to the time that we begin to print and mail our proxy materials.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our Bylaws, if you wish to bring a proposal before the stockholders or nominate a director at the 2023&#160;Annual Meeting of Stockholders, but you are not requesting that your proposal or nomination be included in next year&#8217;s proxy materials, you must notify our Corporate Secretary, in writing, not later than the close of business on February&#160;23, 2023 nor earlier than the close of business on January&#160;24, 2023. However, if our 2023 Annual Meeting of Stockholders is not held between April&#160;24, 2023 and June&#160;23, 2023, to be timely, notice by the stockholder must be received not later than the 10th day following the day on which the first public announcement of the date of the 2023 Annual Meeting is made or the notice of the meeting is mailed, whichever first occurs. In addition, in order to comply with the universal proxy rules (once effective), if you intend to solicit proxies in support of director nominees other than our nominees, you must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than March&#160;25, 2023. You are also advised to review our Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chair of the Annual Meeting may determine, if the facts warrant, that a matter has not been properly brought before the meeting and, therefore, may not be considered at the meeting. In addition, the proxy solicited by the Board for the 2023 Annual Meeting of Stockholders will confer discretionary voting authority with respect to any proposal (i)&#160;presented by a stockholder at that meeting for which we have not been provided with timely notice and (ii)&#160;made in accordance with our Bylaws, if (x)&#160;the 2023 proxy statement briefly describes the matter and how management&#8217;s proxy holders intend to vote on it, and (y)&#160;the stockholder does not comply with the requirements of Rule 14a-4(c)(2) promulgated under the Exchange Act.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NO. 1&#58;</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELECTION OF DIRECTORS</font></div><div style="text-align:center"><font><br></font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_13"></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board currently consists of nine directors, including one vacancy. However, Saira Ramasastry has determined not to stand for re-election at the Annual Meeting, and her term will expire at the conclusion of the Annual Meeting. Accordingly, there are seven nominees for director this year. The Board will have two vacancies following the Annual Meeting. Proxies may not be voted for a greater number of persons than the number of nominees named in this Proxy Statement. Each director to be elected and qualified will serve until the next annual meeting of stockholders and until a successor for such director is duly elected and qualified, or until the earlier death, resignation or removal of such director. The nominees for election have agreed to serve if elected, and management has no reason to believe that such nominees will be unavailable to serve. In the event the nominees are unable or decline to serve as directors at the time of the Annual Meeting, the proxies will be voted for any nominee who may be designated by the present Board of Directors to fill the vacancy. Unless otherwise instructed, the proxy holders will vote the proxies received by them FOR the nominees named below.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the seven nominees has been previously elected by our stockholders. While the Nominating and Corporate Governance Committee and the Board chose to nominate Dr.&#160;Alexander D. Macrae, our Chief Executive Officer, or CEO, for election to the Board for the reasons set forth in his biography below, Dr.&#160;Macrae&#8217;s employment agreement also provides that the Board shall nominate Dr.&#160;Macrae for election as a member of the Board at each annual meeting of stockholders occurring while Dr.&#160;Macrae&#8217;s employment agreement is in effect.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the seven nominees set forth in this Proxy Statement will be elected by the majority of the votes cast with respect to such nominee, which means that the number of votes &#8220;For&#8221; a nominee&#8217;s election must exceed the number of votes &#8220;Against&#8221; that nominee (with abstentions and broker non-votes not counted as either a &#8220;For&#8221; or &#8220;Against&#8221; vote for that nominee&#8217;s election). If an incumbent director does not receive the required majority vote, the director is required under our Bylaws to promptly tender his or her resignation to the Board. Within 90&#160;days after the Annual Meeting, the Nominating and Corporate Governance Committee will make a recommendation to the Board as to whether to accept or reject the resignation. The Board will act by taking into account such committee&#8217;s recommendation. If the Board does not accept the resignation, the Board is required to publicly disclose its decision and the rationale behind the decision.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following includes a brief biography of each nominee for director, including their respective ages as of March&#160;30, 2022. Each biography includes information regarding the specific experience, qualifications, attributes or skills that led the Nominating and Corporate Governance Committee and the Board to determine that the applicable nominee should serve as a member of the Board.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_16"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nominees</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alexander D. Macrae, M.B., Ch.B., Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 59, has served as our President and Chief Executive Officer and as a member of our Board of Directors since June 2016. Dr.&#160;Macrae also serves on the board of directors of 4D Pharma plc, a biopharmaceutical company. He has over 20&#160;years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceutical Company Limited, or Takeda, a public global biopharmaceutical company, from 2012 to March 2016, where he established and led the Global Medical Office, which encompassed medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr.&#160;Macrae held roles of increasing responsibility at GlaxoSmithKline plc, or GSK, a public global healthcare company, including Senior Vice President, Emerging Markets Research and Development, or R&#38;D, from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK&#8217;s global reach by providing R&#38;D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr.&#160;Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr.&#160;Macrae also earned his Ph.D. in molecular genomics at King&#8217;s College, Cambridge. The Nominating and Corporate Governance Committee and the Board believe that Dr.&#160;Macrae&#8217;s day-to-day leadership and intimate knowledge of our business and operations, as well as our relationships with partners, collaborators and investors, provides the Board with an in-depth understanding of the Company.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Robert F. Carey</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 63, has served as a member of our Board of Directors since June 2016. Mr.&#160;Carey has served as co-founder and president of ACELYRIN, Inc., a privately-held biopharmaceutical company, since July 2020. Mr.&#160;Carey served as Executive Vice President, Chief Business Officer for Horizon Therapeutics plc, a biopharmaceutical company, from March </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2014 to October 2019. Prior to that, he served as managing director and head of the healthcare investment banking group at JMP Securities LLC, a full-service investment bank from 2003 to 2014. Prior to JMP, Mr.&#160;Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities International, Inc. He has also held roles at Shearson Lehman Hutton and Ernst&#160;&#38; Whinney. Mr.&#160;Carey also serves on the board of directors of Beyond Air, Inc. (formerly AIT Therapeutics, Inc.), a public medical device and biopharmaceutical company. Mr.&#160;Carey previously served on the board of directors of FS Development Corp., a public blank-check company now known as Gemini Therapeutics, Inc., from July 2020 to February 2021. Mr.&#160;Carey received his BBA in accountancy from the University of Notre Dame. The Nominating and Corporate Governance Committee and the Board believe that Mr.&#160;Carey&#8217;s extensive experience and knowledge in the healthcare investment banking industry, particularly with financings, global expansion and other strategic transactions by life-science companies, as well as his role in senior management and business development for a public biopharmaceutical company, provides the Board with valuable insight and contribution.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kenneth J. Hillan, M.B., Ch.B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 61, has served as a member of our Board of Directors since September 2020. Since February 2019, Dr.&#160;Hillan has served as Head of Therapeutics of 23andMe Holding Co., a public consumer genetics and research company. From October 2011 to December 2017, Dr.&#160;Hillan was Chief Executive Officer of Achaogen, Inc., a public biopharmaceutical company, where he was President and President of R&#38;D from January 2018 to October 2018 and a member of the Board of Directors from October 2011 to October 2018. In April 2019, Achaogen filed a voluntary petition for relief under Chapter&#160;11 of the U.S. Bankruptcy Code and most of its assets were subsequently sold to a multinational pharmaceutical company. Previously, Dr.&#160;Hillan worked at Genentech, Inc. from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair, or ITGR, drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation&#59; Vice President of ITGR&#59; Vice President of Development Sciences&#59; and Vice President of Research Operations and Pathology. He also served as Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. He also serves on the board of directors of Zymeworks, Inc., a public biotechnology company. Dr.&#160;Hillan previously served on the board of directors of Relypsa, Inc. from June 2014 to September 2016, when it was acquired by Galenica AG. Dr.&#160;Hillan received his M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, United Kingdom. The Nominating and Corporate Governance Committee and the Board believe that Dr.&#160;Hillan&#8217;s extensive experience and knowledge in the development of therapeutics and in the biotechnology industry provides the Board with valuable insight and contribution to the Company&#8217;s development of genomic medicines.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">John H. Markels</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 56, has served as a member of our Board of Directors since February 2020. Dr.&#160;Markels has over 30&#160;years of leadership experience in the pharmaceutical industry. Since January 2019, he has served as President of Global Vaccines at Merck &#38; Co., Inc., where he leads an integrated team dedicated to discovery and development, supply and access, and global marketing and long-term strategy for the vaccines portfolio. Earlier roles at Merck included President, Latin America from January 2018 to January 2019, SVP, Global Human Health Business Strategy from January 2017 to December 2017, Managing Director, Mexico from November 2013 to January 2017. Prior to his commercial roles, he had a long career in senior leadership positions in global manufacturing, including operations leadership for Europe, Middle East and Africa, Asia Pacific and emerging markets as well as manufacturing technology and product development roles in active pharmaceutical ingredients (API) and vaccines. Throughout his tenure at Merck, Dr.&#160;Markels has led multiple enterprise level strategy efforts including the Merck manufacturing strategy, portfolio strategy, small molecule commercialization strategy and others. Dr.&#160;Markels received his Ph.D. in chemical engineering from the University of California, Berkeley and his B.S. in chemical engineering from the University of Delaware. The Nominating and Corporate Governance Committee and the Board believe that Dr.&#160;Markels&#8217;s extensive leadership experience in operations, strategy and development provides valuable operational, strategy and management skills to the Board.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">James R. Meyers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 57,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as a member of our Board of Directors since November 2019. He has over 30&#160;years of commercial leadership experience in the biotechnology industry. Since November 2020, Mr. Meyers has served as President and Chief Executive Officer of IntraBio Ltd., a privately-held biopharmaceutical company. Previously, Mr.&#160;Meyers held positions of increasing responsibility at Gilead Sciences, Inc., or Gilead, from 1996 to February 2018, most recently as Gilead&#8217;s Executive Vice President of Worldwide Commercial Operations from November 2016 to February 2018, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. Mr.&#160;Meyers joined Gilead in 1996 and successfully led 25&#160;product launches in seven different therapeutic areas over a 22-year period, including 11&#160;brands with peak annual revenue greater than $1&#160;billion. Prior to Gilead, Mr.&#160;Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the board of directors of two other public biopharmaceutical companies, Arbutus Biopharma Corporation and CytomX Therapeutics, Inc., and one private biotech company, Pumocide, Inc.&#59; he remains an active advisor to several major biopharmaceutical companies. Mr.&#160;Meyers received his B.S. in Economics from Boston College. The Nominating and Corporate Governance Committee and the Board believe that Mr.&#160;Meyers&#8217;s extensive commercial leadership experience in the biotechnology industry provides valuable operational, commercial assessment and management skills to the Board.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. Stewart Parker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 66, has been a member of our Board of Directors since June 2014, and has been Chair since June 2017. Ms.&#160;Parker has over 40&#160;years of experience in the biotechnology industry. Prior to focusing on boards and consulting, she served as the Chief Executive Officer of The Infectious Disease Research Institute (IDRI), a not-for-profit global health research institute from 2011 to 2013. In 1992, Ms.&#160;Parker founded Targeted Genetics Corporation, a publicly traded Seattle-based biopharmaceutical company formed to develop gene-based treatments for acquired and inherited diseases that became a world leader in adeno-associated virus, or AAV, gene therapy. She held the position of President and Chief Executive Officer and was a member of its board of directors from the company&#8217;s inception until 2008. Prior to founding Targeted Genetics, Ms.&#160;Parker served in various capacities at Immunex from 1981 through 1991, most recently as Vice President, Corporate Development. From 1991 to 1993, Ms.&#160;Parker served as President and a Director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry. She currently serves on the board of directors of Impel NeuroPharma, Inc., a public biopharmaceutical company, and previously served on the board of directors of Armata Pharmaceuticals, Inc., a public biotechnology company, from May 2019 to December 2020, and Achieve Life Sciences, a public pharmaceutical company, from August 2017 to May 2021. Ms.&#160;Parker received her B.A. and M.B.A. from the University of Washington. The Nominating and Corporate Governance Committee and the Board believe that Ms.&#160;Parker&#8217;s senior executive experience in AAV gene therapy and biotechnology drug development provides valuable operational, commercial assessment and management skills to the Board.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 54, has served on our Board of Directors since June 2018. Dr.&#160;Smith is a life sciences thought leader with over 20&#160;years of biopharmaceutical experience bringing drugs into the clinic and through commercialization. She has been a key contributor to the successful development of multiple FDA and EMA approved products in several therapeutic areas, including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox), neuroscience (Abilify) and anti-infectives (Teflaro). Since November 2018, Dr.&#160;Smith has been providing consulting services internationally. Dr.&#160;Smith currently serves as Chief Medical Officer for Novosteo, Inc., a private biopharmaceutical company, having previously served as Chief Medical officer for Emergent BioSolutions, Inc. from April 2020 to December 2021. From May 2019 to January 2020, Dr.&#160;Smith served as President and Chief Executive Officer of Medeor Therapeutics, Inc., a biotechnology company. From June 2018 to May 2019, Dr.&#160;Smith served as Chief Executive Officer of Eliminate Cancer, Inc. From April 2015 to May 2018, she served as the Global Head of Research &#38; Development and Chief Medical Officer of Jazz Pharmaceuticals plc, a biopharmaceutical company, where she built the R&#38;D function into a pipeline of neuroscience and oncology products across all stages of discovery and development. From 2011 to 2015, she was Senior Vice President, Global Medical Affairs and Global Therapeutic Area Head (Dermatology) for Allergan, Inc., a multi-specialty health care company. Earlier in her career, she held senior leadership roles at AstraZeneca plc and Bristol Myers Squibb Company. Dr.&#160;Smith holds several degrees, including an M.D. from the University of Warwick, a Ph.D. in oncology from the University of Western Australia, an M.B.A. from the University of New England and an L.L.M. (Masters in Law) from the University of Salford. Dr.&#160;Smith serves on the Board of Antares Pharma, Inc., a public pharmaceutical company and Capstan Therapeutics, a private biotechnology company. Dr.&#160;Smith previously served on the board of directors of Acceleron Pharma, Inc., a public biopharmaceutical company from November 2017 to December 2021, Sucampo Pharmaceuticals, Inc. from July 2017 to February 2018, and Forward Pharma A&#47;S, from June 2016 to June 2017, and serves as the chair of the Strategic Advisory Board of Emyria Limited, a healthcare technology and services company. The Nominating and Corporate Governance Committee and the Board believe that Dr.&#160;Smith&#8217;s extensive executive experience in global research and development, combined with tenure on prior public company boards provides us with access to a valuable skill-set as we translate our science into genomic medicines using our platform technologies in gene editing, gene therapy, gene regulation and cell therapy.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_19"></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECOMMENDATION OF THE BOARD OF DIRECTORS</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends that the stockholders vote FOR the election of each the nominees listed above.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Engagement and Responsiveness</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A priority for our Board of Directors is soliciting and listening to the views of our stockholders on a variety of topics, including our business and growth strategy, corporate governance practices and executive compensation matters. Our discussions with our investors have been productive and informative and have provided valuable feedback to our Board of Directors to help ensure that our Board&#8217;s decisions are aligned with stockholder objectives.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_25"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Independence</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has determined that each of its directors is independent under applicable listing standards of The Nasdaq Stock Market LLC, or Nasdaq, except for Dr.&#160;Macrae, who is our Chief Executive Officer. There are no family relationships between any of our directors and any of our executive officers.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_28"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Committees and Meetings</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors held nine meetings during 2021. The Board of Directors has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Each director attended or participated in 75% or more of the aggregate of (i)&#160;the total number of meetings of the Board of Directors and (ii)&#160;the total number of meetings held by all committees of the Board on which such director served during 2021, in each case held during the period for which each respective director was serving as a director.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_31"></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee consists of three directors&#58; Mr.&#160;Carey, Mr.&#160;Meyers and Ms.&#160;Ramasastry. Mr.&#160;Carey serves as the Chair of this committee. Our Board of Directors has determined that each member of the Audit Committee is independent under the applicable listing standards of Nasdaq and SEC rules. The Board of Directors has determined that Mr.&#160;Carey is an &#8220;audit committee financial expert&#8221; as defined under SEC rules and that each member of the Audit Committee has the requisite financial sophistication in accordance with the applicable Nasdaq listing standards. The Audit Committee held four meetings during 2021. The Board expects to appoint a new director to the Audit Committee prior to the Annual Meeting to reflect Ms.&#160;Ramasastry&#8217;s departure from the Board.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee&#8217;s primary purposes are to (i)&#160;assist the Board in its oversight of the integrity of our financial statements, our systems of accounting and financial controls, our accounting and financial reporting processes and the audit of our financial statements, (ii)&#160;interact directly with and evaluate the performance of our independent auditors, determine whether to engage or dismiss our independent auditors and monitor our independent auditors&#8217; qualifications and independence and (iii)&#160;oversee the implementation of our compliance program with respect to financial, accounting, auditing, information technology and cybersecurity matters. The Audit Committee also pre-approves all audit services and permissible non-audit services provided by our independent auditors. The Audit Committee Report is included herein in the section labeled &#8220;Report of the Audit Committee of the Board of Directors.&#8221; The Audit Committee has a written charter, which is available on our website at https&#58;&#47;&#47;investor.sangamo.com&#47;corporate-governance&#47;governance-overview.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_34"></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee consists of three directors&#58; Dr.&#160;Hillan, Mr.&#160;Meyers and Dr.&#160;Smith. Dr.&#160;Smith serves as the Chair of this committee. Dr.&#160;Hillan was appointed to serve on the Compensation Committee effective June&#160;1, 2021. Mr.&#160;Joseph&#160;S. Zakrzewski, who resigned from the Board effective March&#160;1, 2022, previously served on the Compensation Committee through September 2021, and served as the Chair of this committee through May 2021. Our Board of Directors has determined that each member of the Compensation Committee is independent under the applicable listing standards of Nasdaq and SEC rules and that during his period of service on the Compensation Committee, Mr.&#160;Zakrzewski was independent under the applicable listing standards of Nasdaq and SEC rules.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee&#8217;s responsibilities include, among other things&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">periodically reviewing and approving a philosophy for compensation of our executive officers&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adopting, amending, terminating and administering the Company&#8217;s compensation plans and programs for our executive officers, including, among others, equity plans, incentive plans, bonus plans, stock purchase plans, severance plans, pension and profit sharing plans and retirement plans&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing, considering and approving compensation programs applicable to non-employee members of the Board of Directors&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing total compensation packages for our executive officers, with the exception of Dr.&#160;Macrae&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reviewing and evaluating the performance and leadership of Dr.&#160;Macrae and recommending to the Board his total compensation package&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing with Dr.&#160;Macrae his evaluation of the performance of the executive officers other than himself&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and monitoring management development plans and activities&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing with our Board our succession plan for the CEO and other executive officers&#59; and</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducting risk assessments of our compensation programs.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee may delegate any responsibility or authority of the Compensation Committee under its charter to one or more members of the Compensation Committee, as appropriate and as consistent with applicable laws and rules. The Compensation Committee does not, however, delegate any of its functions to others in determining or recommending director or executive officer compensation.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee is authorized to engage, oversee and terminate independent compensation consultants and other professionals to assist in the design, formulation, analysis and implementation of compensation programs for our executive officers and other key employees. The Compensation Committee retained the services of Aon&#8217;s Human Capital Solutions practice, a division of Aon plc, or Aon, in order to (i)&#160;assess compensation levels and mix of elements for our executive officers and vice presidents for 2021, (ii)&#160;review the peer group criteria and to recommend specific companies, (iii)&#160;assess the compensation of the non-employee directors and (iv)&#160;advise the Compensation Committee on executive compensation and governance trends based on peer group trends and market practices.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee held seven meetings during 2021. The Compensation Committee has a written charter, which is available on our website at https&#58;&#47;&#47;investor.sangamo.com&#47;corporate-governance&#47;governance-overview. For information regarding our processes and procedures for the consideration and determination of executive and director compensation, please see &#8220;Executive Compensation&#8212;Compensation Discussion and Analysis&#8221; and &#8220;&#8212;Director Compensation,&#8221; respectively.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_37"></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Interlocks and Insider Participation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, Dr.&#160;Hillan, Mr.&#160;Meyers, Dr.&#160;Smith and Mr.&#160;Zakrzewski served on the Compensation Committee. None of our Compensation Committee members has been an officer or employee of Sangamo at any time. None of our executive officers serves on the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board or our Compensation Committee.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_40"></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nominating and Corporate Governance Committee</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee consists of two directors&#58; Dr.&#160;Markels and Ms.&#160;Parker. Mr.&#160;Zakrzewski previously served on the Nominating and Corporate Governance Committee until his resignation from the Board effective March&#160;1, 2022 and Dr.&#160;Hillan previously served on the Nominating and Corporate Governance Committee through May 2021. Ms.&#160;Parker serves as Chair of this committee. Our Board of Directors has determined that each member of the Nominating and Corporate Governance Committee is independent under the applicable listing standards of Nasdaq and SEC rules and that during their period of service on the Nominating and Corporate Governance Committee, Dr.&#160;Hillan and Mr.&#160;Zakrzewski were independent under the applicable listing standards of Nasdaq and SEC rules.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee considers and periodically reports on matters relating to the size, identification, selection and qualification of the Board of Directors and candidates nominated for the Board of Directors and its committees, and develops and recommends governance principles and policies applicable to the Company. It also assists the Board in its oversight of our compliance with legal and regulatory requirements relating to matters other than financial, accounting, auditing, information technology and cybersecurity matters. It also has oversight responsibility for the Company&#8217;s policies and practices relating to diversity, equity and inclusion.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee held three meetings during 2021. The Nominating and Corporate Governance Committee has a written charter, which is available on our website at https&#58;&#47;&#47;investor.sangamo.com&#47;corporate-governance&#47;governance-overview. The Nominating and Corporate Governance Committee considers properly submitted stockholder recommendations for candidates for membership on the Board of Directors as described below under &#8220;&#8212;Identification and Evaluation of Nominees for Directors.&#8221; In evaluating such recommendations, the Nominating and Corporate Governance Committee seeks to achieve a balance of knowledge, experience and capability on the Board of Directors and to address the membership criteria set forth below under &#8220;&#8212;Director Qualifications and Composition.&#8221;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_43"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director Qualifications and Composition</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee will use a variety of criteria to evaluate the qualifications and skills necessary for members of our Board of Directors. The Nominating and Corporate Governance Committee may assess character, judgment, business acumen and scientific expertise, and familiarity with issues affecting the biotechnology and pharmaceutical industries. Other qualifications will be determined on a case-by-case basis, depending on whether the Nominating and Corporate Governance Committee desires to fill a vacant seat or increase the size of the Board to add new directors. In addition, the Nominating and Corporate Governance Committee may also evaluate whether a potential director nominee&#8217;s skills are complementary to existing Board members&#8217; skills or meet the Board&#8217;s need for operations, management, commercial, financial or other expertise. The Nominating and Corporate Governance Committee strives to maintain a diverse Board reflecting a variety of skills, experiences, perspectives and backgrounds, including age, tenure, gender, race, ethnicity, sexual orientation and other unique characteristics, as it believes that such diversity enhances the Board&#8217;s effectiveness in fulfilling its oversight role. Below we highlight certain attributes of our current directors. For purposes of the information below, a &#8220;diverse&#8221; director is defined as &#8220;an individual who self-identifies in one or more of the following categories&#58; Female, Underrepresented Minority or LGBTQ+&#8221; using the definitions in Nasdaq Listing Rule 5606(f).</font></div><div style="margin-top:12pt;text-align:center"><img alt="hrdiversitychartsidebyside.jpg" src="hrdiversitychartsidebyside.jpg" style="height:278px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information about the composition and diversity of our Board as required under Nasdaq listing standards&#58;</font></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Board Diversity Matrix (As of March&#160;30, 2022)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of Directors</font></td><td colspan="24" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Female</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Male</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Binary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Did Not Disclose Gender</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Part I&#58; Gender Identity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Part II&#58; Demographic Background</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">African American or Black</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alaskan Native or Native American</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asian</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hispanic or Latinx</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Native Hawaiian or Pacific Islander</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">White</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two or More Races or Ethnicities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LGBTQ+</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Did Not Disclose Demographic Background</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_46"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identification and Evaluation of Nominees for Directors</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee utilizes a variety of methods for identifying and evaluating nominees for director. The Nominating and Corporate Governance Committee assesses the appropriate size of the Board of Directors, and whether any vacancies on the Board of Directors are expected due to retirement or otherwise. In the event that vacancies are anticipated, or otherwise arise, the Nominating and Corporate Governance Committee considers various potential candidates for director. Candidates may come to the attention of the Nominating and Corporate Governance Committee through current members of the Board of Directors or senior management, executive recruiting firms, stockholders or other persons. In addition, we have in the past and may from time to time again in the future engage a third-party search firm to assist in identifying potential directors. The Board often considers specific industry expertise such as research, development or commercial experience in candidates to make sure the Board is able to oversee all aspects of our business. Candidates for director are evaluated at regular or special meetings of the Nominating and Corporate Governance Committee and may be considered at any point during the year. The Nominating and Corporate Governance Committee will consider properly submitted stockholder recommendations for candidates for the Board of Directors. Nominees recommended by stockholders will receive the same consideration that nominees of the Board receive. Any stockholder recommendations proposed for consideration by the Nominating and Corporate Governance Committee must provide all information requested by the Nominating and Corporate Governance Committee relating to such recommendation, including the candidate&#8217;s name and qualifications for membership on the Board of Directors and should be addressed to Investor Relations at the following address&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investor Relations Department</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7000 Marina Boulevard</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brisbane, CA 94005</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating such recommendations, the Nominating and Corporate Governance Committee applies the qualifications standards discussed above and seeks to achieve a balance of knowledge, experience and capability on the Board of Directors.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_49"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leadership Structure of the Board</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Bylaws, the Board is not required to appoint our Chief Executive Officer as the Chair of the Board, and the Board does not have a policy on whether or not the roles of Chief Executive Officer and Chair of the Board should be separate. Currently two individuals serve in these two positions. Ms.&#160;Parker currently serves as the Chair of the Board. Ms.&#160;Parker has extensive knowledge and experience in the life sciences industry and an in-depth understanding of our business strategies and day-to-day operations, which makes her well suited to set the agenda and lead the discussions at Board meetings as the Chair. The Chair is responsible for chairing Board meetings and meetings of stockholders, setting the agenda for Board meetings and providing information to the Board members in advance of meetings and between meetings. In addition, our Chief Executive Officer, Dr.&#160;Macrae, also serves on our Board. The Board believes that Dr.&#160;Macrae&#8217;s membership as a director provides the Board with an in-depth understanding of our business operations because of his extensive experience and knowledge of the day-to-day management of all aspects of our operations. This also facilitates communications between the Board and management by ensuring a regular flow of information, thereby enhancing the Board&#8217;s ability to make informed decisions on critical issues facing our company.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the eight directors on our Board, seven directors are independent under applicable Nasdaq corporate governance rules. The Board believes that this establishes a strong independent board that provides effective oversight of the Company. Moreover, in addition to feedback provided during the course of Board meetings, the independent directors conduct regular executive sessions without the presence of Dr.&#160;Macrae or any other members of management. We believe that our leadership structure of the Board is appropriate given the nature and size of our business, because it provides both effective independent oversight and expertise in the complexity and management of our operations as a life sciences company.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_52"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oversight of Risk Management by the Board</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is generally responsible for the oversight of corporate risk in its review and deliberations relating to our activities. The Audit Committee oversees management of risks associated with our financial and accounting systems, public financial reporting, investment strategies and policy, and certain other matters delegated to the Audit Committee, including risks associated with our information technology systems (including cybersecurity risks). Our Board of Directors regularly reviews information regarding our cash position, liquidity and operations, as well as the risks associated with each. The Board regularly reviews plans, results and potential risks related to our lead therapeutic development programs and other preclinical programs as well as financial and strategic risks related to our business and operations.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Nominating and Corporate Governance Committee monitors the effectiveness of our corporate policies and manages risks associated with the independence of the Board of Directors and potential conflicts of interest. Our Compensation Committee oversees risk management as it relates to our compensation plans, policies and practices for all </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees, including executives, particularly whether our compensation programs may create incentives for our employees to take excessive or inappropriate risks that could have a material adverse effect on the Company. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board of Directors is periodically informed about such risks. With the support of the Board of Directors, we have also established an internal compliance committee staffed by employees led by our General Counsel, who reports directly to the Board on compliance matters. The compliance committee held quarterly meetings in 2021. We also established a COVID-19 Taskforce in 2020 responsible for developing our internal COVID-19 policies and protocols. This Taskforce meets regularly and is led by our Chief People Officer.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_55"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Meeting Attendance</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not have a formal policy regarding attendance by members of the Board of Directors at our annual meetings of stockholders, we encourage our directors to attend annual meetings of our stockholders. Seven directors attended the 2021 annual meeting of stockholders, which was held online-only due to the ongoing public health concerns of the COVID-19 pandemic.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_58"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Communications with the Board of Directors</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors currently does not have a formal process for stockholders to send communications to the Board of Directors. Although we do not have a formal policy regarding communications with the Board of Directors, stockholders may communicate with the Board of Directors, including the non-management directors, by sending a letter to the Sangamo Board of Directors, c&#47;o Investor Relations, 7000 Marina Boulevard, Brisbane, California 94005. Stockholders who would like their submission directed to a particular member of the Board of Directors may so specify. The Board of Directors does not recommend that formal communication procedures be adopted at this time because it believes that informal communications are sufficient to communicate questions, comments and observations that could be useful to the Board.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_61"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has adopted a Code of Business Conduct and Ethics, which is applicable to all employees, including our executive officers, and directors of the Company. A copy of our Code of Business Conduct and Ethics is available on our website at https&#58;&#47;&#47;investor.sangamo.com&#47;corporate-governance&#47;governance-overview in the Investors&#160;+&#160;Media Section under Corporate Governance. In the event that we make any amendments to or grant any waivers of, a provision of the Code of Business Conduct and Ethics that requires disclosure under applicable SEC rules, we intend to disclose such amendment or waiver and the reasons therefor, on our website.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_64"></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prohibitions on Hedging, Pledging and Speculative Transactions</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our insider trading policy, none of our directors, officers and other employees may engage in any hedging or monetization transactions relating to our securities, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. In addition, all of our officers, directors and employees are prohibited from short-selling our securities or engaging in transactions involving Sangamo-based derivative securities (other than those granted under our employee stock option or equity incentive plans) and are further prohibited from holding our securities in a margin account or otherwise pledging our securities as collateral for a loan.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_67"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2021. Dr.&#160;Macrae, our President and Chief Executive Officer, is not listed in the following table because he is our employee. Dr.&#160;Macrae&#8217;s compensation is described under &#8220;Executive Compensation&#8221; and he received no additional compensation for serving on our Board of Directors in 2021. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fees&#160;Earned&#160;or<br>Paid in Cash<br>($) (1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option&#160;Awards<br>($)&#160;(2)&#160;(3)&#160;(4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock&#160;Awards<br>($)&#160;(2) (5) (6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br>($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert F. Carey</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,304&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,758&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,062&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth J. Hillan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,458&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,758&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,520&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John H. Markels</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,304&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,062&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James R. Meyers</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,758&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,562&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. Stewart Parker</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,304&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,062&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saira Ramasastry (7)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,758&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,062&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen L. Smith</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,875&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,304&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,937&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph S. Zakrzewski (8)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,667&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,758&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,729&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists of the annual retainer fee for service as a member of the Board of Directors or any Board committee. For further information concerning such fees, see the section below entitled &#8220;&#8212;Director Annual Retainer and Meeting Fees.&#8221;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents the grant date fair value of the awards computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, or ASC&#160;718. The assumptions used in the calculation of such grant date fair values are described in Note&#160;9 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on February&#160;24, 2022, or the 2021 Form 10-K.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Pursuant to the automatic grant program under the 2018&#160;Plan, each of our non-employee directors received an option to purchase 16,400&#160;shares of common stock with an exercise price per share of $11.19 on February&#160;25, 2021, and each such option had an aggregate grant date fair value of $121,304.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2021, the following non-employee directors held options to purchase the following number of shares of our common stock&#58; Mr.&#160;Carey, 106,400 shares&#59; Dr.&#160;Hillan, 46,400&#160;shares&#59; Dr.&#160;Markels, 46,400&#160;shares&#59; Mr.&#160;Meyers, 66,400&#160;shares&#59; Ms.&#160;Parker, 146,400&#160;shares&#59; Ms.&#160;Ramasastry, 106,400&#160;shares&#59; Dr.&#160;Smith, 81,400&#160;shares&#59; and Mr.&#160;Zakrzewski, 96,400&#160;shares.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Pursuant to the automatic grant program under the 2018&#160;Plan, each of our non-employee directors received an award of 8,200&#160;restricted stock units, or RSUs, on February&#160;25, 2021 and each such RSU award had an aggregate grant date fair value of $91,758.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2021, the following non-employee directors held RSUs for the following number of shares of our common stock&#58; Mr.&#160;Carey, 8,200&#160;shares&#59; Dr.&#160;Hillan, 18,200&#160;shares&#59; Dr.&#160;Markels, 11,533&#160;shares&#59; Mr.&#160;Meyers, 9,867&#160;shares&#59; Ms.&#160;Parker, 8,200&#160;shares&#59; Ms.&#160;Ramasastry, 8,200&#160;shares&#59; Dr.&#160;Smith, 8,200&#160;shares&#59; and Mr.&#160;Zakrzewski, 8,200&#160;shares.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Ms.&#160;Ramasastry is not standing for re-election to the Board of Directors, and her term will expire at the conclusion of the Annual Meeting.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;Zakrzewski resigned from the Board effective March&#160;1, 2022.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_70"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Processes and Procedures for Determining Director Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charter of the Compensation Committee provides the Compensation Committee with the responsibility for reviewing, considering and approving compensation programs applicable to non-employee directors. It is the practice of the Compensation Committee to seek input from outside compensation consultants, including Aon, our Compensation Committee&#8217;s compensation consultant, as it deems appropriate.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_73"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Annual Retainer and Meeting Fees</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the annual cash retainers payable to non-employee members of our Board of Directors&#58;</font></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Annual Cash Retainers</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual retainer for service as a member of our Board of Directors</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional retainer for the Chair of the Board of Directors</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional retainer for service as a committee chair&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Audit Committee</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Compensation Committee</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Nominating and Corporate Governance Committee</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional retainer for service as a committee member&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation Committee</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nominating and Corporate Governance Committee</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these retainers is paid on a quarterly basis. All retainer fees are subject to proration for directors who join or leave the Board of Directors or the respective committee or begin or cease to serve as Chair of the Board or the respective </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">committee, during the year. To the extent the Board of Directors meets more than 10&#160;times in any year, each non-employee member of the Board of Directors will receive, for each meeting in excess of 10, a per meeting fee of $1,000 if attended in person and $500 if attended by video or telephone conference. </font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_76"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentives Granted Under the 2018&#160;Plan</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the automatic grant program of the 2018&#160;Plan, each individual who is a non-employee Board member will automatically be granted a nonqualified stock option, or NSO, to purchase common stock and a RSU award on an annual basis on the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of February of such year (or if such 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day is not a trading day, the immediately preceding trading day in February)&#59; in each case, provided that such individual is a non-employee Board member on the date of grant, has served as a non-employee Board member for at least three months prior to the date of grant, and will continue serving as a non-employee Board member immediately after the date of grant. The number of shares to be automatically granted annually pursuant to a NSO or a RSU award are determined based on a review of our share price and comparative market data from peer companies. </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the automatic grant program of the 2018&#160;Plan, each individual who is initially appointed or elected as a non-employee Board member on or after the 2020 Annual Meeting will, on the date of such appointment or election, automatically be granted a NSO to purchase common stock and a RSU award. The number of shares to be automatically granted pursuant to an initial NSO or a RSU award are determined based on a review of our share price and comparative market data from peer companies.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the equity incentives granted or eligible to be granted to non-employee members of our Board of Directors under our Director Compensation Policy&#58;</font></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vesting (1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Grant&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSO</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 successive equal monthly installments following date of grant</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1st anniversary of date of grant</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Grant&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSO</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 successive equal monthly installments following date of grant</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,300&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">three equal annual installments following date of grant</font></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Subject to the director&#8217;s continuous service through the applicable vesting date(s).</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each automatic NSO grant will have an exercise price per share equal to the fair market value per share of our common stock on the grant date and will have a term of 10&#160;years, subject to earlier termination following the director&#8217;s termination of continuous service. Each automatic NSO grant will be immediately exercisable for all of the option shares&#59; however, we may repurchase, at the lower of the exercise price paid per share or the fair market value per share, any shares purchased under the NSO that are not vested at the time of the director&#8217;s termination of continuous service.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares subject to each automatic NSO grant and each automatic RSU award grant will immediately vest in full upon the director&#8217;s termination of continuous service due to death or disability, or upon the occurrence of a change in control or hostile takeover (each as defined in the 2018&#160;Plan), subject to the director&#8217;s continuous service through the date of such change in control or hostile takeover.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_79"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NO. 2&#58;</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVISORY VOTE ON EXECUTIVE COMPENSATION</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_82"></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;14A(a)(1) of the Exchange Act, our stockholders are entitled to vote to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement in accordance with SEC rules (commonly referred to as a &#8220;say-on-pay&#8221; vote).</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this Proxy Statement. Based on the voting results from the 2017 annual meeting of stockholders, our stockholders voted &#8220;For,&#8221; and we have adopted, an annual advisory vote on the compensation of the named executive officers in our proxy materials, which will remain in effect until the next required vote on the frequency of stockholder votes on the compensation of named executive officers. Accordingly, the next advisory vote on the compensation of our named executive officers will be held at the 2023 Annual Meeting of Stockholders. Although the vote is non-binding, the Board of Directors and the Compensation Committee value the opinions of our stockholders and will consider the outcome of the vote when making future compensation decisions affecting our executive officers.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encourage stockholders to read closely the &#8220;Executive Compensation&#8221; section of this Proxy Statement, beginning with the Compensation Discussion and Analysis, or CD&#38;A, included in the section labeled &#8220;Executive Compensation&#8212;Compensation Discussion and Analysis,&#8221; which describes in detail our executive compensation programs, policies and practices with respect to the compensation of our named executive officers in the year ended December&#160;31, 2021.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_85"></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Resolution</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in the CD&#38;A, we believe that our executive compensation programs effectively align the interest of our executive officers with those of our stockholders by linking a significant portion of their compensation to our corporate performance and by providing a competitive level of compensation designed to attract and retain highly qualified executives critical to our success. Accordingly, the Board is asking our stockholders to indicate their support for the compensation of our named executive officers, as described in this Proxy Statement, by casting a non-binding advisory vote &#8220;FOR&#8221; the following resolution&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Resolved that the Company&#8217;s stockholders hereby approve, on an advisory basis, the compensation of the Company&#8217;s named executive officers as disclosed in this Proxy Statement pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the various compensation tables and the accompanying narrative discussion and any related material included in this Proxy Statement.&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advisory approval of this Proposal No.&#160;2 requires votes &#8220;FOR&#8221; from holders of a majority in voting power of the shares present online or represented by proxy at the Annual Meeting and entitled to vote on this Proposal No.&#160;2.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_88"></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECOMMENDATION OF THE BOARD OF DIRECTORS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends an advisory vote FOR the resolution to approve, on an advisory basis, the compensation of the named executive officers as disclosed in this Proxy Statement pursuant to the compensation disclosure rules of the SEC.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_1744"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NO. 3&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT AND RESTATEMENT OF THE 2018 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Compensation Committee approved an amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, on March&#160;25, 2022, subject to approval by our stockholders. Throughout this Proxy Statement, we refer to the 2018 Plan, as amended and restated by our Compensation Committee on March&#160;25, 2022, as the &#8220;Amended 2018 Plan.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Proposal No.&#160;3, we are seeking stockholder approval of the Amended 2018 Plan to make the following material changes from the 2018 Plan&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase the aggregate number of shares of our common stock that may be issued under the Amended 2018 Plan by 7,900,000 shares, subject to adjustment for certain changes in our capitalization&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">increase the aggregate maximum number of shares of our common stock that may be issued pursuant to the exercise of incentive stock options under the Amended 2018 Plan by 15,800,000 shares (for a total of 53,200,000 shares), subject to adjustment for certain changes in our capitalization.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this Proposal No.&#160;3 is approved by our stockholders, the Amended 2018 Plan will become effective as of the date of the Annual Meeting. In the event that our stockholders do not approve this Proposal No.&#160;3, the Amended 2018 Plan will not become effective and the 2018 Plan will continue to be effective in accordance with its terms.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholder approval of this Proposal No.&#160;3 will also constitute pre-approval of each award granted under the Amended 2018 Plan pursuant to the provisions of the automatic grant program for our non-employee directors (as described below in this Proposal No.&#160;3).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Why You Should Vote to Approve the Amended 2018 Plan</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Awards Are an Important Part of Our Compensation Philosophy</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board believes that the issuance of equity awards is a key element underlying our ability to attract, retain and motivate key personnel, non-employee directors and consultants because of the strong competition for highly trained and experienced individuals among biotechnology and pharmaceutical companies, especially in the greater San Francisco Bay Area. Therefore, the Board believes that the Amended 2018 Plan is in the best interests of our business and our stockholders and recommends a vote in favor of this Proposal No.&#160;3.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of this Proposal No.&#160;3 by our stockholders will allow us to grant equity awards under the Amended 2018 Plan at levels we determine to be appropriate. The Amended 2018 Plan will also allow us to continue to utilize equity awards as long-term incentives to secure and retain the services of our employees, non-employee directors and consultants, consistent with our compensation philosophy and common compensation practice for our industry in the greater San Francisco Bay Area. To date, equity awards have been a key aspect of our program to attract and retain key employees, non-employee directors and consultants. We believe the use of equity awards strongly aligns the interests of our employees with those of our stockholders by placing a considerable proportion of our employees&#8217; total compensation &#8220;at risk&#8221; because it is contingent on the appreciation in value of our common stock. In addition, we believe equity awards encourage employee ownership of our common stock and promote retention through the reward of long-term Company performance.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We Carefully Manage the Use of Equity Awards and the Size of our Share Reserve Increase Request is Reasonable</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation philosophy reflects broad-based eligibility for equity awards, and we generally grant equity awards to all of our employees and non-employee directors. However, we recognize that equity awards dilute existing stockholders, and, therefore, we are mindful to responsibly manage the growth of our equity compensation program. We are committed to effectively monitoring our equity compensation share reserve, including our &#8220;burn rate,&#8221; to ensure that we maximize stockholders&#8217; value by granting the appropriate number of equity awards necessary to attract, reward, and retain employees, non-employee directors and consultants. The tables below show certain historical overhang and burn rate percentages.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determination of Number of Additional Shares to Request for the Amended 2018 Plan</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its determination to approve the Amended 2018 Plan, our Compensation Committee reviewed an analysis prepared by Aon, its compensation consultant, which included an analysis of our historic and estimated prospective share usage needs and the potential costs of the Amended 2018 Plan. Specifically, our Compensation Committee considered&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Market Competitiveness. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2018 Plan plays an important role in our effort to align the interests of participants and stockholders. Moreover, in our industry, equity awards are an important tool in recruiting, retaining and motivating highly skilled and critical employee talent, upon whose efforts our success is dependent.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Estimated Equity Usage and Share Pool Duration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Compensation Committee considered our historic burn rate levels in determining how long the Amended 2018 Plan share authorization could potentially last. We expect the share authorization under the Amended 2018 Plan to provide us with enough shares for awards for approximately one to two years, with actual timing dependent on a variety of factors, including the price of our shares and hiring activity during the next few years, and rates of forfeiture of outstanding awards, and noting that future circumstances may require us to change our current equity grant practices. We cannot predict our future equity grant practices, the future price of our shares or future hiring activity with any degree of certainty at this time, and the share reserve under the Amended 2018 Plan could last for a shorter or longer period of time.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">External Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Aon&#8217;s analysis, which is based on generally accepted evaluation methodologies, concluded that the number of shares under the Amended 2018 Plan is well within generally accepted standards as measured by an analysis of its cost relative to industry standards.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Historic Use of Equity Awards and Outstanding Awards</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overhang</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain additional information regarding our use of equity awards&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March&#160;30, 2022 Record Date</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares of common stock subject to outstanding stock options</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,331,575&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price of outstanding stock options</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining term in years of outstanding stock options</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares of common stock subject to outstanding full value awards</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947,696&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares of common stock available for grant under the 2018 Plan</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673,729&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares of common stock available for grant under other equity incentive plans</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,782,452&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares of common stock outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,664,760&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per-share closing price of common stock as reported on the Nasdaq Global Select Market</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Reflects the number of shares available under the Sangamo Therapeutics, Inc. 2020 Employee Stock Purchase Plan, or the 2020 ESPP, as of the record date. No other shares are available for grant under any other equity incentive plan.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Burn Rate</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides detailed information regarding the activity related to the 2018 Plan for fiscal year 2021&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December&#160;31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares of common stock subject to stock options granted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,619,775&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares of common stock subject to full value awards granted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140,785&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares of common stock outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,568,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Burn Rate (1)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unadjusted Burn Rate (2)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Adjusted Burn Rate is calculated as&#58; (shares subject to stock options granted + shares subject to full value awards granted)&#47;weighted-average common stock outstanding. For purposes of this calculation, shares subject to full value awards granted are increased by a 1.5x volatility multiplier for fiscal year 2021. However, the share reserve under the 2018 Plan is reduced by 1.33 shares for each share issued pursuant to a full value award.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Unadjusted Burn Rate is calculated as&#58; (shares subject to stock options granted + shares subject to full value awards granted)&#47;weighted-average common stock outstanding.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Requested Additional Shares</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to adjustment for certain changes in our capitalization, if this Proposal No.&#160;3 is approved by our stockholders, then under the Amended 2018 Plan, we will have 7,900,000 new shares available for grant after our Annual Meeting for a total of approximately 9,573,729 shares available for grant after our Annual Meeting (based on shares available under the 2018 Plan as of March&#160;30, 2022) (plus the Prior Plans&#8217; Returning Shares (as defined and further described below under &#8220;&#8212;Description of the Amended 2018 Plan&#8212;Shares Available for Awards&#8221;) as such shares become available from time to time).</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our request for 7,900,000 new shares under the Amended 2018 Plan is necessary for us to remain competitive in the greater San Francisco Bay Area marketplace and support our equity grant practices to align the interests of our employees and non-employee directors with our stockholders. We anticipate the available pool of shares in the Amended 2018 Plan will be sufficient for our equity awards for approximately the next one to two years after considering our present average share usage rate, and that such pool of shares is necessary to provide a predictable amount of available equity awards for attracting, retaining, and motivating employees, non-employee directors and consultants.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note Regarding Forward-Looking Statements</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not as a matter of course make public forecasts as to our utilization of equity awards due to the unpredictability of the underlying assumptions and estimates. The inclusion of the information set forth above should not be regarded as an indication or prediction of actual future outcomes, and the statements should not be relied upon as such. Neither we nor any other person makes any representation to any of our stockholders regarding actual outcomes compared to the information contained in the forward-looking statements set forth above. Although presented with some numerical specificity, these statements are not fact and reflect numerous assumptions and estimates as to future events made by our management that our management believed were reasonable at the time this filing was prepared and other factors such as industry performance and general business, economic, regulatory, market and financial conditions, as well as factors specific to our business, all of which are difficult to predict and many of which are beyond the control of our management. The forecasts are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Exchange Act. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those in the forward-looking statements, including our ability to attract and retain talent, achievement of performance metrics, if any, with respect to certain equity awards, the extent of option exercise activity, forfeiture rates, and other factors described in this Proxy Statement.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Features of the Amended 2018 Plan</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2018 Plan includes provisions that are designed to protect our stockholders&#8217; interests and to reflect corporate governance best practices, including the following&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Fungible share counting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2018 Plan contains a &#8220;fungible share counting&#8221; structure, whereby the number of shares of our common stock available for issuance under the Amended 2018 Plan will be reduced by (i)&#160;one share for each share issued pursuant to a stock option or stock appreciation right with an exercise price that is at least 100% of the fair market value of our common stock on the date of grant, referred to as an Appreciation Award, granted under the Amended 2018 Plan and (ii)&#160;1.33 shares for each share issued pursuant to an award that is not an Appreciation Award, referred to as a Full Value Award, granted under the Amended 2018 Plan. As part of such fungible share counting structure, the number of shares of our common stock available for issuance under the Amended 2018 Plan will be increased by (i)&#160;one share for each share that becomes available again for issuance under the terms of the Amended 2018 Plan subject to an Appreciation Award and (ii)&#160;1.33 shares for each share that becomes available again for issuance under the terms of the Amended 2018 Plan subject to a Full Value Award.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2018 Plan contains a minimum vesting requirement for all awards, such that no award may vest until at least 12&#160;months following the date of grant of such award, except that shares up to 5% of the share reserve of the Amended 2018 Plan may be issued pursuant to awards that do not meet such vesting requirements.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">No liberal change in control definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The change in control definition in the Amended 2018 Plan is not a &#8220;liberal&#8221; definition. A change in control transaction must actually occur in order for the change in control provisions in the Amended 2018 Plan to be triggered.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Repricing is not allowed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Amended 2018 Plan prohibits the repricing of outstanding stock options and stock appreciation rights and the cancellation of any outstanding stock options or stock appreciation rights that have an exercise or strike price greater than the then-current fair market value of our common stock in exchange for cash or other awards under the Amended 2018 Plan without prior stockholder approval.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stockholder approval is required for additional shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Amended 2018 Plan does not contain an annual &#8220;evergreen&#8221; provision. The Amended 2018 Plan authorizes a fixed number of shares, so that stockholder approval is required to issue any additional shares, allowing our stockholders to have direct input on our equity compensation program.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Awards subject to forfeiture&#47;clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Awards granted under the Amended 2018 Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law, and any other clawback policy that we adopt. In addition, we may impose other clawback, recovery or recoupment provisions in an award agreement, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including a reacquisition right in respect of previously acquired shares or other cash or property upon the occurrence of cause.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">No discounted stock options or stock appreciation rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All stock options and stock appreciation rights granted under the Amended 2018 Plan must have an exercise or strike price equal to or greater than the fair market value of our common stock on the date the stock option or stock appreciation right is granted.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Material amendments require stockholder approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Consistent with Nasdaq rules, the Amended 2018 Plan requires stockholder approval of any material revisions to the Amended 2018 Plan. In addition, certain other amendments to the Amended 2018 Plan require stockholder approval.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">No liberal share counting provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following shares will not become available again for issuance under the Amended 2018 Plan&#58; (i)&#160;any shares that are reacquired or withheld (or not issued) by us to satisfy the exercise or purchase price of an award&#59; (ii)&#160;any shares that are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with an award&#59; (iii)&#160;any shares repurchased by us on the open market with the proceeds of the exercise or purchase price of an award&#59; and (iv)&#160;in the event that a stock appreciation right is settled in shares, the gross number of shares subject to such award.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Amended 2018 Plan provides that dividends or dividend equivalents may not be paid or credited to stock options or stock appreciation rights. In addition, with respect to any award other than a stock option or stock appreciation right, the Amended 2018 Plan provides that (i)&#160;no dividends or dividend equivalents may be paid with respect to any shares of our common stock subject to such award before the date such shares have vested, (ii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of the applicable award agreement (including any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are forfeited to or repurchased by us due to a failure to vest.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Amended 2018 Plan</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material features of the Amended 2018 Plan are described below. The following description of the Amended 2018 Plan is a summary only and is qualified in its entirety by reference to the complete text of the Amended 2018 Plan. Stockholders are urged to read the actual text of the Amended 2018 Plan in its entirety, which is attached to this Proxy Statement as Appendix&#160;A.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purpose</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2018 Plan is designed to secure and retain the services of our employees, non-employee directors and consultants, provide incentives for our employees, non-employee directors and consultants to exert maximum efforts for the success of our company and our affiliates, and provide a means by which our employees, non-employee directors and consultants may be given an opportunity to benefit from increases in the value of our common stock. The Amended 2018 Plan is also designed to align employees&#8217; interests with stockholder interests.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Types of Awards</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Amended 2018 Plan provide for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards, and other stock awards.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Available for Awards</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the Amended 2018 Plan will not exceed the sum of&#58; (i)&#160;1,703,964 shares (which is the number of shares that were available for the grant of new awards under the Company&#8217;s Amended and Restated 2013 Stock Incentive Plan, or the 2013 Plan, as of immediately prior to the effective date of the 2018 Plan)&#59; (ii)&#160;8,800,000 shares (which is the number of additional shares that were reserved as of the effective date of the 2018 Plan)&#59; (iii)&#160;9,900,000 shares that were approved at the Company&#8217;s 2020 annual meeting of stockholders&#59; (iv)&#160;7,900,000 newly requested shares&#59; and (v)&#160;any Prior Plans&#8217; Returning Shares (as defined below), as such shares become available from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of our common stock available for issuance under the Amended 2018 Plan will be reduced by&#58; (i)&#160;one share for each share of common stock issued pursuant to an Appreciation Award granted under the Amended 2018 Plan&#59; and (ii)&#160;1.33 shares for each share of common stock issued pursuant to a Full Value Award granted under the Amended 2018 Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of our common stock available for issuance under the Amended 2018 Plan will be increased by&#58; (i)&#160;one share for each Prior Plans&#8217; Returning Share or Amended 2018 Plan Returning Share (each as defined below) subject to an Appreciation Award and (ii)&#160;1.33 shares for each Prior Plans&#8217; Returning Share or Amended 2018 Plan Returning Share (each as defined below) subject to a Full Value Award.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;Prior Plans&#8217; Returning Shares&#8221; are shares of our common stock subject to outstanding stock awards granted under the 2013 Plan or the Company&#8217;s 2004 Stock Incentive Plan (each referred to herein as a &#8220;Prior Plan&#8221;) and that following the effective date of the 2018 Plan&#58; (i)&#160;are not issued because the stock award expires or otherwise terminates without all of the shares covered by the stock award having been issued or is settled in cash, or (ii)&#160;are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following actions will not result in an issuance of shares of our common stock under the Amended 2018 Plan and accordingly will not reduce the number of shares of our common stock available for issuance under the Amended 2018 Plan&#58; (i)&#160;the expiration or termination of any portion of an award granted under the Amended 2018 Plan without the shares covered by such portion of the award having been issued&#59; or (ii)&#160;the settlement of any portion of an award granted under the Amended 2018 Plan in cash.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any shares of our common stock issued pursuant to an award granted under the Amended 2018 Plan are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares, then such shares will become available again for issuance under the Amended 2018 Plan and, for purposes of this Proposal No.&#160;3, such shares will be the &#8220;Amended 2018 Plan Returning Shares.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares of common stock will not become available again for issuance under the Amended 2018 Plan&#58; (i)&#160;any shares that are reacquired or withheld (or not issued) by us to satisfy the exercise or purchase price of an award granted under the Prior Plans or the Amended 2018 Plan (including any shares subject to such award that are not delivered because such award is exercised through a reduction of shares subject to such award)&#59; (ii)&#160;any shares that are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with an award granted under the Prior Plans or the Amended 2018 Plan&#59; (iii)&#160;any shares repurchased by us on the open market with the proceeds of the exercise or purchase price of an award granted under the Prior Plans or the Amended 2018 Plan&#59; and (iv)&#160;in the event that a stock appreciation right granted under the Prior Plans or the Amended 2018 Plan is settled in shares, the gross number of shares subject to such award.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eligibility</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our (including our affiliates&#8217;) employees, non-employee directors and consultants are eligible to participate in the Amended 2018 Plan and may receive all types of awards other than incentive stock options. Incentive stock options may be granted under the Amended 2018 Plan only to our (including our affiliates&#8217;) employees. However, participation in the automatic grant program is limited to our non-employee directors (see &#8220;&#8212;Automatic Grant Program for Non-Employee Directors&#8221; below).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;30, 2022, we (including our affiliates) had approximately 427 employees, seven non-employee directors and approximately 69 consultants. However, Ms.&#160;Ramasastry, who is not standing for re-election at the Annual Meeting and whose term will therefore expire at the conclusion of the Annual Meeting, will not be eligible to receive awards as a non-employee director under the Amended 2018 Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Administration</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee administers the Amended 2018 Plan (except the automatic grant program, which is administered by our Board, subject to the terms of such program) and may delegate authority to administer the Amended 2018 Plan to a subcommittee of non-employee directors. Our Compensation Committee may, at any time, revest in itself some or all of the power delegated to such a committee. The Compensation Committee and any other committee of non-employee directors to whom the Compensation Committee may delegate authority to administer the Amended 2018 Plan are each considered to be a Plan Administrator for purposes of this Proposal No.&#160;3. Subject to the terms of the Amended 2018 Plan, the Plan Administrator may determine the recipients, the types of awards to be granted, the number of shares of our common stock subject to or the cash value of awards, and the terms and conditions of awards granted under the Amended 2018 Plan, including the period of their exercisability and vesting, subject to the minimum vesting requirement described under &#8220;&#8212;Minimum Vesting Requirement&#8221; below. The Plan Administrator also has the authority to provide for accelerated exercisability and vesting of awards. Subject to the limitations set forth below, the Plan Administrator also determines the fair market value applicable to an award and the exercise or strike price of stock options and stock appreciation rights granted under the Amended 2018 Plan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan Administrator may also delegate to one or more executive officers the authority to designate employees who are not executive officers to be recipients of certain awards and the number of shares of our common stock subject to such awards. Under any such delegation, the Plan Administrator will specify the total number of shares of our common stock that may be subject to the awards granted by such executive officer. The executive officer may not grant an award to himself or herself.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Repricing&#59; Cancellation and Re-Grant of Stock Options or Stock Appreciation Rights</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended 2018 Plan, the Plan Administrator does not have the authority to reprice any outstanding stock option or stock appreciation right by reducing the exercise or strike price of the stock option or stock appreciation right or to </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cancel any outstanding stock option or stock appreciation right that has an exercise or strike price greater than the then-current fair market value of our common stock in exchange for cash or other awards without obtaining the approval of our stockholders. Such approval must be obtained within 12&#160;months prior to such an event.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minimum Vesting Requirement</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended 2018 Plan, no award may vest until at least 12&#160;months following the date of grant of such award, except that shares up to 5% of the share reserve of the Amended 2018 Plan may be issued pursuant to awards that do not meet such vesting requirements.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends and Dividend Equivalents</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2018 Plan provides that dividends or dividend equivalents may not be paid or credited to stock options or stock appreciation rights.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any award other than a stock option or stock appreciation right, the Amended 2018 Plan provides that dividends or dividend equivalents may be paid or credited with respect to any shares of our common stock subject to such award, as determined by the Plan Administrator and specified in the applicable award agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that (i)&#160;no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such award agreement, (ii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such award agreement (including, but not limited to, any vesting conditions), and (iii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are forfeited to or repurchased by us due to a failure to vest.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options may be granted under the Amended 2018 Plan pursuant to stock option agreements. The Amended 2018 Plan permits the grant of stock options that are intended to qualify as incentive stock options, or ISOs, and NSOs.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of a stock option granted under the Amended 2018 Plan may not be less than 100% of the fair market value of the common stock subject to the stock option on the date of grant and, in some cases (see &#8220;&#8212;Limitations on Incentive Stock Options&#8221; below), may not be less than 110% of such fair market value.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of stock options granted under the Amended 2018 Plan may not exceed ten years from the date of grant and, in some cases (see &#8220;&#8212;Limitations on Incentive Stock Options&#8221; below), may not exceed five years from the date of grant. Except as otherwise provided in a participant&#8217;s stock option agreement or other written agreement with us or one of our affiliates, if a participant&#8217;s service relationship with us or any of our affiliates (referred to in this Proposal No.&#160;3 as &#8220;continuous service&#8221;) terminates (other than for cause or the participant&#8217;s death or disability), the participant may exercise any vested stock options for up to three months following the participant&#8217;s termination of continuous service. Except as otherwise provided in a participant&#8217;s stock option agreement or other written agreement with us or one of our affiliates, if a participant&#8217;s continuous service terminates due to the participant&#8217;s disability, the participant may exercise any vested stock options for up to 12&#160;months following the participant&#8217;s termination due to the participant&#8217;s disability. Except as otherwise provided in a participant&#8217;s stock option agreement or other written agreement with us or one of our affiliates, if a participant&#8217;s continuous service terminates due to the participant&#8217;s death (or the participant dies within a specified period following termination of continuous service), the participant&#8217;s beneficiary may exercise any vested stock options for up to 18&#160;months following the participant&#8217;s death. Except as explicitly provided otherwise in a participant&#8217;s stock option agreement or other written agreement with us or one of our affiliates, if a participant&#8217;s continuous service is terminated for cause (as defined in the Amended 2018 Plan), all stock options held by the participant will terminate upon the participant&#8217;s termination of continuous service and the participant will be prohibited from exercising any stock option from and after such termination date. Except as otherwise provided in a participant&#8217;s stock option agreement or other written agreement with us or one of our affiliates, the term of a stock option may be extended if a participant&#8217;s continuous service terminates for any reason other than for cause and, at any time during the last 30&#160;days of the applicable post-termination exercise period, the exercise of the stock option would be prohibited by applicable laws or the sale of any common stock received upon such exercise would violate our insider trading policy. In no event, however, may a stock option be exercised after its original expiration date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceptable forms of consideration for the purchase of our common stock pursuant to the exercise of a stock option under the Amended 2018 Plan will be determined by the Plan Administrator and may include payment&#58; (i)&#160;by cash, check, bank draft or money order payable to us&#59; (ii)&#160;pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board&#59; (iii)&#160;by delivery to us of shares of our common stock (either by actual delivery or attestation)&#59; (iv)&#160;by a net exercise arrangement (for NSOs only)&#59; or (v)&#160;in other legal consideration approved by the Plan Administrator.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the Amended 2018 Plan may become exercisable in cumulative increments, or &#8220;vest,&#8221; as determined by the Plan Administrator at the rate specified in the stock option agreement, subject to the minimum vesting </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement described under &#8220;&#8212;Minimum Vesting Requirement&#8221; above. Shares covered by different stock options granted under the Amended 2018 Plan may be subject to different vesting schedules as the Plan Administrator may determine.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan Administrator may impose limitations on the transferability of stock options granted under the Amended 2018 Plan in its discretion. Generally, a participant may not transfer a stock option granted under the Amended 2018 Plan other than by will or the laws of descent and distribution or, subject to approval by the Plan Administrator, pursuant to a domestic relations order or an official marital settlement agreement. However, the Plan Administrator may permit transfer of a stock option in a manner that is not prohibited by applicable tax and securities laws. In addition, subject to approval by the Plan Administrator, a participant may designate a beneficiary who may exercise the stock option following the participant&#8217;s death. Options may not be transferred to a third party financial institution for value.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Incentive Stock Options</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with current federal tax laws, the aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to ISOs that are exercisable for the first time by a participant during any calendar year under all of our stock plans may not exceed $100,000. The stock options or portions of stock options that exceed this limit or otherwise fail to qualify as ISOs are treated as NSOs. No ISO may be granted to any person who, at the time of grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power unless the following conditions are satisfied&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exercise price of the ISO must be at least 110% of the fair market value of the common stock subject to the ISO on the date of grant&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the term of the ISO must not exceed five years from the date of grant.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to adjustment for certain changes in our capitalization, the aggregate maximum number of shares of our common stock that may be issued pursuant to the exercise of ISOs under the Amended 2018 Plan is 53,200,000 shares.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Appreciation Rights</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock appreciation rights may be granted under the Amended 2018 Plan pursuant to stock appreciation right agreements. Each stock appreciation right is denominated in common stock share equivalents. The strike price of each stock appreciation right will be determined by the Plan Administrator, but will in no event be less than 100% of the fair market value of the common stock subject to the stock appreciation right on the date of grant. The term of stock appreciation rights granted under the Amended 2018 Plan may not exceed ten years from the date of grant. The Plan Administrator may also impose restrictions or conditions upon the vesting of stock appreciation rights that it deems appropriate, subject to the minimum vesting requirement described under &#8220;&#8212;Minimum Vesting Requirement&#8221; above. The appreciation distribution payable upon exercise of a stock appreciation right may be paid in shares of our common stock, in cash, in a combination of cash and stock, or in any other form of consideration determined by the Plan Administrator and set forth in the stock appreciation right agreement. Stock appreciation rights will be subject to the same conditions upon termination of continuous service and restrictions on transfer as stock options under the Amended 2018 Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards may be granted under the Amended 2018 Plan pursuant to restricted stock award agreements. A restricted stock award may be granted in consideration for cash, check, bank draft or money order payable to us, the participant&#8217;s services performed for us, or any other form of legal consideration acceptable to the Plan Administrator. Shares of our common stock acquired under a restricted stock award may be subject to forfeiture to or repurchase by us in accordance with a vesting schedule to be determined by the Plan Administrator, subject to the minimum vesting requirement described under &#8220;&#8212;Minimum Vesting Requirement&#8221; above. Rights to acquire shares of our common stock under a restricted stock award may be transferred only upon such terms and conditions as are set forth in the restricted stock award agreement. Upon a participant&#8217;s termination of continuous service for any reason, any shares subject to restricted stock awards held by the participant that have not vested as of such termination date may be forfeited to or repurchased by us.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Awards</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU awards may be granted under the Amended 2018 Plan pursuant to RSU award agreements. Payment of any purchase price may be made in any form of legal consideration acceptable to the Plan Administrator. A RSU award may be settled by the delivery of shares of our common stock, in cash, in a combination of cash and stock, or in any other form of consideration determined by the Plan Administrator and set forth in the RSU award agreement. RSU awards may be subject to vesting in accordance with a vesting schedule to be determined by the Plan Administrator, subject to the minimum vesting requirement described under &#8220;-Minimum Vesting Requirement&#8221; above. Except as otherwise provided in a participant&#8217;s RSU award agreement or other written agreement with us or one of our affiliates, RSUs that have not vested will be forfeited upon the participant&#8217;s termination of continuous service for any reason.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Awards</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2018 Plan allows us to grant performance stock awards. A performance stock award is a stock award that is payable (including that may vest or may be exercised) contingent upon the attainment of pre-determined performance goals during a performance period. A performance stock award may require the completion of a specified period of continuous service. The length of any performance period, the performance goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been attained will be determined by the Plan Administrator in its discretion. In addition, to the extent permitted by applicable law and the applicable award agreement, the Plan Administrator may determine that cash may be used in payment of performance stock awards.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance goals under the Amended 2018 Plan will be based on any one or more of the following performance criteria&#58; (i)&#160;earnings (including earnings per share and net earnings)&#59; (ii)&#160;earnings before interest, taxes and depreciation&#59; (iii)&#160;earnings before interest, taxes, depreciation and amortization&#59; (iv)&#160;earnings before interest, taxes, depreciation, amortization and legal settlements&#59; (v)&#160;earnings before interest, taxes, depreciation, amortization, legal settlements and other income (expense)&#59; (vi)&#160;earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense) and stock-based compensation&#59; (vii)&#160;earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation and changes in deferred revenue&#59; (viii)&#160;total stockholder return&#59; (ix)&#160;return on equity or average stockholder&#8217;s equity&#59; (x)&#160;return on assets, investment, or capital employed&#59; (xi)&#160;stock price&#59; (xii)&#160;profit (including gross profit) and&#47;or margin (including gross margin)&#59; (xiii)&#160;income (before or after taxes)&#59; (xiv)&#160;operating income&#59; (xv)&#160;operating income after taxes&#59; (xvi)&#160;pre-tax profit&#59; (xvii)&#160;operating cash flow&#59; (xviii)&#160;sales or revenue targets&#59; (xix)&#160;increases in revenue or product revenue&#59; (xx)&#160;expenses and cost reduction goals&#59; (xxi)&#160;improvement in or attainment of working capital levels&#59; (xxii)&#160;economic value added (or an equivalent metric)&#59; (xxiii)&#160;market share&#59; (xxiv)&#160;cash flow&#59; (xxv)&#160;cash flow per share&#59; (xxvi)&#160;share price performance&#59; (xxvii)&#160;debt reduction&#59; (xxviii)&#160;implementation or completion of projects or processes&#59; (xxix)&#160;employee retention&#59; (xxx)&#160;stockholders&#8217; equity&#59; (xxxi)&#160;capital expenditures&#59; (xxxii)&#160;debt levels&#59; (xxxiii)&#160;operating profit or net operating profit&#59; (xxxiv)&#160;workforce diversity&#59; (xxxv)&#160;growth of net income or operating income&#59; (xxxvi)&#160;billings&#59; (xxxvii)&#160;bookings&#59; and (xxxviii)&#160;other measures of performance selected by the Plan Administrator.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Plan Administrator in the award agreement at the time the award is granted or in such other document setting forth the performance goals at the time the performance goals are established, the Plan Administrator will appropriately make adjustments in the method of calculating the attainment of performance goals for a performance period as follows&#58; (i)&#160;to exclude restructuring and&#47;or other nonrecurring charges&#59; (ii)&#160;to exclude exchange rate effects&#59; (iii)&#160;to exclude the effects of changes to generally accepted accounting principles&#59; (iv)&#160;to exclude the effects of any statutory adjustments to corporate tax rates&#59; (v)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles&#59; (vi)&#160;to exclude the dilutive effects of acquisitions or joint ventures&#59; (vii)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture&#59; (viii)&#160;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends&#59; (ix)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans&#59; (x)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles&#59; and (xi)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Plan Administrator retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any performance goals and to define the manner of calculating the performance criteria it selects to use for a performance period.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Automatic Grant Program for Non-Employee Directors</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the automatic grant program, each individual who is a non-employee Board member will automatically be granted a NSO to purchase 25,000 shares of common stock and a RSU award in respect of 12,500 shares of common stock on an annual basis. Such annual awards will be granted on the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of February of each year (or if such 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day is not a trading day, the immediately preceding trading day in February), provided that such individual is a non-employee Board member on the date of grant, has served as a non-employee Board member for at least three months prior to the date of grant, and will continue serving as a non-employee Board member immediately after the date of grant. The shares subject to each annual 25,000 share automatic NSO grant made to a continuing Board member will vest in 12&#160;successive equal monthly installments over the one-year period following the date of grant, subject to the director&#8217;s continuous service through the applicable vesting dates. The shares subject to each annual 12,500 share automatic RSU award grant made to a continuing Board member will fully vest on the first anniversary of the date of grant, subject to the director&#8217;s continuous service through the applicable vesting date.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the automatic grant program, each individual who is initially appointed or elected as a non-employee Board member will, on the date of such appointment or election, automatically be granted a NSO to purchase 37,500 shares of common stock and a RSU award in respect of 18,750 shares of common stock. The shares subject to each initial 37,500 share automatic NSO grant made to a newly appointed or elected Board member will vest in 36&#160;successive equal monthly installments over the three-year period following the date of grant, subject to the director&#8217;s continuous service through the applicable vesting dates. The shares subject to each initial 18,750 share automatic RSU award grant made to a newly appointed or elected Board member will vest in three equal annual installments over the three-year period following the date of grant, subject to the director&#8217;s continuous service through the applicable vesting dates.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each automatic NSO grant will have an exercise price per share equal to the fair market value per share of our common stock on the grant date and will have a term of 10&#160;years, subject to earlier termination following the director&#8217;s termination of continuous service. Each automatic NSO grant will be immediately exercisable for all of the option shares&#59; however, we may repurchase, at the lower of the exercise price paid per share or the fair market value per share, any shares purchased under the NSO that are not vested at the time of the director&#8217;s termination of continuous service.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares subject to each automatic NSO grant and each automatic RSU award grant will immediately vest in full upon the director&#8217;s termination of continuous service due to death or disability, or upon the occurrence of a change in control or hostile takeover (each as defined in the Amended 2018 Plan and described below), subject to the director&#8217;s continuous service through the date of such change in control or hostile takeover.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Stock Awards</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other forms of stock awards valued in whole or in part by reference to, or otherwise based on, our common stock may be granted either alone or in addition to other awards under the Amended 2018 Plan. Subject to the terms of the Amended 2018 Plan, the Plan Administrator will have sole and complete authority to determine the persons to whom and the time or times at which such other stock awards will be granted, the number of shares of our common stock to be granted and all other terms and conditions of such other stock awards.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clawback Policy</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted under the Amended 2018 Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law, and any other clawback policy that we adopt. In addition, the Plan Administrator may impose other clawback, recovery or recoupment provisions in an award agreement as the Plan Administrator determines necessary or appropriate, including a reacquisition right in respect of previously acquired shares of our common stock or other cash or property upon the occurrence of cause.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to Capital Structure</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of certain capitalization adjustments, the Plan Administrator will appropriately adjust&#58; (i)&#160;the class(es) and maximum number of securities subject to the Amended 2018 Plan&#59; (ii)&#160;the class(es)&#160;and maximum number of securities that may be issued pursuant to the exercise of ISOs&#59; (iii)&#160;the class(es) and number of securities to be granted under the automatic grant program&#59; and (iv)&#160;the class(es) and number of securities and price per share of stock subject to outstanding awards.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Control or Hostile Takeover</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provisions will apply to awards under the Amended 2018 Plan in the event of a change in control (as defined in the Amended 2018 Plan and described below) unless otherwise provided in the instrument evidencing the award or any other written agreement with us or one of our affiliates or unless otherwise expressly provided by the Plan Administrator at the time of grant of the award.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change in control, outstanding awards shall be assumed, continued or substituted for similar stock awards by the surviving or acquiring corporation (or its parent company). If the surviving or acquiring corporation (or its parent company) fails to assume, continue or substitute such awards, the vesting of awards held by participants who are our employees or non-employee directors and whose continuous service has not terminated will be accelerated in full (and with respect to performance stock awards, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the change in control as determined by the Plan Administrator. All awards not assumed, continued or substituted for similar stock awards by the surviving or acquiring corporation (or its parent company) will terminate if not exercised (if applicable) upon the change in control. In addition, the Plan Administrator may also provide, in its sole discretion, that the holder of an award that will terminate if not exercised prior to the occurrence of a change in control may not exercise such award but instead will receive a payment, in such form as may be determined by the Plan Administrator, equal to the excess, if any, of (1)&#160;the value of the property the participant would have received upon exercise of the award (including, at the discretion of the Plan Administrator, any unvested portion of such award) over (2)&#160;the exercise price otherwise payable in connection with the award.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Amended 2018 Plan, a change in control generally will be deemed to occur if (1)&#160;we are acquired pursuant to a merger, consolidation or other reorganization approved by our stockholders, (2)&#160;there occurs a stockholder-approved sale or other disposition of all or substantially all our assets, or (3)&#160;there occurs any transaction or series of related transactions pursuant to which any person or group of related persons becomes directly or indirectly the beneficial owner of securities possessing (or convertible into or exercisable for securities possessing) more than 50% of the total combined voting power of our securities outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from us or the acquisition of outstanding securities held by one or more of our stockholders.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The awards granted to our non-employee directors under our automatic grant program will automatically immediately fully accelerate vesting upon a change in control or hostile takeover (as defined in the Amended 2018 Plan and described below), subject to the director&#8217;s continuous service through the date of such change in control or hostile takeover. The acceleration of vesting of an award in the event of a change in control or hostile takeover under the Amended 2018 Plan may be viewed as an anti-takeover provision, which may have the effect of discouraging a proposal to acquire or otherwise obtain control of us.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Amended 2018 Plan, a hostile takeover generally will be deemed to occur if (1)&#160;there is a change in the majority of our Board as a result of one or more contested elections for Board membership, or (2)&#160;securities possessing more than 50% of the total combined voting power of our outstanding securities are acquired pursuant to a hostile tender offer.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan Amendments and Termination</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan Administrator will have the authority to amend or terminate the Amended 2018 Plan at any time. However, except as otherwise provided in the Amended 2018 Plan, no amendment or termination of the Amended 2018 Plan may impair a participant&#8217;s rights under his or her outstanding awards without the participant&#8217;s consent. We will obtain stockholder approval of any amendment to the Amended 2018 Plan as required by applicable law and listing requirements. No incentive stock options may be granted under the Amended 2018 Plan after April&#160;23, 2028, which is the tenth anniversary of the date the 2018 Plan was first approved by the Compensation Committee.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Federal Income Tax Consequences</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal United States federal income tax consequences to participants and us with respect to participation in the Amended 2018 Plan. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her particular situation, each participant should consult the participant&#8217;s tax adviser regarding the federal, state, local and other tax consequences of the grant or exercise of an award or the disposition of stock acquired the Amended 2018 Plan. The Amended 2018 Plan is not qualified under the provisions of Section&#160;401(a) of the Internal Revenue Code of 1986, as amended, or the Code, and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974. Our ability to realize the benefit of any tax deductions described below depends on our generation of taxable income as well as the requirement of reasonableness and the satisfaction of our tax reporting obligations.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonstatutory Stock Options</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, there is no taxation upon the grant of an NSO if the stock option is granted with an exercise price equal to the fair market value of the underlying stock on the grant date. Upon exercise, a participant will recognize ordinary income equal to the excess, if any, of the fair market value of the underlying stock on the date of exercise of the stock option over the exercise price. If the participant is employed by us or one of our affiliates, that income will be subject to withholding taxes. The participant&#8217;s tax basis in those shares will be equal to his or her fair market value on the date of exercise of the stock option, and the participant&#8217;s capital gain holding period for those shares will begin on that date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Options</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2018 Plan provides for the grant of stock options that are intended to qualify as &#8220;incentive stock options,&#8221; as defined in Section 422 of the Code. Under the Code, a participant generally is not subject to ordinary income tax upon the grant or exercise of an ISO. If the participant holds a share received upon exercise of an ISO for more than two years from the date the stock option was granted and more than one year from the date the stock option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that share and the participant&#8217;s tax basis in that share will be long-term capital gain or loss.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, however, a participant disposes of a share acquired upon exercise of an ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the participant generally will recognize ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the share on the date of exercise of the stock option over the exercise price. However, if the sales proceeds are less than the fair market value of the share on the date of exercise of the stock option, the amount of ordinary income recognized by the participant will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the date of exercise of the stock option, that excess will be short-term or long-term capital gain, depending on whether the holding period for the share exceeds one year.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock acquired upon exercise of an ISO exceeds the exercise price of the stock option generally will be an adjustment included in the participant&#8217;s alternative minimum taxable income for the year in which the stock option is exercised. If, however, there is a disqualifying disposition of the share in the year in which the stock option is exercised, there will be no adjustment for alternative minimum tax purposes with respect to that share. In computing alternative minimum taxable income, the tax basis of a share acquired upon exercise of an ISO is increased by the amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the stock option is exercised.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not allowed a tax deduction with respect to the grant or exercise of an ISO or the disposition of a share acquired upon exercise of an ISO after the required holding period. If there is a disqualifying disposition of a share, however, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant, subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and provided that either the employee includes that amount in income or we timely satisfy our reporting requirements with respect to that amount.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the recipient of a restricted stock award will recognize ordinary income at the time the stock is received equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock is not vested when it is received (for example, if the employee is required to work for a period of time in order to have the right to sell the stock), the recipient generally will not recognize income until the stock becomes vested, at which time the recipient will recognize ordinary income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service, within 30&#160;days following his or her receipt of the restricted stock award, to recognize ordinary income, as of the date the recipient receives the restricted stock award, equal to the excess, if any, of the fair market value of the stock on the date the restricted stock award is granted over any amount paid by the recipient for the stock.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recipient&#8217;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted stock award will be the amount paid for such shares plus any ordinary income recognized either when the stock is received or when the stock becomes vested.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the requirement of reasonableness, the provisions of Section&#160;162(m) of the Code, and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock award.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Awards</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the recipient of a RSU award structured to comply with the requirements of Section&#160;409A of the Code or an exception to Section&#160;409A of the Code will recognize ordinary income at the time the stock is delivered equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. To comply with the requirements of Section&#160;409A of the Code, the stock subject to a RSU award may generally only be delivered upon one of the following events&#58; a fixed calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on another date, unless the RSU award otherwise complies with or qualifies for an exception to the requirements of Section&#160;409A of the Code (including delivery upon achievement of a performance goal), in addition to the tax treatment described above, the recipient will owe an additional 20% federal tax and interest on any taxes owed.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recipient&#8217;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from a RSU award will be the amount paid for such shares plus any ordinary income recognized when the stock is delivered.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the requirement of reasonableness, the provisions of Section&#160;162(m) of the Code, and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the RSU award.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Appreciation Rights</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a stock appreciation right is granted with an exercise price equal to the fair market value of the underlying stock on the grant date, the recipient will recognize ordinary income equal to the fair market value of the stock or cash received upon such exercise. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the requirement of reasonableness, the provisions of Section&#160;162(m) of the Code, and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock appreciation right.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 162(m) Limitations</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;162(m) of the Code, compensation paid to any publicly held corporation&#8217;s &#8220;covered employees&#8221; that exceeds $1 million per taxable year for any covered employee is generally non-deductible. Awards granted under the Amended 2018 Plan will be subject to the deduction limit under Section&#160;162(m) of the Code and will not be eligible to qualify for the performance-based compensation exception under Section&#160;162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act. For further information regarding the deduction limit under Section&#160;162(m) of the Code and such transition relief, see the section entitled &#8220;Compensation Discussion and Analysis&#8212;Additional Compensation Information&#8212;Tax and Accounting Effects of Executive Compensation.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Plan Benefits under Amended 2018 Plan</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding future benefits under the Amended 2018 Plan.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae<br>&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu<br>&#160;&#160;&#160;&#160;Senior Vice President, Chief Financial Officer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung<br>&#160;&#160;&#160;&#160;Executive Vice President, Chief Operating Officer</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier<br>&#160;&#160;&#160;&#160;Executive Vice President, Technical Operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott<br>&#160;&#160;&#160;&#160;Senior Vice President, Head of Development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee<br>&#160;&#160;&#160;&#160;Former Executive Vice President, Chief Financial Officer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current executive officers as a group</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current directors who are not executive officers as a group</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current employees, including all current officers who are not executive officers, as a group</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Awards granted under the Amended 2018 Plan to our executive officers and other employees are discretionary and are not subject to set benefits or amounts under the terms of the Amended 2018 Plan, and we have not granted any awards under the Amended 2018 Plan subject to stockholder approval of this Proposal No.&#160;3. Accordingly, the benefits or amounts that will be received by or allocated to our executive officers and other employees under the Amended 2018 Plan are not determinable.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr. Lee resigned from his position of Executive Vice President, Chief Financial Officer effective February&#160;1, 2021, and, therefore, is not eligible to receive any future awards under the Amended 2018 Plan.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As described above in this Proposal No.&#160;3 under &#8220;&#8212;Automatic Grant Program for Non-Employee Directors,&#8221; each individual who is a non-employee Board member will automatically be granted a NSO to purchase 25,000 shares of common stock and a RSU award in respect of 12,500 shares of common stock on an annual basis. Such annual awards will be granted on the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> day of February of each year (or if such 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> day is not a trading day, the immediately preceding trading day in February), provided that such individual is a non-employee Board member on the date of grant, has served as a non-employee Board member for at least three months prior to the date of grant, and will continue serving as a non-employee Board member immediately after the date of grant. If this Proposal No.&#160;3 is approved by our stockholders, then after the date of the Annual Meeting, any such NSOs and RSU awards will be granted under the Amended 2018 Plan. Under the current terms of the automatic grant program under the Amended 2018 Plan, the aggregate number of shares subject to such NSOs and RSU awards that will automatically be granted to all of our current directors who are not executive officers (except Ms. Ramasastry, who is not standing for re-election at the Annual Meeting) as a group will be 225,000 shares each year.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Plan Benefits under 2018 Plan</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, for each of the individuals and various groups indicated, the total number of shares of our common stock subject to awards that have been granted under the 2018 Plan as of March&#160;30, 2022&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae<br>&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192,925&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu<br>&#160;&#160;&#160;&#160;Senior Vice President, Chief Financial Officer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung<br>&#160;&#160;&#160;&#160;Executive Vice President, Chief Operating Officer</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,780&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier<br>&#160;&#160;&#160;&#160;Executive Vice President, Technical Operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,300&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott<br>&#160;&#160;&#160;&#160;Senior Vice President, Head of Development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,700&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee<br>&#160;&#160;&#160;&#160;Former Executive Vice President, Chief Financial Officer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,250&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current executive officers as a group (1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,030,905&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current directors who are not executive officers as a group</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each nominee for election as a director&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Robert F. Carey</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Kenneth J. Hillan</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Alexander D. Macrae</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;John H. Markels</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;James R. Meyers</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;H. Stewart Parker</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Karen L. Smith</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each associate of any executive officers, current directors or director nominees</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each other person who received or is to receive 5% of awards</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current employees, including all current officers who are not executive officers, as a group (1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,748,875&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes Mr.&#160;Lee&#8217;s shares because he resigned from his position as Executive Vice President, Chief Financial Officer effective February&#160;1, 2021.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vote Required</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of this Proposal No.&#160;3 requires votes &#8220;FOR&#8221; from holders of a majority in voting power of the shares present online or represented by proxy at the Annual Meeting and entitled to vote on this Proposal No.&#160;3.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECOMMENDATION OF THE BOARD OF DIRECTORS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends that the stockholders vote FOR the approval of the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_103"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NO. 4&#58;</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has appointed Ernst&#160;&#38; Young LLP, our independent registered public accounting firm during 2021, to serve in the same capacity for the year ending December&#160;31, 2022 and is asking the stockholders to ratify this appointment.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither our Bylaws nor other governing documents or law require stockholder ratification of the selection of Ernst&#160;&#38; Young LLP as our independent registered public accounting firm. However, the Audit Committee is submitting the selection of Ernst&#160;&#38; Young LLP to the stockholders for ratification as a matter of good corporate practice. In the event the stockholders fail to ratify the appointment, the Audit Committee will reconsider its selection. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if the Audit Committee believes that such a change would be in the best interests of Sangamo and its stockholders.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A representative of Ernst&#160;&#38; Young LLP is expected to be present at the Annual Meeting and will have the opportunity to make a statement if he or she desires to do so and will be available to respond to appropriate questions.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_106"></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Accounting Fees and Services</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents fees for professional services rendered by Ernst&#160;&#38; Young LLP for the audit of our annual financial statements for 2021 and 2020&#58;</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees and expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857,489&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,183&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-related fees</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,720&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,689&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905,903&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes fees and expenses for the audit of our annual financial statements included in our annual reports on Form 10-K and the related audit of internal control over financial reporting, review of interim financial statements included in our quarterly reports on Form 10-Q, consultations regarding accounting and auditing matters, fees in connection with the filing of our registration statements on Form S-3 and Form S-8 and related amendments and services normally provided in connection with statutory and regulatory filings.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists of fees billed for professional services for tax compliance, tax advice and tax planning.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_109"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under its charter, the Audit Committee must pre-approve all engagements of the independent registered public accounting firm for the performance of all audit and non-audit services that are not prohibited and the fees for such services. The Audit Committee has delegated to its Chair the authority to evaluate and approve service engagements on behalf of the full committee in the event a need arises for specific pre-approval between committee meetings. If the Chair approves any such engagements, he will report such approval to the full Audit Committee not later than the next committee meeting.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has determined that the rendering of other professional services for tax compliance and tax advice by Ernst&#160;&#38; Young LLP is compatible with maintaining their independence. The Audit Committee has established a policy governing our use of Ernst&#160;&#38; Young LLP for non-audit services. Under the policy, management may use Ernst&#160;&#38; Young LLP for non-audit services that are permitted under SEC rules and regulations, provided that management obtains the Audit Committee&#8217;s approval before such services are rendered.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The services provided by Ernst&#160;&#38; Young LLP in 2021 were pre-approved in accordance with this policy.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of this Proposal No.&#160;4 requires votes &#8220;FOR&#8221; from holders of a majority in voting power of the shares present online or represented by proxy at the Annual Meeting and entitled to vote on this Proposal No.&#160;4.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_112"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECOMMENDATION OF THE BOARD OF DIRECTORS</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends that the stockholders vote FOR the ratification of the appointment of Ernst&#160;&#38; Young LLP to serve as our independent registered public accounting firm for the year ending December&#160;31, 2022.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_115"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OFFICERS</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding our current executive officers as of March&#160;30, 2022&#58;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae, M.B., Ch.B., Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason D. Fontenot, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Scientific Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Operating Officer</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Technical Operations</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott, M.D., M.P.H., F.A.C.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Head of Development</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott B. Willoughby</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Corporate Secretary</font></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alexander D. Macrae.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biographical information regarding Dr.&#160;Macrae is set forth under &#8220;Proposal No.&#160;1&#58; Election of Directors.&#8221;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prathyusha Duraibabu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Senior Vice President, Chief Financial Officer since June 2021, our Principal Financial Officer since March 2021 and our Principal Accounting Officer since June 2019 and previously served as our Vice President, Finance from March 2019 to May 2021. Ms.&#160;Duraibabu has over 22&#160;years of experience in optimizing financial operations, driving organizational change, building diverse teams and delivering results. Prior to joining the Company, Ms.&#160;Duraibabu served as Corporate Controller at Pacific Biosciences of California, Inc., a publicly-traded commercial biotechnology company, from June 2010 to March 2019. At Pacific Biosciences, she was responsible for global financial operations, strategy, audit and tax. Ms.&#160;Duraibabu received a Bachelors of Accounting from Oxford Brookes University in Oxford, United Kingdom and an M.B.A. from San Jose State University. Ms.&#160;Duraibabu is a Certified Public Accountant in the State of California.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jason D. Fontenot, Ph.D. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Senior Vice President, Chief Scientific Officer since January 2021. Dr.&#160;Fontenot oversees all platform and pipeline research activities &#8211; advancing Sangamo&#8217;s proprietary genomic medicine technology in support of a diverse clinical pipeline. Dr.&#160;Fontenot joined Sangamo in March 2019 as Senior Vice President, Cell Therapy. In that role, Dr.&#160;Fontenot oversaw Sangamo&#8217;s engineered cell therapy portfolio, including a proprietary chimeric antigen receptor regulatory T cells pipeline, and partnerships with Sanofi S.A., or Sanofi, and Kite Pharma Inc., or Kite, a Gilead Company. Dr.&#160;Fontenot has an extensive background in cell therapy and drug development, having previously served as Chief Scientific Officer at Immusoft Corporation, a biotechnology company, from July 2018 to March 2019, Head of Exploratory Research at Juno Therapeutics Inc., a biopharmaceutical company, from January 2016 to January 2018 when it was acquired by Celgene Corporation, and for nearly a decade as a group leader in the immunology department at Biogen Inc. Dr.&#160;Fontenot has expertise in lymphocyte biology, cell and genetic engineering and immune-mediated disease. Dr.&#160;Fontenot conducted post-doctoral work at Rockefeller University in New York City. He received his Ph.D. in Immunology from the University of Washington in Seattle working in the laboratory of Dr.&#160;Alexander Rudensky.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">D. Mark McClung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Executive Vice President, Chief Operating Officer since November 2021. Mr.&#160;McClung previously served as our Executive Vice President and Chief Business Officer since May 2020. Mr.&#160;McClung is responsible for European business operations, corporate and business development, product strategy and planning, alliance management, patient advocacy, government relations, investor relations, corporate communications, facilities and information technology. From February 2019 until joining Sangamo, Mr.&#160;McClung consulted to the biopharmaceutical industry, including Sangamo. Prior thereto, from 2015 through February 2019, Mr.&#160;McClung was Vice President and General Manager of Global Oncology Commercial at Amgen Inc., a public biopharmaceutical company, which he joined following Amgen&#8217;s acquisition of Onyx Pharmaceuticals Inc., where he had served as Senior Vice President &#38; Chief Commercial Officer. For two decades prior, Mr.&#160;McClung held roles of increasing responsibility at GlaxoSmithKline in marketing and sales, commercial operations, clinical development and product strategy, and general management in Canada, the United States, and Europe, including as Vice President and Head of Global Commercial for GSK Oncology from 2009 to 2013. Mr.&#160;McClung received his bachelor&#8217;s degree in Human Kinetics and Biomedical Sciences from the University of Guelph in Ontario, Canada and completed graduate coursework at York University in Toronto and Wharton Business School at the University of Pennsylvania.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R. Andrew &#8220;Andy&#8221; Ramelmeier, Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Executive Vice President, Technical Operations since September 2019 and is responsible for technical operations at Sangamo, including manufacturing, quality, supply chain and process and analytical development. Dr.&#160;Ramelmeier joined Sangamo in January 2018 as Senior Vice President, Technical Operations. Dr.&#160;Ramelmeier has 30&#160;years of experience in the biopharmaceutical industry, developing and transferring biological processes, designing and building manufacturing facilities, and directing contract manufacturers as well as internal manufacturing operations. From 2014 through 2017, Dr.&#160;Ramelmeier served as Senior Vice President, Technical Operations at Portola Pharmaceuticals, Inc., a biopharmaceutical company, where he was responsible for tech transfer, bulk and drug product </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing, technical support and supply chain of Portola&#8217;s pipeline products. From 2006 to 2014, Dr.&#160;Ramelmeier served as Vice President, Manufacturing, Process Sciences and Facilities at BioMarin Pharmaceutical Inc., overseeing multiple commercial biologics products, clinical pipeline, and facilities in Novato, California, and Shanbally, Ireland. Earlier in his career, he held roles of increasing responsibility at Johnson &#38; Johnson and Merck &#38; Co., Inc. Prior to joining industry, Dr.&#160;Ramelmeier conducted post-doctoral work in Germany. He received his B.S. in Chemical Engineering from Johns Hopkins and his Ph.D. in Chemical Engineering from the University of California, Berkeley.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Robert J. Schott, M.D., M.P.H., F.A.C.C.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Senior Vice President, Head of Development since February 2021. Dr.&#160;Schott is responsible for leading our clinical development organization across all phases of drug development and regulatory approval. Prior to joining Sangamo, Dr.&#160;Schott served from March 2017 to January 2021 as the Chief Medical Officer at Chorus, an autonomous early-phase development engine within Eli Lilly and Company, a public pharmaceutical company, where he oversaw teams working to expand Eli Lilly&#8217;s pipeline. He previously joined Eli Lilly in 2014 as a Global Launch Leader. Earlier in his career, Dr. Schott served as a Cardiovascular Department Chair and Vice President of Medical Affairs at Sutter Medical Center Sacramento while continuing to care for patients as an invasive cardiologist. Dr.&#160;Schott received his B.S. in Biomedicine, M.D. and M.P.H. in Epidemiology from the University of Michigan. He trained in cardiovascular medicine at the Massachusetts General Hospital after working as a post-doctoral fellow at the Harvard Medical School.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scott B. Willoughb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y has served as our Senior Vice President, General Counsel and Corporate Secretary since August 2021. Mr.&#160;Willoughby is responsible for all legal matters for Sangamo and has over 20&#160;years of experience in advising global public and private companies across multiple industries, including biotechnology, healthcare and technology. Mr.&#160;Willoughby joined Sangamo in March 2020 as Vice President and Head of Corporate Law. Previously, Mr.&#160;Willoughby served as Vice President, Deputy General Counsel from February 2019 to July 2019, and as Associate General Counsel, Corporate &#38; Compliance from September 2017 to February 2019, at Achaogen, Inc., an anti-infectives biotechnology company. From February 2016 to September 2017, Mr.&#160;Willoughby served as Senior Counsel, M&#38;A at McKesson Corporation, a pharmaceutical distribution and healthcare company. Earlier in his career, Mr.&#160;Willoughby held several senior counsel roles where he built his expertise in corporate governance, SEC reporting, corporate finance, compliance, M&#38;A and international expansion. Mr.&#160;Willoughby received a B.A. and J.D. from the University of California, Berkeley.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_118"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information known to Sangamo with respect to the beneficial ownership of our common stock as of March&#160;30, 2022, except as noted, by (i)&#160;all persons who were beneficial owners of 5% or more of our common stock based on 146,664,760&#160;shares outstanding as of March&#160;30, 2022, (ii) each current director (which includes all nominees for director), (iii)&#160;each of our named executive officers, and (iv)&#160;all current directors and executive officers as a group. Unless otherwise indicated, the principal address of each of the stockholders below is c&#47;o Sangamo Therapeutics, Inc., 7000 Marina Boulevard, Brisbane, CA 94005. Except as otherwise indicated or to the extent authority may be shared by both spouses under applicable law, and subject to applicable community property laws, we believe the persons named in the table have sole voting and investment power with respect to all shares of common stock held by them.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Address of Beneficial Owner</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br>Shares<br>Beneficially<br>Owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br>of Shares<br>Beneficially<br>Owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen, Inc. (1)</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 Binney Street</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge, MA 02142</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,152,466&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BlackRock, Inc. (2)</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 East 52nd Street</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York, NY 10055</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662,880&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wasatch Advisors, Inc. (3)</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 Wakara Way</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt Lake City, UT 84108</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,960,982&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanguard Group Inc. (4)</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 Vanguard Blvd.</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malvern, PA 19355</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,340,555&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae (5)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982,331&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert F. Carey (6)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu (7)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,473&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth J. Hillan (8)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee (9)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John H. Markels (10)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung (11)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,079&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James R. Meyers (12)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. Stewart Parker (13)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saira Ramasastry (14)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier (15)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,236&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott (16)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,869&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen L. Smith (17)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current directors and executive officers as a group (14 persons) (18)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,741,389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Less than 1%.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This information is based solely on information contained in the Form&#160;4 filed with the SEC on December&#160;30, 2021 by Biogen Inc. and Biogen MA Inc. We and Biogen MA, Inc., or BIMA, are party to a voting agreement in which BIMA has agreed that, excluding specified extraordinary matters, it will vote its shares in accordance with our recommendation and has granted us an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i)&#160;April&#160;9, 2022, (ii)&#160;the date that BIMA beneficially owns less than 5% of our common stock and (iii)&#160;the date our collaboration agreement with BIMA and Biogen International GmbH, which we refer to together as Biogen, is terminated. None of the proposals in this Proxy Statement are extraordinary matters for purposes of our voting agreement with BIMA and we intend to instruct BIMA to vote &#8220;For&#8221; each of the proposals, including for each nominee for director, pursuant to the voting agreement.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This information is based solely on information contained in the Schedule 13G&#47;A filed with the SEC on February&#160;1, 2022 by BlackRock, Inc., or BlackRock. BlackRock, as a parent holding company or control person, may be deemed to beneficially own the indicated shares and has sole dispositive power over 11,662,880 shares and sole voting power over 11,303,781 shares. BlackRock reported its beneficial ownership on behalf of itself and the following&#58; BlackRock Life Limited&#59; BlackRock Advisors, LLC&#59; Aperio Group, LLC&#59; BlackRock (Netherlands) B.V.&#59; BlackRock Institutional Trust Company, National Association&#59; BlackRock Asset Management Ireland Limited&#59; BlackRock Financial Management, Inc.&#59; BlackRock Japan Co., Ltd.&#59; BlackRock Asset Management Schweiz AG&#59; BlackRock Investment Management, LLC&#59; BlackRock Investment Management (UK) Limited&#59; BlackRock Asset Management Canada Limited&#59; BlackRock (Luxembourg) S.A.&#59; BlackRock Investment Management (Australia) Limited&#59; BlackRock Fund Advisors&#59; and BlackRock </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fund Managers Ltd. The Schedule 13G&#47;A provides information only as of December&#160;31, 2021 and, consequently, the beneficial ownership of the above-mentioned entities may have changed between December&#160;31, 2021 and March&#160;30, 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This information is based solely on information contained in the Schedule&#160;13G&#47;A filed with the SEC on February&#160;11, 2022 by Wasatch Advisors, Inc., or Wasatch. The Schedule&#160;13G&#47;A provides information only as of December&#160;31, 2021 and, consequently, the beneficial ownership of Wasatch may have changed between December&#160;31, 2021 and March&#160;30, 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This information is based solely on information contained in the Schedule 13G&#47;A filed with the SEC on February&#160;10, 2022 by The Vanguard Group, Inc., or Vanguard. Vanguard may be deemed to beneficially own the indicated shares and has sole dispositive power over 9,035,368 shares, shared dispositive power over 305,187 shares, and shared voting power over 214,657 shares. The Schedule 13G&#47;A provides information only as of December&#160;31, 2021 and, consequently, the beneficial ownership of Vanguard may have changed between December&#160;31, 2021 and March&#160;30, 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes 1,833,670 shares of common stock subject to options exercisable within 60&#160;days after March&#160;30, 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes 131,400 shares of common stock subject to options exercisable within 60&#160;days after March&#160;30, 2022, of which 112,650 shares fully vest within 60&#160;days of March&#160;30, 2022, and the remaining 18,750 shares are currently exercisable but do not vest within 60&#160;days of March&#160;30, 2022 and would be subject to repurchase upon cessation of continuous service if exercised prior to vesting.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes (i)&#160;89,207 shares of common stock issuable upon the exercise of stock options within 60&#160;days of March&#160;30, 2022 and (ii)&#160;RSUs covering 1,917 shares of common stock that vest and become issuable within 60&#160;days of March&#160;30, 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes 71,400 shares of common stock subject to options exercisable within 60&#160;days after March&#160;30, 2022, of which 39,316 shares fully vest within 60&#160;days of March&#160;30, 2022, and the remaining 32,084 shares are currently exercisable but do not vest within 60&#160;days of March&#160;30, 2022 and would be subject to repurchase upon cessation of continuous service if exercised prior to vesting.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;Lee resigned from his position as Executive Vice President, Chief Financial Officer effective February&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes 71,400 shares of common stock subject to options exercisable within 60&#160;days of March&#160;30, 2022, of which 45,150 shares fully vest within 60&#160;days of March&#160;30, 2022, and the remaining 26,250 shares are currently exercisable but do not vest within 60&#160;days of March&#160;30, 2022 and would be subject to repurchase upon cessation of continuous service if exercised prior to vesting.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes 120,833 shares of common stock issuable upon the exercise of stock options within 60&#160;days of March&#160;30, 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes 91,400 shares of common stock subject to options exercisable within 60&#160;days of March&#160;30, 2022 of which 67,650 shares fully vest within 60&#160;days of March&#160;30, 2022, and the remaining 23,750 shares are currently exercisable but do not vest within 60&#160;days of March&#160;30, 2022 and would be subject to repurchase upon cessation of continuous service if exercised prior to vesting.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes 171,400 shares of common stock issuable upon the exercise of stock options within 60&#160;days of March&#160;30, 2022, of which 152,650 shares fully vest within 60&#160;days of March&#160;30, 2022, and the remaining 18,750 shares are currently exercisable but do not vest within 60&#160;days of March&#160;30, 2022 and would be subject to repurchase upon cessation of continuous service if exercised prior to vesting.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes 131,400 shares of common stock issuable upon the exercise of stock options within 60&#160;days of March&#160;30, 2022, of which 112,650 shares fully vest within 60&#160;days of March&#160;30, 2022, and the remaining 18,750 shares are currently exercisable but do not vest within 60&#160;days of March&#160;30, 2022 and would be subject to repurchase upon cessation of continuous service if exercised prior to vesting. Ms.&#160;Ramasastry is not standing for re-election to the Board of Directors at the Annual Meeting.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes 267,812 shares of common stock issuable upon the exercise of stock options within 60&#160;days of March&#160;30, 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes 25,000 shares of common stock issuable upon the exercise of stock options within 60&#160;days of March&#160;30, 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes 106,400 shares of common stock issuable upon the exercise of stock options within 60&#160;days of March&#160;30, 2022, of which 87,650 shares fully vest within 60&#160;days of March&#160;30, 2022, and the remaining 18,750 shares are currently exercisable but do not vest within 60&#160;days of March&#160;30, 2022 and would be subject to repurchase upon cessation of continuous service if exercised prior to vesting.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">The percentages are calculated based on 146,664,760 shares outstanding as of March&#160;30, 2022. Shares of common stock issuable upon the settlement of RSUs or exercise of options, in each case which settle or become exercisable within 60&#160;days after March&#160;30, 2022, are deemed outstanding for purposes of computing the percentage ownership of the person holding such RSUs or options, but are not deemed outstanding for computing the percentage ownership of any other person.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_121"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DELINQUENT SECTION 16(a) REPORTS</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of the Board of Directors, our executive officers and persons who beneficially own more than 10% of our outstanding common stock are subject to the reporting requirements of Section&#160;16 of the Exchange Act, as amended, which require them to file reports with respect to their beneficial ownership of the common stock and their transactions in such common stock. Based upon (i)&#160;a review of Forms&#160;3 and&#160;4 and any amendments thereto filed electronically with the SEC during 2021, (ii)&#160;a review of Forms&#160;5 and any amendments thereto filed electronically with the SEC with respect to 2021, and (iii)&#160;written representations that no Form 5&#160;reports were required, we believe that all reporting requirements under Section&#160;16 for such year were met in a timely manner by our directors, executive officers and greater than 10% beneficial owners, except for the following&#58; Mr.&#160;Willoughby filed one Form&#160;4 report late, disclosing one transaction occurring in 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_124"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_127"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Discussion and Analysis</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent in this CD&#38;A to inform our stockholders of the policies and objectives underlying the compensation programs for our executive officers. Accordingly, we will address and analyze the key elements of the compensation provided to our principal executive officer, our principal financial officers during 2021, and our three other most highly compensated executive officers as of December&#160;31, 2021. We refer to these officers as our &#8220;named executive officers.&#8221;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu (1)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung (2)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Operating Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Technical Operations</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott (3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Head of Development</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee (4)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Former Executive Vice President, Chief Financial Officer</font></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Ms.&#160;Duraibabu was promoted to Senior Vice President, Chief Financial Officer effective June&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;McClung was promoted to Executive Vice President, Chief Operating Officer effective November&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Dr.&#160;Schott commenced employment with us on February&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;Lee resigned effective February&#160;1, 2021.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_130"></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Summary</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Business</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious diseases. We plan to deliver on this mission through development of our clinical and preclinical product candidates leveraging our novel science and our in-house manufacturing capabilities. See &#8220;&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Performance Highlights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Compensation Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below for an analysis of how executive compensation was impacted by the attainment of our corporate objectives.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Product Candidates</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical-stage product candidates are&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Isaralgagene civaparvovec, also known as ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, is currently being evaluated in our Phase&#160;1&#47;2 STAAR clinical study, and we have initiated plans for a Phase&#160;3 clinical trial&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SAR445136, our zinc finger nuclease, or ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease is currently being evaluated in our Phase&#160;1&#47;2 PRECIZN-1 clinical study. We are developing SAR445136 with our collaborator Sanofi S.A., or Sanofi, through June&#160;28, 2022, at which time SAR445136 will become a product candidate wholly-owned by Sangamo&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TX200, our wholly-owned Chimeric Antigen Receptor, or CAR, engineered regulatory T cell, or CAR-Treg, cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation, is currently being evaluated in our Phase&#160;1&#47;2 STEADFAST clinical study&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia&#160;A and is the subject of the registrational Phase&#160;3 AFFINE (efficAcy and saFety Factor vIii geNe thErapy) clinical trial. We are developing giroctocogene fitelparvovec with our collaborator Pfizer Inc., or Pfizer.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preclinical development is focused in two innovative priority areas&#58; (i)&#160;CAR-Treg cell therapies for autoimmune disorders, and (ii)&#160;genome engineering for neurological diseases. Indications for our preclinical programs include neurodevelopmental disorders, cancer, inflammatory bowel disease, or IBD, tauopathies and neurodegenerative diseases such as amyotrophic lateral sclerosis, multiple sclerosis, or MS, and Huntington&#8217;s disease, some of which we are developing with our collaborators Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, Novartis Institutes for BioMedical Research, Inc., or Novartis, Pfizer and Takeda Pharmaceutical Company Limited.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our zinc finger, or ZF, technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal to bring our medicines more rapidly to patients. We believe these collaborations reflect the value of our ZF technology platform and will potentially expand </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the addressable markets of our product candidates. To date, we have received approximately $815.0&#160;million in upfront licensing fees, milestone payments and proceeds from sales of our common stock to collaborators and have the right to earn up to $6.7&#160;billion in future milestone payments from our collaborations, in addition to potential product royalties.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Novel Science</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leader in the research and development of zinc finger proteins, or ZFPs, which are abundantly occurring human proteins that have evolved to regulate the genome through interactions with DNA and regulatory proteins. We have developed and optimized a proprietary synthetic ZF technology platform with potential clinical utility in (i)&#160;genome editing and genome regulation, which we refer to together as genome engineering, and (ii)&#160;gene-edited cell therapy, which we refer to as cell therapy.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to translate our differentiated and versatile ZF technology platform to product candidates with best- or first-in-class clinical potential. For example, ZFPs can be engineered to make ZF nucleases, which are proteins that can be used to edit genomes by specifically modifying DNA sequences by knocking in or knocking out select genes. ZFPs can also be engineered to make zinc finger protein transcription factors, or ZFP-TFs, which are proteins that can be used to regulate genomes by selectively increasing or decreasing gene expression.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the process of developing these genome engineering technologies, we have additionally accrued significant scientific, manufacturing and development capabilities, as well as related know-how, that are broadly applicable to the field of gene therapy, which we have used to develop our gene therapy product candidates.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we have also leveraged our ZF technology platform and technologies obtained through acquisitions to become a leader in researching and developing CAR-Treg product candidates for the treatment of autoimmune and inflammatory diseases in broad patient populations, including kidney transplant rejection, MS and IBD. CAR-Tregs are considered to have enhanced suppressive function over polyclonal Tregs due to the antigen-specificity introduced by the CAR.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our In-house Manufacturing</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our in-house manufacturing capacity provides us a competitive advantage. We currently operate an adeno-associated virus, or AAV, manufacturing facility in our Brisbane, California headquarters and cell therapy manufacturing facilities in Brisbane, California and Valbonne, France. Our manufacturing strategy is to provide greater flexibility, quality and control by building a balanced and necessary capacity achieved through our in-house manufacturing and contract manufacturing organization, or CMO, partnerships, investing in manufacturing processes and analytics and developing a strong supply chain.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Performance Highlights</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fabry Disease</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2022, we presented updated preliminary clinical data from the Phase&#160;1&#47;2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, our wholly&#8209;owned gene therapy product candidate for the treatment of Fabry disease at the 18th Annual WORLDSymposium. As of the November&#160;9, 2021 cutoff date&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The four patients in Cohorts&#160;1 and&#160;2 all exhibited above normal &#945;&#8209;Gal A activity, ranging from 3-fold to 15&#8209;fold above mean normal at last measurement.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The two patients in Cohort&#160;1 maintained elevated &#945;&#8209;Gal A activity for one year and are now in the long-term follow-up study. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The first patient in Cohort&#160;3 exhibited &#945;&#8209;Gal A activity within mean normal range by week&#160;2.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Lyso-Gb3 levels remained significantly reduced in the patient who exhibited the highest baseline levels of this biomarker.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The gene therapy candidate continued to be generally well tolerated in the five treated patients.</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sixth patient in the STAAR study, who is the second patient in Cohort&#160;3, was dosed after the cutoff date. We expect to provide updated data in the second half of 2022.</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on the Phase&#160;1&#47;2 data, we have initiated Phase&#160;3 planning.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sickle Cell Disease</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2021, we presented updated preliminary proof-of-concept clinical data from the Phase&#160;1&#47;2 PRECIZN&#8209;1 study of SAR445136, a ZF nuclease gene-edited cell therapy candidate in development with Sanofi, at the 63rd American Society for Hematology Annual Meeting and Exposition 2021, or ASH. As of the September&#160;22, 2021 cutoff date&#58;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">No adverse events related to SAR445136 were reported.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">None of the patients required blood transfusions post engraftment.</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that the next four patients treated in the study will be dosed with a product candidate manufactured using improved methods, which have been shown in internal experiments to increase long-term progenitor cells. We expect to complete dosing of these patients in the third quarter of 2022.</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and Sanofi are collaborating on planning an orderly transition of Sanofi&#8217;s rights and obligations under the program to Sangamo on June&#160;28, 2022, while we explore options to advance the program, including seeking a potential new partner.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia A</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2021, with our collaborator Pfizer, we presented updated follow-up data from the Phase&#160;1&#47;2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, at ASH. As of the October&#160;1, 2021 cutoff date&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">At 104&#160;weeks, the five patients in the highest dose 3e13 vg&#47;kg cohort had mean factor VIII (FVIII) activity of 25.4% via chromogenic clotting assay.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In this cohort, mean annualized bleeding rate was 0.0 in the first year post&#8209;infusion and was 1.4 throughout the total duration of follow&#8209;up. All bleeding events occurred after week&#160;69 post&#8209;infusion. Two patients experienced bleeding events necessitating treatment with exogenous FVIII. No participants in the highest dose cohort had resumed prophylaxis.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Giroctocogene fitelparvovec continued to be generally well-tolerated.</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2022, Pfizer announced that it hopes to obtain agreements from health authorities to resume the AFFINE trial of giroctocogene fitelparvovec and to begin to reopen trial sites in the first half of 2022. This trial was previously paused when some of the patients treated in this trial experienced FVIII activity greater than 150% following treatment. Pfizer has announced that it currently is in the process of submitting a protocol amendment to health authorities in the countries where this trial is being conducted and preparing responses to the U.S. Food and Drug Administration clinical hold. Over 50% of the patients have been enrolled in the Phase&#160;3 AFFINE trial.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renal Transplant Rejection</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2021, the first patient was enrolled (and in March 2022 dosed) in our Phase&#160;1&#47;2 STEADFAST study evaluating TX200, our wholly&#8209;owned autologous HLA-A2 CAR Treg cell therapy product candidate treating patients receiving an HLA-A2 mismatched kidney from a living donor. We expect the second patient in this study to be dosed by the middle of 2022. We continue to open study sites and screen patients.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 2021, we completed and brought online our in-house cell therapy manufacturing facilities at our Brisbane, California headquarters and in our Valbonne, France facilities. We now have these facilities in addition to the in-house AAV manufacturing facilities we brought online in Brisbane in 2020.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Objectives of Our Compensation Program</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on translating groundbreaking science into genomic medicines with the potential to transform people&#8217;s lives using our platform technologies in gene therapy, cell therapy and genome engineering. To achieve this strategic business objective, we emphasize recruiting executives with significant industry or scientific experience, including in the areas of clinical development, medical affairs, product development, commercial planning and research innovation. This is a highly competitive industry, and our success depends upon our ability to attract and retain qualified executives through competitive compensation packages. The Compensation Committee administers the compensation programs for our executive officers with this competitive environment and our need to attract and retain qualified executives in mind.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To this end, the primary objectives of our compensation program are to&#58;</font></div><div style="margin-top:6pt;text-align:center"><img alt="sangamo-2021cdagraphicprim.jpg" src="sangamo-2021cdagraphicprim.jpg" style="height:206px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alignment of Executive Compensation Program with Business Strategy</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology research, development and commercialization require sustained and focused effort over many years and involve a high degree of risk. In order to align stockholder and executive interests, the Compensation Committee is committed to a program that rewards meeting long-term, strategic objectives. Our annual incentive goals are designed to drive achievement of our long-term, strategic business objectives.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee generally believes that a formulaic or purely quantitative approach to executive compensation is not the best way to foster long-term success for us as a clinical-stage biotechnology company that is not yet profitable. Instead, the Compensation Committee sets annual performance objectives on which it believes our executive officers should focus during the year in order to achieve our business goals, including, for 2021, aggressive pre-established clinical, R&#38;D, manufacturing, business and corporate development objectives.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee strives to create a positive relationship between its compensation program and our corporate performance and considers competitive market dynamics, the business environment in which the results were achieved and any unplanned positive or negative events when making compensation decisions. A significant portion of the total compensation opportunity for each of our named executive officers is directly related to performance tied to specific business and strategic objectives as well as stock price performance through the long-term incentive plan.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to assure that the compensation programs for our named executive officers remain competitive with peer companies, accomplish our pay-for-performance objectives, and create rewards for the realization of our long-term strategic objectives, the Compensation Committee works with Aon to obtain the advice and market data needed to ensure that the compensation programs achieve these goals.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key Features of Our Executive Compensation Program</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">What We Do</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">What We Don&#8217;t Do</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#4fddff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#4fddff;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Design executive compensation to align pay with performance</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#4fddff;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Emphasize performance-based compensation, with 100% of CEO&#8217;s cash incentive compensation based on pre-established corporate performance goals</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#4fddff;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Include a &#8220;double-trigger&#8221; change-in-control provision in all equity awards granted to our named executive officers</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#4fddff;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Cap the cash incentive compensation plan payouts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#4fddff;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject our program to independent review by the Compensation Committee&#8217;s independent compensation consultant</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#4fddff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Provide tax gross-ups</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#4fddff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Allow repricing of stock options without stockholder approval</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#4fddff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Offer significant perquisites or personal benefits to our named executive officers</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#4fddff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Allow hedging or pledging of our securities by employees</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#4fddff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Offer a defined benefit pension plan, deferred compensation plan or supplemental executive retirement plan</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Advisory Vote on Executive Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the 2021 annual meeting of stockholders, we conducted our fifth advisory vote on executive compensation. At such meeting, approximately 95% of the votes cast on the advisory vote proposal were supportive of our named executive officer compensation program as disclosed in our 2021 proxy statement.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee reviewed the advisory vote results in the context of our overall compensation philosophy and programs, and based on the level of support, determined that no significant changes to our compensation policies and programs were necessary. The Compensation Committee will continue to consider the results from future stockholder advisory votes on executive compensation and other relevant market developments affecting executive officer compensation in order to determine whether any subsequent changes to our executive compensation programs and policies would be warranted to reflect any stockholder concerns reflected in those advisory votes or to address market developments.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_133"></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">How We Determine Executive Compensation</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Role of the Compensation Committee and Executive Officers</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee assists the Board of Directors in fulfilling its fiduciary responsibilities with respect to the oversight of our affairs in the areas of our compensation plans, policies and programs, especially those regarding executive officers.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee&#8217;s responsibilities include, among other things&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">periodically reviewing and approving a philosophy for compensation of our executive officers&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adopting, amending, terminating and administering the Company&#8217;s compensation plans and programs for our executive officers, including, among others, equity plans, incentive plans, bonus plans, stock purchase plans, severance plans, pension and profit sharing plans and retirement plans&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing, considering and approving compensation programs applicable to non-employee members of the Board of Directors&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing total compensation packages for our executive officers, with the exception of Dr.&#160;Macrae&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and evaluating the performance and leadership of Dr.&#160;Macrae and recommending to the Board his total compensation package&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing with Dr.&#160;Macrae his evaluation of the performance of the executive officers other than himself&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and monitoring management development plans and activities&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing with our Board our succession plan for the CEO and other executive officers&#59; and</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducting risk assessments of our compensation programs.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee does not delegate any of its functions to others in determining executive compensation.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In making executive compensation determinations, the Compensation Committee considers recommendations from Dr.&#160;Macrae as it relates to company-wide policies and for specific leaders, excluding himself. In making his recommendations, Dr.&#160;Macrae receives input from our human resources department. While Dr.&#160;Macrae discusses his recommendations for the other executive officers with the Compensation Committee, he does not participate in the deliberations or determination of his own compensation. Members of our finance, human resources and legal departments regularly attend Compensation Committee meetings.</font></div><div style="margin-top:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Factors Used in Determining Executive Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee sets the compensation of our executive officers at levels that the Compensation Committee determines to be competitive and appropriate for each named executive officer, using the Compensation Committee&#8217;s professional experience and judgment. The Compensation Committee does not use a formulaic approach to setting executive pay, but rather it considers multiple relevant factors, which may vary from year to year. The figure below reflects the factors the Compensation Committee generally considers in determining and approving the amount, form and mix of pay for our named executive officers.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><img alt="sangamo-2021cdagraphicfact.jpg" src="sangamo-2021cdagraphicfact.jpg" style="height:251px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Role of Independent Compensation Consultant</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee retained the services of Aon in order to&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review the peer group selection criteria and specific peer companies,</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assess compensation levels and mix of elements for our executive officers and vice presidents for 2021,</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advise the Compensation Committee on executive compensation and governance trends based on peer group trends and market practices (including severance arrangements), and</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advise the Compensation Committee on compensation programs applicable to our non-employee directors. </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aon also provides the Compensation Committee with comparative market data in connection with setting the compensation for new executives. The Compensation Committee determined that Aon was independent using criteria established by Nasdaq for evaluating the independence of advisors to the Compensation Committee.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparative Analysis</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In establishing the criteria used for peer group selection, the Compensation Committee considers companies at a similar stage of development with comparable organization complexity as well as with a focus on the San Francisco Bay area. These criteria are designed to be aligned with governance best practices, the nature of the work performed at the Company and the skills required for success at the leadership level in running a complex global, pre-commercial life sciences company. The final criteria for 2021, determined by the Compensation Committee in September 2020, were as follows&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">companies that fall within a specific market capitalization range of approximately one-third to three times our market capitalization at the time of the peer evaluation ($500&#160;million to $5.0&#160;billion at the time we selected our 2021 peer group)&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">biopharmaceutical companies in the pre-commercial Phase&#160;2 or Phase&#160;3 stage of development&#59; and</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">companies with 200 to 800 employees.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we prefer companies that are headquartered in core biotechnology hubs, particularly within the San Francisco Bay Area and other California markets, where we both recruit and may lose executive talent. Because the biotechnology industry is a dynamic industry, the comparator group used by the Compensation Committee to measure the competitive positioning of our compensation packages is periodically updated to ensure that companies continue to meet the established criteria. At the time the peer group was established, our 30-day market capitalization was comparable to approximately the 40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of the peers, validating the reasonableness of the peer group.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selected comparable companies for purposes of making compensation decisions for 2021, or the 2021 peer group, were as follows, with new additions to the 2021 peer group in bold&#58;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adverum Biotechnologies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iovance Biotherapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arena Pharmaceuticals</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MacroGenics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arrowhead Pharmaceuticals</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirati Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assembly Biosciences</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyoKardia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atara Biotherapeutics</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nektar Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">bluebird bio</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NGM Biopharmaceuticals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BridgeBio Pharma</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Odonate Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cytokinetics</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGENXBIO</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denali Therapeutics</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revance Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Editas Medicine</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultragenyx Pharmaceutical</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fate Therapeutics</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xencor</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellia Therapeutics</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following companies were part of the selected comparable companies for purposes of making compensation decisions for 2020 but were excluded from the 2021 peer group as they no longer complied with the updated selection criteria&#58; Acceleron Pharma, Aimmune Therapeutics, AnaptysBio, Audentes Therapeutics, ChemoCentryx, CRISPR Therapeutics and Spark Therapeutics.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Comparative Data</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When setting pay, the Compensation Committee examines the market data independently derived by Aon from the peer group including a range of pay across the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the 75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentiles for each element of pay and for overall total compensation. We do not have a set formula or benchmark for pay. Instead, the Compensation Committee references the market data as one input before making position-specific compensation decisions. We generally seek to manage compensation within the peer group range, if warranted by performance and other factors the Compensation Committee considers relevant in making specific pay decisions. A specific executive officer may be paid below or above the 50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of the range based on individual performance, experience, skills and the importance of the executive&#8217;s position to us. The Compensation Committee considers this approach to determining pay appropriate given that we operate in the highly competitive San Francisco Bay Area talent market, where the particularly intense competition for executive talent requires us to ensure that our overall compensation program is competitive to attract and retain strong leadership for our long-term success based on performance.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_136"></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Design of the Executive Compensation Program and Key Components</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Target Total Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the development and commercialization of biotechnology products involve a high degree of risk. The Compensation Committee regularly evaluates the relative importance of equity and cash components of total compensation when determining the level and structure of annual pay based on the business priorities established by the Board of Directors. Target total compensation for 2021, as shown below for Dr.&#160;Macrae, reflects annual base salary, annual target cash incentive compensation and the grant date fair value of stock options and RSUs granted during the year (as such stock options and RSUs are reported in the Summary Compensation Table). The Compensation Committee at least annually assesses the allocation of equity awards between stock options and RSUs in connection with a review of our outstanding shares, our stock price, comparative market data of peer companies and the retention value of the program.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:center"><img alt="sangamo-2022cdagraphicceo2.jpg" src="sangamo-2022cdagraphicceo2.jpg" style="height:384px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key Elements of Our Executive Compensation Program</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1d5389;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Component</font></td><td colspan="3" style="background-color:#1d5389;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Features</font></td><td colspan="3" style="background-color:#1d5389;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purpose</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Salary</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Fixed cash compensation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Annual increases are not guaranteed</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Amounts are reviewed and determined annually (or at the time of a change in the executive&#8217;s title or position during the year)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Amounts determined based on market data, individual performance, experience, skills and the importance of the executive&#8217;s position</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Enables us to attract and retain skilled and experienced executives and to provide a level of economic security for executives from year to year</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Provides fixed level of compensation that is competitive within our industry and geographic area</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Incentive Compensation</font></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Cash compensation under the Sangamo Therapeutics, Inc. Amended and Restated Incentive Compensation Plan, or the Incentive Plan, which is dependent upon achievement of performance objectives</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Target amounts are reviewed and determined annually (or at the time of a change in the executive&#8217;s title or position during the year) and expressed as a percentage of base salary</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Actual amounts paid are based on the extent performance objectives are attained as determined by the Compensation Committee</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Provides executive officers cash incentive compensation tied to our achievement of pre-defined annual performance goals that support our long-term business strategy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Aligns pay structure and mix with, and ensures that our total cash compensation is within, competitive norms within the peer group and more broadly in the sector</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity Compensation</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Generally in the form of stock options and&#47;or RSUs which are &#8220;at-risk&#8221; because the realized value is dependent upon our stock price. We generally allocate total equity value in a 2&#58;1 ratio between stock options and RSUs. Vesting schedules have been devised with a goal of retention and long-term accountability</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;The exercise price for stock options is equal to the closing price of our stock on the option grant date. For stock options granted in 2021, 25% of the option shares vest and become exercisable on the one-year anniversary of the option grant date and the remaining option shares vest and become exercisable in 36 equal monthly installments over the 36-month period measured from the first anniversary of the option grant date, subject to continuous service through each applicable vesting date</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;Each RSU provides the recipient with one share of our common stock at a designated issue date following the vesting of that unit, without the payment of an exercise price or other cash consideration for the issued share. For RSUs granted in 2021, 1&#47;3rd of the shares vest in three equal annual installments over the three-year period measured from the grant date, subject to continuous service through each applicable vesting date</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Executives are eligible for equity awards in connection with annual performance reviews and at time of hire</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Provides long-term incentives that align the interests of our work force with the achievement of our long-term vision to develop and commercialize pharmaceutical products which occurs over time</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;Given the time periods involved in biotechnology development, we believe that long-term incentives are critical to our success, as they aid in retention, mitigate short-term risk taking and instill a long-term focus on maximizing stockholder value</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;We believe that a mix of stock options and RSUs reinforces the long-term nature of our business and alignment with our stockholders by rewarding for improvements in stock price over a period of time&#59; we issue stock options to reward for future performance and appreciation while providing RSUs to manage the natural market volatilities of a clinical-stage company, provide retention incentives during the vesting period and reinforce a culture of ownership</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;By granting RSUs, we can also reduce the dilutive effect of the equity incentive awards, which benefits our stockholders over time</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_139"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Compensation Decisions</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Base Salary</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine increases to the base salary of all employees annually as part of our annual performance review process. We determine the level of increase based on performance, experience in the role, affordability to the Company and the overall market trends in the competitive talent market where we compete globally, The Compensation Committee typically approves an overall base pay increase budget that is part of the annual operating plan and applies across the Company.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we conducted annual performance reviews for 2020 for the named executive officers. In early 2021, the Compensation Committee considered these reviews, role criticality and advice from Aon and comparative data from our peer group and determined to increase base salaries as set forth below. The Compensation Committee specifically considered Dr.&#160;Macrae&#8217;s responsibility for the Company&#8217;s achievement of its corporate objectives&#59; Mr.&#160;McClung&#8217;s responsibility for the Company&#8217;s achievement of its corporate objectives as well as his evolving leadership role of multiple functions within the Company&#59; and Dr.&#160;Ramelmeier&#8217;s leadership in growing our technical operations capacities and skills, his role in leading the successful completion and articulation of the manufacturing roadmap, and his oversight of our successful global integration of manufacturing and R&#38;D priorities and programs. In general, the base salaries of our named executive officers for 2021 were between the 50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentiles of the market data derived from the peer group. In December 2020, Ms.&#160;Duraibabu was not yet an executive officer and Dr.&#160;Schott was not yet an employee, so they did not take part in the 2020 annual performance review by the Compensation Committee.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.911%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Annual</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base&#160;Salary&#160;($)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Annual</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base&#160;Salary&#160;($)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent<br>Increase</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae (1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,615&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,797&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu (2)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung (3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier (4)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott (5)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee (6)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Dr.&#160;Macrae&#8217;s base salary was positioned near the 75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> percentile of the peer group&#59; accordingly, his increase was capped at 1%.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Ms.&#160;Duraibabu was promoted to Senior Vice President, Chief Financial Officer effective June&#160;1, 2021 and did not serve as an executive officer of Sangamo during any portion of 2020. Her base salary was determined by peer group market data based on the job profile, individual experience and expected contributions into the role.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;McClung was promoted to Executive Vice President, Chief Operating Officer effective November&#160;1, 2021. His initial base salary for 2021 was $419,150, which represented a 1% increase over his 2020 initial base salary. He also received a base salary increase in 2021 for taking on broader responsibilities at the Company during 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:7.52pt">Dr.&#160;Ramelmeier did not receive a base salary increase in 2021 due to a change in his scope of job responsibilities in 2020 and due to his receipt of a special one-time retention bonus in 2019.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Dr.&#160;Schott commenced employment with us on February&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;Lee resigned effective February&#160;1, 2021.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Dr.&#160;Schott&#8217;s commencement of employment with the Company, after taking into consideration his compensation at his prior employer, competitive positioning based on the market data derived by Aon from the peer group that ranges from the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the 75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentiles and internal positioning relative to the Company&#8217;s other executive officers, the Compensation Committee determined that Dr.&#160;Schott&#8217;s annual base salary would be $440,000.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Cash Incentive Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we adopted a 2021 Cash Incentive Compensation Program under the Incentive Plan that provides for annual cash incentive compensation to reward executive officers based on our achievement of pre-established corporate goals and, for all executive officers other than Dr.&#160;Macrae, Mr.&#160;McClung and Dr.&#160;Ramelmeier, their achievement of individual performance goals. The program included several aggressive goals to encourage our employees to achieve more than target performance. In December 2020, the Board approved our 2021 corporate goals and weightings, which are summarized in the chart below.</font></div><div style="margin-top:6pt;text-align:center"><img alt="sangamo-2022cdagraphiccash.jpg" src="sangamo-2022cdagraphiccash.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Achievement of Corporate Objectives</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Board determined that our corporate objectives were attained at 108% based on the Company&#8217;s 2021 achievements, as further described below. The Board did not adjust the corporate objectives to reflect impacts to our business or operations of the global COVID-19 pandemic.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1d5389;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Objective &#38; Weighting</font></td><td colspan="3" style="background-color:#1d5389;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Achievements</font></td><td colspan="3" style="background-color:#1d5389;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Achievement Percentage</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DEVELOPMENT&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accelerate </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">wholly-owned product development with at least two development-stage products successfully ongoing at end of 2021. (30%)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Isaralgagene civaparvovec</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved at target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; number of sites activated and in start-up phase&#59; number of subjects screened and patients dosed&#59; encouraging safety and tolerability study across all cohorts&#59; encouraging biomarker data shared from two cohorts&#59; observation study initiated and CRO selected&#59; initiated Phase 3 trial planning and Phase 3 draft trial design agreed upon&#59; productive CMC Type C meeting held with FDA&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved over target&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">accelerated Phase 3 trial planning&#59; team leadership, culture and effectiveness&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved under target&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">slower patient recruitment&#59; dose escalation timeline.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TX200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved at target&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">number of sites activated and in start-up phase&#59; approvals to dose first patient&#59; tech transfer to CMO and backup&#59; number of patients screened&#59; first patient enrolled, underwent leukapheresis and transplanted&#59; successful manufacturer of first dose&#59; second patient enrolled. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved over target&#58; s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">tudy initiation timeline&#59; stronger partnership between research and development. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved under target&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">manufacturing challenges&#59; dosing timelines.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Other achievements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; completion of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> packages for allogeneic CAR-Treg program&#59; successful scientific advice meetings with European regulators&#59; termination of off-strategy gene therapy programs&#59; close-out of certain long term follow up and legacy studies.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1d5389;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Objective &#38; Weighting</font></td><td colspan="3" style="background-color:#1d5389;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Achievements</font></td><td colspan="3" style="background-color:#1d5389;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Achievement Percentage</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PARTNERSHIPS&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deliver for partners. Execute across all collaborations. Achieve milestone payments. Assess new strategic collaborations. (15%) </font></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved at target&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Pfizer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; Updated Phase 1&#47;2 ALTA data presented&#59; Phase 3 AFFINE lead-in study enrollment completed, and Phase&#160;3 study over 50% enrolled&#59; AFFINE protocol amendments in progress.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Sanofi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; Phase 1&#47;2 PRECIZN-1 study advanced&#59; received fast track and orphan designation&#59; presented data at ASH&#59; obtained manufacturing guidance from FDA in preparation for further studies. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Biogen and Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; all programs progressing productively&#59; presentations of preclinical data.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">New potential partners</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; productive discussions ongoing with various potential partners.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved over target&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> extremely high scores from collaboration survey conducted by independent third party&#59; active pursuit of novel capsids.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved under target&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">projected milestone payments delayed due to partner&#8217;s decision not to submit IND yet.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RESEARCH&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Progress new and existing CAR-Treg and genome engineering programs. Advance allogenic program and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> gene editing program. Optimize and advance zinc finger platform. (25%)</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved at target&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">advanced three preclinical CAR-Treg programs and platform upgrades, including positive analyst coverage, acceleration of timelines, tech transfer, delivery of preliminary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> data and, improved yields&#59; advanced four preclinical wholly-owned CNS programs, including accelerated timelines and encouraging FDA feedback&#59; produced target number of new zinc finger constructs to support all programs&#59; deployed zinc finger process and platform improvements, including new synthetic cell-free gene synthesis process enabling robotic implementation, expanded throughput and accelerated timelines&#59; advanced zinc finger base editor program yielding target percentage of editing of gene target.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved over target&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> re-engineered Scientific Advisory Board formats&#59; highly accelerated undisclosed discovery project&#59; achieved preclinical proof of concept for undisclosed discovery project&#59; papers published&#59; activator platform successfully applied&#59; increase in zinc finger construct production&#59; optimized resource tracking.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved under target&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> timeline delay to certain preclinical programs&#59; delay in initiation of certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> studies.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">TECH OPS&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Deliver on-time manufacturing and platform capabilities to support our pipeline and partnerships. (20%)</font></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved at target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; brought in-house cell therapy manufacturing facilities online in Brisbane and Valbonne&#59; completed operational readiness runs in Brisbane for cell banks and vectors&#59; Phase 3 tech transfer in progress for isaralgagene civaparvovec program&#59; vector manufacturing progress on CNS programs&#59; supply chain infrastructure expanded to support isaralgagene civaparvovec and TX200 programs&#59; AAV helpers ready for GMP production&#59; iPSC research cell bank complete.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved over target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; successful manufacture of first TX200 study dose&#59; accelerated timeline for bringing Brisbane cell therapy facility online&#59; development of alternative formulas for certain programs improving cost of goods and increased doses per batch.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved under target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#58; COVID-19 supply chain impacts to manufacturing timelines&#59; delays to certain cell therapy manufacturing timelines.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#404040;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CORPORATE&#58;</font></div><div><font style="color:#404040;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Build a sustainable, well-financed and high performing business. (10%)</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved at target&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> managed resources to end year with cash in target range&#59; launched new investor communications enabling extended outreach&#59; held target investor meetings and attended target conferences&#59; achieved new analyst coverage&#59; launched new corporate and scientific communications, brand refresh and new websites resulting in increased engagement and traffic&#59; completed two employee engagement surveys with high response rates&#59; successful COVID-19 communications and compliance&#59; successful leadership development sessions&#59; optimized organization structures&#59; launched new DEI strategy and hiring protocols and new employee resource groups&#59; successful launch of new procurement systems enabling cost savings&#59; brought new labs online&#59; negotiated new office leases.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Achieved over target&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> high overall employee engagement scores above industry benchmark&#59; launched new company values ahead of schedule&#59; enhanced team leadership in hybrid work environments&#59; achieved 100% onsite employee COVID-19 vaccination ahead of schedule.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#404040;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL&#58; 100%</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</font></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in January 2022, the Compensation Committee approved individual achievement percentages for Ms.&#160;Duraibabu and Dr.&#160;Schott based on Dr.&#160;Macrae&#8217;s assessment of and recommendations regarding their accomplishments against pre-established individual objectives, as further described below. At the start of the year, Dr.&#160;Macrae recommends individual goals for each leader, which are approved by the Compensation Committee. The goals are designed to align functional and cross-functional activities with the Company&#8217;s business strategy to reward achievement. The 2021 individual </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">goals for Ms.&#160;Duraibabu and Dr.&#160;Schott include those listed below. These specific goals were in addition to the general responsibilities each officer had for managing his or her respective functional operational area. Based on the recommendation of Dr.&#160;Macrae, as well as the observations by Compensation Committee members of these executive officers and its own assessment of each individual&#8217;s effectiveness, the Compensation Committee determined the level of achievement of each named executive officer&#8217;s individual performance goals as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ms.&#160;Duraibabu &#8212; The Compensation Committee determined that Ms.&#160;Duraibabu achieved 100% of her individual objectives. Ms.&#160;Duraibabu&#8217;s key accomplishments in 2021 included&#58; being promoted into the CFO role in June 2021, assuming expanded leadership responsibilities at an enterprise level and representing the Company with external stakeholders. Ms.&#160;Duraibabu&#8217;s individual objectives were not modified following her promotion.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dr.&#160;Schott &#8212; The Compensation Committee determined that Dr.&#160;Schott achieved 100% of his individual objectives. Dr.&#160;Schott&#8217;s key accomplishments in 2021 included&#58; providing direction and leadership on our key programs, and evolving the development organization to be seen as a proactive partner for cross-functional teams. Dr.&#160;Schott commenced employment with us in February 2021.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the allocation of the cash incentive compensation between corporate and individual objectives, as well as target and actual cash incentive compensation for our named executive officers for 2021&#58;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance Objective (1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br>(%)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Individual<br>(%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Base Salary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount&#160;($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual<br>Amount&#160;($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual as a<br>%&#160;of&#160;Target</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEO</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,168&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,223&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu (2)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior VP</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 - 35%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,762&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,439&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung (3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive VP</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,734&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive VP</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,712&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott (4)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior VP</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,680&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,748&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee (5)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive VP</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The CEO and executive vice president&#8217;s cash incentive compensation opportunity was based solely on corporate performance and the senior vice presidents&#8217; cash incentive compensation opportunity was allocated between corporate and individual performance. The Compensation Committee is working to align the leadership team to the broader achievement of corporate performance versus a focus on individual performance. As such, the executive vice presidents were moved to a cash incentive plan based solely on corporate performance in 2021 and all executive officers will be moved to a cash incentive plan based solely on performance in 2022.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Ms. Duraibabu&#8217;s target and actual cash incentive compensation amounts were prorated to reflect her promotion to Senior Vice President, Chief Financial Officer effective June&#160;1, 2021 and her cash incentive compensation as a percentage of her base salary was increased from 30% to 35%.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;McClung&#8217;s target and actual cash incentive compensation amounts were prorated to reflect his promotion to Executive Vice President, Chief Operating Officer effective November&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Dr.&#160;Schott&#8217;s target and actual cash incentive compensation amounts were prorated to reflect that he commenced employment with us on February&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;Lee resigned effective February&#160;1, 2021 and was not eligible for a bonus for 2021.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current practice is to make equity grants at the beginning of the fiscal year after our operating plan has been approved by the Board of Directors and the performance in the prior fiscal year completed. Accordingly, the Compensation Committee approved the grant of stock options and RSUs to Dr.&#160;Macrae, Ms.&#160;Duraibabu, Mr.&#160;McClung and Dr.&#160;Ramelmeier in February 2021. In connection with Ms.&#160;Duraibabu&#8217;s promotion to Senior Vice President, Chief Financial Officer effective June&#160;1, 2021, the Compensation Committee approved an additional stock option grant to acquire 15,000&#160;shares of common stock and an additional RSU covering 7,500&#160;shares of common stock. See &#8220;&#8212;Grants of Plan-Based Awards.&#8221;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Compensation Committee established guidelines for equity compensation targeting the 50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of our peer companies based on an equal value blend of the grant date value and percentage of company market data provided by Aon. Awards were subsequently adjusted for each executive officer based on performance rating. The Compensation Committee also assessed the allocation of equity awards between stock options and RSUs in connection with a review of our outstanding shares, our stock price and comparative market data of peer companies with a view to managing overall dilution.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Dr.&#160;Schott&#8217;s commencement of employment with the Company in February 2021, after taking into consideration competitive positioning based on the market data derived by Aon from the peer group, internal peer comparisons and the compensation required to attract him to the role with the Company, Dr.&#160;Schott was granted a stock option to acquire 80,000&#160;shares of common stock with an exercise price equal to the closing price per share on the grant date. In addition, Dr.&#160;Schott was granted an RSU covering 40,000&#160;shares of common stock.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Elements of Executive Compensation Program</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining elements of our executive compensation program, like our broader employee compensation programs, are intended to make our overall compensation program competitive with those of our peer companies and all of the remaining elements of our executive compensation program (401(k) Plan&#59; Medical, Dental, and Vision Plans&#59; Life and Disability Insurance&#59; and the 2020&#160;ESPP) are available to all of our employees.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Dr.&#160;Schott was granted relocation assistance of $75,000 in connection with the commencement of his employment with the Company in February 2021. If Dr. Schott&#8217;s employment with us terminated within one year of his appointment, either by the Company for cause or by him without good reason, Dr.&#160;Schott&#8217;s relocation assistance was subject to repayment.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Dr.&#160;Ramelmeier was granted a $100,000 one-time special retention bonus to recognize the critical importance of his leadership and experience in advancing our manufacturing capabilities, especially as the Company works toward completing the buildout of its manufacturing facilities in Brisbane and Valbonne. Dr.&#160;Ramelmeier&#8217;s special cash bonus was paid in four equal installments between July 2020 and December 2021.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_142"></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Compensation Information</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Severance Arrangements</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Compensation Committee adopted an Executive Severance Plan, or the Severance Plan, to provide severance benefits to certain of our executive officers and other key employees, including our named executive officers, whose employment terminates under certain prescribed circumstances. In February 2019, the Compensation Committee approved an Amended and Restated Executive Severance Plan, or the Amended Severance Plan, to increase certain severance payments, as described below under &#8220;&#8212;Employment Contracts and Separation and Change in Control Arrangements&#8212;Executive Severance Plan.&#8221; The Amended Severance Plan provides financial protection against the potential loss of employment in designated circumstances, which the Compensation Committee believes will allow the executives to focus attention on the best interests of the stockholders, without undue concern as to an executive&#8217;s own financial situation. The Compensation Committee has been advised by its independent compensation consultant that the benefits provided under these agreements are consistent with peer company and broader market practices and are fair and reasonable.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax and Accounting Effects of Executive Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;162(m) of the Code, or Section 162(m), compensation paid to each of the Company&#8217;s &#8220;covered employees&#8221; that exceeds $1&#160;million per taxable year is generally non-deductible unless the compensation qualifies for (i)&#160;certain grandfathered exceptions (including the &#8220;performance-based compensation&#8221; exception) for certain compensation paid pursuant to a written binding contract in effect on November&#160;2, 2017 and not materially modified on or after such date or (ii)&#160;the reliance period exception for certain compensation paid by corporations that became publicly held on or before December&#160;20, 2019.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Compensation Committee will continue to consider tax implications as one factor in determining executive compensation, the Compensation Committee also looks at other factors in making its decisions and retains the flexibility to provide compensation for the Company&#8217;s named executive officers in a manner consistent with the goals of the Company&#8217;s executive compensation program and the best interests of the Company and its stockholders, which may include providing for compensation that is not deductible by the Company due to the deduction limit under Section&#160;162(m). The Compensation Committee also retains the flexibility to modify compensation that was initially intended to be exempt from the deduction limit under Section&#160;162(m) if it determines that such modifications are consistent with the Company&#8217;s business needs.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee also considers the impact of Section&#160;409A of the Code, and in general, our executive plans and programs are designed to comply with the requirements of that section so as to avoid possible adverse tax consequences that may result from non-compliance.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting impact of our compensation programs is one of many factors that the Compensation Committee considers in determining the structure and size of our executive compensation programs. In general, the Company accounts for equity compensation paid to our employees under ASC&#160;718, which requires us to estimate and record an expense over the service period of the equity award, and our cash compensation is recorded as an expense at the time the obligation is accrued.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Grant Timing</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards are generally granted to employees, including executives, when they are hired, and employees are eligible for additional equity awards in connection with annual performance reviews each year. During 2021, equity awards granted to new employees were granted on the second Friday of each month (or if such day was not a trading day, the immediately preceding trading day) immediately following the month of the employee&#8217;s hire date&#59; and with respect to annual equity awards granted to existing employees, awards were granted on the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of February (or if such day was not a trading </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day, the immediately preceding trading day), provided the Compensation Committee approved the terms of the grants before such date. In February 2022, the Compensation Committee determined that, with respect to equity awards granted to new employees, such awards will be granted on the 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of the month immediately following the month of the employee&#8217;s hire date (or if such day is not a trading day, the immediately preceding trading day) for all new employees whose hire date is prior to this grant date. Because these grant dates are pre-established, the timing of the release of material non-public information does not affect the grant dates for equity awards, and Sangamo does not time the release of material non-public information based on equity award grant dates.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_145"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain summary information for the years ended December&#160;31, 2021, 2020 and 2019, when applicable, concerning the compensation earned by (i)&#160;our President and Chief Executive Officer, (ii)&#160;our Senior Vice President, Chief Financial Officer, (iii)&#160;our three other most highly compensated executive officers who were serving as executive officers at the end of 2021, (iv)&#160;our former Executive Vice President, Chief Financial Officer. These individuals are referred to throughout this Proxy Statement as our &#8220;named executive officers.&#8221; We have omitted certain rows from the table when there is no disclosure required of the compensation for the named executive officer for that fiscal year.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary<br>($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus<br>($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br>Awards<br>($) (1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Awards<br>($) (2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br>Equity<br>Incentive<br>Plan<br>Compensation<br>($) (3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other<br>Compensation<br>($) (4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br>($)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(f)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(g)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(i)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(j)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">688,615&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,548,416&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,047,009&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">446,223&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,554&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,735,817&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">President and</font></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">681,797&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,147,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,488,746&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">511,348&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,639&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,835,030&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661,939&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">571,148&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,274,230&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436,880&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,358&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,986,555&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362,586&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242,063&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">319,108&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127,439&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,554&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,056,750&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior Vice President,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chief Financial Officer (5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D. Mark McClung</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427,673&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591,728&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184,734&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,554&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,657,289&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Executive Vice President,</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276,667&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">916,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,187,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136,245&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,093&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,671,225&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chief Operating Officer (6)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">416,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591,728&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179,712&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,554&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,690,594&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Executive Vice President,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">416,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">485,221&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203,840&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,639&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,534,700&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Technical Operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382,965&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112,875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">449,453&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153,608&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,639&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,104,540&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Robert J. Schott</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397,692&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">723,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150,748&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,899,465&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior Vice President,</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Head of Development (9)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sung H. Lee</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43,826&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,130&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47,956&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Former Executive Vice President,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438,262&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">340,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443,316&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,639&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,442,217&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chief Financial Officer (10)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">452,813&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,757,679&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47,415&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">273&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,530,680&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The amounts in column (e)&#160;reflect the aggregate grant date fair value of the RSUs awarded to the named executive officer for the applicable year, calculated in accordance with ASC&#160;718, without taking into account any estimated forfeitures. The grant date fair value of the RSUs is measured based on the closing price of the underlying common stock on the date of grant.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The amounts in column (f)&#160;represent the aggregate grant date fair value of the stock option grants for each indicated year in accordance with ASC&#160;718 using the Black-Scholes option valuation model and without taking into account any estimated forfeitures. The assumptions used in the calculation of such grant date fair values are described in Note&#160;9 of the Notes to Consolidated Financial Statements included in the 2021 Form 10-K.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The amounts in column (g)&#160;reflect the cash bonus awards made to the named executive officer under the Cash Incentive Compensation Program under the Incentive Plan for the indicated year.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The amounts in column (i)&#160;for 2021 include matching payments of $4,000 made to each named executive officer under our 401(k) Plan, a qualified deferred compensation plan under Section&#160;401(k) of the Code&#59; life insurance premiums paid by us on behalf of the named executive officer in the amount of $1,554 for each of Dr.&#160;Macrae, Ms.&#160;Duraibabu, Mr.&#160;McClung and Dr.&#160;Ramelmeier, $1,425 for Dr.&#160;Schott and $130 for Mr.&#160;Lee&#59; and relocation assistance of $75,000 for Dr.&#160;Schott.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Ms.&#160;Duraibabu was promoted to the position of Senior Vice President, Chief Financial Officer effective June&#160;1, 2021. Ms.&#160;Duraibabu was hired in March 2019 as our Vice President, Finance and did not serve as an executive officer of Sangamo during any portion of 2019 or 2020.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Mr.&#160;McClung was promoted to the position of Executive Vice President, Chief Operating Officer November&#160;1, 2021. Mr.&#160;McClung was appointed as our Executive Vice President, Chief Business Officer effective May&#160;1, 2020 did not serve as an executive officer of Sangamo during any portion of 2019.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists of a sign-on bonus.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In December 2019, the Compensation Committee approved a one-time special retention bonus of $100,000 to be paid to Dr.&#160;Ramelmeier in four equal payments of $25,000 in July 2020, December 2020, July 2021 and December 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Dr.&#160;Schott was appointed as our Senior Vice President, Head of Development effective February&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Mr.&#160;Lee was appointed as our Executive Vice President, Chief Financial Officer effective October&#160;31, 2019 and resigned effective February&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Consists of Mr.&#160;Lee&#8217;s annual incentive cash compensation under the Incentive Plan paid pursuant to the terms of his consulting agreement under which he agreed to provide consulting services to us through February&#160;26, 2021 following his resignation effective February&#160;1, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Consists of a sign-on bonus.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_148"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants of Plan-Based Awards</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows for the fiscal year ended December&#160;31, 2021, certain information regarding grants of plan-based awards to our named executive officers. Mr.&#160;Lee has been omitted from this table since he resigned from his position as Executive Vice President, Chief Financial Officer effective February&#160;1, 2021 and received no grants for 2021.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.370%"></td><td style="width:0.1%"></td></tr><tr style="height:56pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated&#160;Future</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payouts&#160;Under</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Equity</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Incentive Plan Awards</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">All<br>Other<br>Stock<br>Awards&#58;<br>Number<br>of<br>Shares<br>of Stock<br>or Units<br>(#) (2)</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">All Other<br>Option<br>Awards&#58;<br>Number&#160;of<br>Securities<br>Underlying<br>Options<br>(#) (3)</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise<br>or Base<br>Price of<br>Option&#160;or<br>Stock<br>Awards<br>($&#47;Sh)</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grant<br>Date<br>Fair&#160;Value<br>of Stock<br>and<br>Option<br>Awards<br>($) (4)</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Award Type</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grant<br>Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approval<br>Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Target<br>($) (1)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum<br>($) (1)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(j)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(k)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(l)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(m)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Cash</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413,168&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619,752&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual RSU Grant</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;09&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548,416&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Option Grant</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;09&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276,750&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,047,009&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Cash</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,762&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,643&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual RSU Grant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;09&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,750&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153,863&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Option Grant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;09&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,407&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promotion RSU Grant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;11&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">05&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,200&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promotion Option Grant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;11&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">05&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.76&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,701&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">D. Mark McClung</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Cash</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256,575&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual RSU Grant</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;09&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Option Grant</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;09&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591,728&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual&#160;Cash</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,400&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual RSU Grant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;09&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Option Grant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;09&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591,728&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Robert J. Schott</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual&#160;Cash</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,680&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,520&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual RSU Grant</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;12&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01&#47;06&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Option Grant</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;12&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01&#47;06&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The dollar amounts represent the target and maximum amounts of each named executive officer&#8217;s potential annual cash bonus award for the year ended December&#160;31, 2021 pursuant to the 2021 Cash Incentive Compensation Program under the Incentive Plan. In Dr.&#160;Schott&#8217;s case, the amounts reflect proration as he commenced employment in May 2020 and in Ms.&#160;Duraibabu&#8217;s case, the amounts reflect proration due to her promotion to Senior Vice President, Chief Financial Officer effective June&#160;1, 2021. The amount shown as target reflects the target payment level if Sangamo and each individual had achieved 100% of the corporate and individual performance goals established pursuant to the Incentive Plan. Each of Ms.&#160;Duraibabu&#8217;s and Dr.&#160;Schott&#8217;s target bonuses were allocated between corporate and individual performance (80% to 20%, respectively), and Dr.&#160;Macrae&#8217;s, Mr.&#160;McClung&#8217;s and Dr.&#160;Ramelmeier&#8217;s target bonuses were allocated 100% to corporate performance. The Compensation Committee determines the level of attainment of the corporate performance objectives following the end of the performance period. The amount shown as maximum reflects the payment level pursuant to the 2021 Cash Incentive Compensation Program if Sangamo had achieved a 150% corporate performance percentage and if Ms.&#160;Duraibabu and Dr.&#160;Schott had each achieved a 150% individual performance percentage, which were the maximum percentages allowed for the corporate and individual performance percentages. Actual payouts differed based on the actual performance objectives achieved. The actual cash bonus award earned for the year ended December&#160;31, 2021 pursuant to the 2021 Cash Incentive Compensation Program for each named executive officer is set forth in the Summary Compensation Table above. As such, the amounts set forth in these columns do not represent additional compensation earned by the named executive officers for the year ended December&#160;31, 2021. For more information regarding the 2021&#160;Cash Incentive Compensation Program, see &#8220;&#8212;Compensation Discussion and Analysis&#8212;2021&#160;Compensation Decisions&#8212;2021&#160;Cash Incentive Compensation&#8221; above and &#8220;&#8212;Employment Agreements and Compensation Arrangements&#8212;Annual Cash Bonus Awards&#8221; below.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The reported RSU was granted under the 2018&#160;Plan and will vest and become exercisable in accordance with the following schedule&#58; 1&#47;3rd of the shares vest in three equal annual installments over the three-year period measured from the grant date, subject to the grantee&#8217;s continuous service through each applicable vesting date.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The reported option was granted under the 2018&#160;Plan and will vest and become exercisable in accordance with the following schedule&#58; 25% of the option shares will vest and become exercisable on the one year anniversary of the option grant date and the remaining option shares will vest and become exercisable in 36&#160;equal monthly installments over the 36-month period measured from the first anniversary of the option grant date, subject to the optionee&#8217;s continuous service through each applicable vesting date.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:7.52pt">Represents the grant date fair value of such stock option and RSU as determined in accordance with ASC&#160;718. The grant date fair value of the RSUs is measured based on the closing price of the underlying common stock on the date of grant. The assumptions used in the calculation of the grant date fair values of stock options using the Black-Scholes option valuation model are included in Note&#160;9 of the Notes to Consolidated Financial Statements in the 2021 Form 10-K.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_151"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements and Compensation Arrangements</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Agreements</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our named executive officers has entered into a written employment agreement with our company. For a description of these employment agreements, please see the section of this Proxy Statement under the heading &#8220;&#8212;Employment Contracts and Separation and Change in Control Arrangements&#8221; below.</font></div><div style="margin-top:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Cash Bonus Awards</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Compensation Committee of the Board adopted the Incentive Plan, which amended and restated the prior plan adopted in 2012. The Incentive Plan is a performance-based cash incentive program for our eligible employees, including our executive officers. Under the Incentive Plan, unless the Compensation Committee determines otherwise, each performance period is coincident with the calendar year. The Compensation Committee establishes the specific corporate objectives and&#47;or individual objectives that must be attained in order for Incentive Plan participants to receive a bonus for that performance period. For each performance and individual objective, the Compensation Committee may set threshold and target levels of attainment. The Compensation Committee will then establish for each participant dollar levels for the bonus to which he or she may become entitled for that performance period based on the level at which the corporate objectives and&#47;or individual objectives are actually attained.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance objectives established under the Incentive Plan are based on one or more of the following criteria&#58; (i)&#160;revenue, organic revenue, net sales, or new-product revenue, (ii)&#160;achievement of specified milestones in the discovery and development of the Company&#8217;s technology or of one or more of the Company&#8217;s products, (iii)&#160;achievement of specified milestones in the commercialization of one or more of the Company&#8217;s products, (iv)&#160;achievement of specified milestones in the manufacturing of one or more of the Company&#8217;s products, (v)&#160;expense targets, (vi)&#160;share price, (vii)&#160;total stockholder return, (viii)&#160;earnings per share, (ix)&#160;operating margin, (x)&#160;gross margin, (xi)&#160;return measures (including, but not limited to, return on assets, capital, equity, or sales), (xii) productivity ratios, (xiii)&#160;operating income, (xiv)&#160;net operating profit, (xv)&#160;net earnings or net income (before or after taxes), (xvi) cash flow (including, but not limited to, operating cash flow, free cash flow and cash flow return on capital), (xvii) earnings before or after interest, taxes, depreciation, amortization and&#47;or stock-based compensation expense, (xviii)&#160;economic value added, (xix)&#160;market share, (xx)&#160;working capital targets, (xxi)&#160;achievement of specified milestones relating to corporate partnerships, collaborations, license transactions, distribution arrangements, mergers, acquisitions, dispositions or similar business transactions, (xxii)&#160;employee retention and recruiting and human resources management, and (xxiii)&#160;other corporate performance criteria approved by the Compensation Committee.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual performance objectives established under the Incentive Plan are based on one or more of the following criteria&#58; (i)&#160;the participant&#8217;s contribution toward the achievement of a specific corporate objective, (ii)&#160;the contribution of the business unit or division supervised by the participant toward the achievement of a specific corporate objective, and (iii)&#160;the participant&#8217;s development of professional skills.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A participant will not become entitled to a cash bonus under the Incentive Plan for a particular performance period unless the participant is employed before October&#160;1st of the applicable performance period. Following the close of the applicable performance period, the Compensation Committee will determine the actual bonus amount for each participant based on the actual levels at which the actual performance objectives are attained, and bonuses will be paid promptly following the end of the applicable performance period. The 2021 criteria for the Incentive Plan required continuous service through the date of the Compensation Committee&#8217;s determination of the level of attainment of the corporate performance objectives.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event any payment to which a participant becomes entitled under the Incentive Plan would otherwise constitute a parachute payment under Section&#160;280G of the Code, then that payment will be subject to reduction to the extent necessary to assure that such payment will be limited to the greater of (i)&#160;the dollar amount that can be paid to the participant without triggering a parachute payment under Code Section&#160;280G or (ii)&#160;the dollar amount of that payment which provides the participant with the greatest after-tax amount after taking into account any excise tax the participant may incur under Code Section&#160;4999 with respect to such payment and any other benefits or payments to which the participant may be entitled in connection with any change in control of the Company or the subsequent termination of the participant&#8217;s employment.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted a 2021 Cash Incentive Compensation Program under the Incentive Plan that provides for annual bonus awards to reward executive officers based on our achievement of specific corporate goals and their achievement of individual performance goals. For more information regarding the 2021 Cash Incentive Compensation Program under the Incentive Plan, please see the section of this Proxy Statement under the heading &#8220;&#8212;Compensation Discussion and Analysis&#8212;2021 Compensation Decisions&#8212;2021 Cash Incentive Compensation&#8221; and footnote (1)&#160;to the Grants of Plan-Based Awards table above.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Awards</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discretionary options that we granted in 2021 under the 2018&#160;Plan vest according to the following schedule&#58; 25%&#160;of the option shares will vest and become exercisable on the one-year anniversary of the option grant date and the remaining option shares will vest and become exercisable in 36&#160;equal monthly installments over the 36-month period measured from the first anniversary of the option grant date, subject to the executive officer&#8217;s continuous service through each applicable vesting date. Each option will vest on an accelerated basis in connection with certain terminations and changes, as described under the heading &#8220;&#8212;Employment Contracts and Separation and Change in Control Agreements&#8221; below. Each option has an expiration date at the end of the 10-year period measured from the grant date, unless terminated earlier following the optionee&#8217;s termination of service. Options granted under the 2018&#160;Plan have an exercise price equal to the fair market value on the date of grant (generally the closing price of our common stock on the grant date on the Nasdaq Global Select Market), and the 2018&#160;Plan permits the exercise price of stock options to be paid by cash, check, other shares of our common stock (with some restrictions), broker assisted same-day sales, and cashless &#8220;net exercise&#8221; arrangements. Discretionary RSUs that we granted in 2021 under the 2018&#160;Plan vest in three successive equal annual installments over the three-year period measured from the grant date, subject to the executive officer&#8217;s continuous service through each applicable vesting date. For a discussion of the effect on outstanding equity awards under the 2018&#160;Plan in connection with certain terminations and changes in control of the Company, including accelerated vesting, see the discussion under the heading &#8220;&#8212;Employment Contracts and Separation and Change in Control Arrangements&#8221; below.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Compensatory Arrangements</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our executive officers are eligible to participate in the 401(k) Plan. The 401(k) Plan is intended to qualify as a tax-qualified plan under Section&#160;401 of the Code. The 401(k) Plan provides that each participant may contribute a portion of his or her pre-tax compensation, up to a statutory annual limit. The 401(k) Plan also permits us to make discretionary contributions and matching contributions, subject to established limits. In 2021, we made a matching contribution, which was subject to an annual limit of $4,000 per employee.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our executive officers are eligible to participate in all of our benefit plans, such as our medical, dental, vision, short-term disability, long-term disability and group life insurance plans and our employee stock purchase plans (including the 2020&#160;ESPP), in each case generally on the same basis as other employees. We also have a Section&#160;125 flexible benefits healthcare plan and a flexible benefits childcare plan under which employees can set aside pre-tax funds to pay for qualified healthcare expenses and qualified childcare expenses not reimbursed by insurance, respectively. We do not currently offer pension or other retirement benefits in the United States but do offer pension or other retirement benefits in certain other countries.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_154"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain summary information concerning outstanding equity awards held by the named executive officers as of December&#160;31, 2021. Mr.&#160;Lee has been omitted from this table since his outstanding equity awards expired subsequent to his resignation effective February&#160;1, 2021.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br>Securities<br>Underlying<br>Unexercised<br>Options (#)<br>Exercisable<br>(1)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br>Securities<br>Underlying<br>Unexercised<br>Options (#)<br>Unexercisable<br>(1)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Exercise<br>Price<br>($)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Expiration<br>Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Incentive Plan Awards&#58;<br>Number of<br>Unearned Shares,<br>Units or Other Rights<br>That<br>Have Not<br>Vested<br>(#) (2)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Incentive Plan Awards&#58;<br>Market or Payout<br>Value&#160;of<br>Unearned Shares,<br>Units or Other Rights<br>That<br>Have Not<br>Vested<br>($) (3)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(f)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(g)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alexander&#160;D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276,750&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.19&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2031</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,687&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182,813&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.80&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2030</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2019</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268,812&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,688&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.03&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2029</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01&#47;24&#47;2018</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,062&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,938&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.05&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01&#47;23&#47;2028</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01&#47;26&#47;2017</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01&#47;25&#47;2027</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;03&#47;2016</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.07&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;02&#47;2026</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,037,813&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,505&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">843,788&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2019</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,153&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prathyusha Duraibabu (4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;11&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.76&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;10&#47;2031</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2031</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2030</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04&#47;25&#47;2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,666&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,834&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04&#47;24&#47;2029</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;11&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,250&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,750&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03&#47;25&#47;2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04&#47;25&#47;2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,917&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,378&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">D. Mark McClung (5)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2031</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;25&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;24&#47;2030</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06&#47;25&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,025&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2031</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,416&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,584&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2030</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.03</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;24&#47;2029</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01&#47;31&#47;2018</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.85</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01&#47;30&#47;2028</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,668&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275,010&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;25&#47;2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,167&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,253&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Robert J. Schott (6)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;12&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.68</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;11&#47;2031</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02&#47;12&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Except as otherwise provided in the footnotes below, each option was subject to the following vesting schedule&#58; 25% of the option shares will vest and become exercisable on the one year anniversary of the option grant date and the remaining option shares will vest and become exercisable in 36&#160;equal monthly installments over the 36-month period measured from the first anniversary of the option grant date, subject to the executive officer&#8217;s continuous service through each applicable vesting date. Each option will vest on an accelerated basis in connection with certain terminations and changes in control, as described under the heading &#8220;&#8212;Employment Contracts and Separation and Change in Control Agreements.&#8221; Each option has an expiration date at the end of the 10-year period measured from the grant date, unless terminated earlier following the optionee&#8217;s termination of service.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents an RSU subject to vesting in three successive equal annual installments over the three-year period measured from the grant date, subject to the executive officer&#8217;s continuous service through each applicable vesting date. The award will vest on an accelerated basis in connection with certain terminations and changes in control of the Company, as described under the heading &#8220;&#8212;Employment Contracts and Separation and Change in Control Arrangements.&#8221;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Based on the $7.50 closing price of our common stock on December&#160;31, 2021, the last trading day of fiscal 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Ms.&#160;Duraibabu&#8217;s option granted June&#160;11, 2021 was subject to the following vesting schedule&#58; 25% of the option shares will vest and become exercisable on the one-year anniversary of her promotion to Senior Vice President, Chief Financial Officer (June&#160;11, 2022) and the remaining option shares will vest and become exercisable in 36&#160;equal monthly installments over the 36-month period measured from the first anniversary of the promotion date, subject to Ms.&#160;Duraibabu&#8217;s continuous service through each applicable vesting date. The RSU vests in a series of three successive equal installments upon completion of each year of service measured from the grant date, subject to Ms.&#160;Duraibabu&#8217;s continuous service through each applicable vesting date. The option and RSU award will vest on an accelerated basis in connection with certain terminations and changes in control, as described under the heading &#8220;&#8212;Employment Contracts and Separation and Change in Control Agreements.&#8221; The option has an expiration date at the end of the 10-year period measured from the grant date, unless terminated earlier following the optionee&#8217;s termination of service.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:7.52pt">Mr.&#160;McClung&#8217;s option granted June&#160;25, 2020 was subject to the following vesting schedule&#58; 25% of the option shares will vest and become exercisable on the one-year anniversary of employment start date (May&#160;1, 2021) and the remaining option shares will vest and become exercisable in 36&#160;equal monthly installments over the 36-month period measured from the first anniversary of the employment start date, subject to Mr.&#160;McClung&#8217;s continuous service through each applicable vesting date. The RSU vests in a series of three successive equal installments upon completion of each year of service measured from the grant date, subject to Mr.&#160;McClung&#8217;s continuous service through each applicable vesting date. The option and RSU will vest on an accelerated basis in connection with certain terminations and changes in control, as described under the heading &#8220;&#8212;Employment Contracts and Separation and Change in Control Agreements.&#8221; The option has an expiration date at the end of the 10-year period measured from the grant date, unless terminated earlier following the optionee&#8217;s termination of service.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:7.52pt">Dr.&#160;Schott&#8217;s option granted February&#160;11, 2021 was subject to the following vesting schedule&#58; 25% of the option shares will vest and become exercisable on the one-year anniversary of employment start date (February&#160;1, 2022) and the remaining option shares will vest and become exercisable in 36&#160;equal monthly installments over the 36-month period measured from the first anniversary of the employment start date, subject to Dr.&#160;Schott&#8217;s continuous service through each applicable vesting date. The RSU vests in a series of three successive equal installments upon completion of each year of service measured from the grant date, subject to Dr.&#160;Schott&#8217;s continuous service through each applicable vesting date. The option and RSU will vest on an accelerated basis in connection with certain terminations and changes in control, as described under the heading &#8220;&#8212;Employment Contracts and Separation and Change in Control Agreements.&#8221; The option has an expiration date at the end of the 10-year period measured from the grant date, unless terminated earlier following the optionee&#8217;s termination of service.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_157"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option Exercises and Stock Vested</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the number of shares of our common stock acquired and the value realized upon the vesting of RSUs and on each exercise of stock options for each of the named executive officers during the year ended December&#160;31, 2021&#58;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:24.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards</font></td></tr><tr style="height:36pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br>Shares<br>Acquired<br>on&#160;Exercise&#160;(#)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;Realized<br>on&#160;Exercise&#160;($)&#160;(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br>Shares<br>Acquired&#160;on<br>Vesting (#)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;Realized<br>on<br>Vesting ($) (2)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(e)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,826&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,253&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,416&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,627&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,498&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,753&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Value realized is determined by multiplying (i)&#160;the amount by which the market price of the common stock on the date of exercise exceeded the exercise price by (ii)&#160;the number of shares for which the options were exercised.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Value realized is determined by multiplying (i)&#160;the market price of the common stock on the date of vesting by (ii)&#160;the number of shares acquired on vesting.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_160"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pension Benefits</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sponsor a tax-qualified defined benefit retirement plan or a supplemental executive retirement plan.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_163"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonqualified Deferred Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sponsor a nonqualified deferred compensation plan.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_166"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Assessment of Compensation Policies and Practices</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs throughout the organization are designed to maintain an appropriate balance between long-term and near-term incentives by utilizing a combination of compensation components, including base salary, annual cash </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incentive awards, and long-term equity awards. Although not all employees in the organization may have compensation comprising all three components, the compensation programs are generally structured so that any near-term cash incentives are not likely to constitute the predominant element of an employee&#8217;s total compensation. The Compensation Committee annually reviews our compensation policies and practices to assess whether they encourage employees to take inappropriate risks. After reviewing each of our compensation plans, and the checks and balances built into, and oversight of, each plan, in February 2022, the Compensation Committee determined that any risks arising from our compensation policies and practices for our employees are not reasonably likely to have a material adverse effect on us as a whole. In addition, the Compensation Committee believes that the mix and design of the elements of executive compensation do not encourage management to assume excessive risks, and significant compensation decisions, as well as decisions concerning the compensation of our executive officers, include subjective considerations by the Compensation Committee or the Board of Directors, which restrain the influence of formulae or objective factors on excessive risk taking. Finally, the mix of short-term compensation (in the form of salary and annual bonus, if any) and long-term compensation (in the form of stock options and RSUs) also prevents undue focus on short-term results and helps align the interests of our executive officers with the interests of our stockholders.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_169"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Contracts and Separation and Change in Control Arrangements</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_172"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chief Executive Officer Employment Agreement</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dr.&#160;Macrae</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016 we entered into an employment agreement with Dr.&#160;Macrae that took effect June&#160;1, 2016, which sets forth the terms and conditions of his employment as President and Chief Executive Officer. Pursuant to his employment agreement, Dr.&#160;Macrae will receive a base salary and an annual cash bonus based upon our company&#8217;s achievement of specified objectives under our Incentive Plan with a target cash bonus based on a percentage of his base salary. Dr.&#160;Macrae&#8217;s base salary and target bonus percentage are subject to annual review by the Compensation Committee and adjustment from time to time by such Committee. In 2021, Dr.&#160;Macrae&#8217;s base salary was $688,615 and his target cash bonus was 60% of his base salary.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Macrae&#8217;s employment agreement also provided for a $200,000 sign-on bonus, as well as an initial equity grant of stock options under the 2013&#160;Plan to acquire 700,000&#160;shares of our common stock, which is vesting on the same terms as other discretionary awards under the 2013&#160;Plan. Dr.&#160;Macrae is also entitled to be nominated for election to our Board of Directors for so long as his employment agreement is in effect.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Dr.&#160;Macrae&#8217;s employment agreement includes certain benefits payable to him in connection with separation from service, such terms were waived by Dr.&#160;Macrae in connection with the March 2017 adoption of the Severance Plan, as amended and restated in February 2019 by the Amended Severance Plan, which now governs his severance benefits. The terms of the Severance Plan and Amended Severance Plan are described below under &#8220;&#8212;Executive Severance Plan.&#8221;</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_175"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Vice President and Senior Vice President Employment and Other Agreements</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ms.&#160;Duraibabu</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we entered into an employment agreement with Ms.&#160;Duraibabu setting forth the terms and conditions of her employment as Vice President, Finance. Effective June&#160;1, 2021, Ms.&#160;Duraibabu was promoted to Senior Vice President, Chief Financial Officer and her base salary pursuant to her employment agreement was increased to $400,000&#160;per year and her annual target cash bonus based upon our company&#8217;s and her individual achievement of specified objectives under our Incentive Plan was increased to 35% of her base salary. Ms.&#160;Duraibabu&#8217;s base salary and target bonus percentage are subject to annual review by the Compensation Committee and adjustment from time to time by such Committee.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Ms.&#160;Duraibabu&#8217;s employment agreement provides that she will be eligible to receive certain severance benefits under the Amended Severance Plan, which is described below.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr.&#160;McClung</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered into an employment agreement with Mr.&#160;McClung setting forth the terms and conditions of his employment as Executive Vice President, Chief Business Officer. Pursuant to his employment agreement, Mr.&#160;McClung received an initial base salary of $415,000&#160;per year, and an annual cash bonus based upon our company&#8217;s and his individual achievement of specified objectives under our Incentive Plan with a target cash bonus of 40% of his base salary. Mr.&#160;McClung&#8217;s base salary and target bonus percentage are subject to annual review by the Compensation Committee and adjustment from time to time by such Committee, and his salary was subject to proration for partial service in 2020. Effective November&#160;1, 2021, Mr.&#160;McClung was promoted to Executive Vice President, Chief Operating Officer and his base salary was increased to $470,000&#160;per year and his target cash bonus for 2021 was based solely upon our company&#8217;s achievement of specified objectives under our Incentive Plan.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr.&#160;McClung&#8217;s employment agreement also provided for an initial equity grant of stock options under the 2018&#160;Plan to acquire 200,000&#160;shares of our common stock, which vests on the same terms as other discretionary awards under the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018&#160;Plan and a restricted stock award covering 100,000&#160;shares of our common stock, both of which vest on the same terms as other discretionary awards under the 2018&#160;Plan.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Mr.&#160;McClung&#8217;s employment agreement provides that he will be eligible to receive certain severance benefits under the Amended Severance Plan, which is described below.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dr.&#160;Ramelmeier</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into an employment agreement with Dr.&#160;Ramelmeier setting forth the terms and conditions of his employment as Senior Vice President, Technical Operations. Effective September&#160;16, 2019, Dr.&#160;Ramelmeier was promoted to Executive Vice President, Technical Operations and his base salary pursuant to his employment agreement was increased to $400,000&#160;per year and his target cash bonus was increased to 40% of his base salary. Dr.&#160;Ramelmeier&#8217;s base salary and target bonus percentage are subject to annual review by the Compensation Committee and adjustment from time to time by such Committee. In 2021, Dr.&#160;Ramelmeier&#8217;s base salary was $416,000 and his target cash bonus was 40% of his base salary and is based upon our company&#8217;s achievement of specified objectives under our Incentive Plan.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Ramelmeier&#8217;s employment agreement also provided for an initial equity grant of stock options under the 2013&#160;Plan to acquire 120,000&#160;shares of our common stock, which vests on the same terms as other discretionary awards under the 2013&#160;Plan. In December 2019, the Compensation Committee approved a special cash bonus of $100,000 to be paid to Dr.&#160;Ramelmeier in four equal payments of $25,000 in July 2020, December 2020, July 2021 and December 2021.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Dr.&#160;Ramelmeier&#8217;s employment agreement provides that he will be eligible to receive certain severance benefits under the Amended Severance Plan, which is described below.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dr.&#160;Schott</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February&#160;1, 2021, we entered into an employment agreement with Dr.&#160;Schott setting forth the terms and conditions of his employment as Senior Vice President, Head of Development. Pursuant to his employment agreement, Dr.&#160;Schott received an initial base salary of $440,000&#160;per year, and an annual cash bonus based upon our company&#8217;s and his individual achievement of specified objectives under our Incentive Plan with a target cash bonus of 35% of his base salary. Dr.&#160;Schott&#8217;s base salary and target bonus percentage are subject to annual review by the Compensation Committee and adjustment from time to time by such Committee, and his salary was subject to proration for partial service in 2021.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Schott&#8217;s employment agreement also provided for an initial equity grant of stock options under the 2018&#160;Plan to acquire 80,000&#160;shares of our common stock, which vests on the same terms as other discretionary awards under the 2018&#160;Plan and a restricted stock award covering 40,000&#160;shares of our common stock, both of which vest on the same terms as other discretionary awards under the 2018&#160;Plan.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Dr.&#160;Schott&#8217;s employment agreement provides that he will be eligible to receive certain severance benefits under the Amended Severance Plan, which is described below.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr.&#160;Lee</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we entered into an employment agreement with Mr.&#160;Lee setting forth the terms and conditions of his employment as Executive Vice President, Chief Financial Officer. Pursuant to his employment agreement, Mr.&#160;Lee received an initial base salary of $435,000 per year, and an annual cash bonus based upon our company&#8217;s and his individual achievement of specified objectives under our Incentive Plan with a target cash bonus of 40% of his base salary. Mr.&#160;Lee&#8217;s base salary and target bonus percentage were subject to annual review by the Compensation Committee and adjustment from time to time by such Committee, and his salary was subject to proration for partial service in 2019. In 2021, Mr.&#160;Lee&#8217;s base salary was 438,262. Mr.&#160;Lee resigned effective February&#160;1, 2021 and was not eligible for a bonus for 2021.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr.&#160;Lee&#8217;s employment agreement also provided for a $200,000&#160;sign-on bonus, as well as an initial equity grant of stock options under the 2018&#160;Plan to acquire 262,500&#160;shares of our common stock and a restricted stock award covering 43,750&#160;shares of our common stock, both of which vest on the same terms as other discretionary awards under the 2018&#160;Plan.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Mr.&#160;Lee&#8217;s employment agreement provided that he would be eligible to receive certain severance benefits under the Amended Severance Plan, which is described below. As Mr.&#160;Lee voluntarily resigned effective February&#160;1, 2021, he did not receive any payments or benefits under the Amended Severance Plan.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Mr.&#160;Lee&#8217;s resignation, on January&#160;22, 2021, we entered into a letter agreement with Mr.&#160;Lee pursuant to which Mr.&#160;Lee agreed to provide services to us in an independent contractor role for the period from February&#160;2, 2021 through February&#160;26, 2021. Mr.&#160;Lee&#8217;s compensation for this independent contractor role consisted solely of a payment of $215,000, payable in one lump sum on February&#160;26, 2021, which was deemed to be the annual cash bonus payable to him under the Incentive Plan for 2020.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_178"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Severance Plan</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Compensation Committee of the Board adopted the Amended Severance Plan, which amended and restated the Severance Plan.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended Severance Plan, Dr.&#160;Macrae is eligible to receive the following severance benefits&#58; (a)&#160;cash equal to the sum of (i)&#160;18&#160;months of his base salary and (ii)&#160;1&#47;12 of the target bonus for the year of termination multiplied by 18, payable over 12&#160;months, reimbursement for his health care coverage costs under COBRA for 18&#160;months, and full acceleration of his outstanding equity awards, and any outstanding options as so accelerated will remain exercisable for a period of 12&#160;months following termination, in the event of an involuntary termination during the Change in Control Period or (b)&#160;cash equal to 18&#160;months of his base salary, payable over 18&#160;months, and COBRA reimbursement for 18&#160;months, if he has an involuntary termination other than during the Change in Control Period.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended Severance Plan, Mr.&#160;McClung and Dr.&#160;Ramelmeier are eligible (and had he not resigned, Mr.&#160;Lee would have been eligible) to receive the following severance benefits&#58; (a)&#160;cash equal to the sum of (i)&#160;15&#160;months of base salary and (ii)&#160;1&#47;12 of the target bonus for the year of termination multiplied by&#160;15, payable over 15&#160;months, reimbursement for health care coverage costs under COBRA for 15&#160;months, and accelerated vesting of all outstanding equity awards, and any outstanding options as so accelerated will remain exercisable for a period of 12&#160;months following termination, in the event of an involuntary termination during the Change in Control Period&#59; or (b)&#160;cash equal to 15&#160;months of base salary, payable over 15&#160;months, and COBRA reimbursement for 15&#160;months, if there is an involuntary termination other than during the Change in Control Period.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended Severance Plan, Ms.&#160;Duraibabu and Dr.&#160;Schott are eligible to receive the following severance benefits&#58; (a)&#160;cash equal to the sum of (i)&#160;12&#160;months of base salary and (ii)&#160;1&#47;12 of the target bonus for the year of termination multiplied by&#160;12, payable over 12&#160;months, reimbursement for health care coverage costs under COBRA for 12&#160;months, and accelerated vesting of all outstanding equity awards, and any outstanding options as so accelerated will remain exercisable for a period of 12&#160;months following termination, in the event of an involuntary termination during the Change in Control Period&#59; or (b)&#160;cash equal to 12&#160;months of base salary, payable over 12&#160;months, and COBRA reimbursement for 12&#160;months, if there is an involuntary termination other than during the Change in Control Period.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the severance benefits under the Amended Severance Plan would constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code, such payments are subject to reduction to the extent doing so would put the recipient in a better after-tax position after taking into account any excise tax that may be incurred under Code Section&#160;4999 in connection with any change in control of the Company or subsequent termination of employment.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_181"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013&#160;Plan</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of the Board of Directors, as the administrator of the 2013&#160;Plan, has the authority to provide that any outstanding options held by the Chief Executive Officer or any other executive officer or any other unvested equity award made to such individual under the 2013&#160;Plan will vest on an accelerated basis in connection with certain changes in control of the Company or the subsequent termination of the officer&#8217;s employment following the change in control event. In addition, all outstanding options and RSUs under the 2013&#160;Plan will immediately vest upon a change in control, to the extent not assumed or continued in effect by the successor entity or replaced with an incentive compensation program that preserves the intrinsic value of the award at that time and provides for the subsequent vesting and concurrent payout of that value in accordance with the pre-existing vesting schedules for those awards.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_184"></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018&#160;Plan</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors, or any committee properly constituted thereof, as the administrator of the 2018&#160;Plan, has the authority to accelerate the time at which an equity award made under the 2018&#160;Plan may first be exercised or vest on an accelerated basis in connection with certain changes in control of the Company. In addition, all outstanding options and RSUs under the 2018&#160;Plan will immediately vest upon a change in control, to the extent not assumed or continued in effect by the successor entity or replaced with a similar incentive compensation program, for which the Board of Directors shall set the terms of any assumption, continuation or substitution.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_187"></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential Payments Upon Termination or Change in Control as of December&#160;31, 2021</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below quantify the potential payments our named executive officers, other than Mr.&#160;Lee, would receive under various scenarios. The value attributed to the accelerated vesting of equity awards represents the intrinsic value of each stock option or RSU vesting on an accelerated basis in connection with the identified triggering event, which is assumed to occur on December&#160;31, 2021. The intrinsic value is calculated by multiplying (i)&#160;the aggregate number of shares that vest on an accelerated basis by (ii)&#160;the amount by which the $7.50 closing selling price per share of our common stock on December&#160;31, 2021, exceeds the exercise price or other issue price (if any) payable per vested share. Because Mr.&#160;Lee resigned effective February&#160;1, 2021, he was not eligible for any potential payments or benefits under any of the various scenarios below as of December&#160;31, 2021, and he did not receive any payments or benefits under our Amended Severance Plan.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quantification of Benefits Upon Involuntary Termination in the Absence of a Change in Control</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below quantifies the compensation each named executive officer would have received had the officer&#8217;s employment terminated without cause in the absence of a change in control of the Company but under circumstances entitling the officer to severance benefits under the Amended Severance Plan.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:60.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance&#160;($)&#160;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">COBRA&#160;($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,923&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,375&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,531&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,917&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Cash severance upon termination in the absence of a change in control is payable in a series of successive equal monthly installments over a period ranging from 12&#160;months (named executive officers other than CEO) to 18&#160;months (CEO).</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefits Upon Involuntary Termination in Connection With a Change in Control</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below quantifies the payments our named executive officers would each have received had their employment terminated without cause or with good reason in connection with a change in control under circumstances entitling them to severance benefits under the Amended Severance Plan.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash<br>Severance&#160;($)&#160;(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target<br>Bonus&#160;($)&#160;(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated<br>Vesting of<br>Equity<br>Awards&#160;($)&#160;(3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">COBRA&#160;($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,923&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,754&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167,722&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,375&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,531&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,025&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,971&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,917&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Cash severance upon termination in connection with a change in control is payable in a series of successive equal monthly installments over a period ranging from 12&#160;months (named executive officers other than CEO) to 18&#160;months (CEO).</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Target bonus represents the amount of severance benefit that an executive is entitled to payable in a series of successive equal monthly installments over a period ranging from 12&#160;months (named executive officers other than CEO) to 18&#160;months (CEO).</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">No value is included in this table with respect to the accelerated vesting of options for which the exercise price was in excess of the closing price of our common stock on December&#160;31, 2021. </font></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefits Upon a Change in Control (No Termination)</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below quantifies the value of the accelerated equity the named executive officers are entitled to receive under the 2013&#160;Plan and 2018&#160;Plan upon a change in control of the Company in which their outstanding equity awards are not assumed or otherwise continued in effect, terminated or canceled in connection therewith.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:80.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated<br>Vesting of<br>Equity<br>Awards&#160;($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167,722&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Mark McClung</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,025&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Andrew Ramelmeier</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,971&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Schott</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefits upon Death or Disability</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2013&#160;Plan, if a named executive officer&#8217;s service with us is terminated as a result of death or permanent disability, or a named executive officer dies or becomes permanently disabled during the three months after a termination other than for misconduct, the period of time in which an option may be exercised following termination shall be the earlier of </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;months following the date of such named executive officer&#8217;s death or the expiration date of the option, whichever is earlier, rather than the standard three-month post-termination exercise period provided for in the 2013&#160;Plan or the 2018&#160;Plan.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_190"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CEO Pay Ratio Disclosure</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules, we are required to calculate and disclose the annual total compensation of our median employee, as well as the ratio of the annual total compensation of our median employee as compared to the annual total compensation of our President and Chief Executive Officer, Dr.&#160;Macrae, our CEO, for our last fiscal year, or the CEO Pay Ratio. To identify our median employee, we used the following methodology&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To determine our total population of employees, we included all of our employees as of November&#160;15, 2021 regardless of their full- or part-time schedule or anticipated employment duration.</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To identify our median employee from our employee population, we calculated the aggregate amount of the 2021 base compensation of each of our employees excluding the CEO using a reasonable estimate of the hours worked during 2021 for our hourly employees and actual salary paid for our remaining employees, target 2021 bonus, and the grant date fair value of equity awards granted in fiscal 2021 (using the same methodology we use for estimating the value of the equity awards granted to our named executive officers and reported in our Summary Compensation Table).</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In making this determination, we annualized the base compensation, target bonus and other cash incentive compensation of those permanent employees who were employed by us for less than the entire fiscal year.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using this approach, we determined our median employee and determined their annual total compensation in accordance with the requirements of the Summary Compensation Table.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, for fiscal 2021, the median of the annual total compensation of our employees (other than our CEO) was $170,218 and the annual total compensation of our CEO, as reported in the Summary Compensation Table included in this Proxy Statement, was $4,735,817. Based on this information, the ratio of the annual total compensation of our CEO to the median of the annual total compensation of all our employees was approximately 28 to 1.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CEO Pay Ratio above represents our reasonable estimate calculated in a manner consistent with SEC rules and applicable guidance. SEC rules and guidance provide significant flexibility in how companies identify the median employee, and each company may use a different methodology and make different assumptions particular to that company. As a result, and as explained by the SEC when it adopted these rules, in considering the pay ratio disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparisons of pay ratios among different companies, even companies within the same industry, but rather to allow stockholders to better understand and assess each particular company&#8217;s compensation practices and pay ratio disclosures.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Compensation Committee nor our management used our CEO Pay Ratio measure in making compensation decisions.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_193"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPENSATION COMMITTEE REPORT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis contained in this Proxy Statement with management, and based on such review and such discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis, as contained herein, be included in this Proxy Statement.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted by the Compensation Committee of the</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board of Directors of Sangamo Therapeutics, Inc.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Karen L. Smith</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Kenneth J. Hillan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr.&#160;James R. Meyers</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The material in this Compensation Committee Report is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_196"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EQUITY COMPENSATION PLAN INFORMATION</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information as of December&#160;31, 2021, with respect to the shares of our common stock that may be issued under our existing equity compensation plans. There are no outstanding options that we have assumed in connection with our acquisition of other companies, and there are currently no assumed plans under which we can grant options.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Column (A)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Column (B)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Column (C)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br>Securities&#160;to&#160;be<br>Issued Upon<br>Exercise of<br>Outstanding&#160;Options,<br>RSUs<br>and Other Rights</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br>Exercise Price of<br>Outstanding<br>Options</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;Securities<br>Remaining&#160;Available&#160;for<br>Future Issuance Under<br>Equity Compensation<br>Plans<br>(Excluding Securities<br>Reflected in Column A)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation Plans Approved by Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,978,871&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,582,307&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation Plans Not Approved by Stockholders </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,102,871&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,582,307&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The equity compensation plans approved by stockholders consist of the 2013&#160;Plan, the 2018&#160;Plan and the 2020&#160;ESPP. In November 2017, the Compensation Committee approved the amendment and restatement of the 2013&#160;Plan to reserve an additional 1,000,000 shares of our common stock to be used exclusively for grants of awards to individuals who were not previously employees or non-employee directors of the Company (or following a bona fide period of non-employment with the Company), as an inducement material to each such individual&#8217;s entry into employment with us within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules, or Rule 5635(c)(4) (such awards, the Inducement Awards). The 2013&#160;Plan was amended and restated by the Compensation Committee without stockholder approval pursuant to Rule 5635(c)(4). Accordingly, for purposes of this table, information with respect to Inducement Awards and the shares reserved for issuance under the 2013&#160;Plan therefor, are included in the row in the table above with respect to equity compensation plans not approved by stockholders.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes 3,139,594 shares subject to RSUs that will entitle the holder to one share of common stock for each unit that vests over the holder&#8217;s period of continuous service.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes purchase rights accruing under the 2020&#160;ESPP and shares subject to outstanding options granted under the 2013&#160;Plan as Inducement Awards (which Inducement Awards are included in the row in the table above with respect to equity compensation plans not approved by stockholders). Under the 2020&#160;ESPP, each eligible employee may purchase up to 5,000&#160;shares of common stock at semi-annual intervals on the last U.S. business day of May and November each year at a purchase price per share equal to 85% of the lower of (i)&#160;the closing selling price per share of common stock on the employee&#8217;s entry date into the two-year offering period in which that semi-annual purchase date occurs or (ii)&#160;the closing selling price per share on the semi-annual purchase date.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The calculation does not take into account the 3,139,594 shares of common stock subject to outstanding RSUs. Such shares will be issued at the time the RSUs vest, without any cash consideration payable for those shares.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists of shares available for future issuance under the 2020&#160;ESPP and the 2018&#160;Plan. As of December&#160;31, 2021, 4,782,452 shares of common stock were available for issuance under the 2020&#160;ESPP, and 7,799,855 shares of common stock were available for issuance under the 2018&#160;Plan.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2021, the maximum aggregate number of shares of common stock reserved for issuance under the 2018&#160;Plan and the 2020&#160;ESPP was 19,542,736 shares and 5,000,000 shares, respectively. This maximum aggregate share reserve is not the same as the shares available for future issuance, which is described in Footnote&#160;5. As of December&#160;31, 2021, the aggregate number of shares of our common stock that may be issued under the 2018&#160;Plan will not exceed the sum of (i)&#160;1,703,964 shares (the number of shares that were available for grant under the 2013&#160;Plan as of immediately prior to the effective date of the 2018&#160;Plan)&#59; (ii)&#160;8,800,000 shares (the number of additional shares that were reserved as of the effective date of the 2018&#160;Plan)&#59; (iii)&#160;9,900,000 shares (the number of additional shares that were reserved as of the approval of the amendment to the 2018&#160;Plan)&#59; and (iv)&#160;any returning shares subject to outstanding awards granted under the Prior Plans as such shares become available from time to time due to expiration or termination of such awards, settlement of such awards in cash or forfeitures or repurchases. The number of shares of our common stock available for issuance under the 2018&#160;Plan is increased by&#58; (i)&#160;one share for each Prior Plans&#8217; returning share of common stock or 2018&#160;Plan returning share of common stock subject to a stock option grant or stock appreciation right award and (ii)&#160;1.33 shares for each Prior Plans&#8217; returning share of common stock or 2018&#160;Plan returning share of common stock subject to a full value award. The number of shares of common stock reserved for issuance under the 2018&#160;Plan is reduced&#58; (i)&#160;on a 1-for-1 basis for each share of common stock subject to a stock option grant or stock appreciation right award, or pursuant to a full-value award made under the 2018&#160;Plan, and (ii)&#160;by a fixed ratio of 1.33&#160;shares of common stock for each share of common stock issued pursuant to a full-value award made under the 2018&#160;Plan.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists of stock options granted as Inducement Awards under the 2013&#160;Plan. All options granted as Inducement Awards have a maximum term of 10&#160;years.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2021, options to purchase 124,000&#160;shares were outstanding as Inducement Awards. As a result of the adoption of the 2018&#160;Plan at our 2018&#160;annual meeting of stockholders, no additional stock awards may be granted as Inducement Awards. Accordingly, for purposes of the table above, no shares remained available for issuance as Inducement Awards as of December&#160;31, 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_199"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained under the heading &#8220;Report of the Audit Committee of the Board of Directors&#8221; in this Proxy Statement shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any filing of the Company with the SEC, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, or subject to the liabilities of Section&#160;18 of the Exchange Act.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December&#160;31, 2021 with the management of the Company.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has discussed with Ernst&#160;&#38; Young LLP, the independent registered public accounting firm that audited our financial statements for the fiscal year ended December&#160;31, 2021, the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board, or PCAOB, and the SEC.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has received the written disclosures and the letter from Ernst&#160;&#38; Young LLP required by applicable requirements of the PCAOB regarding Ernst&#160;&#38; Young LLP&#8217;s communications with the Audit Committee concerning independence, and has discussed with Ernst&#160;&#38; Young LLP its independence from the Company.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the review of the audited financial statements and the discussions noted above, the Audit Committee recommended to our Board of Directors that the audited financial statements be included in our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2021 for filing with the SEC.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted by the Audit Committee of the<br>Board of Directors of Sangamo Therapeutics, Inc.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr.&#160;Robert F. Carey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr.&#160;James R. Meyers</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms.&#160;Saira Ramasastry</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The material in this Report of the Audit Committee is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_202"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy and Procedures for Review of Related Party Transactions</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the requirement under Nasdaq listing rules, the Audit Committee of the Board of Directors is responsible for reviewing and providing oversight of all related party transactions as defined under SEC rules and regulations. While we do not have a formal written policy or procedure for the review, approval or ratification of related party transactions, the charter of the Audit Committee requires that the Audit Committee approve all related party transactions as defined under SEC rules and regulations. In making its decision to approve or ratify a related party transaction, the Audit Committee will consider the relevant facts and circumstances available and deemed relevant to the Audit Committee, including but not limited to the risks, costs and benefits to us, the terms and aggregate value of the transaction, the availability of other sources for comparable services or products, and, if applicable, the impact on a director&#8217;s independence.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Related Persons&#59; Indemnification</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transactions with Related Persons.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Since January&#160;1, 2021, there has not been nor is there currently proposed any transaction or series of similar transactions to which we were or are to be a party in which the amount involved exceeds $120,000 and in which any director, executive officer, holder of more than 5% of our common stock, or any member of the immediate family of any of the foregoing persons, had or will have a direct or indirect material interest other than described below and other than compensation agreements and other arrangements, which are described elsewhere in this Proxy Statement.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we entered into a global licensing collaboration agreement with Biogen for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases which became effective in April 2020. Our collaboration aims to leverage our proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, we also entered into a stock purchase agreement with BIMA, pursuant to which BIMA purchased 24,420,157 shares of our common stock, or the Biogen Shares, for an aggregate purchase price of $225.0&#160;million. Under the collaboration agreement, Biogen paid us an upfront license fee payment of $125.0&#160;million. We are also eligible to earn research, development, regulatory and commercial milestone payments that could total up to approximately $2.4&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.5&#160;billion in first commercial sale and other sales-based milestone payments. In addition, we are also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Under the collaboration agreement, we granted to Biogen an exclusive, royalty bearing and worldwide license, under our relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and&#47;or AAV-based products directed to up to 12&#160;neurological disease gene targets selected by Biogen. Biogen has already selected four of these&#58; our ST-501 product candidate to treat tauopathies, our ST-502 product candidate to treat synucleinopathies including Parkinson&#8217;s disease, a third product candidate targeting DM1, a neuromuscular disease and a fourth undisclosed neurological disease gene target. Biogen has exclusive rights to nominate up to eight additional targets over a target selection period of five years. For each gene target selected by Biogen, we perform early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZF&#160;transcription factors targeting therapeutically relevant genes. Biogen then assumes responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. We are primarily responsible for GMP manufacturing activities for the initial clinical studies for the first three products of the collaboration and plan to leverage our in-house manufacturing capacity. Biogen is responsible for GMP manufacturing activities beyond the first clinical study for each of the first three products. Subject to certain exceptions set forth in the collaboration agreement, we are prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen. The collaboration agreement continues, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, we may terminate the collaboration agreement if Biogen challenges any patents licensed by us to Biogen. Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without our prior written and subject to specified conditions and exceptions, directly or indirectly acquire shares of our outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in us. Subject to customary exceptions, such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the Biogen collaboration agreement and the date that Biogen beneficially owns less than 5% of our common stock. The stock purchase agreement also provides that until the first anniversary of the effectiveness of the Biogen collaboration agreement, Biogen must hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen must hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">volume limitations. The stock purchase agreement further provides that, subject to certain limitations, upon Biogen&#8217;s request, we must register for resale any of the Biogen Shares on a registration statement to be filed with the SEC, until such time as all remaining Biogen Shares may be sold pursuant to Rule&#160;144 promulgated under the Securities Act during any 90-day period. In addition, Biogen has agreed that, excluding specified extraordinary matters, it must vote the Biogen Shares in accordance with our recommendation and has granted us an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i)&#160;the two-year anniversary of the effectiveness of the Biogen collaboration agreement, (ii)&#160;the date that Biogen beneficially owns less than 5% of our common stock and (iii)&#160;the date the Biogen collaboration agreement is terminated&#59; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the Biogen collaboration agreement.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the indemnification provisions contained in our Seventh Amended and Restated Certificate of Incorporation, as amended, we have entered into separate indemnification agreements with each of our directors and executive officers containing provisions that may require us to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors and executive officers. We may amend these indemnification agreements from time-to-time as appropriate.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_205"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Proxy Statement contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements regarding&#58; our business strategy and the therapeutic potential of our product candidates&#59; anticipated plans and timeliness of us and our collaborators for conducting clinical trials and bringing in-house manufacturing facilities online&#59; and other statements that are not historical fact. In some cases, you can identify forward-looking statements by terms such as&#58; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; and &#8220;will.&#8221; These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to&#58; the effects of the ongoing COVID-19 pandemic and the impacts of the pandemic on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials&#59; the research and development process&#59; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended&#59; the potential for technological developments that obviate technologies used by Sangamo&#59; the potential lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates and our ability to achieve expected future financial performance&#59; and the uncertain timing and unpredictable results of clinical trials, including whether initial clinical trial data will be representative of final clinical trial data and whether final clinical trial data will validate the safety and efficacy of product candidates. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in our operations and business environments, including the risks and uncertainties that are described in the 2021 Form 10&#8209;K. Forward-looking statements contained in this Proxy Statement are made as of the date of this Proxy Statement, and we undertake no duty to update such information except as required under applicable law.</font></div><div id="i89eaa63eb2fa4775974405ea28334ee8_208"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HOUSEHOLDING OF PROXY MATERIALS</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC has adopted rules that permit companies and intermediaries (such as brokers) to satisfy the delivery requirements for Notices and proxy materials with respect to two or more stockholders sharing the same address by delivering a single Notice or a single set of proxy materials, as applicable, addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This year, a number of brokers with account holders who are our stockholders will be &#8220;householding&#8221; Notices and our proxy materials. A single Notice or a single set of proxy materials, as applicable, will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that it will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate Notice or set of proxy materials, please notify your broker or us. Direct your written request to Sangamo Therapeutics, Inc., Scott B. Willoughby, Corporate Secretary, 7000 Marina Boulevard, Brisbane, California 94005 or contact Louise Wilkie at 510-970-6000. Stockholders who currently receive multiple copies of the Notice or sets of proxy materials at their address and would like to request &#8220;householding&#8221; of their communications should contact their broker. In addition, we will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of a Notice or the full set of proxy materials, as applicable, to a stockholder at a shared address to which a single Notice or set of the proxy materials, as applicable, was delivered.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_211"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER MATTERS</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors knows of no other business that will be presented to the Annual Meeting. If any other business is properly brought before the Annual Meeting, or with respect to any adjournment or postponement thereof, it is the intention of the proxy holders to vote on such matters in accordance with their best judgment.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important that your shares are represented at the Annual Meeting. We urge you to vote your shares via the Internet, over the telephone or, if you received a paper proxy card or voting instruction form by mail, by marking, dating and signing the proxy card or voting instruction form and mailing it promptly in the return envelope provided.</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By Order of the Board of Directors,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SCOTT B. WILLOUGHBY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott B. Willoughby<br>Senior Vice President, General Counsel and Corporate Secretary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brisbane, California</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;1, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Annual Report on Form 10-K for the year ended December&#160;31, 2021 is available without charge upon written request to&#58; Corporate Secretary, Sangamo Therapeutics, Inc., 7000 Marina Boulevard, Brisbane, California 94005. Our Annual Report on Form 10-K is not incorporated into this Proxy Statement and is not considered proxy soliciting material.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_1758"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2018 Equity Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted by the Compensation Committee of the Board&#58;  April 23, 2018</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approved by the Stockholders&#58;  June 11, 2018</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amended and Restated by the Compensation Committee of the Board&#58;  March 20, 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approved by the Stockholders&#58;  May 18, 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amended and Restated by the Board&#58;  February 23, 2022</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amended and Restated by the Compensation Committee of the Board&#58;  March&#160;25, 2022</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approved by the Stockholders&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</font></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:10.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares Subject to the Plan</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eligibility</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options and Stock Appreciation Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards Other Than Options and Stock Appreciation Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments upon Changes in Common Stock&#59; Other Corporate Events</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Automatic Grants To Eligible Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administration</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Withholding</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covenants of the Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Rules for Awards Subject to Section 409A</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severability</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination of the Plan</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definitions</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">1.&#160;&#160;&#160;&#160;General.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Successor to and Continuation of Predecessor Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Plan is the successor to and continuation of the Predecessor Plan.  As of the Effective Date, (i) no additional awards may be granted under the Predecessor Plan&#59; (ii) the Predecessor Plan&#8217;s Available Reserve will become available for issuance pursuant to Awards granted under this Plan&#59; and (iii) all outstanding awards granted under the Prior Plans will remain subject to the terms of the Prior Plans&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that any Prior Plans&#8217; Returning Shares will become available for issuance pursuant to Awards granted under this Plan.  All Awards granted under this Plan will be subject to the terms of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Eligible Award Recipients and Plan Purpose.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.  Only Eligible Directors will receive Awards under the Automatic Grant Program.  The Company, by means of the Plan, seeks to secure and retain the services of such persons, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Available Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Plan provides for the grant of the following Awards&#58; (i) Incentive Stock Options&#59; (ii) Nonstatutory Stock Options&#59; (iii) SARs&#59; (iv) Restricted Stock Awards&#59; (v) RSU Awards&#59; (vi) Performance Awards&#59; and (vii) Other Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Effective Date.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan will come into existence on the Effective Date.  No Award may be granted under the Plan prior to the Effective Date.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Shares Subject to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Share Reserve.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to the adjustments in this Section 2 and in Section 6(a), the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed the sum of&#58; (A) 8,800,000 shares (which were approved at the Annual Meeting in 2018)&#59; plus (B) 9,900,000 shares (which were approved at the Annual Meeting in 2020)&#59; plus (C) 7,900,000 shares (which were approved at the Annual Meeting in 2022)&#59; plus (D) the number of Prior Plans&#8217; Returning Shares, if any, as such shares become available from time to time&#59; plus (E) 1,703,964 shares (which is the Predecessor Plan&#8217;s Available Reserve).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The number of shares of Common Stock available for issuance under the Plan will be reduced by&#58; (A) one share for each share of Common Stock issued pursuant to an Appreciation Award granted under the Plan and (B) 1.33 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The number of shares of Common Stock available for issuance under the Plan will be increased by&#58; (A) one share for each Prior Plans&#8217; Returning Share or 2018 Plan Returning Share (as defined in Section 2(d)(i)) subject to an Appreciation Award and (B) 1.33 shares for each Prior Plans&#8217; Returning Share or 2018 Plan Returning Share (as defined in Section 2(d)(i)) subject to a Full Value Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Incentive Stock Option Limit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Notwithstanding anything to the contrary in Section 2(a) and subject to Section 6(a) regarding Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 53,200,000 shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Actions that Will Not Constitute Issuance of Shares and Will Not Reduce Share Reserve.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The following actions will not result in an issuance of shares of Common Stock under the Plan and accordingly will not reduce the number of shares of Common Stock subject to the Share Reserve and available for issuance under the Plan&#58; (i) the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued&#59; or (ii) the settlement of any portion of an Award in cash (i.e., the Participant receives cash rather than shares of Common Stock).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Reversion of Shares to the Share Reserve.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;Shares Available For Subsequent Issuance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  If any shares of Common Stock issued pursuant to an Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, then such shares will revert to the Share Reserve and become available again for issuance under the Plan and, for purposes of the Plan, such shares will be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Plan Returning Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;Shares Not Available For Subsequent Issuance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares of Common Stock will not become available again for issuance under the Plan&#58; (A) any shares that are reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of an Appreciation Award or a Full Value Award (including any shares subject to such award that are not delivered because such award is exercised through a reduction of shares subject to such award (i.e., &#8220;net exercised&#8221;))&#59; (B) any shares that are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Appreciation Award or a Full Value Award&#59; (C) any shares repurchased by the Company on the open market with the proceeds of the exercise or purchase price of an Appreciation Award or a Full Value Award&#59; and (D) in the event that a Stock Appreciation Right granted under the Plan or a stock appreciation right granted under any of the Prior Plans is settled in shares of Common Stock, the gross number of shares of Common Stock subject to such award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Share Reserve Limit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For clarity, the Share Reserve limit in Section 2(a) is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards.  Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Eligibility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Eligibility for Specific Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Incentive Stock Options may be granted only to Employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and (f) of </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Code).  Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company (as such term is defined in Rule 405) unless the stock underlying such Awards is treated as &#8220;service recipient stock&#8221; under Section 409A because the Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Ten Percent Stockholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (i) the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (ii) the Option is not exercisable after the expiration of five years from the date of grant of such Option.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Options and Stock Appreciation Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Option and SAR will have such terms and conditions as determined by the Board.  Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that if an Option is not so designated, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for.  The terms and conditions of separate Options and SARs need not be identical&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subject to Section 3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Exercise or Strike Price.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subject to Section 3(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Change in Control and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code.  Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Exercise Procedure and Payment of Exercise Price for Options.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement.  The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment.  The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by cash or check, bank draft or money order payable to the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;pursuant to a &#8220;cashless exercise&#8221; program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (A) at the time of exercise the Common Stock is publicly traded, (B) any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (C) such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (D) any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (E) such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;if the Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (A) any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment, and (B) shares of Common Stock will no longer be subject to such Option and will not be exercisable thereafter to the extent that shares issuable upon exercise are reduced to pay the exercise price pursuant to such &#8220;net exercise&#59;&#8221; or</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Exercise Procedure and Payment of Appreciation Distribution for SARs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement.  The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of (i) the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii) the strike price of such SAR.  Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Options and SARs may not be transferred to third party financial institutions for value.  The Board may impose such additional limitations on the transferability of an Option or SAR.  In the absence of any such determination, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;Restrictions on Transfer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#8217;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company, an Option or SAR may be transferred pursuant to a domestic relations order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subject to Section 10(a), the Board may impose such restrictions on or conditions to the vesting and&#47;or exercisability of an Option or SAR as determined by the Board and which may vary.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#8217;s Continuous Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subject to Section 4(h), if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a))&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant&#8217;s Disability or death)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 months following the date of such termination if such termination is due to the Participant&#8217;s Disability&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 months following the date of such termination if such termination is due to the Participant&#8217;s death&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 months following the date of the Participant&#8217;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i) or (ii) above).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;Extension of Exercisability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period&#58; (i) </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the exercise of the Participant&#8217;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii) the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&#8217;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;Termination of Continuous Service for Cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)&#160;&#160;&#160;&#160;Non-Exempt Employees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award.  Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i) such Participant&#8217;s death or Disability, (ii) a Change in Control in which such Award is not assumed, continued or substituted, or (iii) such Participant&#8217;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#8217;s then current employment policies and guidelines).  This Section 4(j) is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k)&#160;&#160;&#160;&#160;Whole Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Awards Other Than Options and Stock Appreciation Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Restricted Stock Awards and RSU Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board.  The terms and conditions of separate Restricted Stock Awards and RSU Awards need not be identical&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;Form of Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To the extent consistent with the Company&#8217;s Bylaws, at the Board&#8217;s election, shares of Common Stock subject to a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until such shares become vested or any other restrictions lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A RSU Award represents a Participant&#8217;s right to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award.  As a holder of a RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#8217;s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Award Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person.  A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award).  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;Consideration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of consideration (including future services) as the Board may determine and permissible under Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unless otherwise determined by the Board at the time of grant, a RSU Award will be granted in consideration for the Participant&#8217;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU Award.  If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#8217;s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to Section 10(a), the Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board and which may vary.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&#8217;s Continuous Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason, (i) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and (ii) any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(v)&#160;&#160;&#160;&#160;Settlement of RSU Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  A RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement.  At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Performance Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board.  In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Other Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock may be granted either alone or in addition to Awards provided for under Section 4 and the preceding provisions of this Section 5.  Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Adjustments upon Changes in Common Stock&#59; Other Corporate Events.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Capitalization Adjustments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust&#58; (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 2(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 2(b), (iii) the class(es) and number of securities to be granted pursuant to the Automatic Grant Program, and (iv) the class(es) and number of securities and exercise price, strike price or purchase price of stock subject to outstanding Awards.  The Board shall make such adjustments, and its determination shall be final, binding and conclusive.  Notwithstanding the provisions of this Section 6(a), no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section 6(a).  The Board shall determine an equivalent benefit for any fractional shares or fractional shares that might be created by the adjustments referred to in this Section 6(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Dissolution or Liquidation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the Board may determine to cause some or all Awards to become fully vested, exercisable and&#47;or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The following provisions will apply to Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;Awards May Be Assumed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In the event of a Change in Control, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar stock awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Change in Control), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Change in Control.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar stock award for only a portion of a Award, or may choose to assume or continue the Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;Awards Held by Current Eligible Participants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In the event of a Change in Control in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants who are Employees or Directors and whose Continuous Service has not terminated prior to the effective time of the Change in Control (referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Eligible Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full (and with respect to Performance Awards, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of such Change in Control (contingent upon the effectiveness of the Change in Control) as the Board determines (or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective time of the Change in Control), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Change in Control, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Change in Control).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;Awards Held by Persons other than Current Eligible Participants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In the event of a Change in Control in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar stock awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Eligible Participants, such Awards will terminate if not exercised (if applicable) prior to the effective time of the Change in Control&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;Payment for Awards in Lieu of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Notwithstanding the foregoing, in the event a Award will terminate if not exercised prior to the effective time of a Change in Control, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (B) any exercise price payable by such holder in connection with such exercise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Appointment of Stockholder Representative.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Change in Control involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#8217;s behalf with respect to any escrow, indemnities and any contingent consideration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;No Restriction on Right to Undertake Transactions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Automatic Grants To Eligible Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Automatic Grant Program set forth in this Section 7 provides that Eligible Directors shall automatically receive the grant of certain Awards at designated intervals over their period of Continuous Service on the Board.  For the avoidance of doubt, Awards granted under this Automatic Grant Program are subject to all the terms and conditions of the Plan.  Each Option granted under this Automatic Grant Program shall (i) be a Nonstatutory Stock Option, (ii) have an exercise price equal to one hundred percent (100%) of the Fair Market Value on the date the Option is granted, and (iii) have a maximum term of 10 years.  For the avoidance of doubt, any shares of Common Stock issued pursuant to Awards granted under the Automatic Grant Program which may vest any earlier than 12 months following the date of grant will count against the 5% permitted exception to the minimum vesting requirements set forth in Section 10(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Initial Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  If an Eligible Director is first elected or appointed to serve on the Board on or after the Annual Meeting in 2020, such person shall, upon the date of his or her initial election or appointment as an Eligible Director, be granted an Option to purchase 37,500 shares of Common Stock and a RSU Award in respect of 18,750 shares of Common Stock (each such Option and RSU Award an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Initial Awards of Options shall vest monthly with respect to 1&#47;36th of the shares over the three year period following the date of grant, subject to the Eligible Director&#8217;s Continuous Service through the applicable vesting dates, so that the Option will be fully vested on the third anniversary of the date of grant.  Initial Awards of RSU Awards shall vest annually with respect to 1&#47;3rd of the shares over the three year period following the date of grant, subject to the Eligible Director&#8217;s Continuous Service through the applicable vesting dates, so that the RSU Award is fully vested on the third anniversary of the date of grant. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Annual Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Each person who is an Eligible Director shall be granted an Option to purchase 25,000 shares of Common Stock and a RSU Award in respect of 12,500 shares of Common Stock (each such Option and RSU Award, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on an annual basis as follows&#58; (i) with respect to 2020, such Annual Awards shall be granted on the date of the Annual Meeting in 2020&#59; and (ii) with respect to each year following 2020, such Annual Awards shall be granted on the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of February of such year (or if such 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day is not a trading day, the immediately preceding trading day in February)&#59; in each case, provided that such person is an Eligible Director on the date of grant, has served as an Eligible Director for a period of at least three months prior to the date of grant, and will continue serving as an Eligible Director immediately after the date of grant. Annual Awards of Options shall vest monthly with respect to 1&#47;12th of the shares over the one (1) year period following the date of grant, subject to the Eligible Director&#8217;s Continuous Service through the applicable vesting dates, so that the Option will be fully vested on the first anniversary of the date of grant. Annual Awards of RSU Awards granted in 2020 shall fully vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the next Annual Meeting, subject to the Eligible Director&#8217;s Continuous Service through such date. Annual Awards of RSU Awards granted in each year following 2020 shall fully vest on the first anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service through such date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Vesting Upon Change in Control or Hostile Take-Over.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Option and RSU Award granted pursuant to this Automatic Grant Program shall automatically fully accelerate vesting immediately prior to the effectiveness of a Change in Control or Hostile Take-Over, subject to the Eligible Director&#8217;s Continuous Service through the date of the Change in Control or Hostile Take-Over, as applicable.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Vesting Upon Death or Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  If the Eligible Director&#8217;s Continuous Service terminates due to death or Disability, such Eligible Director&#8217;s Options and RSU Awards granted pursuant to this Automatic Grant Program shall automatically fully vest.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Administration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Administration by Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section 8(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Powers of Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Except with respect to the Automatic Grant Program, the Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan&#58;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To determine from time to time (A) which of the persons eligible under the Plan will be granted Awards&#59; (B) when and how each Award will be granted&#59; (C) what type or combination of types of Award will be granted&#59; (D) the provisions of each Award granted (which need not be identical), including the time or times when a person will be permitted to receive cash or Common Stock pursuant to an Award&#59; (E) the number of shares of Common Stock with respect to which an Award will be granted to each such person&#59; and (F) the Fair Market Value applicable to an Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest, including in connection with a Change in Control or Hostile Take-Over.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to thirty days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock including any Change in Control, for reasons of administrative convenience.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To suspend or terminate the Plan at any time.  Suspension or termination of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To amend the Plan in any respect the Board deems necessary or advisable, provided that stockholder approval will be required to the extent required by Applicable Law.  Except as provided above, rights under any Award granted before amendment of the Plan will not be impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To submit any amendment to the Plan for stockholder approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that except with respect to amendments that disqualify or impair the status of an Incentive Stock Option, a Participant&#8217;s rights under any Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, including, but not limited, to, an amendment that imposes reasonable restrictions on the minimum number of shares subject to an Option that may be exercised, and (2) subject to the limitations of Applicable Law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code&#59; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code&#59; (C) to clarify the manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section 409A&#59; or (D) to comply with other Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Administration of Automatic Grant Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Board shall have the power, subject to and within the limitations of, the express provisions of the Automatic Grant Program&#58;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To determine the provisions of each Award to the extent not specified in the Automatic Grant Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To construe and interpret the Automatic Grant Program and the Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Automatic Grant Program or in any Award Agreement, in a manner and to the extent it shall deem necessary or expedient to make the Automatic Grant Program fully effective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To amend the terms of the Automatic Grant Program or an Award granted thereunder, except that rights under any such Award granted before amendment of the Automatic Grant Program shall not be impaired by any amendment of the Automatic Grant Program unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Automatic Grant Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Delegation to Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Board may delegate some or all of the administration of the Plan (except the Automatic Grant Program) to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.  The Committee may, at any time, abolish the subcommittee and&#47;or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.  As of the Effective Date the Board has delegated administration of the Plan to the Compensation Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;Rule 16b-3 Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.  In addition, the Board or the Committee, in its sole discretion, may delegate to a Committee who need not be Non-Employee Directors the authority to grant Awards to eligible persons who are not then subject to Section 16 of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Effect of Board&#8217;s Decision.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Cancellation and Re-Grant of Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither the Board nor any Committee will have the authority to&#58; (i) reduce the exercise price or strike price of any outstanding Options or SARs under the Plan, or (ii) cancel any outstanding Options or SARs that have an exercise price or strike price greater than the current Fair Market Value in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved such an action within twelve months prior to such an event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;Delegation to an Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii) determine the number of shares of Common Stock to be subject to such Awards granted to such Employees&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the resolutions evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself.  Any such Awards will be granted on the form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority.  Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Tax Withholding</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Withholding Authorization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agree to make adequate </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for (including), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable.  Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Satisfaction of Withholding Obligation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state, local or foreign tax withholding obligation relating to an Award by any of the following means or by a combination of such means&#58; (i) causing the Participant to tender a cash payment&#59; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award&#59; (iii) withholding cash from an Award settled in cash&#59; (iv) withholding payment from any amounts otherwise payable to the Participant&#59; (v) by means of a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board&#59; or (vi) by such other method as may be set forth in the Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Withholding Indemnification. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#8217;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company, each Participant agrees to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Miscellaneous.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Minimum Vesting Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No Award may vest (or, if applicable, be exercisable) until at least twelve (12) months following the date of grant of the Award&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that shares of Common Stock up to five percent (5%) of the Share Reserve may be issued pursuant to Awards that do not meet such vesting (and, if applicable, exercisability) requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Dividends and Dividend Equivalents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Dividends or dividend equivalents may not be paid or credited to Options or SARs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With respect to any Award other than an Option or SAR, dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to such Award, as determined by the Board and specified in the applicable Award Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that (i) no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Award Agreement, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such Award Agreement (including, but not limited to, any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Source of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Use of Proceeds from Sales of Common Stock.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Corporate Action Constituting Grant of Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Stockholder Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i) such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Award is reflected in the records of the Company.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;No Employment or Other Service Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.  Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and&#47;or Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;Change in Time Commitment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;Incentive Stock Option $100,000 Limitation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)&#160;&#160;&#160;&#160;Execution of Additional Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#8217;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and&#47;or other regulatory requirements, in each case at the Plan Administrator&#8217;s request.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k)&#160;&#160;&#160;&#160;Electronic Delivery and Participation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Any reference herein or in an Award Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).  By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator.  The form of delivery of any Common Stock (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(l)&#160;&#160;&#160;&#160;Clawback&#47;Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law, and any other clawback policy that the Company adopts.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#8217;s right to voluntary terminate employment upon a &#8220;resignation for good reason,&#8221; or for a &#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(m)&#160;&#160;&#160;&#160;Securities Law Compliance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered under the Securities Act&#59; or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(n)&#160;&#160;&#160;&#160;Transfer or Assignment of Awards&#59; Issued Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant.  After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(o)&#160;&#160;&#160;&#160;Effect on Other Employee Benefit Plans. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The value of any Award granted under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(p)&#160;&#160;&#160;&#160;Deferrals.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants.  Deferrals by will be made in accordance with the requirements of Section 409A. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(q)&#160;&#160;&#160;&#160;Section 409A.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A, and, to the extent not so exempt, in compliance with the requirements of Section 409A.  If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A is a &#8220;specified employee&#8221; for purposes of Section 409A, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section 409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(r)&#160;&#160;&#160;&#160;Data Privacy.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By accepting an Award granted under the Plan, a Participant thereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of such Participant&#8217;s personal data as described herein by and among, as applicable, the Employer, and the Company and its other Affiliates and the Plan Administrator for the exclusive purpose of implementing, administering and managing such Participant&#8217;s participation in the Plan.  Each Participant understands that the Company and the Employer may hold certain personal information about such Participant, including, but not limited to, the Participant&#8217;s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Awards or any other entitlement to ordinary shares awarded, canceled, exercised, vested, unvested or outstanding in the Participant&#8217;s favor, for the purpose of implementing, administering and managing the Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Each Participant understands that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the Participant&#8217;s country or elsewhere, and that the recipients&#8217; country (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., the United States) may have different data privacy laws and protections than the Participant&#8217;s country.  Each Participant understands that such Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the Participant&#8217;s local human resources representative.  Each Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom such Participant may elect to deposit any ordinary shares acquired pursuant to an Award.  Each Participant understands that Data will be held only as long as is necessary to implement, administer and manage such Participant&#8217;s participation in the Plan.  Each Participant understands that such Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, without cost, by contacting in writing such Participant&#8217;s local human resources representative.  Each Participant understands, however, that refusing or withdrawing such Participant&#8217;s consent may affect such Participant&#8217;s ability to participate in the Plan.  For more information on the consequences of refusal to consent or withdrawal of consent, each Participant understands that such Participant may contact his or her local human resources representative.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(s)&#160;&#160;&#160;&#160;Choice of Law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of California, without regard to conflict of law principles that would result in any application of any law other than the law of the State of California.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Covenants of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Securities Law Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award.  If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Awards unless and until such authority is obtained.  A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;No Obligation to Notify or Minimize Taxes&#59; No Liability for Taxes.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award.  Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award.  As a condition to accepting an Award under the Plan, each Participant (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section 409A only if the exercise or strike price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award.  Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise price or strike price is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Additional Rules for Awards Subject to Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Application. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless the provisions of this Section 12 of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section 12 shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Non-Exempt Awards Subject to Non-Exempt Severance Arrangements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  To the extent a Non-Exempt Award is subject to Section 409A due to application of a Non-Exempt Severance Arrangement, the following provisions of Section 12(b) apply.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the Non-Exempt Award vests in the ordinary course during the Participant&#8217;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of&#58; (i) December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the calendar year that includes the applicable vesting date, or (ii) the 60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day that follows the applicable vesting date. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant&#8217;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement of such Non-Exempt Award upon the Participant&#8217;s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day that follows the date of the Participant&#8217;s Separation from Service.  However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section 409A applicable to &#8220;specified employees,&#8221; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such Participant&#8217;s Separation from Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant&#8217;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during the Participant&#8217;s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award.  Such issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Treatment of Non-Exempt Awards Upon a Change in Control for Employees and Consultants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The provisions of this Section 12(c) shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award in connection with a Change in Control if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Vested Non-Exempt Awards&#58;  The following provisions shall apply to any Vested Non-Exempt Award in connection with a Change in Control&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the Change in Control is also a Section 409A Change of Control, then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award.  Upon the Section 409A Change of Control the settlement of the Vested Non-Exempt Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award.  Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change of Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the Change in Control is not also a Section 409A Change of Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non-Exempt Award.  The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Change in Control had not occurred.  In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unvested Non-Exempt Awards.  The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to Section 12(e).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the event of a Change in Control, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award.  Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Change in Control.  The shares to be issued in respect of any Unvested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Change in Control had not occurred.  In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Change in Control.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Change in Control, then such Award shall automatically terminate and be forfeited upon the Change in Control with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award.  Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the Change in Control, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in Section 12(e)(ii) below.  In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Change in Control, and regardless of whether or not such Change in Control is also a Section 409A Change of Control.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Treatment of Non-Exempt Awards Upon a Change in Control for Non-Employee Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The following provisions of this Section 12(d) shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of a Non-Exempt Director Award in connection with a Change in Control. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the Change in Control is also a Section 409A Change of Control, then the Acquiring Entity may not assume, continue or substitute the Non-Exempt Director Award.  Upon the Section 409A Change of Control the vesting and settlement of any Non-Exempt Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director Award.  Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change of Control pursuant to the preceding provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the Change in Control is not also a Section 409A Change of Control, then the Acquiring Entity must either assume, continue or substitute the Non-Exempt Director Award.  Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Change in Control.  The shares to be issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Change in Control had not occurred.  In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the RSU Award is a Non-Exempt Award, then the provisions in this Section 12(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Any exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Change of Control, to the extent it is required for compliance with the requirements of Section 409A, the Change in Control or Change of Control event triggering settlement must also constitute a Section 409A Change of Control.  To the extent the terms of a Non-Exempt Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation From Service.  However, if at the time the shares would otherwise be issued to a Participant in connection with a &#8220;separation from service&#8221; such Participant is subject to the distribution limitations contained in Section 409A applicable to &#8220;specified employees,&#8221; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#8217;s Separation From Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The provisions in Section 12(e) for delivery of the shares in respect of the settlement of a RSU Award that is a Non-Exempt Award are intended to comply with the requirements of Section 409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;Severability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;Termination of the Plan.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board may suspend or terminate the Plan at any time.  No Incentive Stock Options may be granted after the tenth anniversary of the earlier of&#58; (i) the Adoption Date, or (ii) the Effective Date.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;Definitions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in the Plan, the following definitions apply to the capitalized terms indicated below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquiring Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the surviving or acquiring corporation (or its parent company) in connection with a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means the date the Plan is first approved by the Compensation Committee of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act.  The Board may determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the annual meeting of stockholders of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means shall mean any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of the NASDAQ Stock Market or the Financial Industry Regulatory Authority).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appreciation Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (i) a stock option or stock appreciation right granted under any of the Prior Plans or (ii) an Option or SAR granted under the Plan, in each case with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the option or stock appreciation right, as applicable, on the date of grant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Automatic Grant Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the grant program in effect for Eligible Directors under Section 7 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a RSU Award, a SAR, a Performance Award or any Other Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.  The Award Agreement generally consists of the Grant Notice and General Terms and Conditions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company.  Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all Participants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalization Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events that has a material negative impact on the business or reputation of the Company&#58;  (i) such Participant&#8217;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company&#59; (ii) such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company&#59; (iii)  such Participant&#8217;s unauthorized use or disclosure of the Company&#8217;s confidential </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information or trade secrets&#59; or (iv) such Participant&#8217;s gross misconduct. The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#8217;s Chief Executive Officer with respect to Participants who are not executive officers of the Company.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events constituting a change in ownership or control of the Company&#59; provided, however, to the extent necessary to avoid adverse personal income tax consequences to the Participant in connection with an Award, such transaction also constitutes a Section 409A Change of Control&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a merger, consolidation or other reorganization approved by the Company&#8217;s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company&#8217;s outstanding voting securities immediately prior to such transaction,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a stockholder-approved sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets in complete liquidation or dissolution of the Company, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;the closing of any transaction or series of related transactions pursuant to which any person or any group of persons comprising a &#8220;group&#8221; within the meaning of Rule 13d-5(b)(1) of the Exchange Act (other than the Company or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly the beneficial owner (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company&#8217;s securities (as measured in terms of the power to vote with respect to the election of Board members) outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company&#8217;s existing stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that (1) if no definition of Change in Control (or any analogous term) is set forth in such an individual written agreement, the foregoing definition shall apply&#59; and (2) no Change in Control (or any analogous term) will be deemed to occur with respect to Awards subject to such an individual written agreement without a requirement that the Change in Control (or any analogous term) actually occur.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Compensation Committee and any other committee of Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with Section 8(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the common stock of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Sangamo Therapeutics, Inc., a Delaware corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Compensation Committee of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.  Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.  In addition, to the extent required for exemption from or compliance with Section 409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#8220;separation from service&#8221; as defined under Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a member of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the date of the Annual Meeting in 2018, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eligible Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a Director who is not an Employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Company or the Affiliate of the Company that employs the Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(bb)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(cc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dd)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Full Value Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Award granted under the Plan or an award granted under the Prior Plans that is not an Appreciation Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the written summary of the general terms and conditions applicable to an Award and which is provided to a Participant along with the Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ff)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Body</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any&#58; (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature&#59; (b) federal, state, local, municipal, foreign or other government&#59; (c) governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority&#59; or (d) self-regulatory organization (including the Nasdaq Stock Market and the Financial Industry Regulatory Authority).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(gg)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the written notice provided to a Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(hh)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hostile Take-Over</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a change in ownership or control of the Company effected through either of the following transactions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a change in the composition of the Board over a period of thirty-six (36) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a Hostile Tender-Offer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hostile Tender-Offer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the acquisition, directly or indirectly, by any person or related group of persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Company&#8217;s stockholders which the Board does not recommend such stockholders to accept.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(jj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an option granted pursuant to Section 4 of the Plan that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(kk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation S-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K&#59; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ll)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Exempt Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii) the terms of any Non-Exempt Severance Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(mm)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Exempt Director Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable grant date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(nn)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Exempt Severance Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#8217;s termination of employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such severance benefit does not satisfy the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(oo)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonstatutory Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any option granted pursuant to Section 4 of the Plan that does not qualify as an Incentive Stock Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(pp)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(qq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(rr)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant and which includes the Option Grant Notice and the Option Terms and Conditions.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Optionholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(tt)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 5(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(uu)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means a written agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant.  Each Other Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(vv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Own,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Owned,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Owner,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means that a person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ww)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(xx)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Award that may vest or may be exercised contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section 5(b). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(yy)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board&#58; (i) earnings (including earnings per share and net earnings)&#59; (ii) earnings before interest, taxes and depreciation&#59; (iii) earnings before interest, taxes, depreciation and amortization&#59; (iv) earnings before interest, taxes, depreciation, amortization and legal settlements&#59; (v) earnings before interest, taxes, depreciation, amortization, legal settlements and other income (expense)&#59; (vi) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense) and stock-based compensation&#59; (vii) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation and changes in deferred revenue&#59; (viii) total stockholder return&#59; (ix) return on equity or average stockholder&#8217;s equity&#59; (x) return on assets, investment, or capital employed&#59; (xi) stock price&#59; (xii) profit (including gross profit) and&#47;or margin (including gross margin)&#59; (xiii) income (before or after taxes)&#59; (xiv) operating income&#59; (xv) operating income after taxes&#59; (xvi) pre-tax profit&#59; (xvii) operating cash flow&#59; (xviii) sales or revenue targets&#59; (xix) increases in revenue or product revenue&#59; (xx) expenses and cost reduction goals&#59; (xxi) improvement in or attainment of working capital levels&#59; (xxii) economic value added (or an equivalent metric)&#59; (xxiii) market share&#59; (xxiv) cash flow&#59; (xxv) cash flow per share&#59; (xxvi) share price performance&#59; (xxvii) debt reduction&#59; (xxviii) implementation or completion of projects or processes&#59; (xxix) employee retention&#59; (xxx) stockholders&#8217; equity&#59; (xxxi) capital expenditures&#59; (xxxii) debt levels&#59; (xxxiii) operating profit or net operating profit&#59; (xxxiv) workforce diversity&#59; (xxxv) growth of net income or operating income&#59; (xxxvi) billings&#59; (xxxvii) bookings&#59; and (xxxviii) other measures of performance selected by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(zz)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows&#58; (1) to exclude restructuring and&#47;or other nonrecurring charges&#59; (2) to exclude exchange rate effects&#59; (3) to exclude the effects of changes to generally accepted accounting principles&#59; (4) to exclude the effects of any statutory adjustments to corporate tax rates&#59; (5) to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles&#59; (6) to exclude the dilutive effects of acquisitions or joint ventures&#59; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture&#59; (8) to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends&#59; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company&#8217;s bonus plans&#59; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to expensed under generally accepted accounting principles&#59; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles.  In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period.  Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(aaa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to vesting or exercise of an Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(bbb)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means this Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ccc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the person, persons, and&#47;or third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company&#8217;s other equity incentive programs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ddd)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Termination Exercise Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the period following termination of a Participant&#8217;s Continuous Service within which an Option or SAR is exercisable, as specified in Section 4(g).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(eee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s Amended and Restated 2013 Stock Incentive Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(fff)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prior Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means the Predecessor Plan and the Company&#8217;s 2004 Stock Incentive Plan (together).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ggg)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prior Plans&#8217; Returning Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means shares of Common Stock subject to outstanding stock awards granted under the Prior Plans and that following the Effective Date&#58; (A) are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued&#59; (B) are not issued because such stock award or any portion thereof is settled in cash&#59; or (C) are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(hhh)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor Plan&#8217;s Available Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the number of shares available for the grant of new awards under the Predecessor Plan as of immediately prior to the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the document containing the Plan information specified in Section 10(a) of the Securities Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(jjj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(kkk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(lll)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(mmm)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means a written agreement between the Company and a holder of a RSU Award evidencing the terms and conditions of a RSU Award grant.  Each RSU Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(nnn)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 16b-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ooo)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 405</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ppp)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Section 409A of the Code and the regulations and other guidance thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(qqq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 409A Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(rrr)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(sss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the number of shares available for issuance under the Plan as set forth in Section 2(a), subject to adjustment pursuant to Section 6(a) in connection with Capitalization Adjustments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ttt)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Appreciation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(uuu)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SAR Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a written agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant.  Each SAR Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(vvv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ten Percent Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(www)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trading Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s policy permitting certain individuals to sell Company shares only during certain &#8220;window&#8221; periods and&#47;or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(xxx)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unvested Non-Exempt Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(yyy)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vested Non-Exempt Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Change in Control. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-23</font></div></div></div><div id="i89eaa63eb2fa4775974405ea28334ee8_217"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:justify"><img alt="sgmoproxycardp1.jpg" src="sgmoproxycardp1.jpg" style="height:892px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i89eaa63eb2fa4775974405ea28334ee8_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:justify"><img alt="sgmoproxycardp2.jpg" src="sgmoproxycardp2.jpg" style="height:884px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>hrdiversitychartsidebyside.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hrdiversitychartsidebyside.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &K _D# 2(  A$! Q$!_\0
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MS)$KJ)E9-CA3SM89=B2:QY%J]D:\[LENS]*J*^'?^"97[7'Q-F^+GQ:_9_\
MB[<1>+/B+\(52[L-8@5+=_$5A( T1D!VJK[9+<ACU$XW'*EFY'PO^Q-^T7^T
MCI&O^-_CO^T!X^^"=S)J$PL/#?@W7(;+3])M 0L327$,FV3=DC#?-PI9MS;5
M7L[.S8_:75TC]$**_/C_ ()$_M$>.Q^U7\:/@;XJ^)D7QDT7X?I:W^B>*S<)
M<3SQRA=T32J[[\;T!!=BDB2#/8>,?L-_#SXW?\%"/B!\;]&OOV@OB;X)\'>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M) W1N3Q\HFC)^4,PX#_@KC_P4$^&W[47QQ_9Z\&?#K7(/%ZZ'\0--U75-4L
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M?_:1T.V:34_@OXHM_P"US&K;IM)N9%256(_AW[8_I<OSV.K_ ,$0_!%_XX\
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MZG>P@1@12W(7S70"&(!68C]TG'RC'2UB[=#97ZA1112&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%6U8(_D1^2F#Y.YN22?TBJ9QY79E0ES*X4445)04444 %%%% !1110 4444
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M]6N89KD*\5O;6\G[ICY;J3NQR'&Y=H#'LW\@]HOF?;E<I\&_CAX3_:$\&?\
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M)\0/"">&-<U73;)[I_#%U#*DB23(F3Y++&GS=3NDP"4 ;A[S]NOP_P#MO_\
M!9/]ERZ\#V6MW'@3P]#XJBL/$%[ILUE;ZU=2Z1(;A;<2JKLD21VV25!W2D8Q
M@G].J*%45M5KL#IN^CTW/Q;\0?LK?L[?LE_M=_%K3/VL? .NRZ'XI\0W'B+P
M;XWCDU9K">RN'9S:2C3Y!B5&('^K)+%L[5V9^FO^"1OP_P#@GK'[07C#Q?\
M!#X#^)? _@[3],&EV'CO4]>U/;XE\UXGEMXK&Z=AY8:)6\S<2-B9"%L5^A5%
M.59M6_44:*3O^A\.?\&[7_*+GPG_ -A75/\ TKDK[CHHK.4N:39I&/+%(***
M*DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG]ISX5_&/QYX$UCXD?"+1+&;P[XQTW2I;A+S2XW>1[>] MW25D624EL-C]V
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M_1K34K?3]/AWDS&_6<&-(UP-PC8QX4[AC=7[?T4H5.5#G3YF%%%%9&H4444
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MM0\%>*!=-H>JO";M+9E225$D5S'N96VJX4HQ7#;'8!E)R.XHHV#?1G&?L_\
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M>\+Z/>Z):V\<D8M)(;IX7D9U*%RX,";2'  +9!XQWE92=S6*L%%%%24%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5^<?\ P4(\":HG[>MG\-["
M&9M#_:KBT"WU7;"6RNAWCS:@0<=]/,2GVZ\5^CE%5"7*[DRCS*Q^<O[=GP\U
M%_\ @HAI_P -K2&67PY^T_+X>N]95$ZKH%S)/?88@@!K..U0^O ((Z^EZ_\
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M^!KQ=0\-^$M;UB.YT319X\^2R1B%99/)R?+$\L@3L!BM;XQ_\$\?#'Q:\?\
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MGC74O%'C?XB>,!IW]D6FL>++^&ZGTRS+;WAMUAAAC3>P4N^PNVT98BN0T_\
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M+FGTDN)L-C:V'A0H6A*45>-2]DVM?WI^NG_#S[X&_P#0\?\ E&U#_P",4?\
M#S[X&_\ 0\?^4;4/_C%?D7175_Q!?)/^?M7_ ,"A_P#('#_Q,YQ3_P ^,/\
M^ U/_EI^NG_#S[X&_P#0\?\ E&U#_P",4?\ #S[X&_\ 0\?^4;4/_C%?D711
M_P 07R3_ )^U?_ H?_(!_P 3.<4_\^,/_P" U/\ Y:?KI_P\^^!O_0\?^4;4
M/_C%7-)_X*4_ 74_,\_XK>#M$V8V_P!O7PT7SLY_U7VORO-QCYMF[;N7.-PS
M^/\ 7S3_ ,%$/^90_P"WW_VWKS,X\(LIPV#G7HU:G,K;N+6Z6R@OS/H^$OI#
M<0YEFU+!8JA1Y)<U^6,T](MJS=22W79Z']$7_#Q3]GW_ *+K\'/_  M--_\
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M3]GW_HNOP<_\+33?_CU?RCT4?ZA8?_GZ_N0?\1&Q/_/F/WL_JX_X>*?L^_\
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M;NE.:BVO-7/ZK_\ AOOX$_\ 1:OA+_X5^G__ !ZC_AOOX$_]%J^$O_A7Z?\
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M_1:OA+_X5^G_ /QZOYAJ*/[.CW#_ (@/@/\ H*G]T3^GG_AOOX$_]%J^$O\
MX5^G_P#QZC_AOOX$_P#1:OA+_P"%?I__ ,>K^8:BC^SH]P_X@/@/^@J?W1/Z
M>?\ AOOX$_\ 1:OA+_X5^G__ !ZC_AOOX$_]%J^$O_A7Z?\ _'J_F&HH_LZ/
M</\ B ^ _P"@J?W1/Z>?^&^_@3_T6KX2_P#A7Z?_ /'J/^&^_@3_ -%J^$O_
M (5^G_\ QZOYAJ*/[.CW#_B ^ _Z"I_=$_IY_P"&^_@3_P!%J^$O_A7Z?_\
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MU%']G1[A_P 0'P'_ $%3^Z)_3S_PWW\"?^BU?"7_ ,*_3_\ X]1_PWW\"?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M****Q.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .M\!_P#('D_Z['_T%:VZQ/ ?_('D_P"NQ_\ 05K;K\NS
MG_?:GJ?ZQ>"G_)#99_UZ7YL****\P_4@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K^M2OY*Z_K4KR\R^S\_T/YU\??\ F _[B_\ N,_$
MW]JS_DZ+XD_]C3J?_I7+7T3_ ,$S/V5? 7[0?PY\9W_B_0?[7NM)N8X[1_MM
MQ;^4IB9B,12*#R!U!KYV_:L_Y.B^)/\ V-.I_P#I7+7V7_P1E_Y)%\1/^OR'
M_P!$O7]-\8XNOAN%%6PTW"25+6+:>KCU6I_C?X:9=A,=X@2PV-I1J4W*O>,X
MJ4793:T::T>J/A#X:IHLOQ&T!?$CR1^'6U*W&JO'NWK:>:OG$;06SLW8P,^E
M?=7P0_9Y_9G_ &R=.\0Z1X*T#Q+H&J:.@_TR>ZN/,*L2$F17FDC921]U@K>P
MZU^?=?H5_P $G_BGI'COX2:W\-;+3KSPYXAM;2:[GU_3XXO,NDDE(5RY0@2Q
M^8JJ'WY5<CH0-/$>.*H9?_:&$J5(R@TO=GRQ2;UE*/VNUM=_4Q\%9X'%9PLG
MS&A1J4ZJD_WE-2G)J.D(3?\ #;^*^FV]VCQW]C']D+PSXP\9_%"7QC9:MXLM
M/AI)]F72=&W>?J\ADG0E CJY_P!1\JAADN.>.=7]JS]A/2;CQ7\,C\--'U;P
M_+\1O,B/A_67=;K32BH[2.KEW541B9 6;;M&,[L5X:GCOQ=^Q_\ 'KQ/;>%_
M$=S9ZIHVHW6E37B(CK>+%,R$O&X9&R5W88'!]Z^Q/ .@_$#QQI,6F:[XI/\
MPN'X@Z*]U=7]U&D7_"%^'@ZABD484)-,[*,+L/()(,63YF=U\SP..CFL<4G2
MG'W8MRM\&K<+6Y8O]XY?%M!:M'N<*X3(\VRJID$LO:Q%.3YYI0O?VMXQC5;Y
MN>4?W,86Y%K5;M&1\@_M7V'@3PM\08?#G@.U\RS\.6XLK_6&N)9&UN[7 EF"
MLQ1$# A0@ /S'D%<?#'_  40_P"90_[??_;>OT4_:B_88_X4'\.]/\7^'_&F
MC^/O"]W=FQEOK"-4%O-S@'9)(I&58$[L@X!'-?G7_P %$/\ F4/^WW_VWKZ.
M6+PV(R%RPM5U4K)RE?F;4E>ZE9IWZ65NBM8^7RO+\;@^-:<,?0C0E+FDH0Y>
M11=.7+RN+<6K?:3=W=MN5SYIHHHKX@_> HHHH **** "BBB@ HHHH *]_P#^
M"6WP3\,?M&?M]_#;P5XRTS^V/#.OW\L%_9?:);?ST6VF<#S(F21?F53\K#I7
M@%>L?L._M+Q_L=?M5^#_ (ER:._B!?"=Q+=#3ENOLQNV:"2-5\W:^P9<9.UN
M >#7-C(U)8>I&E\33MTUMH=> E3CB:<JWPJ2OUTOKIUT/T7_ &SK+_@G9^Q=
M\?/%'PP\0_ 3XDWGB7PW' );K2]7O);)FGM8KF,HTFK(YPLR Y0<ANHP3\P_
M\$3O^":6F?\ !13X_:S_ ,)7<W-OX"\"VL-[K$=M)Y<U_),SB"V#_P#+-6\N
M5F<<[8R!@L&7]&?V8_%OP"_X.#OAS\2?^$C^"MGX)\=Z>EM'J&OVZ03ZBC2I
M)':S1:BD4<DK1K; &.5-NU57#KFO/_\ @V1L+?PMX9_:,\&'R9O$.CZG:13R
M1*,7*!+R%=K=6 >.3KP/,']XU\-_:%;#9?7A>:K04%+FES6OI>.KM>[_  /T
M#^S:&*S+#SM!T)N;CRQY;VUM+17M9?B<#\7O^"<7[,/[;G[#/Q%^(_[+^B^(
M/#>O?"V[NXYH;N]NIX];6U02R82>:8[98#OA9"A)PK*#D#:_8@_X)0_ :U_9
M5^#NL?$#X8_%#XM^(_C2JW#:SX>6Y_L[P>LH78+GR+B,11(#S)(LA+"3@#"#
M;_X-Q5;P-^P5^T+K>L2"QTFSO9A.T^Y1;&WTXO.6&.,*ZY[\<XXKX6_X)M_M
M<_M0IXGT/X(?!#QUJ6FP>)[YQ!8R6EK=6^G!_FGG#SQ2-!&JAI'\LCD,0"[<
M[<F,FL1AJ5=J-*2=Y2=[.+NG):Z/4PY\#3>&Q=:@G*M%KEC%-74E9J+TU6AZ
M=H7_  2M\%?!K]M+XTW7Q#U2]O/V?/@%<+<:G>,Q@N-?DGA26STB.1&7-P3+
M&DAC(.0,",RJ5^$?B#KVF>*/'.K:CHNA6_AG2+RZDELM)@N9KF/3H2Q*0B65
MFDDVC W,<D\\=*_8CXQ?L1:-^V9\#(/#=E\;M ^&/P&^'_B">S;Q3KZ)<7/Q
M*\5NSKJ&IS22W$"D><SQ1,78NWG;04$9/YC_ +>_[$GB+]@#]HF^\ >(KRRU
M4K;QZAINI6G$6I6<I81S!224.4=64DX9&P6&&/L9-CXUIN-6I>I9*VJT6[[<
MS;N^JT70\3/<ME0IJ=*E:G=OFT>KV7?E25HO:5G+JCQ>BBBOI#Y8**** "BB
MB@ HHHH **** "M+PC_R,-O_ ,"_]!-9M:7A'_D8;?\ X%_Z":XLQ_W2K_AE
M^3/M_#3_ )*_*O\ L)H?^G8G;4445^4'^OH4444 %%%% !1110!]Q?L/Z[^Q
M/IOPB\'Z7\8/"_BSQ)\0M>NYX=3N[2:^CLM'!N'6#>(IXL@Q>63Y22G).<'@
M1?\ !;3_ ()T>$?V"OB=X2N_ UU>)X>\<07;II5U*9WTR6V,(?;*3N:-Q.F
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M[#-Y_P"CWKF:^6Q/\:7J_P S]LRW_<Z7^&/Y(****Q.T**** "BBB@ HHHH
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MWV);@'R9PTTCNI$@,,BF1QN9"N &)]M\+VS>+O\ @TVU&STN(W5WI_FO=)$
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M'P2U3P?\%/@5X,^"SZDL@6[TV[BFCLW<8::*WBM+>/SL=&?< 0"5;&*^/OV
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M;3?'>E>)?A+X:^+F@>/!8?:M.UF>...!K3[3M($D$R-N^TMG*?PBO7/VX?\
M@O=XC_:?_9T?X4^!OAYH?PB\$WD"VE[:Z=>_:9);92"+:(I# D,)(^95CRP.
MW(!8-\ T5YM3*,)4Q'UF<+SNGN]UHG:]OP/5I9WC:>&^J4YVA9K97LW=J]K]
M>Y]>_P#!-3_@KOXC_P""?'AKQ)X1O?"FD_$;X<^*BTU[X=U"86X6=D$;NDAC
MD&V2-55XWC=6"KC;\VYO_!2[_@KEXA_X*&>'O#'A2T\)Z3\._AWX199K#P]8
M3"X'GK&T2.T@CC4+'$S(B)&@4.^=V1M^1**?]E83ZS];Y/?[Z^E[;7\[7)_M
MC&_5?J?M'[/MIZVOO;RO8]_UO]N-=,_84L/@=X,\+'PI9ZEJ7]K>,]9;4_M=
MUXNG3!@1E$48@MXB 1$"^2B'=G<7^E/V:?\ @O\ 3?!?X'>"?#GBGX)^"_B#
MXJ^&5@-,\)>*+RX2"YT>!(A%$ IMY'W*BJI:*6+<J@'G+'\[**5?*<)6AR5(
M75V]W>[WUO?RMM;38=#.L90G[2E.SLH[*UEMI:V^M[7OKN=/\:/BYK7Q\^+7
MB/QKXCG2YUWQ3J$VI7KHNU/,E<L0@R<(,X49X  [5S%%%>A&*BE&.R/-E*4I
M.4M6PHHHJB0HHHH **** "BBB@ HHHH ZWP'_P @>3_KL?\ T%:VZQ/ ?_('
MD_Z['_T%:VZ_+LY_WVIZG^L7@I_R0V6?]>E^;"BBBO,/U(**** "BBB@#H_@
M_P#$)_A'\6_"WBN.TCOY/#&KVFK+;2-L2X,$R2B,G!P&V8S@]:_1#2?^#AK0
M/ <VL:IX-_9J\$^%_%>M1[;K5K?4XU:Z89VF<16<<DH!.<&7UY&:_,RBLJE&
M$_B1\]G7"V5YM*,\PI\_*K?%)*U[V:C))Z][GMW@#_@H+\2/AY^V-<_'&VU*
M"Y\9ZA>2W-\L\;&TO(Y1M:V>,,#Y(0*JJ&RH1,$%0:^R-8_X./'LH-;U7PO\
M"/"7A[QWKUND-YX@?4Q.UR8P1&9D2VCDE5,G:K3<9K\R:*4L/3E\2,,RX+R7
M,)PGB\.FX)15FX^ZMHM1:32Z)W1[G^RO^V<G[/O[0&M_%37O"Z^/?'=TMU=Z
M3>7U^+>WT[5+@LS7\L(B;SV#.Q";HP"Q.<[2O3_L3?\ !3;Q%^R=\2_'.KZ]
MH.G?$S1_B>N?%>EZQ(%_M>0-*XD,A1U!S-+D-&RL)",="/F6BJ=*+O='=B^'
MLNQ4:D:].ZJ*,7J]HN\4M?=L]5RVUUW/I3_@H+_P4;OOVY!X5T>P\'Z-\._
MW@F!XM'\/:7('BMV<*&8LJ1IP$4*JQJ%&[KDFOFNBBJC%17+$[,MRW#8##QP
MF$CRPCLM7N[O5W;;>K;=PHHHJCN"BBB@ HHHH *_K4K^2NOZU*\O,OL_/]#^
M=?'W_F _[B_^XS\3?VK/^3HOB3_V-.I_^E<M<#7U5^T#_P $Z?C)XW^/7C;6
MM+\'?:=-U?7[^]M)O[6L4\V&2XD=&VM,&&58'! (SR*Y'_AV#\<O^A'_ /*S
MI_\ \?K^M\LXHR:.#I1EBZ2:C'_EY#LO,_Q$SS@/B:IF6(G#+J[3G-IJC4LU
MS/5>Z>!T5[Y_P[!^.7_0C_\ E9T__P"/T?\ #L'XY?\ 0C_^5G3_ /X_7=_K
M7DG_ $&4O_!D/\SR_P#B'_%/_0MQ'_@FI_\ (G@=%>^?\.P?CE_T(_\ Y6=/
M_P#C]'_#L'XY?]"/_P"5G3__ (_1_K7DG_092_\ !D/\P_XA_P 4_P#0MQ'_
M ()J?_(G@=?-/_!1#_F4/^WW_P!MZ_1+_AV#\<O^A'_\K.G_ /Q^O#OVS/\
M@C#^TK\5_P#A&_[ ^&_V_P"P?:O/_P"*@TJ+R]_D[?OW*YSM;IZ5X^?<39/4
MP$X4\72;TT52+ZKS/KN!.".(\/GM"M7R^O&*YKMTJB2]R2W<;;GYD45]C_\
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M%?8__#@']KC_ *)-_P"71HW_ ,ET?\. ?VN/^B3?^71HW_R71_;& _Y_P_\
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M_1+O_+DTC_Y*H]O3_F7WA_KAD/\ T&T?_!D/_DCY*HKZU_X<7_M3_P#1+O\
MRY-(_P#DJC_AQ?\ M3_]$N_\N32/_DJCV]/^9?>'^N&0_P#0;1_\&0_^2/DJ
MBOK7_AQ?^U/_ -$N_P#+DTC_ .2J/^'%_P"U/_T2[_RY-(_^2J/;T_YE]X?Z
MX9#_ -!M'_P9#_Y(^2J*^M?^'%_[4_\ T2[_ ,N32/\ Y*H_X<7_ +4__1+O
M_+DTC_Y*H]O3_F7WA_KAD/\ T&T?_!D/_DC]:O\ @A?_ ,HL?A=_W%O_ $[W
MM?6M?.__  2C^!?BK]FK]@3P%X*\:Z7_ &+XFT7^T/MME]IAN?)\W4;J:/\
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MI?\ @R'^8?\ $/\ BG_H6XC_ ,$U/_D3P.BO?/\ AV#\<O\ H1__ "LZ?_\
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M*Z7_ &U<Z5]FM[.P,_D+=W5U=0VENC28;8AFGCW-@X7)P<5\\>)],^*6G_\
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M@&>@T5\47?\ P3+\;3_L9Z/\*(O'4T%Y8:D-.DUE]=U.XM?[$C_=Q2)IKO\
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ML[JQL-/TSPB=*CU)9[ V;33NUY.?/^ZQ*;8_E($2[MU?3-%'/(.2)\?^+_\
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MHC#I^YCMR7*2'=M*-T?Q"_X)D?\ ">:I\0+G_A-OLO\ PG7Q!T7QWM_L??\
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MMKOAGX?:Q=2MIE]#:,(Y[BTN$\R(R1L[%F?+-(3CYN'.G'5=10G)V['H-O\
M\%Y_A1KO@B'Q#X>\$?&?Q?I,-JEWK-SH7A=;V#PP&Y"7TRS>5&X7#$([X!P>
M<BO5_B?_ ,%./AC\-_V)K7X_02ZUXG\ WK0I"='MD:\9Y)O(*F.:2(*R2!E<
M%@05.,UQ7_!##PUI^E?\$J?A<EO9V\:ZC;7UQ=@(/])D>^N0S/\ WB0 .>R@
M= !7YYZC +'_ (-L_%UI'N%O9?$)X($+%A$@U&+"C/;DGZD^M/DBY67<.>2C
M=]KG[#?M4?M(Z'^R)\ ?$?Q&\26NJWNB>&(8YKJ#3(HY+J0/,D0V+(Z(3ND&
M<N. ?I7F7[2?_!4+X<_LIVWPQF\56?BOR?BQI]W?Z*UC81W+)Y%O!,()4$F_
MSI3<111K&K@R-@E1\U<I_P %Q?$=A;_\$I?BE,][:B'4;.QCM7\T;;EGOK8J
M$/\ %D9(QV!/05XS^TQI=OJ_[6G_  3BBN84GC2VU*=5<9 >/3M,D1OJKJI'
MN!40@FKOS_(J<VG9>7YGTI9?\%./ >D_LU:S\4O&^A^/?A7HFBZD=(?3_&.B
M_P!GZM=76Q9$BAM5=WD+JPVXXX8G 1B.8^$?_!8KX<?$?XE^'_"^N^$_BM\+
M[OQ>XB\/W?C?PV=*L=;<XV+!,)'4ELC;NV@D@9R0#XI_P74A\47?[1/[)D/A
M_P#X1+#>++XP?\)9YO\ 8!U(?8OL2W?E?/@GS@ O4Y[5C_\ !0OX&_M8?M#?
MLYS>'?BQXI_8X\$^&SJ=I=6^N?VKK6ESZ?>1R9A,,]PK1K(WS)]TDJ[ 8)R*
M4(M)]R7.2;2Z'Z:T5G^$FO&\*Z8=0FM[F_-I$;F:W;=%++L&]D.U<J6R0=HX
M(X'2M"N<Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **Q/B3\1=&^$/P]USQ5XCO5TW0/#=A-J>HW;1O(+>
MWA0R2/M0%V(53A5!8] "2!5/X7?&3PU\9OA9IGC7PYJD=]X7U>U-[:WTD4EL
MK0C.69955TQM.0Z@C!S19[A?H=/17%? +]H;P?\ M0?#F'Q;X&U8ZYX>N9I(
M(;S['/:B5HSM;:LR(Q7/1@-K#D$BNUHVW#?8**YGQ3\8/#O@KXA^%O"FIZC]
MFU_QJUTNC6GV>5_MAM8?.G^=5*(%CP<N5!R ,DXK2\(>+[7QOHWVZRBU2&'S
MI8-NH:;<Z?-NC=D8^5<(DFTE3M?;M=<,I92"0+FI1110 45QGQ?^/.A? Z&S
MDURU\77$=\LK(VB>$]5UT1"/:6,IL;>;R1\XQYFW=AMN=K8YGX%_MM> ?VDW
MTQO!K>,]4L=9A:>RU.;P1K=EI=S&H)++>W%I';X^4@?O/F/ R>*=G:XN97L>
MLT444AA1110 4444 %%%<CX!^._A+XH^./%GASP_K5OJNK^!KF*RUV*!'*6$
M\J%UB,FWRV<*#N5&8H>&"GB@#KJ*XKXP_M">$_@1_9*>([Z\6]U^:2WTS3M-
MTRZU;4M1:-#))Y-I:1RSR+&@W.RQE4&"Q&16I\*OBKX>^-WP]TOQ5X5U2WUG
M0-9B\ZUNH0R[L,59&5@'CD1U9'C<*\;HR,JLI =G:X75['0T444@"BBB@ HH
MHH **** "ORQ_82\1_MD_M^_"O6_&FD?M+:7X5L;#Q%>:(EC<>!=+NG'D^6P
M;>(%X(D Y&?EZU^IU? __!NI_P F1^*O^R@ZM_Z+MJUAI%LRFKR2&> _VN/C
MU^PY^U7X)^&W[1NJ^&O'G@_XHW!T[P[XWTFQ73Y+;4,JJV]U$BI&H9F0<+_R
MT#!V"LJ_0!\>>*/#_P"WOXA35OBG\/8/AAIO@(ZB_@^6_MH]<TVZ2YB+ZK,I
MB$B68BWH9&FV!G'R]Q\\?\'!KC4_A-\"]&L&C/B?4OBQI1TN(1[I7 AN48KC
M!P))8 1D9++^&SH&FP:S_P '!WC.TNH8[BUNO@<(9HI%RLJ-JEJ&4CN""156
M37,3=I\OFC[4\$^.M$^)?A:SUSPYK&E>(-$U!2]KJ&FW<=W:W*ABI*2QDJP!
M!'!/(-5/!OQ8\+?$:76$\/>)= UU_#UV^GZJNG:C#='3+E/OP3A&/E2+@Y1\
M,,<BOSQ_8X_:&C_X)J_L\?M2?#/7)OWG[/>I76K>&DG!!N]/U$&33U ).=UP
MR[B"0#<#/J?'/VD?"?B/]CO_ ((Q_![P.3XE_M[X[>+K>]\:'21YNK:@M\KW
M$MK$@QOG=!;1;<_.8RIX<TO9:V'[;2Y^JG@O]JCX8?$CQ>_A_P ._$?P'KVO
M1DA]-T[Q!:75XA'7,22%QC!SQVK7\:_&KP=\-M8MM.\1>+/#.@:A>VTUY;VN
MI:I!:S3P0C=-*B2,"R1CEF PHZD5^2W[3NB_#'Q;^S:NA_";]C']IKX>_$3P
MVL5SX6\36OPT:RO+:[B=65KFZBF::4, 02X<C.0,@5Z1^T[X%/[97[<7["VF
M?$[1[FWN/%?A._U+Q/HU[:26I-U#8)>3VDT#!6"^?"49& &,\8I^R0O:L_1+
M2OVD_AUKOPYG\86/C[P5>>$K64PS:W!KEM)IT,@QE&N YC#?,O!;/(]:G^%O
MQ^\"?'*&XD\$^-?"7C".TQY[:)K%OJ @STW&%VV]#UKXI_X*??L"75EH_P )
M-1^%/PAT#Q?X ^'_ (CO=<\3?#;3#%I=MKK3Q0HDRQ "-C'Y3C8%;/F_<8;A
M7$_LC_%#]F_Q+^W]X+O8OAAX[_9B^,EK:7.F6_AJ;1H=%T?Q&)4P8W1(]LC
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M5!#&L<:_@J@?A64H<JU-8SYGIL:]%%%06%%%% !1110 4444 %%%% !1110
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MDZGI6GNN=FR$1ID+G[K%E(&"""0?L.BDIR2LF-PBW=H****DH**** "BBB@
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ME6^@> )- U?1=-U[3;35/"KRW37<-Y(E[/"B07*PLA?>&Q;9"L%(KYX^ OQ
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M*63^:WS2)M#JK'JJKC@"OJ2H--TVWT;3K>SL[>&TM+2-88((8PD<** %15'
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M"B7PZAU^:+QY)HO[/MFL.JZKIAA?4)#J"1O>-;39:*252Q*MED\UU)ZUX?\
MM)Z/I'PX\._'[Q)H/B#X-?%GX='Q5?ZIXS\(^+K>YT;Q-IVHK(C36EE?1E96
M8,B" E ,85&. 3^GG_"%Z/\ \)C_ ,)%_9.F_P#"0?8_[._M/[*GVS[+O\SR
M/.QO\K?\VS.W=SC-<SXB_9C^&WB_Q_%XKU;X>^!]3\4P.LD6LW>@VLVH1LH
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M&K^#O"VJ^$].BBAM-$O-)@GTZUCB39$B6[(8U5%^50% 4<# JSHWPE\*^'/
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M "^/_O?1_P 1:/\ U0'_ ,OC_P"]]?CC11_JEE/_ #Z_\FE_F'^N><_\_O\
MR6'_ ,B?L=_Q%H_]4!_\OC_[WT?\1:/_ %0'_P OC_[WU^.-%'^J64_\^O\
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M_+X_^]]?CC11_JEE/_/K_P FE_F'^N><_P#/[_R6'_R)^QW_ !%H_P#5 ?\
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MO/\ ^X*/^(I#_JAG_EY__<%?DK16?U*CV_,]7_B$_"G_ $"_^3U/_DS]:O\
MB*0_ZH9_Y>?_ -P4?\12'_5#/_+S_P#N"OR5HH^I4>WYA_Q"?A3_ *!?_)ZG
M_P F?K5_Q%(?]4,_\O/_ .X*/^(I#_JAG_EY_P#W!7Y*T4?4J/;\P_XA/PI_
MT"_^3U/_ ),_6K_B*0_ZH9_Y>?\ ]P4?\12'_5#/_+S_ /N"OR5HH^I4>WYA
M_P 0GX4_Z!?_ ">I_P#)GZU?\12'_5#/_+S_ /N"C_B*0_ZH9_Y>?_W!7Y*T
M4?4J/;\P_P"(3\*?] O_ )/4_P#DS]:O^(I#_JAG_EY__<%'_$4A_P!4,_\
M+S_^X*_)6BCZE1[?F'_$)^%/^@7_ ,GJ?_)GZU?\12'_ %0S_P O/_[@H_XB
MD/\ JAG_ )>?_P!P5^2M%'U*CV_,/^(3\*?] O\ Y/4_^3/UJ_XBD/\ JAG_
M )>?_P!P4?\ $4A_U0S_ ,O/_P"X*_)6BCZE1[?F'_$)^%/^@7_R>I_\F?K5
M_P 12'_5#/\ R\__ +@H_P"(I#_JAG_EY_\ W!7Y*T4?4J/;\P_XA/PI_P!
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M]1_JEE/_ #Z_\FE_F?)?ZYYS_P _O_)8?_(G['?\1:/_ %0'_P OC_[WT?\
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M(?\ 5#/_ "\__N"OR5HH^I4>WYA_Q"?A3_H%_P#)ZG_R9^M7_$4A_P!4,_\
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M4,_\O/\ ^X*_)6BCZE1[?F'_ !"?A3_H%_\ )ZG_ ,F?K5_Q%(?]4,_\O/\
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MN!1110 4444 %%%% !1110 45ZW^RW^PO\4_VTO[=_X5IX6_X27_ (1K[/\
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M?9>[&W=GC9IA*^,PE2O%J+C\?Q/X(I\KEK\*_F?O3OV1^+]%%%?>GYR%%%%
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MD%]_9GG_ -F_:)/LGGX\WR=QV;L<;MN,^]4J]0_H9.ZN%%%% PHHHH ****
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M??\ +W_P#_V:NDKF_A]_R]_\ _\ 9JZ2OS3B#_?ZGR_])1_J/]'3_DWF7_\
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M?#7P^TI?"/PT35;1H[SQIKJO*YOY V#]EM2S$;@&\Q)F&U@JGX;^!/P.N?\
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M"J?_ "H_(NBOUT_X=@_ W_H1_P#RLZA_\?H_X=@_ W_H1_\ RLZA_P#'Z/\
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MC6?_ )+H_P!>L!_)/[H__)!_Q#S,?YX??+_Y$_FJHK^E7_AP#^R/_P!$F_\
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M^>G1O^0/:_\ 7%/_ $$59K^AV'_@A3^RM;PK&GPMPJ *H_X275^ /^WJG?\
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MX<7_ ++'_1+O_+DU?_Y*H_M"GV?]?,/^(YY#_P ^:W_@,/\ Y8?SP45_0_\
M\.+_ -EC_HEW_ER:O_\ )5'_  XO_98_Z)=_Y<FK_P#R51_:%/L_Z^8?\1SR
M'_GS6_\  8?_ "P_G@HK^A__ (<7_LL?]$N_\N35_P#Y*H_X<7_LL?\ 1+O_
M "Y-7_\ DJC^T*?9_P!?,/\ B.>0_P#/FM_X##_Y8?SP45_0_P#\.+_V6/\
MHEW_ )<FK_\ R51_PXO_ &6/^B7?^7)J_P#\E4?VA3[/^OF'_$<\A_Y\UO\
MP&'_ ,L/YX**_H?_ .'%_P"RQ_T2[_RY-7_^2J/^'%_[+'_1+O\ RY-7_P#D
MJC^T*?9_U\P_XCGD/_/FM_X##_Y8?SP45_0__P .+_V6/^B7?^7)J_\ \E4?
M\.+_ -EC_HEW_ER:O_\ )5']H4^S_KYA_P 1SR'_ )\UO_ 8?_+#^>"BOZ'_
M /AQ?^RQ_P!$N_\ +DU?_P"2J/\ AQ?^RQ_T2[_RY-7_ /DJC^T*?9_U\P_X
MCGD/_/FM_P" P_\ EA_/!17]#_\ PXO_ &6/^B7?^7)J_P#\E4?\.+_V6/\
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M2;_RZ-9_^2Z/]>L!_)/[H_\ R0?\0\S'^>'WR_\ D3^:JBOZ5?\ AP#^R/\
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M0\S'^>'WR_\ D3^:JBOZ5?\ AP#^R/\ ]$F_\NC6?_DNC_AP#^R/_P!$F_\
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MT*?9_P!?,/\ B.>0_P#/FM_X##_Y8?SP45_0_P#\.+_V6/\ HEW_ )<FK_\
MR51_PXO_ &6/^B7?^7)J_P#\E4?VA3[/^OF'_$<\A_Y\UO\ P&'_ ,L/YX**
M_H?_ .'%_P"RQ_T2[_RY-7_^2J/^'%_[+'_1+O\ RY-7_P#DJC^T*?9_U\P_
MXCGD/_/FM_X##_Y8?SP45_0__P .+_V6/^B7?^7)J_\ \E4?\.+_ -EC_HEW
M_ER:O_\ )5']H4^S_KYA_P 1SR'_ )\UO_ 8?_+#^>"BOZ'_ /AQ?^RQ_P!$
MN_\ +DU?_P"2J/\ AQ?^RQ_T2[_RY-7_ /DJC^T*?9_U\P_XCGD/_/FM_P"
MP_\ EA_/!17]#_\ PXO_ &6/^B7?^7)J_P#\E4?\.+_V6/\ HEW_ )<FK_\
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M\3V.MRPZ7X(6=O$":AIMWI]]HHAB\Y_M%I<1)<1'ROG :,%EP5R"*Y_X?_\
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MX* :]XD\._L5_$N3P=HVJZ_XIN]"GT_2[+3;62YNI+BY'V=&2- 6.PR[R<8
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M1G34K2TU:9Y!:6S7L-M;V\L\4^HW3JL<2%5@4A64%C]Q44_:,7LT?G/^T/\
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M@*PTC4M6TGQ=X_T>/Q(+>RDGMX-(M93>W#7#@%8XV-M''ES@M*HP<UPWQO\
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M,2@?G1I/@CQ1\0?^";_@K]F+2/A[XVT/QQ.EGI'BN_U+0KJTT?0%MK^.>_U
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G2]TW3M#N+30K!IHSFWLKDQ+:S+&R."D#LT8V;U7>N>^HHK(T/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>macraesignaturea02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 macraesignaturea02.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1*^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&*@           *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/      0 ".$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]       $@ U
M     0 M    !@       3A"24T#]P      '   ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              (    %O
M      $                          0             !;P   (
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   (
M4F=H=&QO;F<   %O    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   "      %)G:'1L;VYG   !;P
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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MH):[-R-OJ,WU,]=S:JZF6OK]6S]']-*]X'U7S;Z7;W]2.196_C<RXV>F\?\
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M^JDE\JI)*?JI)?*J22GZI27RLDDI_]DX0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !+DU-
M "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0
M *0   #0 !:\4   )Q  %KQ0   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3DZ,#0Z,C @,#<Z,S8Z-#<   .@ 0 #     ?__  "@ @ $
M     0   6^@ P $     0   (          !@$#  ,    !  8   $:  4
M   !   !'@$;  4    !   !)@$H  ,    !  (   (!  0    !   !+@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0$P34T *@    @ !P$2  ,    !      $:  4    !    8@$;
M  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
MD(=I  0    !    I    -    /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-#HR," P-SHS-CHT-P   Z !  ,
M   !__\  * "  0    !   !;Z #  0    !    @          & 0,  P
M  $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$
M!     $   $N @( !     $              \     !   #P     '_X4%S
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE
M=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-
M4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR
M-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W
M+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @
M/'AM<#I-;V1I9GE$871E/C(P,3DM,#0M,C!4,#<Z,S8Z-#<K,#4Z,S \+WAM
M<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q."TP
M-"TQ.%0R,CHU,3HR."TP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,3DM,#0M,C!4,#<Z,S8Z-#<K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O
M;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF
M;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.D1O
M8W5M96YT240^=75I9#HY931D,S U.2TP-C=F+31D8S$M8F)A,BTV9CED,&(S
M8CDV-#D\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T
M86YC94E$/GAM<"YI:60Z-S!"-3$U-44P0S8S13DQ,4(X.#A%-D8R,S)&1# Q
M0S$\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I
M;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C Q-S<P0S1!030T,T4X,3%",3 X035#,#-"04-"0S1$/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#$X+3 T+3$Y5#$S.C0W.C$U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-D5"-3$U-44P
M0S8S13DQ,4(X.#A%-D8R,S)&1# Q0S$\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,#0M,C!4,#<Z,S8Z
M-#0K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C9&0C4Q-35%,$,V,T4Y,3%".#@X139&,C,R1D0P,4,Q/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#$Y+3 T+3(P5# W.C,V.C0T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-S!"-3$U-44P
M0S8S13DQ,4(X.#A%-D8R,S)&1# Q0S$\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,#0M,C!4,#<Z,S8Z
M-#<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^=75I9#HY931D,S U.2TP-C=F+31D8S$M8F)A,BTV9CED,&(S8CDV-#D\
M+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D1E
M<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HV14(U,34U13!#-C-%.3$Q
M0C@X.$4V1C(S,D9$,#%#,3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @/'-T4F5F.F1O8W5M96YT240^=75I9#HY931D,S U.2TP-C=F+31D8S$M
M8F)A,BTV9CED,&(S8CDV-#D\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HY931D,S U.2TP
M-C=F+31D8S$M8F)A,BTV9CED,&(S8CDV-#D\+W-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^07-P
M;W-E+E=O<F1S(&9O<B N3D54(#$U+C0N,"XP/"]P9&8Z4')O9'5C97(^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \
M<&AO=&]S:&]P.D-O;&]R36]D93XQ/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( %, [0,!$0 "$0$#$0'_Q  >  $  @$%
M 0$             !P@& 0($!0D#"O_$ #D0  $%  (! @0"" 0& P    0!
M @,%!@ '$0@2$Q0A,2)!%18C45)A@=$7<9&2"20RH;'!<O#Q_\0 % $!
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D/ =]P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>sangamo-2021cdagraphicfact.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sangamo-2021cdagraphicfact.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" '%!- # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOE3]OW_@K_\
M"G]@1I=(U6YG\4>.O)$L7AS2F!FBW#*&YE/R6ZG*G#9D*L&6-AS7Y3_M"?\
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M_P"@F'W,_J:HK^67_AOSX\_]%P^,?_A;:G_\?H_X;\^//_1</C'_ .%MJ?\
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M]%P^,?\ X6VI_P#Q^C_AOSX\_P#1</C'_P"%MJ?_ ,?H_L2K_,OQ#_B"F/\
M^@F'W,_J:HK^67_AOSX\_P#1</C'_P"%MJ?_ ,?H_P"&_/CS_P!%P^,?_A;:
MG_\ 'Z/[$J_S+\0_X@IC_P#H)A]S/ZFJ*_EE_P"&_/CS_P!%P^,?_A;:G_\
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M_P"@F'W,_J:HK^67_AOSX\_]%P^,?_A;:G_\?H_X;\^//_1</C'_ .%MJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_#/[6O\ ;,4?W+'Q/X"L9UD_WKB-A+^0I#XT_;I^%W_'_P""O@)\4[6/[O\
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M-4BD/2/9+\CO_LQNQXKZ3J6FM&>7B\#B,+/V>)@XOS5ON[KS"BBBD<H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^;_\ P= ?\F&^"_\
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M HHHH ]:_8#_ .3\O@?_ -E"\/\ _ISMZ_J:K^67]@/_ )/R^!__ &4+P_\
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M ,+D_P#RNH_XBL)O^B!Q_P#A<G_Y75^15%']DX;M^(?\0OX9_P"@;_R>I_\
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M+>'VR2%M;$ +(1TWR@[L E-W-?4?C7Q_X;^#GA3[?KFIZ9H&D6JB-&G=8HU
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M;B!@* JCPNBBM(0C"*C%:(]'!X.AA*$<-AHJ,(JR2Z!1115G4%%%% !1110
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M+C'=6KN%)3V;MY[GVV=9W4PN50Q3?LZD^1)-.34I6]U)6O+=+5*^YX3^TO\
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M_6E,\\6IR*KPRB(*T$L:H'(8N0=R,H;AA[':V/[/W[?7[7MQ]@U+]I']G_\
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M_A5XE^-7_!LCX1T#PCH.K>)M;N-2E:*PTRU>YN9 /$=R6(1 6(4').. "3@
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M (-U)-.\)^&?^%H_'7P;\,_&'BS":?X=FM([J:>4XQ CO=0^;*-RAEB1P"<
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M=_ Z,0?&7A4$'!!U:WX_\?KXEC_X-H?V:D3!'C]SZG7%R?RBJ=?^#:O]F=5
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MN6XN)9)YYW,DDDC%FD8G)))Y))[U^F<!^&4L7RYCG"M#>,.LO.7:/EN_3?\
MSY\9/'V5"K5RS(JG/B&VJE;=1?50[R[O:.RN_AUOB!\1=<^*OBJYUOQ%J=WJ
M^JWC9EN+A]S'T '15'0*  !P !6+117]#TZ<*<%3II)+1):)>A_%E:O4K5)5
M:TG*4G=MN[;?5M[L****T,@HHHH **** "BBB@ HHI"<"@!:*S-0\;:/I38N
M=5TZ!O[KW"!ORSFLRX^,OA>U^_K-I_P'+?R%<\\50AI*:7S1ZN'R+,JZO0P\
MY>D)/\D=-17'/\?_  BA_P"0N/PMIC_[)4D'QU\)W!PNL1#_ 'HI%_FHK/\
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MV2.OS?@*\IHJXT:<6G%;:?(ZL/DV!P]6%:A2490CR*RM:-[V7E?4^B?VCO\
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M*7E%I]+^SG^SGX0_92^$&D>!O ^DQ:1H&C1[(XUYDG<_?FE?J\KGEF/4^@
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M [#+@ $D$E1[K^TW D/_  <K_ ]E4 R^%"SD?Q'[/JXS^0'Y5XA^T#JMT_\
MP<^Z4IN9RMMK^AP0@R'$4;:/:ED7T4EW) X)=O4TOK->=N65O<YMEN+_ %CS
MK&^S]AB/9_[)[9^Y%WE&375:7TOT[(^8?"7_  2I\03_ /!36T_9L\2^(K;0
M[^\>X:/7K:Q:\@D@2PEO8I4A9XBP=8PI&\;6+<MMY=_P["_XVG?\,T?\)O\
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M6 '&>N*[*TZL8.F[O1^]H?89UC,SP^#JY=*,ZC=.5Z]H)+1OX4K>6WGN0?\
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M5_CG%-^H4445T'T!ZU^P'_R?E\#_ /LH7A__ -.=O7]35?RR_L!_\GY? _\
M[*%X?_\ 3G;U_4U7S.=_Q8^A_.7C9_OV&_P/\PK^3GX]?!K4OV=_C7XJ\#:O
M$\6H>%-4GTR7<I7S!&Y59%SU5UVLIZ$,",@U_6-7PY_P59_X(NZ#_P % KQ?
M&/AO4[;PE\3;6V6V-W-$6L-:C0$1I=! 75UX"S*&(4;2K@+MYLMQ<:%1\^S/
MG_#/BS#Y+C:D,9I3JI)OLU>S?EJ[G\]U%?9/BG_@@/\ M4>']:FM;3X=V6N0
M1,52\L?$FFI#,/51//')C_>0&L__ (<1?M8_]$DD_P#"GT7_ .3*^D^O8?\
MG1_1<>+LCDKK&4O_  ./^9\C45]<_P##B+]K'_HDDG_A3Z+_ /)E'_#B+]K'
M_HDDG_A3Z+_\F4_KV'_G17^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/
M_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P S
MY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_Y
MT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1
M))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/
M_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P S
MY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_Y
MT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1
M))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/
M_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P S
MY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_Y
MT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1
M))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/
M_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P S
MY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_Y
MT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1
M))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/
M_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P S
MY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_Y
MT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1
M))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/
M_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P S
MY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DRCZ]A_Y
MT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/_"GT7_Y,H_X<1?M8_P#1
M))/_  I]%_\ DRCZ]A_YT'^MF2?]!E+_ ,&1_P SY&HKZY_X<1?M8_\ 1))/
M_"GT7_Y,IT'_  0=_:PFF53\*#$"<%W\3:-A?KB[)_2E]>P_\Z%_K;D?_092
M_P#!D?\ ,^1*_IC_ ."0WP<U/X"_\$W?A1X<UB)H-2&ER:G-"ZE7@-[<S7HC
M8'D,HN I!Z$$5\5_\$Y/^#="X^'OCO2_&OQSOM(U)M*E2[LO"NG.;BW>5<%3
M>2LH5U4@YA0,K?+ERNY&_66O"S7&PK-0I[(_#/%/C/!YG&GE^ ESQ@^9RZ7L
MTDN^C=WL%%%%>.?C84444 %%%% !1110 5Y3^VE^UEH?[%G[/>L^.M;CEO'M
MMMII6FP M<:QJ$N5M[6,#)+._7 .%#-CY:]5+;1D\ =37PK\!H/^'GW[<=W\
M7;X-<_!KX(WTND?#^#>?L^OZRI'VK5RIX=(CA(CTR%8897!N*3U>QZ^4X.G5
ME+$8G^%3UEY]HKSD]/)7ET/2_P#@G!^R'KWPGTK6?BG\4KG^V/CA\4UCO?$-
MTZ_+HMO@&'2K<<[(H1M# 'EEZD(IKOOVU/VL]._90^%4FH,8;GQ%J8>#1[)C
M_K9<<R,.OEID%O4E5R-V1ZAXO\6Z?X#\+:AK6K7*6>FZ7;O<W,S](T49)]2?
M0#DG@5^-7[5O[1FI?M/?&/4?$EX98K,MY&FVC'_CRME)V)]>2S'NS,>G%?H/
MA[PB\\Q_M<0OW%.SEYOI'_/R]4?A_CKXJU,BP+=&2^MU]();0BM.9+HHJT8+
MOW29POBKQ3J/C?Q)>ZOJUW-?ZEJ,S7%S<2G+RNQR2:H445_648QC%1BK)'^<
M]2I.I-SF[MZMO=ONPHHHJB HHHH ***Y#XH_%^P^'%KY?%SJ<BYBM@?N_P"T
MY[#]3V[D8UZ].C!U*KLD>CE>58O,<3'!X*#G.6R7YOLEU;T1T'B3Q18>$=,:
M[U"XCMX5Z;CRY]%'4GV%>&?$3]HC4O%#26^F;]-L#QE3B>0>[#[OT7\S7&>*
M_&&H>-=3-WJ-PT\G(0=%B'HHZ ?Y-9E?#YCGM6O[E+W8_B_Z[']3<%^$V!RI
M1Q.8I5J__DD?1/=^;^20I.XY/)/4^M)117@GZZ%%%% !1110 4444 %%%% !
M1110 4444 %%%% !6KX4\;:IX)O?/TV[DMR3\Z=8Y/\ >4\'^?I65151E*+Y
MHNS,<1AJ6(I.C7BI1EHTU=/U3/HGX7_'NP\;M'9WVS3]3;@*3B*<_P"P2>#_
M +)_#-=_7QO7J/PD_:"FT"2.PUV66XL.$CN"-SVP[9[LOYD=LXQ7U>6\0[4\
M5_X%_G_F?SSQQX.<JECL@7FZ7_R#_P#;7\GLCW>BHK*^AU*TCGMY8YX)5#)(
MC;E<'N#4M?7)IJZ/YYE&49.,E9H****9(4444 %>X_L)_M?WG[*/Q262Y::X
M\)ZRRPZO:+R5'1;A!_?3)X_B4L.I!'AU%<.99=A\?A9X/%1YH35FOZZK=/HS
MULCSK&91CZ698"?+4INZ?Z/NFM&NJ=C]Y=!UVS\4:)::EIUS#>6%_"MQ;W$+
M;DFC8 JRGN""*^(/VOO"FH?\$V/VD3^TEX.BO)/AOXLNH;+XM^'K2$R(JL2D
M6N0QCI+&S 2X^\&)_C=AD_\ !(W]KDVMVWPLUZZ_=3;[CP_+(W"-RTEKGWY=
M??>.ZBOO+Q-X:L/&?AO4-'U6T@O]+U6VDL[RUG7='<PR*4>-AW5E)!'H:_CC
MB;(*V29C/!5M5O%_S1>S_1]FF?Z?>%_B#AL]RRGFM%7C-<E6G?9Z<T?EI*#_
M ,,O(=X=\0V/B[P_8ZKIEU!?:;J=O'=VES"^^.XAD4.CJ1P592"#Z&KE?$7[
M!6OWW[#'[36M_LK^)KNXG\-7$4WB/X4:E=RM))=Z869KC2V<]9;9@Q ZE-QX
M78*^W:^>DK,^QS/ _5*_)%\T&E*,OYHO9^O1KHTUT"BBBI/."BBB@ HHHH *
M*** /S?_ .#H#_DPWP7_ -E"L_\ TV:G7X5U^ZG_  = ?\F&^"_^RA6?_ILU
M.OPKKZG)O]W?K_D?U3X1?\D^O\<OT"BBBO7/T\DM+N6PNHYX))(9X7$D<D;%
M6C8'(((Y!![U]-W7_!9W]IV\\$)X??XMZW_9Z0BW#K9V:7A4#'-T(1.6Q_$9
M-Q]:^8**SG3A/XTF<.+RW!XMQ>*I1GR[<T4[>EUH>[^._P#@IA\;/B7\>/"W
MQ-UKQC%>>.O!<30:/JHT/3HGM8VWY4HD"QR#]Y)@2*V-[8QFN9^(_P"VA\2_
MBY^T5I?Q8\0^)/[0^(&BW-G>66J_V?:Q>3+:.KV[>2D2PG8RJ<,A!Q\P->74
M4*E36T5VV(I93@:5G3HP5H\JM%*T7JX[?"WK;8]O\4?\%'?C-XS_ &E="^+^
MI>,OM/Q%\-6GV'3=6_LFQ3[-#MF7;Y*PB%N+B;ED)^?KP,8/B#]M#XE^*?VH
M$^,U]XD\_P")45S!>+K']GVJXE@A2")O($0@^6.-%QY>#C)!))KRZBA4H+9+
MM\NPX95@8?!1@O=Y-(KX-^7;X;_9V\CU'XR_MH_$_P"/WQNT[XC^*?%EW=^-
M](2".RU>UMX-/FM1"S/$4%ND:@JS$[L9YY->KZK_ ,%L/VH=:FTQ[CXKZ@3I
M,RW$ 32=/C5G4$#S56W F SG;(&&0#C(!'RO12="DTDXK3R,JN1Y;4C"%3#P
M:@K13A%\J[+31>2/8C^W[\8%_:<O?C'%XWO[7XCZE&D-WJ]K;V]O]JC2&.%8
MY($C$#)Y<,0*F,J2BL06&:]*F_X+>?M2S^)8-6;XL7_VNVB>%$&CZ<MOM?;D
MM +?RF;Y1AF0LO."-QS\IT4GAZ3WBON%5R'+*O+[7#4Y<JY5>$7:*VBM-%Y;
M'M_P4_X*-_&7]G7Q5XYUKP;XP71=2^)-V+[Q'*NCV$PU"8/.X8)) RQ?-<S'
M$00?/C& N/$***M0C%W2.VC@\/1G*I2@HRE:[22;LK*[6]EHK[+8^@_@-_P5
M3_: _9F^'$7A'P7\2-2TKP[;EOL]G-96E\MJ&Y*Q-<12-&N<G:A !).,FLSX
MV?\ !1_XU?M'_"%/ GCKQQ<>)_#,=]_:*07VG6;SI<;Y'$@N/*$X(\UP!YF
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MVYOBO\!_C=JOQ(\->,[^#QQKEO):7^L7L$.I3W4<C1LP;[2DBGF*/G&0% !
MXKEO^%\^*_\ A??_  L_^U?^*Y_X2#_A*/[3^RP_\A'[1]I\_P K9Y7^N^;9
MLV=MN.*X^BK]G&]['8L!A5)S5.-VN5NRNXK9/R\MCUOXK_MT_%3XX?'_ ,._
M%'Q1XI_M/QWX3:T?2M3_ +-LX?LIM9S<0?NHXEB?;*Q;YT.<X.1Q3/C#^W!\
M4?CY\=M!^)?BWQ/_ &MXV\,?9?[,U+^S;2#[-]FF:>']U%$L3;9&9OF0YS@Y
M'%>3T4E2@MDC.&5X*'+R48KE7*O=6D7O%::)]MCT?]I[]K;X@_ME^/K3Q/\
M$GQ!_P )'KECIZ:7!<_8;:SV6R222JFRWCC0X>:0Y(S\V,X  \XHHJHQ45:*
MLCIH8>E0IJC0BHQ6R2LEZ):!1115&QZU^P'_ ,GY? __ +*%X?\ _3G;U_4U
M7\LO[ ?_ "?E\#_^RA>'_P#TYV]?U-5\SG?\6/H?SEXV?[]AO\#_ #"BBBO%
M/Q0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEHNB[?\ !/[/X+X+P?#V$]E1]ZK+XY]6^R[171?-ZA1117GGV04444 %%%%
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M_9-^.T_C/PI\+/C[XAG\?^"X6>^_M2:WETZW*L$9CBVA$L0<A6>*9@A9<G.
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M([>?G_D?V%X7\%1R7 +%8F/^T55>7>,=U']9>>G1!1117BGZB%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_D^OPKHH_L;#^?]?(/^(1\/]I_^!?\  /W4_P"(H#X#?]"7\8__  5Z9_\
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MI_(_>O _?&_]P_\ V\DHHHKZ,_?@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OZ-/^""DK3?\ !)_X5EB20VL*,^@UF^ _0"OYRZ_HR_X(
M(?\ *)WX5_[^L_\ IZOZ\3._X4?4_(/&C_D2TO\ KZO_ $B9]A4445\T?S,%
M%%% !7._%WQNOPS^$_B?Q(Y 3P_I-WJ3%N@$,+R'/_?-=%7@W_!4;Q+_ ,(G
M_P $YOC;=[MA?P;J5H#GH9[=X1_Z,IQ5VD=> H>WQ5.B_M22^]V.1_X(H^"&
M\!_\$O?A);R@^?J&FSZO*[?>D-W=37(8GO\ +*OX8K _X+1>)EL?@'X:TG?M
MDU#7!< #^-889 1],RJ?P%>\?L4>&O\ A#/V-?A+I&W9_9G@W2+4C'=+*%3^
MHKY-_P""W.K>;JWP\L=W^HBOIROKO,"@_P#CA_6ONO#J@J_$N'3V3D_NC)K\
M3\P^D+F;CPSFN(6]25O_  .JD_P;/@^BBBOZ]/\ ,\**** "BBFR2"*-F8X5
M1DGT% ]]$?,/QGU?^V?B?K$F21%/]G'MY8"?S!KEZL:M?OJFJW-S(,/<2O*P
M]"Q)_K5>ORBM4]I4E4[MO[S_ $#RG!K!X&CA%]B,8_<D@HHHK(] *]=_8L\'
M?!WQO\6KFS^-_BO7_!WA!=,EE@OM(A:6=[P21".,A;>X.TH92?D'*CYAT/D5
M??'_  ;F?\GXZS_V)M[_ .E5G7F9SB'0P-6LKZ+H[/Y.S_)G9@*?M,1"#ZOK
MJOT_,^*/BWIWAW1_BKXFM/"%_=ZKX2M=6NH=$O;I2L]Y8K,XMY9 40AVB",0
M47DGY5Z#GJ_97_@DC;I=_P#!2#]L2*0;HY/$UVC#.,@ZI?@UTG_!/+]O+3/V
MR/CW\2/@3>_#7PAHWP]\.Z7<G1]/MK7,9LX+B*SDAN48F-RXF0C8BA0&4[N&
MKP*W$]2CSQC1YE3C!R?,MI)/MO\ GY'I4\HA4Y7*I9S<DE;L_4_$:OOW_@E;
M_P $O/A9^V;^S3XM\>?$3Q-XJ\.+X8UB>TEGL-1M+.RM[2*UAG>:9IX)-NWS
M'+,6"A5[8)KXQ_:"\$VWPT^/?C?PY9(T=GH&OW^FVZ,Y<K'#<21J"QY/"CGO
M7Z0?\$H_^4+/[37_ %[^(?\ TQ15W\18JK' *IAY.+E*.JWLV<^5482Q+C55
MTD]/0Z+1O^"&'[-?QQT348/A?\;M5UO6;>)MDEOKVEZU!;/CY3+%;Q(VW)&1
MO7ZU^8O[1GP!\0?LN_&K7_ GBB**+6O#]P(93"VZ*=&57CE0X!*.C*PR <-R
M <BNZ_X)I:]K/AW]OSX13:$]PEY-XIL;6;R1DM:RS+'<@C^[Y#2Y]!D]J_6[
MXG_L@^%?VC/^"R,>L^)=-M-9TKP;\.K'4);"YC62"XOY;^]BA,B'AU6)&;!!
M&Y4STQ7DSS#$91B94\55=6FX.2NE=-.UOG_7GVQPM+'45.C!0ES6\FG_ )'X
M05]2?\$L_P#@G.G_  4-^*&MV-_XC?P[H7A:""ZU!K>#S;NZ$KLJQQ;OD0_(
MV7;=CCY&R<?K?X$3XJ_M(_$GQIX%^-'P'\+:7\&KN&:/0[LZG:7<^U'546:-
M)Y#OD7,BO&D?E% /F.&'D/\ P1;\0ZQ\*/BM\;O@));V0\.?"[7IY-,NF5C?
M7*S7,J!I7W["#'%&P"HI&XY]!CC.*ZM3!5G0BHU(J+NI*2LW:]TMULUTO<TH
M9+"&(IJHVXMM:IK5?IYGXE45^QO_  3%\07?_!2?XL^,?VA?B1X1\+ZMXD\%
M6%MX;\.:9I]N8[42Q^==-*%N)9 )R98T5RP5=Q/!YKV[P=\+_B1^WK\*?'/@
MW]I7X->&O!ELZY\-7^GZE;7LMOO$@4J4FF:.>'Y#Y@VK)O(V 9![,5Q<L/5=
M*K32Y+<WOJZ;_E5KRMUM8YZ.1NK!3A/XKV]U].[Z7/P$HK]FO^"8WBB#X%?\
M$<?&FNZ[H%KK;^"-4U74VTJZVF.6[LWCFB5C@@;9XD.X X*@C.!5G_@CM^VY
MXN_;\_:'^)WB+QK::#9SV/AW3=,AM=(MY(+<1^?=,6(DDD<LQ?DEN@& ,5K7
MXFJTXUZD:-X479OFWU25ER^9-/)X2=*#J6E-7M;;\3\7**_<_P#X)[_M8:7^
MWCXE^,'PDU;X<>#='^''@S9I^E:7:6F$>U+S0%)4SY>[]T&!C5-N<<D;JK_\
M$\?VO-"_;,^(?Q6^"<_PV\(:/\-O!T#6ND:?;VVY)[19FMV$Z-E&9@%8%5&,
MD'<?FK*KQ57I>TY\-_#LY>\M%*UNF^NWXEPR6G/DY:OQ72]U[K?KMY_@?EM^
MQ!\/?V>_'=GXO/QU\=>*O!DUFEJ?#RZ-;O*+]F$_GB3;:7&-I6#&=GWV^]_#
MX#7ZX?\ ! ;P@OP]\:_M2:!&24T.^L-/4EMQ(BDU6,<X&?N]<4G_  1M\3:1
MX'_X)!_&/7M=T*V\3:5X>\0ZGJ\^E7! BO\ [-INGSK$V01M+1KG((]0>E77
MS]X>OB'&+GRNDDN96]]=--/.[=WU1-/+/:TJ2;4;J;O;^5]==?N5O,_)"OH?
MX6?#C]G+5OV._$&M>*_'WBW3/C/;I=G2=!MK=VT^Z90/LX=Q9NHW'.?WZ]/X
M:_1[X/?M"O\ \%9?^"7_ ,9)?&/@WPO9ZSX:M]1@TI+*)EMX9XK/[1:2IYA9
MHW5R Q#8(!X 8K7 _L1_\J^?Q5_ZX:Y_Z E1B,_G.FXU(.$X5(Q:4EU\^5W7
M=67J52RR,97C)2C*#:NGT\K[^?X'Y,45^R'[-7QJL/V;_P#@@1X-\?W?AC3/
M%MUX4N;NZTRQU 9MDO)-<NK>*9QW\LS%\#GY>"IPPJ?M2?$&/_@HQ_P1 U#X
MIZ_X8T&Q\9Z&XN();5"J6CP:@D$[0LQ9U1[??^[+'DCDX!K=<33]MRRH^Y[7
MV7-S+>^]K??V\S+^R(^SNJGO<G/:W3UN?CU17[(>+/B;:?\ !&3_ ()E?#75
M?!GA#P[JWC;QPMJ-2OK]"T<EQ/;-<RO*R;))47B-$W( N#G((:7]IWXSZ3^T
M3_P0%\7>.=)\,V'A'_A)9[:ZOM-L5"VZ7@U^VCGD0#'$DB-)ZDN2<DDE+B><
MI0E&C^[G45-2YEO>U[6^[OY#>3Q2DG4]^,>9JWEM>Y^-5%%%?6GAA1110 5]
M,? /6EUKX2Z7^]>26R,EI+N.=I5RR@>VQTXKYGKWG]D_5FG\$ZO8^7\EK?)<
M"3WEC*D?^017L9#4Y,;%=[K\+_H?F'C!@EB.&:L^M.4)?CR_E)GI]%%%?HA_
M'04444 %/MIVMKB.169&1@RLO52#U%,HI#3L[H_>#PEK\?BOPKIFJ18\K4K2
M*Z3'3:Z!A_.OD?\ X*%?\4-^WW^Q]XU'R+#XHU;PM*W9_P"TK#RT4^OS1DCW
MKZ!_8^U?^V_V5_A[.#NQX?LX<^ICA5#_ .@U\_\ _!:#_B4?"_X*>(NG_")?
M&3PSJI?^ZHEEC/X?O!7\+8JA[#%U*'\LI1^YM'^O_ F+^N2PU9_\OJ?_ *<I
MM?\ MQ]CT445PG&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7\@]G_QYQ?[@_E7]?%?R#V?_'G%_N#^
M5>[D?Q3^1^]>!^^-_P"X?_MY)1117T9^_!1110 4444 %%%% !1110 4444
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M<?\ 1NWP<_\ !E!_\NJ_.;_@L'^V]^T'\:?B)9?#OXW:7H?@K5?!ZK/<>'M
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MU4]K&K43=N:TK<UMN;3Y:6'_ &I-PY'"+2O;3:_;7\[GZ&_LM?MS?"SX<_\
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M445\^=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8&^.%]KWP^\6>*;J[\50S6T^IW^FZC/:^'K7Y9/LT2M;+,0\D<8!*RMQ\T@
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M *>K^OYS:_HR_P"""'_*)WX5_P"_K/\ Z>K^O$SO^%'U/R#QH_Y$M+_KZO\
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M3Q6)PLW:4U%KSY>:_P#Z4CYZHHHKZ8_HD**** "BBB@ HHHH **** "BBB@
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M_8V^)'B:ZUKQ%\!M4U[6;XJ;F_U'P3H=U<W!50JEY'N2S855 R>  .U?(_\
MP4@_;%^#/QVUKX>:C\"/ $_PPO\ PI/>7-_<0:%8:-+<2LUJUJZM9R,6:)HI
M2"V-I?Y>IQ\CT5SX+AS"X6K&K2<M.CDVMK;&F(S:M6@X32U[+7ON?JC\,/\
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MQ^D8^E8W_$*?-_T7R/\ \(8__+&OU_HKL68XE?;/M(>)?$L8\JQ3_P# 8/\
M%Q/R _XA3YO^B^1_^$,?_EC1_P 0I\W_ $7R/_PAC_\ +&OU_HI_VEB?YR_^
M(G<3?]!/_DE/_P"1/R _XA3YO^B^1_\ A#'_ .6-'_$*?-_T7R/_ ,(8_P#R
MQK]?Z*/[2Q/\X?\ $3N)O^@G_P DI_\ R)^0'_$*?-_T7R/_ ,(8_P#RQH_X
MA3YO^B^1_P#A#'_Y8U^O]%']I8G^</\ B)W$W_03_P"24_\ Y$_(#_B%/F_Z
M+Y'_ .$,?_EC1_Q"GS?]%\C_ /"&/_RQK]?Z*/[2Q/\ .'_$3N)O^@G_ ,DI
M_P#R)^0'_$*?-_T7R/\ \(8__+&C_B%/F_Z+Y'_X0Q_^6-?K_11_:6)_G#_B
M)W$W_03_ .24_P#Y$_(#_B%/F_Z+Y'_X0Q_^6-'_ !"GS?\ 1?(__"&/_P L
M:_7^BC^TL3_.'_$3N)O^@G_R2G_\B?D!_P 0I\W_ $7R/_PAC_\ +&C_ (A3
MYO\ HOD?_A#'_P"6-?K_ $4?VEB?YP_XB=Q-_P!!/_DE/_Y$_(#_ (A3YO\
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M&"V\4?"W2?$&LQ)MDO['6WTZ*8]F,)@FP>F<.!G. .@^3?\ @H%_P4J\;_\
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M_I?Q$FAFO-'OI5ENK0Q0B)1%>B(-@X)*F,J<_=!^:NYUS_@O1;^#? >N:?\
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M"'_$$\'_ -!,O_ 4?U(_\/$_V?O^BZ?!S_PM--_^/4?\/$_V?O\ HNGP<_\
M"TTW_P"/5_+=11_8:_G_  _X(?\ $$\'_P!!,O\ P%']2/\ P\3_ &?O^BZ?
M!S_PM--_^/4?\/$_V?O^BZ?!S_PM--_^/5_+=11_8:_G_#_@A_Q!/!_]!,O_
M  %']2/_  \3_9^_Z+I\'/\ PM--_P#CU'_#Q/\ 9^_Z+I\'/_"TTW_X]7\M
MU%']AK^?\/\ @A_Q!/!_]!,O_ 4?U(_\/$_V?O\ HNGP<_\ "TTW_P"/4?\
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M[L[N)9X)X)!)%/&P#*ZL,AE((((X(-3UY)^0[:,**** "BBB@ HHHH ****
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M504444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$#C_ /"Y/_RNH_LW$_R!_P 0QXF_Z!O_ ">G_P#)'Z_T5^0'_$5A-_T0./\
M\+D__*ZC_B*PF_Z(''_X7)_^5U']FXG^0/\ B&/$W_0-_P"3T_\ Y(_7^BOR
M _XBL)O^B!Q_^%R?_E=1_P 16$W_ $0./_PN3_\ *ZC^S<3_ "!_Q#'B;_H&
M_P#)Z?\ \D?K_17Y ?\ $5A-_P!$#C_\+D__ "NH_P"(K";_ *(''_X7)_\
ME=1_9N)_D#_B&/$W_0-_Y/3_ /DC]?Z*_(#_ (BL)O\ H@<?_A<G_P"5U'_$
M5A-_T0./_P +D_\ RNH_LW$_R!_Q#'B;_H&_\GI__)'Z_P!%?D!_Q%83?]$#
MC_\ "Y/_ ,KJ/^(K";_H@<?_ (7)_P#E=1_9N)_D#_B&/$W_ $#?^3T__DC]
M?Z*_(#_B*PF_Z(''_P"%R?\ Y74?\16$W_1 X_\ PN3_ /*ZC^S<3_('_$,>
M)O\ H&_\GI__ "1^O]%?D!_Q%83?]$#C_P#"Y/\ \KJ/^(K";_H@<?\ X7)_
M^5U']FXG^0/^(8\3?] W_D]/_P"2/U_HK\@/^(K";_H@<?\ X7)_^5U'_$5A
M-_T0./\ \+D__*ZC^S<3_('_ !#'B;_H&_\ )Z?_ ,D?K_17Y ?\16$W_1 X
M_P#PN3_\KJ/^(K";_H@<?_A<G_Y74?V;B?Y _P"(8\3?] W_ )/3_P#DC]?Z
M*_(#_B*PF_Z(''_X7)_^5U'_ !%83?\ 1 X__"Y/_P KJ/[-Q/\ ('_$,>)O
M^@;_ ,GI_P#R1^O]%?D!_P 16$W_ $0./_PN3_\ *ZC_ (BL)O\ H@<?_A<G
M_P"5U']FXG^0/^(8\3?] W_D]/\ ^2/U_HK\@/\ B*PF_P"B!Q_^%R?_ )74
M?\16$W_1 X__  N3_P#*ZC^S<3_('_$,>)O^@;_R>G_\D?K_ $5^0'_$5A-_
MT0./_P +D_\ RNH_XBL)O^B!Q_\ A<G_ .5U']FXG^0/^(8\3?\ 0-_Y/3_^
M2/U_HK\@/^(K";_H@<?_ (7)_P#E=1_Q%83?]$#C_P#"Y/\ \KJ/[-Q/\@?\
M0QXF_P"@;_R>G_\ )'Z_T5^0'_$5A-_T0./_ ,+D_P#RNH_XBL)O^B!Q_P#A
M<G_Y74?V;B?Y _XACQ-_T#?^3T__ )(_7^BOR _XBL)O^B!Q_P#A<G_Y74?\
M16$W_1 X_P#PN3_\KJ/[-Q/\@?\ $,>)O^@;_P GI_\ R1^O]%?D!_Q%83?]
M$#C_ /"Y/_RNH_XBL)O^B!Q_^%R?_E=1_9N)_D#_ (ACQ-_T#?\ D]/_ .2/
MU_HK\@/^(K";_H@<?_A<G_Y74^#_ (.KF:9?-^ H6//S%/&^X@>P.GC/YTO[
M-Q/\@O\ B&7$W_0-_P"3T_\ Y(_7RBODO]@W_@LK\(_V\=93P_IEQ?>$_&KH
M730M:V))>X&6^S2JQ2; _A^63"L=FT$U]:5RSA*#Y9JS/D<PRW%8"L\/C*;A
M-='_ %JO-!1114'"%%%% !1110 4444 ?(__  54^#NO:3H/A3X^_#ZS>Y^(
MOP,NGU3[+%D-KNBN,:A8-M&6S%EUZXVOM&YZ^C?@;\:?#_[1?P@\.^./"MY]
MN\/^)[)+ZRE(VMM8<HX_A=6!5E_A96':NJ(W#!Y!ZBOA7X#3_P##L']N.[^$
M5\6MO@U\;KZ75_A_/L/V?0-98C[5I!8\(DIP\0Z9*J,LSD:+WHVZH^AP_P#M
M^!^K?\O:*;C_ 'H;RCZQUFO)S\CS[_@K+^R@?AO\05^(6C6^-$\43%=11%XM
M+X\EC[2C+?[ROG&5%?'=?N?\5OAEI7QE^'6K>&-;A\_3-8MS!*!C<AZJZYZ,
MK!64]BHK\7_CQ\%]6_9^^*FK>%=97_2=,EVI,%(2[B/*2I_LLI!]N0>0:_IO
MPKXM_M'!?V=B7^]I+3^]#H_6.S^3[G^=_C]X>?V-FG]M8*/^SXAN]MH5-VO2
M6LEY\RT21R%%%%?K)_/04444 %%%% 'E?QR^"']O^9K&CP_Z=]ZYMT'_ !\_
M[2C^_P"H_B^O7PQT,3E6!5E."".0:^QZ\[^+WP*M_&XDU#3MEKJV,L.D=U_O
M>C?[7Y^H^6SC(_:-U\.M>J[^:\_S]=_WGPX\5/J<8Y5G,OW:TA/^7LI?W>S^
MSL]-OGNBK&JZ3<Z'?R6MW!);W$1VNDBX(_\ K>]5Z^-::=F?TQ3J1J14X.Z>
MJ:V84444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBNZ^$W
MP2N_B#.+F[\ZRTE>3+MP\_M'G@]QNZ#GJ>*UHT:E::ITU=L\[-<VPF6X:6+Q
MTU"$>K_)=V^B6IF?#'X7WOQ)U;9$&BLH6'VFY*_+$/0>K'L/Y#)'TKX?T"T\
M*Z-!I]A"(+6W'RKU+$]68]V/<_0<   T#0;3POI$-C8P+;VL PJ+Z]R3U)/<
MFKE??95E$,)'FEK-]>WDC^0^/O$+$\0UO94[PP\7[L>K?\TO/LMEZW;****]
MD_. HHHH **** '0PO<S+'&K/([!551DL3T %?KQ_P $^_V5U_9@^",,=]$H
M\3^(-E[J[=XC@^7;_P#;,,0>OS,^#C%?)O\ P2=_9)/Q$\=?\+$URV)T7PW,
M%TN.1>+N]&").>JQ<'_?*X/RL*_1KQ-XEL/!GAO4-8U6[@L-+TJVDO+RZG;;
M';0QJ7>1CV55!)/H*_GCQ<XM]M46285^['6IYOI'Y;OSMU1_9?T<_#MT*7^L
M^-A[]2\:*ZJ.SGZR^&/]V_22/G__ (*:_M6ZE^S9\!X=)\'1O??%3XEW:^&/
M!5A$,R/>S85K@_W4@1C(6/RA@@/#9KN/V)_V6-+_ &,_V:/#'@#37^U2Z5;^
M;J5\<E]3OY3ON;EB>3OD9B,Y(4*N?EKYX_8*T"^_;G_::UO]JCQ-:7$'AJWB
MF\.?"C3;N)HY+33 S+<:HR'I)<L6 /4)N'*[#7V[7XE+1<I_9.:6P=".60^)
M/FJ?X[:1_P"W%=?XG+I8****S/GPHHHH **** "BBB@#\W_^#H#_ ),-\%_]
ME"L__39J=?A77[J?\'0'_)AO@O\ [*%9_P#ILU.OPKKZG)O]W?K_ )']4^$7
M_)/K_'+] HHHKUS]/"BOT;_X-PO@?X*^.7Q[^(EGXU\(>%_&%I9:!#-;P:WI
M4&H1V\AN%!=%E5@K8XR.<5]"^(/^"CO[!WAWXOZCX)U7]G?3-/N-.U:;1;O4
M&^'>B-:0O'*T3R9CD:;9E205C+8Q\N>*X*F-<:CIQ@W;L?"YGQG5P^85<OPV
M$G6E32;<;;-7V/Q?HK]!O^#@7]A/P1^R-\<?!FK?#[2X]"TWQ]:7;SZ/;!OL
M]M<V\D09XE).Q7$Z_NUPJE#@ ' \9T/_ ((P_M.^(O L7B.V^$NM?V=/ +E$
MFO;."\*$;A_HKS+<!L?PF/=VQFMJ>*IRIJHW9/N>O@.*LMQ. HYA.HJ<*NW.
MU%W3LUJ];-=#Y?HK[3_X(T?\$ZA^V'^UIJ%EXY\+ZA>>"/ 89/$UL]W]@EM;
MN19EMX)DW+/S)!*&$8RICPQ4'!Q_^"L/[!GB_P#9X_;(U!+'P(-&\+?$#6KF
M'P/9:28)_P"T(HO(4QPV\#-(AS-$ KHK,7X!.:/K5/VOL;ZVO_7YE+B; O-7
ME',O:*/-NK=[+6[?+[S5M(Z['R)17T]XK_X(R_M-^"_ L_B._P#A-K/]F6T)
MN)!;7UG=72H!DG[-%,T^0.VS/M7FO[,/[%'Q-_;*NM<A^&WAK_A(Y/#<$=SJ
M0_M&TL_LT;E@K?OY8]V=C<+D\5HJ]-IR4E9>9VT\[RZI2E7AB(.$?BDIQLK[
M7=[+YGE=%?2L7_!'O]I6;X7_ /"8+\)M>_L7[(;[!N+87QBV;\_8S+]IW;?X
M/*W=L9XKZ=_X($?\$Q= _:5OM:^(_P 3?!Z:_P"#M/*6_A\7-Y&;.[O4<^>)
MK=7\QP@\O D7RVWMP_;*KBZ4(.I>]NQYN:<6Y9@L%5QWM8SC3LFH2BW=[+??
MR[)OH?F;17Z'?\$_OV./BI^RM^TUXJ\)>,/V6?"_QG\1R^&[?4QH.MZ_HJQZ
M7;/<LB7223">(LS1NFU2' &3P1GY);]G[QM^T9^U7XH\)^"_ 5U_PDDVL7[G
MPYI?ERQZ.JW#!XO,3;$L41(C\SY4X7&,@54<1&4FM++K='1AL_PU:O5A&4?9
MPBI<ZG!II];)W2\VDGT/)Z*^A_CM_P $HOVA/V:_ -QXH\8_#35-/T&S7?<W
MEK>6FHI:)_?E%M+(T:#NS@ =S7(? C]AWXJ?M-_#GQ5XL\"^$Y_$.A>"HVEU
MB:&]MHY+8+$TI"PO(LLK;$8A8E8DC !) JU6IN/,I*WJ=D,YR^='ZS"O!TT[
M<RE'EN^E[VOY'D]%?1_Q$_X)&?M&_"CX57GC37OA=J]EX>T^V^V74RW=I//;
M0CEG>WCE:=0HY;*#: 2V "1\X54*D)ZP=S;!YAA<7%SPE2,TM&XM2L^VEPHH
MK[T^+'A_6H?^"//A^\E_9<\'Z%I316>WXKPZMI3ZG?9N\!F@2(78\P_NSN?@
M<GCBHJ5>1I=W;='/F69+"2HQ<4_:34=91C:_5<S7-_AC>3Z(^"Z*^EK3_@C[
M^TAJ-[X9@MOAAJ%T?%]@^IZ6\&I6,L4EN@A8R22+.4@XGBP)BA;<0 2K8\[_
M &GOV+/BA^QGK>GZ?\2_"%]X8GU:-I;)Y)H;F"Z"D!@DT+O&67(RH;< RD@!
MAEQKTY.T9)OU'0SK+Z]14:%>$I.]DI1;=M[).^EG?T/+:*^B/@1_P2?_ &A?
MVE? -MXH\'?#34]0T&]&ZUO+J]M-.6Z7^_$+F6-I$/9E!4\X/%0_ O\ 9B\1
M_!C_ (*,_"?P!\4/!\VF75SXTT."^TC5[5)8+ZUEOX48$'='-"XWJ2"R-\PY
MY%+V]/5)IM=")9W@?WD*56,YTTVXJ2<E;>ZO=?,^?:*_1O\ X+._L4_\)C_P
M4]\)_#'X*^ O#VG:GX@\(0W-KHNC6]GH]O<RH]_++(<F*$-Y4!)9B"0@')P*
M^//^&'_BC_PU/_PI3_A&/^+F^;Y/]C?VE:??^S?:L>?YOD?ZGYO]9[=>*FEB
M(3@I7MI?Y'-E?$6#QF%AB7-0<H>TY7)74/YG_=7\VQY/17HWCW]DGXC?#7]H
MB3X3ZKX5OO\ A8D4T%N=$LGCOYV>:%)XU5H&=&S%(C':QP"<XP<?9_\ P3W_
M ."0'Q=^$W[<'PSO_B_\(8[CP#=W=U%?K?FQUBQYL;DQ_:(HY)0@\P)@R*!O
MV_Q8IU,33A'F;6UUKOZ%9EQ%@,%AGB)U8OW'.*YHWFDK^[KK?HU<_.JBOU$\
M<_"FR\!_\%X/B=X;\"?L\^"/BOIEAHEJUMX'D;3='TRU5M-TYWN46XB:W5E=
MV. @8F5CGKGYA\>?L2_%3]L/]MGXI:'X ^$6G>&=:T*^>ZU#PC8:QIL5MX=C
M+*@BCEWPP.H8C_5#'/2LX8N,M7HK)[KJ<>"XIP]?EG5M3@Z4*EY3AHIVT:OS
M+?XFN5O1,^6:*^E-$_X(^_M*>(_A@GC"S^$^NR:)+:?;H]US:I>21;=P*VC2
MBX)(Y"B/<<C .17COP/_ &>_&O[2?Q%A\)^!O#>I>)/$,R/)]CM8QF)%P&>1
MF(6- 2 6<@ L!G)%;JM3:;4EH>Q2S; U8SG2K0DH?$U)-1_Q:Z?,XVBOJ2X_
MX(K_ +3UKXZM?#DGPJU!=3O+62\A/]JZ?]E:.,HK#[3Y_D!_G7$9?>1DA2%8
MCYO\<>#-2^&_C75_#VM6WV/6-!O9M.O[?S%D\B>&1HY$W(2K892,J2#C@D40
MJPG\#3*P>:X+%OEPM:,W:_NR3T[Z/8RZ*_4G_@E__P $B;;XM_L _$SQ_P")
M? B:WXY\4Z!J,/PZ^U:C UNY>QEC@G2/S D<IN3@-<8V%%8!,;CT/_!#G]A#
M3= \:_M&^#/C1\-?"6K^*O!D.AJMIK=A8ZP=+:>"_E/E2?O47>GDD^6W.U<\
MKQR3S"G%3:UY3Y7'<?9=AZ>*E#WWAW%-)QN[RC%M:O2+DDWWT/R5HKZ/\1_\
M$C/VCO"7PEF\;ZC\*];MO#UO:?;IG-S:M=0PA=Q=[42FX7 Y(,8( .0,&O-_
MV;?V1_B1^U]XKN=%^''A/4O%%]91B:Z\@I%!:*20IEFD98H]Q!QN8;MIQG!K
MJ5:FTY*2LO,^GIYQ@*E*=>%>#A#XFI1M'U=[+YGG%%>R?M/?\$_?C%^QK96-
MU\2/ NI>';'49#%;W@G@O+1I,9\LS6[R1JY&2%9@2%; .#CQNKC.,E>+NCJP
MN+H8FFJV&FIQ?6+37WK0****HZ#UK]@/_D_+X'_]E"\/_P#ISMZ_J:K^67]@
M/_D_+X'_ /90O#__ *<[>OZFJ^9SO^+'T/YR\;/]^PW^!_F%?R\?\%#?VM-4
M_;3_ &M?%OC:^NY9].EO)++0X6)VV6G1.RV\:J3@97YVQ@%Y';'S5_4/7\@]
MG_QYQ?[@_E3R2"=24GT-O!/"4IXG%8F2]Z"BEY<W-?\ ])1)1117TI_0X444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %WPUXDU#P;XCL-8TF
M]N=-U72KF.\LKNWD,<UK-&P9)$8<AE8 @CTK^H?]@/\ :0D_:Y_8W^'WQ#N$
M1+_Q#I:F_")L3[9"[07.U>R^=%)@=ABOY:Z_HR_X((?\HG?A7_OZS_Z>K^O"
MSN"Y(SZW/Q?QJPE)Y;0Q37OJ?+?R<9-K[XH^PJ***^</YO"BBB@ HHHH ***
M* "O*?VTOV3=#_;3_9[UGP+K<DMF]SMN]*U* E;C1]0BRUO=1D8(9'ZX(RI9
M<_-7JU%--IW1MA\14H58UJ+M*+NGV:/E_P#X)P?M>:]\6-*UGX6?%*V_L?XX
M?"Q8[+Q#:NWRZU;X AU6W/&^*8;2Q X9N@#J*V/^"A7[&$/[47PZ_M'288T\
M::!"S:>_W?MT?+-:L?<Y*$\*QZ@,QK#_ ."B/['FO_$JXT/XO_">==(^./PR
M1IM'E'$7B.SY:;2;D9 :.4;MF?NLQY7<6'H_[%'[8GAS]MOX'VGBW0TFT^^@
MD:PUW1;H;;S0-0CP)K692 0RGH2!N4J<#.!Z>69GB,NQ4,?@W:47_P .GY/8
MGC/A?+N(<JJ1JT[T*ONSBO\ EW/=./9-^]!]&G%[:_CC>V4VFWDMO<12P7$#
MF.6*1"KQL#@JP/((/!!J*OT&_P""I/["[Z\MU\3O"-GNNHH]^OV,"<S*H_X^
MU4?Q ?ZS'4 -V8G\^:_L+ACB/#9U@8XS#[[2CUC+JO\ )]4?Y<\=<%8[A?-9
MY;C%=;PETG'HU^371W7F%%%%?1'QH4444 %%%% &#X[^&^E_$.P\J^A_?("(
MKA.)8?H>X]CQ7@7Q"^#>K_#^5I)(S=Z>#\MU$OR@?[0ZK^/'O7TW2,H=2" 0
M1@@CK7DYAD]'%>\])=_\^Y^@\'^(V9Y U2@_:4>L)/;_  O[+^]=U<^.**^@
MO'W[..E^)G:XTPC2;L\E47,$A]U_A_X#Q[&O'_&/PJUSP,S-?6;&W'2XA_>1
M'\>W_ @*^+QF4XG#:S5UW6W_  /F?TWPUXAY-G24:%3DJO[$M)7\NDODV^Z1
MSM%%%>:?<!1110 4444 %%%% !1110 4444 %%%3Z=IESK%XEO:6\UU/)PL<
M2%W;Z <T"E)13E)V2(*LZ5I%UKM\EM9V\UU<2?=CB0LQ]3@=O>O2?!7[,.HZ
MFR2ZS,NGP'DPQD/.P^OW5X[\].5KV+PGX+TWP1I_V?3;6.W4@>8XY>4^K-U/
MTZ#L!7NX'(<16]ZI[L?/?[O\S\FXI\7LIRU.C@7[>K_=?N+UEU](W]4>>?#'
M]F^'3#'>^( ES/C*V0.Z.,^KD?>^@X]<YQ7JRJ(T"J JJ JJHP% X  ["EHK
M[/!X&CA8<M)?/JS^9^(^*<QSS$?6,?._:*TC'T7Z[OJV%%%%=A\Z%%%% !11
M10 5Z=^R9^S)JW[5/Q:M?#]COMM/B_?ZI?[,I96X/)]"[?=5>Y/8 D<?\,OA
MIK7Q@\<Z?X=\/V4M_JFIRB*&)!T[EF/154 DL>  2>E?L%^R5^S#I/[*OPGM
MM!L?+N=2GQ/JM^%PU]/CD^H1>BKV'/5F)_/?$#C2&283V=%WKS7NKLOYGZ=.
M[\DS]C\'_#*KQ3F/ML4FL)2=YO\ F>ZII]W]IK:/9M';?#OX?Z5\*O!&F>'=
M#M4LM*TF 6]O$O8#J2>[$DL2>222>37Q?^U]XKU#_@I/^TB?V;O!TMY'\-_"
M=U#>_%OQ#:3&-&527BT.&0=99&4&7'W0I'\#J>]_X*'_ +7'B'P_KFB_ SX/
MR+<_&[XD1E;>91OB\(:;R)M5N2 =@4!A&"/F<9 ) 5O6OV./V2/#7[%7P+T[
MP3X:\^Z$+-=ZGJ=T=UWK5])@S7<[9)+NWN=JA5'"BOY0G4G*3K5'>3UUWOW9
M_I?EF'I91A(8I149VM1C:RBEISVZ*.T%W5]HZ^C^'?#UCX1\/V.E:9:P6.FZ
M9;QVEI;0ILCMX8U"(B@<!54  >@JY116!X3;;NPHHHH$%%%% !1110 4444
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M<'BG0H(KCQAI?CO6K*V3R_,98K:2[EMU$8YP\K/D#[VP#^&OS5_8H_X*8?\
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M_P !?^1['17CG_#Q/]G[_HNGP<_\+33?_CU'_#Q/]G[_ *+I\'/_  M--_\
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M ("_\CV.BO'/^'B?[/W_ $73X.?^%IIO_P >H_X>)_L_?]%T^#G_ (6FF_\
MQZCEEV#^S,9_SYE_X"_\CV.BO'/^'B?[/W_1=/@Y_P"%IIO_ ,>H_P"'B?[/
MW_1=/@Y_X6FF_P#QZCEEV#^S,9_SYE_X"_\ (^0O^#H#_DPWP7_V4*S_ /39
MJ=?A77[+_P#!Q;^U5\+_ (Z?L5^$M*\$_$CP%XQU2V\=6EW-9Z'X@M-0GBA&
MG:BID9(9&8(&=!N(QEE'<5^-%?49-=4'?O\ Y']/^%%&I2R%0JQ:?/+1JW8*
M***]8_2PHKZ1_8I_X);?$G]OCX;^,/$G@.Z\+[/!S".:PU"[F@N[^1HFD2.
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M4TYT[<R[75U?U044459UGK7[ ?\ R?E\#_\ LH7A_P#].=O7]35?RR_L!_\
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MG313R.D,L4*M%;B-R'\V4JC>9UX./R7^-'_!4OX]?M#_  :N/ 'C3X@W>O\
MA2[$(GM)]-LEDG\J1)8R\ZPB9B'13DODXYSS6Q\+O^"Q7[2GP;\!V?AK0?BG
MJD6CZ?$(+:*\T^RU"2",<!%EN(9) H' &[Y0 !@ 5BL!648ZJ\=-VM/EJ>33
MX%SB%'#/GIN=&,J=E.K&+@]4^:'+)2O>Z^%JVI^@6C?M%^,/C[_P79^ "^/O
M@[=_"'Q1H.CZS;M!<:RFJ'4[9]-U!HG61(HTV*XF VE@2S<C%?#/_!<V^FO?
M^"IOQ4\Z627R9M/BCWL3L4:;:X4>@Y/'N:\>\/\ [;/Q3\-?M)P?%^#QEJ4_
MQ'M6E:+6KV.*]DC\V&2!U$<R/%M\J1U"[-J@_*!@8YCXX_'#Q1^TC\5-6\:^
M--3_ +9\3:XT;WU[]FBM_/*1I$O[N)4C7"(H^51TSU)-=5#".G54]+*-NN][
M]3Z?(^%*N S*GBURJG&A[*T7)VE[1S=N:[Y==+ROY6/U%_X.@[Z:/P;^SU;+
M-*+>6'697B#G8[JFF!6(Z$@.X![;F]37IW_!5KX-6W[1_P"S3^Q_X3U#4%TX
M^+/$FC:1-J,K_O(8[FQ59"I.07.!M!^\^T=Z_)O]J+]NGXJ?MGVWAV'XE>*?
M^$DC\)K.FE#^S;.S^RB81"7_ (]XH]^[R(OOYQMXQDYN_&K_ (*&_&/]H;P'
MX6\->+?&D^HZ/X*FAN=$BAT^TLI-/EAC\N)UE@B20LJ\ LQYYZ\UA# U(PIQ
MNKQO^)XV!X(S"AA<OHJI!3P[JN35W\=^7E]W6UU>]OF?JQX9^"?PH_81_P""
MC_PO^#WPW_9_.O:[JEM!K%WXZUB\GOI]/@5G26>)&!C1D$?S2*8U5I5 7D Y
MO[1(Q_P<R?"#W\.<>_\ H6IU^>M[_P %J?VH-0\,PZ3)\6M7^R0!55DT^Q2X
M8*01NG$ E?ISN8YYSG-<?XM_X*4_&KQS^T7X=^+.J>,8[GXA>%+1K'2]7&BZ
M?&UO"PF!0Q+ (I.)Y<%T8C><'@8F.!K7YI-7Y6MV]^IR8?@;-_:RK8FI"4I4
M:E)MSJ2<I23M)\T=%T<5HNESTG_@O)_RE=^*O_<(_P#3/8U]0?\ !K%_R4SX
MP_\ 8,TS_P!&W%?FE\>?CSXK_:;^*^J^./'&J_VWXHUOR?MM[]EAMO.\J%((
M_P!W"B1KB.-%^51G;DY))K] ?^#;;X\^!O@7\0OBK-XV\9^%/!T.HZ=IZ6DF
MN:O;Z>MTRR3E@AF=0Q (R!G&16N+IRC@O9]4DOR/6XJRVOA^#'@6N:<*=.+Y
M;N[BX)VTO;3ML>B_\$@/V"/C9^S_ /\ !4OQEK_C30M=L]&TVTU."^\07<6R
MU\0M<3*T;1/]V7S& F.W.S9AMK8%7/AE^Q'\'?VK/B5^U?\ M >+-%UCXBZ9
MX/\ %VL6^E^&=*NGMEU)K.!+B24&$B20S,VU,,!C<2K%ACXI^+G_  5P_:!N
M[+Q+X'LOBOJ\G@UKNZL[<6\=J9FM#(ZJJWBQ_:"FP@ B7[N.U>4_LP?MP?%7
M]C/4=0N/AIXRO_#)U55%Y"D,-U;7!7[K-#.CQEAR VW< 2,X-1]5KRO4YDI-
M):7V.2?"V>XF57'.M"G6G"$(\CE%<L7=W=N:+EM[J=MKGZ_? OXA6?Q7_P""
M('QUU[2/A'H_P<\/ZAH^NMI&DZ<&9=1METR)?MKR,JF9W=9$\PJ,K O7&3X%
M_P $9-6M_P!MS_@GA\;/V9-5N+9M3@M)-5\.?:RNR 389& 'S;8;Z.*1CS_Q
M\@9[5\B:O_P62_:4\0V?B&UU'XG76HV7BFS.GZE:7>CZ=/;30%9$:-8GMRD8
M997#>6JE@1G.U<?5W_!$OPK\$/V3?#%M^T#XQ^/7AC2]?O-&O["X\%/=6\5]
M8J+ED)>,2M/.9%@CE1%A3'F+R^ 3C5P\J5*3ENVFK7>IY&9\/U\KRK%3K)>T
MG5A.BH<]1J<=4FW&_1KF>]^C:1G?\'"/Q)T_X1^%?@Y^S=X:E;^Q/A[HD&HW
MJG#>9(L1M;7<>N]8UG=O7[0IKXA_8(\6Z)X#_;<^$NL^(Q"-$TSQ;IMQ=233
M>3';*MS&1,[< +&<2'/!"$'@FJ/[97[15S^UI^U'XW^(EU')#_PE&IO<6T,@
M >WM5 CMXVP2-R0I&I(/)4UYE7I8>AR4%3>_7U>Y^AY#D3PN2QR^J_>E%\[Z
M\T[N3OZMV]#]Z/\ @IK\.4N_VQO"&OQ?LA^)?CAK#VEG'I7BS3/&]_I<.G31
M3R.D,L4*M%;B-R'\V4JC>9UX..3^&_[8FL_$G_@M-\-K?XJ?"&?X.>+!X1U'
M1+%+S64U3^T?-8S0,LR0QH%_=7*+M+9:4C.3@_FW\+O^"Q7[2GP;\!V?AK0?
MBGJD6CZ?$(+:*\T^RU"2",<!%EN(9) H' &[Y0 !@ 5XI\0?CQXS^*OQ2?QO
MXA\3ZUJGBU[A+H:M+=-]JBD0AHVC<$&/80-H3 7 V@8KAIY=/EY)VV:3N_RV
M/BL!X>XI47A<:X-1ISA":G6E)<RM?DE+DBK;Q2?E8_3#XE?\$^/CEXG_ ."\
MD7BZS\-Z[%X:/C"R\3CQ.2_]GIIL+PL\?VC[OF>6AA$!.X],>7\U>M_M4W<=
ME_P<H? MY76-3X5$8+' +-%JZJ/J20!]:^(_V<?^"POQX^(7[0?PH\/^//BY
M=IX'B\8Z*VK27$5GIZ?9([^!I3<W21I(8MBDOYDFTJ#NR,UN?\%]?C]H7CW_
M (*"^&O%GPY\9Z/KBZ1X8T]K?5_#NK17:V=W%>7<B[9H6(65"4;KD94]Q4JA
M5=54ZEOA:T.59'FL\RHX#'\B_P!FJ4E*"DTE;E3DVEKY;=CZU\7?L8?$W6?^
M#C*#XCP^$=6_X0(&UU5M?,6+!8HM%CM&7S>GF^>A01_?P0VW9\U5/B!_RM'^
M!_\ L"2?^F&^KX#U7_@M;^U!K4.G1W'Q7U(II<\=S $TO3X]SQD,OF[8!YPR
M 2LFY3CD&N"U#_@H9\8-4_:DL?C3/XOW_$O38#;6VL_V59#RXS;O;D>0(?(/
M[J1UR8R?FSU -5'!5_MM?#R]3KP_!6<RNL5.EIA98>/*Y=K1;O'[[;=$S]4_
MV8#C_@Y5^.?_ &*8_P#1&CU\P? SQ;XO_8 _X+AWGB+QAH&M^&?#/Q)\::UH
MHGO[-H(]2L;N^8)/$SX#0K,UK*77(*KQG-?'T?[=OQ9@_:;NOC'#XRO;7XCW
MV/M.L6UM;P?: (4AVO"D8A9/+1 5,>T[02,\U[W\&_&-]_P6#^+J0_M(_M":
M)X*L_!MF)].O=4L]-T];Q))4$]M$P-O&LA558,1)C;]P\U3PLJ:O.W+RI/>^
MG8VGPS7P,95<;*+H2P\*52RE*2<8\MX)1UUMO9];'Z)_M4>!-(_X),?LT_M0
M_$O0Y+>S\0?&'7E30&ADQ+!)=0* !N!&Z*XFU&X"C(V(H[8'X*U^C7_!P)_P
M4!\,_M+>,/!OPZ^'_B.+Q-X5\$Q/>:AJ5M*)K;4+^10B;9 ,2>5$&^=#M)N'
M'5:_.6M<MI2C2YZGQ/\ X9'K>'668BAEOUO'7]M6LW??EBE&"?R5_F%%%%>B
M?H 4444 %%%% !7[/?\ !(__ ()!?L[?M1_\$^/ 7CKQU\//[<\5:X^I_;K[
M^WM3MO/\K5+N"/\ =PW"1KB.)%^51G;DY))K\8:_HR_X((?\HG?A7_OZS_Z>
MK^O&SJ35.+7<_*_%S'XG"912J86I*$G42O%N+MRSTNK::$?_  X$_9(_Z)-_
MY=&L_P#R71_PX$_9(_Z)-_Y=&L__ "77V-17S?M9]V?SO_K/G/\ T%U?_!D_
M\SXY_P"' G[)'_1)O_+HUG_Y+H_X<"?LD?\ 1)O_ "Z-9_\ DNOL:BCVL^[#
M_6?.?^@NK_X,G_F?'/\ PX$_9(_Z)-_Y=&L__)='_#@3]DC_ *)-_P"71K/_
M ,EU]C44>UGW8?ZSYS_T%U?_  9/_,^.?^' G[)'_1)O_+HUG_Y+H_X<"?LD
M?]$F_P#+HUG_ .2Z^QJ*/:S[L/\ 6?.?^@NK_P"#)_YGQS_PX$_9(_Z)-_Y=
M&L__ "71_P .!/V2/^B3?^71K/\ \EU]C44>UGW8?ZSYS_T%U?\ P9/_ #/C
MG_AP)^R1_P!$F_\ +HUG_P"2Z/\ AP)^R1_T2;_RZ-9_^2Z^QJ*/:S[L/]9\
MY_Z"ZO\ X,G_ )G\W_\ P7/_ &"M*_8;_:LM;;P;H,NA_#OQ%ID5SHD7VB>Y
MCBD10ES'YLSN[-YGSD,QP)DZ @5Y!_P39\$>.O$G[7OA+6OA_P"%+SQGK?@6
M\3Q2=*MY?)-W'9,L[1>800I<)L'7+,J@$D _TU_'?]G7P/\ M.^!G\-^/O#.
ME^*-%9Q*MO>Q9,,@!&^-P0\;X)&Y"#@D9P36+^S9^QG\+_V0='N;+X;^#-)\
M+QWN/M$D&^6XG Y"O-*S2,H/0%L#)P*]6.84U%3:?.DEY:*R=[W^5CZNAXB5
MXY)+*:U+GE+F3FY/6,FW*ZW;=VK\R[[[T_V._P!L_P %_MM_"_\ X2/PE<SQ
M7-E+]DUG1KY/)U+0+L9#V]S%U1@0P!^ZVTX)P<> _MW_ /!,&#QVUYXP^'%M
M%9ZT<S7VBH D-^>IDA[))ZK]U^HPWW^L_:^_X)^:GKWQ#;XQ_ S5[?X?_&ZR
M0>?*5QI/C&%<9M-2B'#[@ !+C<N!GHK)I?LE?\%)=(^-7CJ7X:_$/0[KX3_&
MK2XU^V>%=8D4+J/7]_I\^=ES$V"1M.[ /# ;CMD6?8S*,2L9@)6?5=&NS75?
MBNEF?EW&_AWD_%663IRAST][?\O*+_F3ZK^\E9K2:6S_ "PU32[G1-1GL[RW
MGM+NV<Q3031F.2)P<%64\@@]0:@K]?\ ]KC]@_PE^U9IKW4Z#1?%42;;?6+>
M,%WP,!)DX$J<#J0PQPP&0?S"_:&_9@\7_LR>*SIGB?3FCBD)^RW\&7L[Y1WC
MDP.>F5.&&1D#(K^H>$N/<!GD%3B^2MU@_P XO[2_%=4?YU^(GA)F_"M1UIKV
MN&;TJ16B\IK7E?X/H[Z+SVBBBON3\I"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *** ,F@ KO_ -GG]FOQ5^TSXV31O#5B
MT@4@W=[*"MK8H?XI'P<=#@#+-@X!KVO]CK_@F%XA^.WV77O%OVKPSX38B1$*
M;;[4D/(\M6&$0_WV'.1M5@<C](_AY\-_#?P/\#Q:/H&GV>AZ+8(9"B?*HP/F
MDD=CEFP.68D\<FORCC/Q/PN6<V$RZU2MM?[,?7N_)?-]#^@_#/P(S#/'#,,Y
M3HX;=+:=1>2^S%_S/5_93O=<7^RG^R#X7_9.\'_8M'C^VZO=J/[1U:= )[QA
MV YV1@]$!X[ECDGQ[_@I-^V#9V6C:E\ ? VBW'Q"^,'Q-T>YTJ'0;"8(FBVE
MS"T3WU]-T@B1)-PW8+<=%.ZN?^+W_!0#QA^UKXPU7X8?LJ6D&M7]G,++Q!\2
M[I0WAWPL#]_[.W(O+D+RJH"H)!^<9*^W_L9_L+^$/V+_  M>KI+7FO\ B[Q"
MXN?$GBO5G\_5?$%R>6DED.2$W$E8P<+GNQ+'^;\5C\1B,0\9BIN51N]WO?\
M1=E^A_H#E/#.6\/X&&&G24(Q5H45IIWGU2>]OCF]=$^8_E^^-WP1\2_L_P#Q
M8UOP;XHTF[TK7=#NWM+BVFC(.X'@J?XE8896&0RL""00:_5O_@B=_P $5_ ?
MQW_9BO/&OQR\#SZN=?O0_ARWGU&]T]X;55P\V+>6/<LK$8WYXBR,!LM^LGCK
MX%>"/BAK-GJ/B;P;X5\1:AIW_'I=:GI-O=S6O.?W;R(2O//!%=3'&(HPJ@*J
MC  & !55L?%P:IIIRW\M;Z?U]^Y]?G'B-F>/PE'#+]W*&KG%M2DTFO+ENF[I
M-W[I:'QW_P .!/V2/^B3?^71K/\ \ET?\.!/V2/^B3?^71K/_P EU]C45Y_M
M9]V?.?ZSYS_T%U?_  9/_,^.?^' G[)'_1)O_+HUG_Y+H_X<"?LD?]$F_P#+
MHUG_ .2Z^QJ*/:S[L/\ 6?.?^@NK_P"#)_YGQS_PX$_9(_Z)-_Y=&L__ "71
M_P .!/V2/^B3?^71K/\ \EU]C44>UGW8?ZSYS_T%U?\ P9/_ #/CG_AP)^R1
M_P!$F_\ +HUG_P"2Z/\ AP)^R1_T2;_RZ-9_^2Z^QJ*/:S[L/]9\Y_Z"ZO\
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MXE>'/C)_P4$_:C\6>$],U?1M#\1SV>HPV6J0)#>6TDL]P\RR(CNJGSC)P&.
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MN)^%<YQM>M&C9TVZ;@E+E24;74HV]Y]FVTEM;8^@O^"5O_* +]IG_KY\1?\
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M%W=1RCRIO167VG>_O:]=/L+_ (.>?^3]_"/_ &(%G_Z<=2KS_P#X-[DT-_\
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M/HO_ ,F4?\.(OVL?^B22?^%/HO\ \F5_1W11_;.(\@_XC/G?_/NE_P" R_\
MDS^<3_AQ%^UC_P!$DD_\*?1?_DRC_AQ%^UC_ -$DD_\ "GT7_P"3*_H[HH_M
MG$>0?\1GSO\ Y]TO_ 9?_)G\XG_#B+]K'_HDDG_A3Z+_ /)E'_#B+]K'_HDD
MG_A3Z+_\F5_1W11_;.(\@_XC/G?_ #[I?^ R_P#DS^<3_AQ%^UC_ -$DD_\
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M'_HDDG_A3Z+_ /)E?T=T4?VSB/(/^(SYW_S[I?\ @,O_ ),_G$_X<1?M8_\
M1))/_"GT7_Y,H_X<1?M8_P#1))/_  I]%_\ DROZ.Z*/[9Q'D'_$9\[_ .?=
M+_P&7_R9_.)_PXB_:Q_Z)))_X4^B_P#R91_PXB_:Q_Z)))_X4^B__)E?T=T4
M?VSB/(/^(SYW_P ^Z7_@,O\ Y,_G$_X<1?M8_P#1))/_  I]%_\ DRC_ (<1
M?M8_]$DD_P#"GT7_ .3*_H[HH_MG$>0?\1GSO_GW2_\  9?_ "9_.)_PXB_:
MQ_Z)))_X4^B__)E'_#B+]K'_ *)))_X4^B__ "97]'=%']LXCR#_ (C/G?\
MS[I?^ R_^3/YQ/\ AQ%^UC_T223_ ,*?1?\ Y,H_X<1?M8_]$DD_\*?1?_DR
MOZ.Z*/[9Q'D'_$9\[_Y]TO\ P&7_ ,F?SB?\.(OVL?\ HDDG_A3Z+_\ )E'_
M  XB_:Q_Z)))_P"%/HO_ ,F5_1W11_;.(\@_XC/G?_/NE_X#+_Y,_G$_X<1?
MM8_]$DD_\*?1?_DRC_AQ%^UC_P!$DD_\*?1?_DROZ.Z*/[9Q'D'_ !&?._\
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M_!G\\Y[]%_/,+-K+\3"I;I-2IR^[WE][1^45%??GB_\ X(E1L\LF@^/G0?\
M+."_TS./K(DG_LE>8^(O^".WQ5T>-FM+OPGJV/NK;WTD;$?]M(U /X_C7V6$
M\1.'<0O=Q*7^)./YI(_,LP\&.,\&_P!Y@927]QQG_P"DMO\ "Y\HT5[MJO\
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MH..M?FV<^(6?9BG&I6]G!_9A[OXZR^]V/Z+X9^CMPUD+57$T8J:^U7ESS_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_D3\BJ*_77_B%/F_Z+Y'_P"$,?\ Y8T?\0I\W_1?(_\ PAC_ /+&C^UL-W_
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MY'_X0Q_^6-.C_P"#5"0.-WQ[4KGD+X'P3^/]H&E_:V&[_@+_ (BAPS_T$_\
MDE3_ .1/R(KUS]C/]B;Q[^W7\6H?"G@;3#.4VR:CJ<X9+#1X2<>;/( <=#M4
M9=\$*#@X_7#X(?\ !LA\(?!-]%=>-_%GB[QVT39-I$4TFRF'<.L>Z;Z;9E_&
MOT!^$/P8\)_ +P+:^&?!?A[2?#.@V?,5EI]NL,>XXR[8Y=VP-SL2S'DDFN3$
M9S&UJ*U[GRG$/C#@Z=)T\HBYS?VI*T5YV>K]+(X[]BK]CWPM^PS^S]I/@#PG
M&SV]H3<W]](H$^JWCA1+<R=?F;:H R=J(B@X45ZQ117SS;;NS^>,3B:N(JRK
MUI<TI.[;ZMA1112,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>sangamo-2021cdagraphicprim.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sangamo-2021cdagraphicprim.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %I!*X# 2(  A$! Q$!_\0
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M_/#[Y?\ R(?ZT87^67W+_,_H*HK^?7_A]]^U#_T4[_RW-)_^1:/^'WW[4/\
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M_/#[Y?\ R(?ZT87^67W+_,_H*HK^?7_A]]^U#_T4[_RW-)_^1:/^'WW[4/\
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M_/#[Y?\ R(?ZT87^67W+_,_H*HK^?7_A]]^U#_T4[_RW-)_^1:/^'WW[4/\
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M?]_M;_\ 16?_ "U]&_\ D2CZI/R#_B$&<_\ /VE_X%/_ .0/Z4J*_FM_X?\
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M\[-K[FS\]S3+JF Q<\'6:<H.SMM\KI?D%%%%>T< 445^1?\ P\^^.7_0\?\
ME&T__P",5]=PKP7CL_\ :_4Y0C[/EOS-KXKVM:,OY7?8_.N/_$[*^$/8?VE3
MJ3]MS<O(HNW)RWOS3C_,K6OUV/UTHK\B_P#AY]\<O^AX_P#*-I__ ,8H_P"'
MGWQR_P"AX_\ *-I__P 8KZ__ (@OG?\ S]I?^!3_ /D#\Y_XF<X7_P"?&(_\
M!I__ "T_72BOR+_X>??'+_H>/_*-I_\ \8H_X>??'+_H>/\ RC:?_P#&*/\
MB"^=_P#/VE_X%/\ ^0#_ (F<X7_Y\8C_ ,!I_P#RT_72BOR+_P"'GWQR_P"A
MX_\ *-I__P 8H_X>??'+_H>/_*-I_P#\8H_X@OG?_/VE_P"!3_\ D _XF<X7
M_P"?&(_\!I__ "T_72BOR+_X>??'+_H>/_*-I_\ \8H_X>??'+_H>/\ RC:?
M_P#&*/\ B"^=_P#/VE_X%/\ ^0#_ (F<X7_Y\8C_ ,!I_P#RT_72BOR+_P"'
MGWQR_P"AX_\ *-I__P 8H_X>??'+_H>/_*-I_P#\8H_X@OG?_/VE_P"!3_\
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M_P#/VE_X%/\ ^0#_ (F<X7_Y\8C_ ,!I_P#RT_72BOR+_P"'GWQR_P"AX_\
M*-I__P 8K]=*^0XJX+QV0>R^N2A+VG-;E;?PVO>\8_S*VY^C< >)V5\7^W_L
MVG4A['EYN=15^?FM;EG+^5WO;IN?B9_P<C_\GQ^%?^Q%M/\ TX:C7Y]5^@O_
M  <C_P#)\?A7_L1;3_TX:C7Y]5^H\,_\BNA_A.;-_P#?:GJ%%?9G_!$#]D_1
M/VE/VM5O_%EGI>I>%O"=N99;#4(XYH-4O)8Y?(MVB<$2?)%<3;<=+8YXS7DO
M_!1W]EY_V0OVP_&'A".%HM'^U'4=%.W"M83DR1!>3GR\M$3W:)N!TKKCFE&6
M-E@%\:BI?U^#^9@\'46'6)^RW8\-HK[\^%7[3_@[]H+_ (**?#[P5X5^&GPB
MLOAE<:I;Z5(A\ :6]SKD8C4232R36[2IN=6*[/+(5AN^;->K_P#!:_4?#W[$
M7Q.^&0\ ?#/X.V5AJMM>7.HV%UX!TBYAU Q20A5=FM_-489@?+=#SUK@>=U%
MB:>$E2M.HG):[6OH]-]#I_LZ+HSKJ?NQ=MORU/RLHK[5^./[=?PHTSPYXOO?
MAQ\+_A<OB#QGJFG75JFH>"[2ZA\*VRZ)9)<Q6Z30>5N^W_: ,*R,8Y'*GS%8
M_:'A;X7>!]1_X(V2_%:;X:_"A_'R^#KK51JG_""Z./\ 24,FV3R1;>3QM'&S
M;QTJ,5GT\/"G.K1:YY**3>MVNNFRV_0JCEL:LI1A4ORIO;HC\6J*^E]>_;8T
M7Q;^RS96DO@7X5Z3\4_#?BRUN[35;'P'I<:ZSICV5]'.EQ"+8VS>7*T!VL@#
M;XV";HB]??/[9GA'P9\/_P#@D7X:^+7A[X8?"'1/&^M:+X?U&:[A\":3-&DE
MXL#3A8IK=T"GS& R"0._>M<5G53#U*=*I2UG+E6O7OMMKZ^1%'+XU8RG">D5
M?;_@[GXWT5^NW[ /[/7PR_X*D_L)^([OQE\./ OA'Q1HNISZ1'XA\,:1#H\F
M]+:&9+DK"JID>=AD(*';G SQ^1-=67YI'%5*M#E<9TW9KUVL_D8XK!NC"%2]
MXS5T%%?IQ_P3,_X);Z%^T/\ \$[?B+JFMV&ES^-/'4);PQ/<(K7&C1VYD^SS
M*2N^(3W,<JN5.'BC7L2*_,[4=.N-'U">TNX)K6ZM9&AFAF0I)"ZG#*RGD,""
M"#R"*O!YI1Q-:K0I[TW9_P!>MU\B<1@ZE&G"I/::NB"BOT?_ &9/^"=?@/\
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MMHTVM?P,LQQ-+%RC64N5VLT[_A9/0\/9&0*2" PRI(ZCIQ^1_*OVD_X-L?\
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MY2<HM*-[Z<LFVWT5K=VCY8\>Z]!XJ\<ZSJEM!]EMM2OY[J*$@?N4>1F5>..
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MG;NG*7-=;WZ.Z6_"N58K+\+/#8N7.U)VEWBE%1^Y*UO+YA1117YZ?3!1110
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M%*%/RQ_OI"_4Y)"].,]:@_9\_;CT/]E.'6Y/ _@2^&H:VBI)/K?B$7J1A,E
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MKSK/!'-+ E_<;I8K=Y!-,G!&Z-&!((&2,5RO[)D?QF\(?LU?&2_\%>"+/5?
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M-2R?*]=M-SAZ*]<\3_L,?$SP<?#$FH:/I$.F>,I7@T?65\2:9)HUY(@8F/\
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MO>J\%_X)X?\ )%=3_P"PW+_Z(MZ]ZK_3+PB_Y([+_P#KVOS9_)_&O_(\Q/\
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M#'[)WCOQA\)9?'5AI5B_A2 2&74)=8LH%AV,48,LDRNK;N I4%MRX!W#./\
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M-Z^?",CU'!Y]J\OO/^"KO[0=_J6@WDOQ*U)KKPVRM9RBQM S[49%\\B+_20
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M=G=VLK:]-]?71['6_P#!1?X#S? CXYZ2B>+AXYT'Q/X7TO6O#FKM!Y$\^D&
M6]FLJ  !TAME3/\ $%5B 6*CN?\ @D%\2-,7XZZ]\*/$TQB\(_'#19_"UX=P
M40W3(QM)@3_&'+HO^U,#VKYP^+GQD\3_ !X\;W'B/Q=K%UK>L7*)$T\VU0D:
M#"1HB@)&BC@(@"CL*Q?#OB"]\)>(+'5=-N9;/4=,N([NUN(SAX)8V#(ZGU#
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MY\=/^R>Z_P#^FVXK^4JOZM?^"B?_ "C\^.G_ &3W7_\ TVW%?RE5Z&#^%G]
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M ,$5/@1XLTGX4>%/B?H>B:OXC/BS[=-K"MHUW)>'R;B1-.O;88-M"BM),&V
M1 %0_/PMXO\ C7XI\>_#GPGX2U?6+B^\.^!DNDT*Q=4":<+F433[2 &.]P"=
MQ., # &*[C]E?]OSXP?L3MJ/_"L?&^H>&(=697N[86\%Y:SN!@.8;B.2/?CC
M<%W8P,\4O9R2\R?]7L93PE.,*BE4IS35W**<(QE",7*/O)\KYF[/W[Z-,^L]
M!_;N^-.K>/\ X*^/K[X2^!+G2O O@O6;:P\,60NX+K5O"D=K'#/-/)>3W$K0
M!!)Y,JLS,8+@E77.[D_VDOV?_AE\3/V!/$WQ8_9\\0^*=#\"Z1XEL'\7?#_Q
M*%EDTJ\99+>UGM;D;C(N+F08+L623+,&C"#Y^TW_ (*%?&72_P!HZX^+:>.M
M1F^(=U;/9/K%S;V]RP@==AB6*2-HD3;P%5 !DXQFLKXQ?MF_$3X[>#AX=U_5
M]-B\/_;VU633-&T+3]#L[J\88-S-%900I--C(\R0,PR<'FA4VG=%4LAQ-*O3
MJ45&"7+>TI--<TI.+BXVE:_NSO&2;;\CRVOUG_;#L/#O_$1A\)O^$R2!-!FC
MT"13=@K#),+<BV)/0K]J6,<_+D$-QFORV^&/Q)U3X0>/-.\2:)_9G]JZ3(9;
M8ZAI=KJ=NCE2NXV]S')"Y&[*ED.U@K+AE!'H_P"U!^W[\5/VS392?$G7-(\1
M7NG.C6^H+X:TNRU"-4\S;']JM[>.<Q R.?*+[-Q#;=P!%2BVSOS?*\3B\5"5
M-I0]G4@W=\R]IRZI6MIR]UOY'T1/:^/?A!_P<-(#_:2^)IOBV'4\RR7&G7E[
M[Y_=/8S$'^[&QZ;>/I?PGKNB:9XH_P""GE[X$G6STV/3$\F:Q8QA;C;?K=%"
M,8!G\[D<<\<8K\^M4_X*B?'76]/M4N_'37&H66EG1;?7)-'L&U^"S92K1+JG
MD?;@""<D39))).3FJ'[/W_!1CXN?LM_#;4?"/@;7="T;0-:5TU*W?PGI%X^J
M(V[*7$L]J\DZ8=@%D9@%8@ #BH=.31XF,X;QV(I1OR<\84X6N^5J$XS;?N:?
M#:*L[<SU[^1>)O&FL>-)+-M8U;4M6;3K5+&T:]NGG-K;IG9#'N)VQKDX48 R
M<#FON?4/!<.O_P#!NQI]]X/ DN='^*#7OCE;9V\Q0898;=IAW0"2SP!\N7!^
M\&-?!VL:I)KFK75[,MNDUY,\\BV]O';Q*S$L0D<85$7)X5%"J,   8KOOV>O
MVM_B)^RO<:PW@7Q+/H]OXBM39:K8RVT%]8:G#S\L]K<))!+@%@"R$@.X!PS
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MYJ[:C'82B>&&2WB$(<="T84(_<?,#P2.A-,\=?'#Q+\2])M['6KRUO+>TP(
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M2?Z7;:JLGS HL;E_,)[;U4Y/<#UJY\#/LLMG\8?[.'^@G0KPVP /$6YBOO\
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M8B$C=AMKJP^5LG._X)KZQ'IVL?%*SUK/_"(S>"[R768Y4)BS&R",MWW@/*%
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MKV0LK*6&W<H=C@'(536?\0/@/JOPW\+KJE]>Z+*OVYM/DM[:Z\RX@D 9OG7
MV@A<X)R-PR >*UK\'YU1I5:]7#24*3E&3:T3C;F7JKJ]B*>>8"I.%.%5.4TF
MEW3V?SL<316OX*\$WOCS5GM;/R$$$+7-Q//)Y<-K"N-TCMV49'OD@ $FN@O_
M (&7=IX7M->AUG0[_0+BY^R3:C;-.T=A)Q@3(8A*N<CHAZCU&>+"9%C\51>(
MH4VX*[OHM%:[U?PQNN:6T;^\T=%;,<-1J*E4E:3_ #>R]7;1;OH<117I^M?L
MJZQHNN^&[%M9\.W)\5;VL9[>2XE@*JF_>S"'A2".1G&<G"@D<I9_#*ZU?QM<
MZ+IU]IFI?8U:2:_@F864<:*"\ID=5PB]"V,$CC.1GKQG"F;86:I5Z+4G)02T
M;<G%2223;^&47?:S6NIC0SG!5HN=.HFDN:^MK)M;^J:^3.;HKL=?^"M]I/@+
M_A)K+4=(US1HY_LT\]A)+FUDX $B21HPSD8.,'(]15SPY^SSJNO7.EVLNI:'
MI6I:W&)K"PO)Y!<7"$95L(C*F[!QO*DU,>%<UE66'C1;DU%K:S4G:+4K\KYG
MI&SU>BUT!YQ@E3=1U%9-I[W36KNMU9:NZT6KT."HKNX_V?M6;PQXBU![W2HI
M_"C%=3T^1I1=6YWE1C]WY;!MI(*N1CO5:3X+70^%T?BZ/6-$GTLW26<R1O-Y
M]K*P!*NIB'W01G:3[9HEPMFL5>5%KW'4W7P1;C)[_9DFI+>+332L"SC!MV4_
MM*/7=JZ6W5--=T]#C:M:EH5]HT-M)=V=U:I>Q">W::%D$\9Z.A(^9?<<5ZS\
M9_@OHG@[X<^"VT[6M):ZU&TDNVEFBFADU-I&C*E6,>U$4$ >:R8&3QDU1\<_
M#KQ5K&H^"M%\1>(]"6*[TU%T:22<FV@AX"(7CC().% ;Y@>/FKV<9P/C,).M
MAZT7*I%4FG!PE!.KRM*<N;W?BLK7N[/X6F<-#B"A7C"K!VBW._,I*5H7UBK:
M[7?9>:L>545VGC#X)W7@CXF0>%+S6-&;4972.1XOM#16SN 45SY6XDAE^ZK?
M>&<<TR?X+WL/BC5]/&J:-);Z N=1U)99!96ISMVEB@9F+?* JDD],X->)4X9
MS.%2=*5+WH3<)*\;J23;3UTLDW)[1L[M69Z$<VPDHQFIZ27,G9ZINR:TZMJW
M5W5MSCJ*[3Q%\"-9T73]"O;2;3]<T_Q'.MK876GRLT<DQ.!$1(J,KYSPP'0^
MAH\0_!6;0=*UJX77O#M_+X>VB^M;6:4S1%I4BXW1JKX9P"58@>N>*=3AC-*?
M.YT6N5<SO;5<O/>+O[RY%S>[?W==A1S?!RY>6:=W;KO?EL^WO::VUT.+HHHK
MP#T@HHHH ^RO^">'_)%=3_[#<O\ Z(MZ]ZKP7_@GA_R174_^PW+_ .B+>O>J
M_P!,O"+_ )([+_\ KVOS9_)_&O\ R/,3_B"BBBOT8^7"OP/K]\*_ ^OWSP/_
M .8W_N'_ .Y#^1?I4?\ ,K_[C_\ N$*TK/P=J^H>&[O68-*U*?2+!UCN;Z.V
M=K:V9B JO(!M4DLH )YW#UKW/]C']G?PW\5/AY\2O$>LZUI<=SX:\/79M[.Y
MMKATL7DA=5O)2L; JF&*K&)'W#=M!5<^A_"#POJ'C/\ X)S_ !.\-V6OV>NP
M6?B&RBM;UKF6&P@A#VTDCAKE8S%$OSLVY5Z$X.1G]0S+BFEAZLJ5..L*E.$V
MTTESM:IVL[)I[_D?@^2< U\90CB*TK*I2K5*:BXRE)TD[)J]U>46MG;9ZL^-
MZ*]*^-O[+>M_!#PEH7B";5?#GB+P_P"(FDCL]3T.\:ZMC)&<-&S,BD,.>W\+
M<\&MGPE^Q1XA\6^([;P]_;_A'3O&-Y9_;8?#E[=S1Z@RE/,5&(B,*2E,,(WE
M5]IR5%>L\\P"HK$>U7)KK_ATE?JE'[3>W4^>7"N;/$O!^P?M%RZ::\ZO!)WL
MW-:Q2;<NESQRBK.M:/=>'=8N]/OH)+6]L9GM[B&08:&1&*LI'J""/PKN/!G[
M.U]XE\(:?KVJ:]X9\(:/K-PUKIMSK=S+&-0=6V2&-8HY'V(Q :1E5%)Y;KCL
MKXRC1@JE26CVZWZZ):O373IJ>9A,MQ.)JRHT87E'5].57M>3=DE=I:M:M+=G
MGU%>G>(/V0?'7ASX\#X=3:6DGB)@)5,<H-LT&"WVCS#@"(*"2S8Q@@C/%3WG
M[)6KW?@+7?$7AWQ#X3\9V7A<DZO%HUU,9[",9S*4FBBWQ#:?GCW*<$@D D<G
M]MX"T9>U5I)-/I:6D7?9<ST5[7>B/17"^;7J1^KRO!R335G>"O-)/5N"UE9/
ME6KLCRJBO7?#W[%WBGQ!\(=,\<?VEX3M/#VHWRV37%QJR*+'<C-YD[ %(U&T
M*5+>9ND1=FXXJSKW[&.I>!/BEX)T3Q!XD\.P:+XY$<FG:]I[S7UG<(S*N$"Q
MAR_SI@%57YURP&2,_P#6#+N=TU53DN;1:OW5>2TW:6MEJ;+@_.?9QK2P\E&7
M)9NR5INT&VVK1;:7,[*^[/&:5%,C  $DG  '6OI;]H[]CZSU#]KB[\$>!]:\
M)P3LUI9V^DS336LUH%M(1OD>2)8I'=OF(B>21BY8K]XCG/$'["/C/X?6MS?R
MZ]X)@O='UL:3+;_VXD-S;R[CY<Q\P*J(X =-S!RK*=G.*YJ'%&75:5.;J*+J
M14E&6CM+:_EY[=CMQ? ><T,17I1HNI&C.4)2A:4;PWL[[VUMNNJ6IY/)\,O$
MD7C >'F\/ZXNOG&-,-A*+PY7</W6W?RI!Z=#FLB_L)]*OIK:YAEMKFVD:*:&
M5"CQ.IPRLIY!!!!!Z5]?_!W5_B-X,_X*CZ3I'C;Q*=1\12R16VK2V,I2VNXC
M8&6.,JJ1JP577C9C<"1D_,>3\>_L%^,/B5X[\<ZGHFJ^#M0U2WU&\OI/#L.K
MJ^L)$TSLI:$*54E2#M9PW(! /%<-+BJE3KQIXV4(QE3A-23;3<FUI=+W=-&^
MZO8];$>'^(JX6=;*Z=2<X5ZM)PE%*25-1>J4G>>KO%7U3M>USYGHKT>^_9JU
M"#]GO_A9-KK_ (;U+1([V/3KBVMGN1>6EPZAO+=)(57*@C)5V7G@M6AXR_92
MN/ G@SPAXGO?&/A&?POXQN)(+?4[(WDRVWE_ZQI(S;K(,$$;0I.1T'6O<_MG
M!W4>?5R<=G\25W';>VMNO2Y\K_JSF7*Y^ST4(S;YHVY)2Y5*]_AYM&]D]['E
M**9&  )).  .M7?$OA;4_!FL2Z=K&G7VE:A %,EK>6[P31[@&&48 C(((XZ$
M5]'_ +8W[+ND?"?XM^$_#_A3Q'X<M-1M])L8T@N7EL;JZFW2,U[),\8MUW$9
MP9M_"J%.%%<'^TA\/OB5XL_:MN_"OBBY7Q;\0)FM;4FQ V3%[>.2-5PD:@*C
MC<=H PQ)QEJX<!Q#0QGLZM*24)0E/WKJ5DXI2LU;EUU=][6OK;U<WX-Q>6^V
MH5XRE5A4A3]RTH<TE)N+:=^?1<L4M5=NVE_'J*]A@_8OUS78M>A\/>(_!WBO
M6?#,33:AH^E7DSWL:(0)&C$D*1S!,\^4[\X R2 8/ /[&GBKXB?"";QO9W_A
M:#0[:[2UG:YU:-&M]VTEY<96)5# D2,KXQA22 >IY_EZCSRJI:I:Z.\OAT>N
MO1[/H>>N$<YE-4X8>4FU*6FJM#26JNO=>DE>Z>C1Y+17IOQB_92\1?!^R\,W
MOVS1/$^F>+R\>E7^@7+W=O<RJP1H@2BG?N.,8Y(..AQ>UC]D'4M('B6W'BWP
M1=:SX/LY;S5])@O+AKJT$0/F("8!%(ZD;6$<C;6X8BK6=X&4(U(U$U*]M^CY
M7?M:6CO;73<B7"V:QJSHRHM2A:][+XH\ZMK[UX^\N6]XZ['DE%2Z?9/J=_#;
MQF)9+B18U,LJQ1@L<#<[D*HYY9B .I(%>XZG_P $_/%?AWQ/HVG:QXB\!Z+'
MK]C#>V-[>ZQLM;@RN56%"$+/)P&.Q60!TRWS 5KC,TPF$:CB:BBW>R>[MO9'
M-EF0YAF,93P5)S46DVMDY;7>RN>$T5[QIW_!/+QG)\1+GPKJ>L^"O#NN+,8;
M&UU/5O+EU?C(:W149V1NS,%!.1U5@.-\#?LO^)/&FN>+[25],T.#P%O_ +?O
M=2G9;?3F21HRI\M7=V+(X 16SM/M7/#/\NG%RA6BTDGOTD[)KO=Z*U]=-SMJ
M\(9U2G&G5PTDY.44FK:P5Y)_R\J]YWM[OO;:GG-3:=IUQK%_#:VD$UU=7#B.
M*&%"\DK'@*JCDD^@KN/B[^SOJ_PB\*^'/$$E_H^O>'?%<<DFFZII4LLEO*8S
MM>-A)'&Z.IX*LH.0PZJP'JW[-O[-GB7X9?M > 7O/%WA[PKXBO;NTO?["EU"
MX@U.:U,J,8G"1&)&DCZ0R2*S XV]JC%Y]A:6%>)IS3TE9:ZN/Q7LFURO26GN
M];&N7<)8_$8^."JTW'6',]-%4MRM-M1?,G>"3]Y?#<^=_$/AS4/"6LSZ=JMA
M>:9J%L0LUK=P-#-$2 0&1@"."#R.]4Z^C_VP?A1JGQ9_;G^)%OI[6=K;Z:ZW
MU_?7LWDVNGP+!"#)(^"0,E0  6)8  FO-_B)^S+K'@7X7:?XUL]5T'Q3X4U"
MY:R_M'1Y9F2UG R(YDFBBDC8CIE,=.>5S.7Y[AZ]"A.K)1G5C%V\Y1YDK]][
M)ZOH/-^$\9A<5BH8>#G2H3J1YM+N,)\KE;>R=N9I63>K/.****]T^5"OWPK\
M#Z_?"OP/QP_Y@O\ N)_[C/ZZ^BO_ ,S3_N!_[F/Q,_X.1_\ D^/PK_V(MI_Z
M<-1KQ[_@C7XKT'PI_P % _!Y\03VEE%J<%]IEE=W03RK6[GM)8HB=_RDL6\L
M @Y:4#'->P_\'(__ "?'X5_[$6T_].&HU^?58Y+AUB,CIT&[<T+7];G[EF%7
MV68RJ)7M*Y]^)X8_:M_9=\=^+[2^TOPU\-?#6FZ?<IK_ (NTSX=:#::=<Z<N
M<B.XBLXQ.TI"". .'9W0$(<E:/\ P34^,Y_X)[^&;7Q1\39M3M_ OQ?GBLM.
MT 6WF&XCAE0OKC!U.R.#<JQ[?GF+L0,1 U\A>-OVAO'_ ,2_#5OHOB/QSXP\
M0:/:%6@L-2UFYN[:$J, K'(Y5<#I@5)XE_:2^(GC/3]'M-8\>^--5M?#TT=Q
MI4-YK=S/'IDL8Q&\"LY$3*.%*8('2M991.I1=&LH6E;FY5RWMMWUO]RVUU(6
M.C"HJE-RTVN[[[_*WW]3Z+^)/[(?B+]C3_@I_P##ZUUVZO\ 6-"UGQKIFK:1
MXDNR7&LVTE_$YDDE/!G7/[T'G=\V-K*3]3V7@>XT;_@M/\84\00KX=M/B;H6
MH^&?#&J:M81R6=Y?S6-H5$:3JT4X"JX*E70EE1@?,"M^:'Q%_:;^)/Q@T:#3
MO%OQ!\;^*-/MKA;N&UU?7;J]ABF5659525V4.%=P& R S#/)K+\>_&3Q?\5-
M7M-0\3^*O$GB._L$$=K<ZIJ<UY-;*#D*CR,Q4 \X!J*F48FO%>VFK\C@VEYI
MIV^6JV'#'4J;?LXNW,I+\;K\=#Z^\0:-^U)\"O!_Q1T?Q+HVB?##P4VB7=EX
MDU2R\ Z'IECK4;0RQP6L5Q!:Q>>T\CB)3$[-'YQ? P:K_P#!133+F/\ X)N?
ML=SM;SB&/2-:5Y#&=JEY+-D!/0%E5B/4*2.E?*?Q#^/_ (\^+NEVMCXL\:^+
MO$]E8-OMK?5M8N+V*W;!&461V"G!(X[&MW7/VS_C#XGM8H-2^*_Q*U"&"XAO
M(H[GQ/>RK'/#(LL4H#2D!TD1'5ARK*""" :TAEE95*5:T$XRN^5<J?NN/GKK
MU[)>9+QE-PG#WK-65W?JG^GZGWI^UA:?%/P9^WU\(]=^&=A'+XKT#X-VE_'8
M7UM))%JT,$5T+JS\I1F5RC$>7D'=MP0VTUXW^T;X&^&W[0?[#7B;XO>$O"FH
M?!GQ#X=\2VNEZ]X6CNG;1-<NCN13;1-MV30I)(VU5'EJTR[3NWU\XZE^VI\9
M-9EMY+OXM?$RZ>T<R0--XHOG,#%2A929?E)5F&1V8CO6'X__ &A_'_Q7O+"X
M\4^.?&'B6?2G\VREU76;F\>S?(.Z,R.Q0Y .5QTK+"Y/7I^S;DDXVU5]4FW9
MK9IWTO\ "[M%UL?3GS:.SOH[:.R5UU7Z[,^I_P#@J'I-U8_L?_LC/-;3PI_P
M@\B9>,J,XMFQS[$'Z$5ZA?>./#WQ_P#V2?AO^U!K-U:3>,_@593>&=:M+F-I
M7US4X57^QI&.1N EFBGD;G(\U<_+Q\)?$']J3XF_%OP\=(\5_$7QWXFTDR+,
M;+5M?N[VW+K]UO+DD9<C)P<9&:Y"+Q!?P:#/I:7MVFF7-Q'=S6:S,()9HU=8
MY&3.TNJRRA6(R!(X'WCG2&33="%.<K2C*3NNL9-\T?FG]Z3(>/BJDI15TTM^
MZ2L_O7Z'W-_P3!MM6^-_[*_[0G@_PH?#^I_%S5I-,U^QMO$%E9:F-?B@ED:9
M/*O4DCD<%F^9UX>>,EAG(X'X]:]^T!X1_9,UC0/B9#:_#SP5>ZQ%'I_AD>"M
M,T)]<OU8/)-%';V\+B.-$!:<95B8D^;?E?EOPKXLU7P+X@MM6T34M0T?5;)M
M]O>V-P]O<6[8(RDB$,IP2.#WK1^(WQ:\5?&#6(]0\6^)O$'BF_BC\I+G5]1F
MOID3.=H>5F(&>V:W_LN2Q4JONN+:EK&\DTDM'VT7FM;&?UQ.BH:II-:/1IMO
M5?/YG7_L1V,^I?ME_">*WAEGE/C#26"1H68A;R)B<#T )/L#7Z#_ ++&EW-I
M_P '%'Q#62"5"KZI.P*'Y8WMT*,?8AUP>^X>M?F-\._BCXF^$/B#^UO"?B+7
M?"^JF)H#>Z1?RV5P8VP63S(F5MIP,C.#@5UT/[:?QCM]<N-3C^+/Q,34KR"*
MUGNU\47PGGAB:1HHV?S=S(C33%5)PIE<C&XYSS3+*V*E/D:2E!PUOU:U+P>,
MA14>9/22E]Q]$_\ !*[PSJ4WP?\ VK[1;"\-U#\,[ZVDA\EMZ2XD_=E<9#_(
MWR]?E/'%=7^UG\#M4_:1_P""8O[-?B7X7Z/<^)-*\"Z?>Z/K]EI5N\]U87TS
M0&61H47=AI89"S8_Y:1ME@X:ODK2OVS_ (PZ%=7\]E\5_B59S:K<?;+Z2#Q/
M>QM>3^6D7FR$2@N_EQ1IN;)VQH,X4"LCPC^TA\1/A_J>KWN@^/?&FB7GB"9K
MC5)[#6[FVEU*1B69YV1P9&)9B2V223ZU%3*\3+$_6HR2?,I):M?#RM/;O=/\
M"HXRDJ/L6G:S7X\R_P""???[8O@;6_ ?PG_84U#6M'U32K'PI%;QZW<75I)%
M%H[_ &C3CLN&(Q"WR/\ *^#\C<<&NFF^ OC.W_X.#W\4R>&M8B\,+K<=T-7E
MM6BL94DTP(NR9@$=BYV[5);*MQ\K8_,GQE\5?%'Q%L["W\0>)->UVWTM#'91
M:CJ$MTEFIY*QAV(0'T7%;=S^U!\2[PZ*9OB'XYE/AO\ Y!!?7KIO[*^0Q_Z/
MF3]U\A*_)CY21TKG615XTN135W&I%Z/[<N;37IM_6NG]I4W/F<7HXO?^56/L
M.+Q9\1/V6;KXWW_BGX76OC_X+:_X]O+7Q'X>U>UG@GM)=[36]]')LS KHZ[)
MQN!**/E)1CWWP6^!O@WX+?\ !4[]F;6O!>I:W;>&O'>@3ZQ8>'-=NC+?^&8I
M;.\*0<DD1/)(Y3DY;S>6SD_GWX(_:8^(_P ,VO#X<^('C;P^=1N7O+LZ;KMU
M:?:IWX>63RW&YVP,L<DXZUC:I\4_$^N>/%\4WOB/7KOQ.DR7*ZO/J$LE^LJ8
MV2"<MYFY<#!SD8&*TEDM62G'F2YHM.U];QY4W':Z[K5K0F.80BXNU[--7MI9
MWT?9]MNI^C?_  33^%OB3P1_P5V^)<NKZ'JFEC5+'Q)<68N;=HGN(C?*JRJI
M&XHS9"OC:Q5@"<''YY_"#XGZ[^SE\:-"\5:5YUCKWA/4H[I(Y-T;!XW^>*0<
M$!AN1E/4,P-;>F_MD?%[1M6O[^S^*GQ(M+[561KVYA\37J2WA0;4,C"3+E02
M!N)P.E;_ ,!/A:_[;?Q7\02^.OB_H'A351IS7[:YXUU1V.JS)LC2$SR-DMMQ
MU8L%3Y5;&!O1PDL/*I6Q33A*,4[7?PW6UNM_ZZ93K*JH4Z-[IM].MO\ (^M_
MV]]%\%?!KP+XP^/7@:^@5/VF]%M]/T*QC9/-TW[23+KC,G3I%%"Q!)5[V4<8
M!K\X:]D_:_\ B1HNJWGA/P)X0U0ZQX,^&>E'2[*^6-XXM5O)9&GOKU$?YU66
M=R%!_P"6<4? Z5XW71D^%E1PZYVVWWWLM(I^?*E?SN9X^LJE7W5;T[[O\?PL
M?=?_  6$\"-\5[+X)_%3P192:EX \0>"K#P]8M8VY9+"ZMY)?]#=4RL;_O0B
MIUW1R #Y:^A_"/BP:I_P4<_8V\(WRR7'COP'X#%OXL9B)9[*=]*D*V]PP)82
MI@LP;H9P<Y:OR^^'/[0WC_X/:5<V/A+QQXP\+65XYDN+?2-9N;&*=R I9UB=
M0QPH&2.@'I3? ?[0/CWX6:SJ6H^&/&WB[PYJ&M-OU"ZTO6+BSFOVW%LRO&X,
MAW,Q^8GEB>]>=4R*K+#K#\RM%347U]]-:^B?S=MCJCF4%5]K;=Q;_P"W==/5
M_=YFG^UM93Z?^U3\2HKF*6"=?%.I%DE0JXS=2'D'GH?UKU;_ ()Y>//B)\(]
M'^(_BOPEX7TCQ[X0T_3[:T\:^&-0MGN4U/3YY' <1JIXC*-E^=@DR59=V/!?
MB)\4?$WQ>\0?VMXL\1:[XHU41+ +W5[^6]N!&N2J>9*S-M&3@9P,FK'PW^-'
MC'X-W-Q-X0\6>)?"LUYL%Q)H^J3V+3[,E=QB92V-S8STR?6O7K8653">PDDW
M9;WMI;Y^CZ/4X85E&M[17MKZGZ*?!KPQ\(OA]\=?V7/C7X;.J> /"?C?7]2M
M'\':S?M=PZ7>-"]O]KM&<Y\AI_(5I#_TQ)VXVKXM\5/V _CG\#?VNO'DMO)X
MH\%^%9);^]U'QU:S3V^G#1I)6DD:2XC91(S)C-MNWNX V]#7R9\0_BIXG^+N
MN#4_%GB/7O$^I+&(A=ZMJ$M[.$&2%WR,S8Y/&>]:7BK]H7Q]XZ\'6_AW6_''
MC#6/#]H%$&F7VLW-Q9PA?N[87<HN,#&!Q7FTLIQ-.?/&HG=<KYES:<S:L^K5
M[7>^[.N>-HSCRN-K.ZMIK9)^E[7TV/JCX&Z3=3?\$,OC3,MM.T(\<:<_F",[
M<+]D#'/L67/ID5Z=^T#X%^)OQ(_91^ _CSX-^%O"OQ#\.V7@+3?#FL6T?@32
M/$FIZ9J-J"DH/VBUFN-A=S\B_*A1V(&_)^&=#_:Q^*?AGP9'X<TWXE_$#3_#
MT4#6J:7;>(;N*R2%L[HQ"L@0(<G*XP<GUK+^'/Q[\=?!ZSN[?PEXT\6>%K>_
MYNHM(U>XL4N>,?.(G4-QQS2GE%9U)54XWYW))JZLXJ-GYZ7301QU-14'?X4M
M-'=._P"MC])_V$?$GQ*\:?\ !1?Q6?BKKJ>(?'VG_"2\M-5AAL+:V_L5C<Q2
M163_ &95C>18Y$9B!E6E:,Y,=?/W_!.S0KV\_8'_ &O_ "[6=MOAW2\D(<#R
MY;IY.?55!)'85\R^ ?VF_B3\*;>]B\+_ !!\<>&XM2N#=WB:5KMU9K=S'@RR
M"-UWN<#+')]ZUM+_ &U_C+HB3+9?%OXFVBW$SW,H@\4WT8EE<Y>1L2\LQY)/
M)/6HEDU9<ZARI2]GY)<COLEHGLNWF4L?3]UROIS>?Q*V_P#7R/J?XE^ -;^)
MG_!#CX(PZ!I=[J[Z7XLU:>^-M$76QB62^=I)FZ1H%Y+.0H')-</^V)X6U/3_
M /@E?^R/<W&GWD%O"?%8>22%D5/M&I1RP9)'_+2-6=?[R@D9%?--M\;?&=EX
M/U/P]#XN\3Q:!K4[76H:8FJ3K9W\S8W22Q!MDCG RS DX%;_ (A_;!^+?B[2
M$T_5?BE\1=3L(Y8ITMKOQ)>30K)$ZR1.$:0@,CJK*<95E!&"!6]/+*].<6FF
ME4E/K]I25O\ R;\//3.>,IRBTT[N*C]UO\OQ/I#_ (*+>%]2T_\ X)[?LBW<
M]A>0VT>A:I"\CPLJH[RV\D:L2."R LN?O $C(!KKOVA;R#X>_ /]@;Q!X@MI
M[?0-(:6\U"62W9D6 7UE,<C'.Z(%@/XATS7R)XF_;*^+_C7P_>:3K/Q5^).K
M:5J$3075E>^)KV>WN8VX*/&\A5E/<$$54\>_M6?%'XJ^&I=&\4?$GQ]XDT>=
ME>6QU3Q!=WEM(RG<I,<DC*2" 1D<$5%/*J_+3A-JT93D[7VGS;:=.;\//2I8
MVG><HWU45_X#;_+\3[-_;]_8:^.*_P#!1?5O''PWLO$4NF^,KH:SHWB_1KJ2
M&UTV*2!?,::\C(%LJ*7&YF4,GW=V<5\%_$"".U\>:W'#J[>(88[^=8]5964Z
MFHD8"X(8EAY@^?DD_-R:V5_:%\?)\//^$1'CCQ@/">PQ_P!BC6;G^SMIZK]G
MW^7CVVUQ]=^6X6O0IJ%:2?*E%65KI=]_N6F_?3FQ=:G4DY4TU=W=WW[!1117
MIG&%%%% !1110 4444 ?T%?\$0?^47OPQ_[BO_IVO:^KJ^4?^"(/_*+WX8_]
MQ7_T[7M?5U?SMG?_ ",<1_CG_P"E,_5,O_W6E_AC^2"BBBO,.P\<_P""B?\
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MVMIIK2R\/@W$ZK^[A^6(?,W0'/ '<\"L[]J*RFM/!7PP\V*2/_BFXD^92/F
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MUK]H#P=!XM\(/9O;:/<:5<))?P7 BR[M&TAC==[MY4:3/Y:H[!!( ,/]L/\
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M=1^'_B[5=!UBU>QU?1+R:POK9R"UO/$YCD0D$C*LI'!QQ7W7KO[,GA_X]_\
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MK.Y8( ,?Q%L <"N@^ %KIR?M->,1IUW>7+2:?J7G_:K5+<12?:$R%(D?<O\
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M'?YF&<%E&!DDD8!KFJ]C_9$^"]_\7+WQ1_9'CI_"6H:9H=W=S6]JEQ]IOK5
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MV<-!M_A?X/\ %'C#QH_AVW\=7EQ;:7%9Z3]O,4<$HBEGN&::(1('/\.]L$$
M\X]J>>X*$Y4Y2?-&7*URR;YN7GLDE=^ZG*ZNK=3YFEPGF=2G3K1@N2</:)N=
M-+D4U3NVY)1]]J-I6=W:QP/PU^%GB'XP^*8M%\,Z3=ZQJ4P+"&!1\JCJS,<*
MJ^[$#D>M9OB7P[>>$/$=_I.HP_9]0TNYDM+J+>K^5+&Q1URI(.&!&02/0U]
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MDS\<O#O[/_[<?A;6?%=['I.A7L-WI5QJ;N4&F&XMWC2;<!\H#E06R JLS$@
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M&54Y YI82>)Q5>G*Z@W#[+UMKI+1>3W-8UXTJ-.:UE[W5:7[K?\ (^_/VO\
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M>+=,\?7,L^D1:I:RW;,_VQ$AB19"9IRTL8\F+?)E\%<@@:W[6_[)_P 2;?\
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M&P0 RKX+\"?V3_B&W_!"3XWZ58^$]9UFYU#QU9WNFG3+9[M=8M+9[9);NTV
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MM&DN>$UHXRYM8*Z]V]Y/=Z?;?[5?[.6J_'']HK2/B[X)FL->\%>)7L+NYO\
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MBO\ Z=KVOJZOYVSO_D8XC_'/_P!*9^J9?_NM+_#'\D%%%%>8=AXY_P %$_\
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MQ&HX2GB\9+_ES"I)*+W=KM/\+6TWN?"U>K?\,?\ B;_ACG_A=_V_PY_PB?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6>EPVOD+%8BZB8PR3/\ 9U8F-V5<,"<%2=+]JO\ 9/\ @C\:/BWJGQ?\.?M
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M>_ /C+X@^%?'%_=:K+<:])+=ZK/*)HXQ$UP%D>+?)&INIO+@"(SARH7=R/\
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M>, %B%<ECT0L1WQQGP#XP:;_ &=\2M9*W6GWL5U>2W,,UE=QW,3H\C%3N0D
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MQ'_;#A\5'4M+TOP_H4#6T<^HW<=J\Z>1)&I578%BSN3P.%QG!P#@?"2YT9/
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M@?\ \QO_ '#_ /<A_(OTJ/\ F5_]Q_\ W"%%%%?OA_(H4444 %%%% !1110
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MG*%20*Y;]FCQ_P#"^?\ 8F^//AWQ1\3_  OX*\6?&6YTVXL=)C\/:K)::/\
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M?BW_ ,+I_P"#?7X=ZS)X>\,>'+T?%O[-=Q:!IL6FV=W*FG:@//%M"JQ1.R[
MPC4*64L -V*)3=U;N5F&<59XBC'#74%65.3NM79MJV]KZ7NM5M;4_-^OWO\
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MGQS\ OB[I'B35_AQXKNDUC3=0T%HGU/PWJ*;#YD44SI')&QC0E-Z=).OF$C
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M/6BATXO<FOPY@Z[?M[RNI)7?P\S4GRVLUJDUK[MM+'UE\3?VF_V>_A!<1_\
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M4HJ=:/++6ZNGL[=/Z6QQ5X0A-QINZ[[!111748A1110 4444 %%%% !1110
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M^X__ +A"BBBOWP_D4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _H*_P""(/\
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MO@I_P5:\2_ [_A8OV'X9?!_45^)]K_96KQWFDWL<,6EB 0)IMO%;W<4<5NJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _H*_X(@_\HO?
MAC_W%?\ T[7M?5U?*/\ P1!_Y1>_#'_N*_\ IVO:^KJ_G;._^1CB/\<__2F?
MJF7_ .ZTO\,?R04445YAV'CG_!1/_E'Y\=/^R>Z__P"FVXK^4JOZM?\ @HG_
M ,H_/CI_V3W7_P#TVW%?RE5Z&#^%G] >#G^Y8C_$OR"BBBNP_9 HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OWO_X-:/\
ME'YXP_[*%>_^FW3*_!"OWO\ ^#6C_E'YXP_[*%>_^FW3*YL5_#/SCQ4_Y$,O
M\4?S/TIHHHKS#^8@HHHH _+NBBBO\AS^V HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#^@K_ ((@_P#*+WX8_P#<5_\ 3M>U
M]75\H_\ !$'_ )1>_#'_ +BO_IVO:^KJ_G;._P#D8XC_ !S_ /2F?JF7_P"Z
MTO\ #'\D%%%%>8=AXY_P43_Y1^?'3_LGNO\ _IMN*_E*K^K7_@HG_P H_/CI
M_P!D]U__ --MQ7\I5>A@_A9_0'@Y_N6(_P 2_(****[#]D"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_>_P#X-:/^4?GC
M#_LH5[_Z;=,K\$*_>_\ X-:/^4?GC#_LH5[_ .FW3*YL5_#/SCQ4_P"1#+_%
M'\S]*:***\P_F(**** /R[HHHK_(<_M@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#[*_X)X?\ )%=3_P"PW+_Z(MZ]ZKP7
M_@GA_P D5U/_ +#<O_HBWKWJO],O"+_DCLO_ .O:_-G\G\:_\CS$_P"(****
M_1CY<*_ ^OWPK\#Z_?/ _P#YC?\ N'_[D/Y%^E1_S*_^X_\ [A"BBBOWP_D4
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_?"OP/K]\*_ _'#_F"_[B?^XS^NOHK_ /,T_P"X
M'_N8_$S_ (.1_P#D^/PK_P!B+:?^G#4:_/JOUR_X+:_\$Z/C)^UW^U7X?\2?
M#SP=_P )!HMEX4M],GN?[6L;39<)>7DC)MGF1CA)8SD#'S=<@X^._P#AR#^U
M#_T3'_RX])_^2JXN'LVP-/+:-.I6@FEJG))_F?NV:8+$SQ=24*<FK]F?*-%?
M5W_#D']J'_HF/_EQZ3_\E4?\.0?VH?\ HF/_ )<>D_\ R57L_P!MY=_T$0_\
M"C_F>?\ V?B_^?4O_ 7_ )'RC17U=_PY!_:A_P"B8_\ EQZ3_P#)5'_#D']J
M'_HF/_EQZ3_\E4?VWEW_ $$0_P# H_YA_9^+_P"?4O\ P%_Y'RC17U=_PY!_
M:A_Z)C_Y<>D__)5'_#D']J'_ *)C_P"7'I/_ ,E4?VWEW_01#_P*/^8?V?B_
M^?4O_ 7_ )'RC17U=_PY!_:A_P"B8_\ EQZ3_P#)5'_#D']J'_HF/_EQZ3_\
ME4?VWEW_ $$0_P# H_YA_9^+_P"?4O\ P%_Y'RC17U=_PY!_:A_Z)C_Y<>D_
M_)5'_#D']J'_ *)C_P"7'I/_ ,E4?VWEW_01#_P*/^8?V?B_^?4O_ 7_ )'R
MC17U=_PY!_:A_P"B8_\ EQZ3_P#)5'_#D']J'_HF/_EQZ3_\E4?VWEW_ $$0
M_P# H_YA_9^+_P"?4O\ P%_Y'RC17U=_PY!_:A_Z)C_Y<>D__)5'_#D']J'_
M *)C_P"7'I/_ ,E4?VWEW_01#_P*/^8?V?B_^?4O_ 7_ )'RC17U=_PY!_:A
M_P"B8_\ EQZ3_P#)5'_#D']J'_HF/_EQZ3_\E4?VWEW_ $$0_P# H_YA_9^+
M_P"?4O\ P%_Y'RC17U=_PY!_:A_Z)C_Y<>D__)5'_#D']J'_ *)C_P"7'I/_
M ,E4?VWEW_01#_P*/^8?V?B_^?4O_ 7_ )'RC17U=_PY!_:A_P"B8_\ EQZ3
M_P#)5'_#D']J'_HF/_EQZ3_\E4?VWEW_ $$0_P# H_YA_9^+_P"?4O\ P%_Y
M'RC17U=_PY!_:A_Z)C_Y<>D__)5'_#D']J'_ *)C_P"7'I/_ ,E4?VWEW_01
M#_P*/^8?V?B_^?4O_ 7_ )'RC17U=_PY!_:A_P"B8_\ EQZ3_P#)5'_#D']J
M'_HF/_EQZ3_\E4?VWEW_ $$0_P# H_YA_9^+_P"?4O\ P%_Y'RC17U=_PY!_
M:A_Z)C_Y<>D__)5'_#D']J'_ *)C_P"7'I/_ ,E4?VWEW_01#_P*/^8?V?B_
M^?4O_ 7_ )'RC17U=_PY!_:A_P"B8_\ EQZ3_P#)5'_#D']J'_HF/_EQZ3_\
ME4?VWEW_ $$0_P# H_YA_9^+_P"?4O\ P%_Y'RC17U=_PY!_:A_Z)C_Y<>D_
M_)5'_#D']J'_ *)C_P"7'I/_ ,E4?VWEW_01#_P*/^8?V?B_^?4O_ 7_ )'R
MC17U=_PY!_:A_P"B8_\ EQZ3_P#)5'_#D']J'_HF/_EQZ3_\E4?VWEW_ $$0
M_P# H_YA_9^+_P"?4O\ P%_Y'RC17U=_PY!_:A_Z)C_Y<>D__)5'_#D']J'_
M *)C_P"7'I/_ ,E4?VWEW_01#_P*/^8?V?B_^?4O_ 7_ )'RC17U=_PY!_:A
M_P"B8_\ EQZ3_P#)5'_#D']J'_HF/_EQZ3_\E4?VWEW_ $$0_P# H_YA_9^+
M_P"?4O\ P%_Y'RC17U=_PY!_:A_Z)C_Y<>D__)5'_#D']J'_ *)C_P"7'I/_
M ,E4?VWEW_01#_P*/^8?V?B_^?4O_ 7_ )'RC17U=_PY!_:A_P"B8_\ EQZ3
M_P#)5'_#D']J'_HF/_EQZ3_\E4?VWEW_ $$0_P# H_YA_9^+_P"?4O\ P%_Y
M'RC17U=_PY!_:A_Z)C_Y<>D__)5'_#D']J'_ *)C_P"7'I/_ ,E4?VWEW_01
M#_P*/^8?V?B_^?4O_ 7_ )'RC17U=_PY!_:A_P"B8_\ EQZ3_P#)5'_#D']J
M'_HF/_EQZ3_\E4?VWEW_ $$0_P# H_YA_9^+_P"?4O\ P%_Y'RC17U=_PY!_
M:A_Z)C_Y<>D__)5'_#D']J'_ *)C_P"7'I/_ ,E4?VWEW_01#_P*/^8?V?B_
M^?4O_ 7_ )'RC17U=_PY!_:A_P"B8_\ EQZ3_P#)5'_#D']J'_HF/_EQZ3_\
ME4?VWEW_ $$0_P# H_YA_9^+_P"?4O\ P%_Y'ZN?\$0?^47OPQ_[BO\ Z=KV
MOJZOGS_@EC\$/%'[.'[!W@7P9XSTS^QO$NC?VA]LL_M,5QY/FZC=3)\\3.AS
M'(AX8XS@X((KZ#K\(S><9X^O.#NG.33775GZ5@8N.&IQDK-17Y!1117G'4>.
M?\%$_P#E'Y\=/^R>Z_\ ^FVXK^4JOZSOVSO &K_%C]CWXK^%M M/M^O>)?!V
MKZ5IMKYJ1?:;F>RFBBCWN51=SNHRQ"C.20.:_GW_ .' G[6__1)O_+HT;_Y+
MKNPLXJ+NS]P\*,VP.$PE>.+K0IMR5N:2C?3S:/CFBOL;_AP)^UO_ -$F_P#+
MHT;_ .2Z/^' G[6__1)O_+HT;_Y+KJ]K#NC]7_UGR;_H+I?^#(?YGQS17V-_
MPX$_:W_Z)-_Y=&C?_)='_#@3]K?_ *)-_P"71HW_ ,ET>UAW0?ZSY-_T%TO_
M  9#_,^.:*^QO^' G[6__1)O_+HT;_Y+H_X<"?M;_P#1)O\ RZ-&_P#DNCVL
M.Z#_ %GR;_H+I?\ @R'^9\<T5]C?\.!/VM_^B3?^71HW_P ET?\ #@3]K?\
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M7_T+?_E0M?\ X[1_Q#[BG_H6XC_P34_^1#_67*/^@JG_ .!Q_P SRZBO4?\
MAB_XE_\ 0M_^5"U_^.T?\,7_ !+_ .A;_P#*A:__ !VC_B'W%/\ T+<1_P""
M:G_R(?ZRY1_T%4__  ./^9Y=17J/_#%_Q+_Z%O\ \J%K_P#':/\ AB_XE_\
M0M_^5"U_^.T?\0^XI_Z%N(_\$U/_ )$/]9<H_P"@JG_X''_,\NHKU'_AB_XE
M_P#0M_\ E0M?_CM'_#%_Q+_Z%O\ \J%K_P#':/\ B'W%/_0MQ'_@FI_\B'^L
MN4?]!5/_ ,#C_F>745ZC_P ,7_$O_H6__*A:_P#QVC_AB_XE_P#0M_\ E0M?
M_CM'_$/N*?\ H6XC_P $U/\ Y$/]9<H_Z"J?_@<?\SRZBO4?^&+_ (E_]"W_
M .5"U_\ CM'_  Q?\2_^A;_\J%K_ /':/^(?<4_]"W$?^":G_P B'^LN4?\
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MI?\ @R'^8?\ $/\ BG_H6XC_ ,$U/_D3P.BO?/\ AV#\<O\ H1__ "LZ?_\
M'Z/^'8/QR_Z$?_RLZ?\ _'Z/]:\D_P"@RE_X,A_F'_$/^*?^A;B/_!-3_P"1
M/ Z*]\_X=@_'+_H1_P#RLZ?_ /'Z/^'8/QR_Z$?_ ,K.G_\ Q^C_ %KR3_H,
MI?\ @R'^8?\ $/\ BG_H6XC_ ,$U/_D3P.BO?/\ AV#\<O\ H1__ "LZ?_\
M'Z/^'8/QR_Z$?_RLZ?\ _'Z/]:\D_P"@RE_X,A_F'_$/^*?^A;B/_!-3_P"1
M/ Z*]\_X=@_'+_H1_P#RLZ?_ /'Z/^'8/QR_Z$?_ ,K.G_\ Q^C_ %KR3_H,
MI?\ @R'^8?\ $/\ BG_H6XC_ ,$U/_D3P.BO?/\ AV#\<O\ H1__ "LZ?_\
M'Z/^'8/QR_Z$?_RLZ?\ _'Z/]:\D_P"@RE_X,A_F'_$/^*?^A;B/_!-3_P"1
M/ Z*]\_X=@_'+_H1_P#RLZ?_ /'Z/^'8/QR_Z$?_ ,K.G_\ Q^C_ %KR3_H,
MI?\ @R'^8?\ $/\ BG_H6XC_ ,$U/_D3P.BO?/\ AV#\<O\ H1__ "LZ?_\
M'Z/^'8/QR_Z$?_RLZ?\ _'Z/]:\D_P"@RE_X,A_F'_$/^*?^A;B/_!-3_P"1
M/ Z*]\_X=@_'+_H1_P#RLZ?_ /'Z/^'8/QR_Z$?_ ,K.G_\ Q^C_ %KR3_H,
MI?\ @R'^8?\ $/\ BG_H6XC_ ,$U/_D3P.BO?/\ AV#\<O\ H1__ "LZ?_\
M'Z/^'8/QR_Z$?_RLZ?\ _'Z/]:\D_P"@RE_X,A_F'_$/^*?^A;B/_!-3_P"1
M/ Z*]\_X=@_'+_H1_P#RLZ?_ /'Z/^'8/QR_Z$?_ ,K.G_\ Q^C_ %KR3_H,
MI?\ @R'^8?\ $/\ BG_H6XC_ ,$U/_D3P.BO?/\ AV#\<O\ H1__ "LZ?_\
M'Z/^'8/QR_Z$?_RLZ?\ _'Z/]:\D_P"@RE_X,A_F'_$/^*?^A;B/_!-3_P"1
M/ Z*]\_X=@_'+_H1_P#RLZ?_ /'Z/^'8/QR_Z$?_ ,K.G_\ Q^C_ %KR3_H,
MI?\ @R'^8?\ $/\ BG_H6XC_ ,$U/_D3P.BO?/\ AV#\<O\ H1__ "LZ?_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>sangamo-2022cdagraphiccash.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sangamo-2022cdagraphiccash.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$817AI9@  34T *@    @ ! $[  (
M   :   (2H=I  0    !   (9)R=  $    T   0W.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N;F5T=&4@
M36%K82 H0V]N=')A8W1O<BD   60 P "    %   $+*0!  "    %   $,:2
MD0 "     S@P  "2D@ "     S@P  #J'  '   (#   "*8     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M ,;H_MW+O^?GX/\ R#^S\5_)^1V=%<9_PGMQ_P! F/\ \"S_ /&Z/^$]N/\
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MV[EW_/S\'_D']GXK^3\CLZ*XS_A/;C_H$Q_^!9_^-T?\)[<?] F/_P "S_\
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M ,;H_MW+O^?GX/\ R#^S\5_)^1V=%<9_PGMQ_P! F/\ \"S_ /&Z/^$]N/\
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M**^M/&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6L/^OR#_ -&+7JU?>\+?P*GK^A\WF_\ %CZ!1117UQXH4444 %%%% !1110
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MU:BC_5:A_P _'^ ?VO5_E1Y3]AOO^@=?_P#@))_\31]AOO\ H'7_ /X"2?\
MQ->K44?ZK4/^?C_ /[7J_P J/*?L-]_T#K__ ,!)/_B:/L-]_P! Z_\ _ 23
M_P")KU:BC_5:A_S\?X!_:]7^5'E/V&^_Z!U__P" DG_Q-'V&^_Z!U_\ ^ DG
M_P 37JU%'^JU#_GX_P  _M>K_*CRG[#??] Z_P#_  $D_P#B:/L-]_T#K_\
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MAOO^@=?_ /@))_\ $UZM11_JM0_Y^/\  /[7J_RH\I^PWW_0.O\ _P !)/\
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M:]7^5'E/V&^_Z!U__P" DG_Q-'V&^_Z!U_\ ^ DG_P 37JU%'^JU#_GX_P
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M)/\ XFO5J*/]5J'_ #\?X!_:]7^5'E/V&^_Z!U__ . DG_Q-'V&^_P"@=?\
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M^*KY2HH_LZ/\P?6GV/JW_A,_"_\ T,FD?^!\7_Q5'_"9^%_^ADTC_P #XO\
MXJOE*BC^SH_S!]:?8^K?^$S\+_\ 0R:1_P"!\7_Q5'_"9^%_^ADTC_P/B_\
MBJ^4J*/[.C_,'UI]CZM_X3/PO_T,FD?^!\7_ ,51_P )GX7_ .ADTC_P/B_^
M*KY2HH_LZ/\ ,'UI]CZM_P"$S\+_ /0R:1_X'Q?_ !5'_"9^%_\ H9-(_P#
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M^QW_ #_A_P $]BHKQW[+;_\ /"/_ +X%'V6W_P">$?\ WP*/]:E_SY_\F_X
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M )X1_P#? H^RV_\ SPC_ .^!1_K4O^?/_DW_   _L=_S_A_P3V*BO'?LMO\
M\\(_^^!1]EM_^>$?_? H_P!:E_SY_P#)O^ ']CO^?\/^">Q45X[]EM_^>$?_
M 'P*/LMO_P \(_\ O@4?ZU+_ )\_^3?\ /['?\_X?\$]BHKQW[+;_P#/"/\
M[X%'V6W_ .>$?_? H_UJ7_/G_P F_P" ']CO^?\ #_@GL5%>._9;?_GA'_WP
M*/LMO_SPC_[X%'^M2_Y\_P#DW_ #^QW_ #_A_P $]BHKQW[+;_\ /"/_ +X%
M'V6W_P">$?\ WP*/]:E_SY_\F_X ?V._Y_P_X)[%17COV6W_ .>$?_? H^RV
M_P#SPC_[X%'^M2_Y\_\ DW_ #^QW_/\ A_P3V*BO'?LMO_SPC_[X%'V6W_YX
M1_\ ? H_UJ7_ #Y_\F_X ?V._P"?\/\ @GL5%>._9;?_ )X1_P#? H^RV_\
MSPC_ .^!1_K4O^?/_DW_   _L=_S_A_P3V*BO'?LMO\ \\(_^^!1]EM_^>$?
M_? H_P!:E_SY_P#)O^ ']CO^?\/^">Q45X[]EM_^>$?_ 'P*/LMO_P \(_\
MO@4?ZU+_ )\_^3?\ /['?\_X?\$]BHKQW[+;_P#/"/\ [X%'V6W_ .>$?_?
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M /['?\_X?\$]BHKQW[+;_P#/"/\ [X%'V6W_ .>$?_? H_UJ7_/G_P F_P"
M']CO^?\ #_@GL5%>._9;?_GA'_WP*/LMO_SPC_[X%'^M2_Y\_P#DW_ #^QW_
M #_A_P $]BHKQW[+;_\ /"/_ +X%'V6W_P">$?\ WP*/]:E_SY_\F_X ?V._
MY_P_X)[%17COV6W_ .>$?_? H^RV_P#SPC_[X%'^M2_Y\_\ DW_ #^QW_/\
MA_P3V*BO'?LMO_SPC_[X%'V6W_YX1_\ ? H_UJ7_ #Y_\F_X ?V._P"?\/\
M@GL5%>._9;?_ )X1_P#? H^RV_\ SPC_ .^!1_K4O^?/_DW_   _L=_S_A_P
M3V*BO'?LMO\ \\(_^^!1]EM_^>$?_? H_P!:E_SY_P#)O^ ']CO^?\/^">Q4
M5X[]EM_^>$?_ 'P*/LMO_P \(_\ O@4?ZU+_ )\_^3?\ /['?\_X?\$]BHKQ
MW[+;_P#/"/\ [X%'V6W_ .>$?_? H_UJ7_/G_P F_P" ']CO^?\ #_@GL5%>
M._9;?_GA'_WP*/LMO_SPC_[X%'^M2_Y\_P#DW_ #^QW_ #_A_P $]BHKQW[+
M;_\ /"/_ +X%'V6W_P">$?\ WP*/]:E_SY_\F_X ?V._Y_P_X)[%17COV6W_
M .>$?_? H^RV_P#SPC_[X%'^M2_Y\_\ DW_ #^QW_/\ A_P3V*BO'?LMO_SP
MC_[X%'V6W_YX1_\ ? H_UJ7_ #Y_\F_X ?V._P"?\/\ @GL5%>._9;?_ )X1
M_P#? H^RV_\ SPC_ .^!1_K4O^?/_DW_   _L=_S_A_P3V*BO'?LMO\ \\(_
M^^!1]EM_^>$?_? H_P!:E_SY_P#)O^ ']CO^?\/^">Q45X[]EM_^>$?_ 'P*
M/LMO_P \(_\ O@4?ZU+_ )\_^3?\ /['?\_X?\$]BHKQW[+;_P#/"/\ [X%*
M+>%3E8D4CH54 BG_ *U+_GS_ .3?\ 7]CO\ G_#_ ()[#17$>%O$%Q%?1Z=?
M2M-#-\L+N<LC=E)[@^_0XKMZ^FP.-I8VC[6G\UV9Y.(H3H3Y)A115+6=6MM"
MT6ZU.^;;!;1EV]3Z >Y. /<UWI-NR,-CD?B7\04\):>+/3G5]7N%S&" 1 O]
M\C^0_P ,'YXN;J>]NI+F[F>>>5BTDDC99CZDU8UC5KG7=9NM3OFW3W,A=O1?
M11[ 8 ]A5*OHL/AU1CYGDU:KJ2\@HHHKJ,@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KLOA_\0+OP?J*0W#O-I$K
M?O[?KY>?XT]#ZCO]<&N-HK.<(U(\LBHR<7='V%:W4%[:175I*LT$R!XY$.0R
MGD$5+7C?P1\5G=-X9O)..9[+)_%T'_H0_P"!5[)7SE:DZ4W%GK4YJ<>9!111
M6)84444 %%%(S!5+,0 !DD]J *NH3.L:6]N<3W!VH?[H[M^ _7%3P0);6Z0P
MC:B# %5;!3<2/?R @RC;$#_#'V_$]?R]*O4 %%%% '&>/?\ C[TP?[$W\XZY
M:NI\>_\ 'YIG_7.?^<=<M7YAG_\ R,:GR_)'UN6_[M'Y_F<%9MXEU_Q)K\-I
MXF?3K>PNQ#%$MC#)P5!ZL,U>T#7-1L]:UG1_$5[%>?V9"ER+Y(A%F-@20ZC@
M$8[=16+HWAU=:\7>*I&U75;'R[\+ML;QH5;Y!R0.IJ7Q1H5MHGA[^PM",G]H
M^)+I+:2ZN)#)(Z]79F/) 4$8_P!JM9QHSG[!VU4=HI6T3;<MWI?N3%U(Q]IV
M;ZO7=)6];%KP1XGU;4=6>WU]P1J5K_:.G*(POEPEV'EY'4@;#SSSWJ1I]=U?
MQ_K.EV>O3:=:V,,#QI%;0R9+J2<EU)[5E>);3Q%H::5X@OGTM[?0I5!2Q@D1
M_(?"./F8@C&.W;-3V^DPZ[\4/$+?;[ZW1;6T9'L;MX=X*'J5/(]*;IT6YUXV
MLXO9)I-2BMGY-?>Q*4[*F[WOWM=-/]30CO-=TOQ=!H%[K']H1ZE:2R07+6R)
M+;.@ZD* K+SQD=>/K1U"W\6V7BC1])'C*5UU%+AC(=-@!3RU4],<YW4OA:VC
M\.>.[S2=8\RYO[J+S+#5+F5I)+F$')B)8G#*>PQD#..E:VN_\E*\)_\ 7*^_
M] CK-R4*W+&*:<&[\L;-J,FFE;3MZK57*LY4[MOXDMWIJM/Z[Z&1XIU;Q/X6
M_L*&UU!M8GEEGDN0UM'&9XHT#E %'!"AL$<D^M;'B+Q(W_"%VVLZ!= +<3VX
M20*&^1Y%5A@@\X)!]*3Q%_R4'P=_UUO/_2<UQWB^VF\*2OI$4;-HVK7T%Q9[
M1Q;3"53)'[*1\P_'CK54*=+$.BG%<WQ;)<RYI)JVVB5UY7\A5)3I\[3=MO31
M6.EO9O$&J_$&_P!)TS7WTNUM;2*8*MI%+N+$@\L,]O6M.WT_7M)M[VZU#Q+)
MJ:+:R>7$UE%%L<#(;*CG&",'CFN8U/3/#NI_%;5$\4"U,26$!B^T3>6-V3G'
M(S6W8Z5X2TNPU/\ X1C["L\MHXD6WN?,8J >VXUG548TX12WC'[$;;*_O;E0
MNY2;[O[3_+8J^&K7Q-KOA>QU.3Q?<PRW4(D*"QMRJG_OBHH_&VIV_@'5;^X6
MWFU#3+]M/,^TK"[!U42D#HOS9/TK-T'P=<:E\,;"?2M:U6WO7M@\<7V^00,>
M?D*@C"GIQC%:.F>(]+L_ALDUOH2BTMIA::GIXY^R_-B5F!!+8SGGD@\GK6]6
M%.4Y*,5*TTK)*-M7I=;WV7]7SA*2BKNWN[W;_JVY>>S\:6-NFH66O0:\=RLU
MB;2*%9%)YV2 C! SC)/2KG]K7O\ PM7^Q_._T#^Q?M7D[%_UOG[=V<9Z<8SB
MN0URV\*Z/H[ZMX)UP6.H$AK:WL;SS%N')P$,.3G/3&!BK^HZ)8^)/BY;V_B"
MR2=1X=64Q%B LGGD=CVW$5'LH23G46EI?847I;I>SMT=[[WZ%<\D[1WNOM77
M7KN=-K^IW=EXA\.VUK+LAO;J2.==H.]1$S 9(R.0.E8DOB/55TWQQ*MUA]*=
MA9GRT_= 1[O3GGUS5>_\)Z'X=\9^%IM%T]+226[E5V5F.X>2QQR35.?_ )!'
MQ*_ZZ/\ ^B:5&C0<8\JNK+=)/^);N^FF^P3G4N[Z:O9_W?D:MO8>+Y/#L.JQ
M^,=TCVJW AFTZ$(25W;20 0.V:A/C#5-9T_PS!83V^DW&M0R22W4T>\1F,#*
MQJ3@DDY&>WK4NC^ K._\.:>;W6-<GAFM8VDM7U%_*(*#Y=H_A]JM>(Y_#UC-
MIWA[Q#I=O'HLT)$%S,=L4,B\"/./D.W)W9%+GHRJ\BCS--[1BK*SZ?:L[.S[
M>8^6:AS-V6F[;ZK[NWS+FG6_BK3-<MX;^_CUK39T?S;@P)!);,!E>%.&!Z<#
M(K>@O+:Z:9;6XBF:!S'*(W#&-AU5L=#[&O/[-+#0_&FD67@[69;N"Z9UN].%
MT;B**(*3Y@.3L(.!UYXKNK#^S?-N_P"S/LGF>>?M7V?;GS>^_'\73KS7%C*=
MFI6W71<O5K5;+Y:;>9T4)7NO/O?IT?\ F<YXOOM8'BOPWH^C:JVF+J7VKSI5
MMTE/[M%9>'!]QVZU7OKSQ'X.GM+S5M8CUK2IKA(+DO:I#);[SA7!3@C.,Y__
M %+XMN8+3XD^"Y[N:.")?MVZ21PJC,*CDGWJ/QSK-AKFGVWAS1[R"]OM1NH1
MLMY!)Y4:N'9VP>  M=E&%XT(<B<9)\SLOYI)OFM=62[]#"I*SJ2YG=/37R6E
MMM6='JWBK1M#N4M]2O1'.R;Q$D;R,%_O$("0/<\5GZ]X@86_AVZT.]C>VU#5
M88'DC"NLD3*^1D@XY4=,$8KG(/M]MX^\2K_PD%GH\\LD<JB\M%D,T.P!65BZ
M\#!!'8U1L8T71=#F@O'O(;CQ<)8Y3;"!#E7!V*&;Y"P8CD=>@IT\%1ARRO=V
M7>SO%OM;3U=_(4L1.5UM_P !V[_HCN++Q!9VK7?V_6?M0?5C91?Z*T8MY"%V
MP$@<X_OG@[L9K6N-4L[74;2QGFVW-YO\B,*27VC+'@8  [G'6N&L](;7/#OC
M6RA.VX.MSR6[#JLJK&R$?B!46FW=SXUAUG7[%&$L.D?8+)1QBX>/?+CW#%%S
M[5C+!TY-RO9+?;JER].[U\DRXUYJRMOM\KW_ *\SJD\;^')-1%DFJ1F4R>2&
MV,(R_P#=$F-A/MFI-1\8:%I.HO87]Z8[I%5C$L$CMALX/RJ>.#D]N^*\WW^=
M\+K>VG\4V?V)X([?^SXM+5[A9.!L \T$N&YS@>M=CH4.WXEZNTV7FCTVT0R,
M,,<[LY^I JZN!P])2E=NU]-MG%;N*[[:V[BAB*L[+36WXI]GY&_X@U>/0_#]
MWJ,F?W,1*#RV?+8^4$*,XSCGM7.^%O%4,?@]-:\1:\T_GE 1+:>3Y<A4,8XU
M"@R?>ZC=G'!KH_$?_(K:K_UY3?\ H!KA[:6"RD^'E[JA6.Q73/+6:0XCCF:%
M-N3T!(# &LL+2IU*#36M_*^D6[+32]O^ RZTYQJ)IZ6_-VON=G8^*=&U*SNK
MFSO0Z6:E[A6C97B &<E" PX![<T:/XIT?7Y&32+LW)6,2%A"ZKM/^T0 3SR.
MH[UR.N7%M?\ C+59=*=)EM_#T\=[+"05#$YC5B."< GZ5U7@N-(O FA+&H4'
M3X&P/4Q@G]2:BOAJ5*C[2SN[65UI===-?+;1E4ZLYSY=-+_/\?\ ,EU7Q/H^
MAW4=OJEZMO-)&9$0HS%P"!Q@')R1QU/I3K#Q'I&IZ;-?V=]&UM;DB9WRGE8Y
M.X-@K^(KG-=NM/L_BSH<FIR11#[!,L+RD +(6&.3T.-P_&LG4]7M+75O&&LV
M%I#J=C%9V\%PA4/#-/N(.>H8*K#=Z 5I3P,*D(V3NTG?2VLN6VWZD2Q$HR=[
M63MY[7O_ $CK['QMX?U&_BL[74,SS_ZD/#)&LO\ NLR@-^!IMUXX\/6=]/9S
M7S?:+=RDL4=M*Y0@ \[5/J.>AZ"N*\07MU+?^%TOO$6G7[R:O:2)9Z=;@*B[
M\;]^YFV\X'3.:ZCP;&@U_P 62!1O;5-I;U C7 _4_G55,'0IT_:N[5MK];I;
MN*_+YBA7J2ER*V_Z7[_J0>&?'UE>^'+G4=9N_*\BZ,<CFW=%56D98A]WG@#/
M7'?%;6F^+]"U?4!9:??K+<,I9$,;IYBCJ4+ !Q[J37G[F"Y^$LULS))_Q.=L
ML>02 UYW';(KKO%"*OB[P@RJ 5O)E! Z PMD?3@5=?"X?VDDDTVYVU5ERI/M
MU^6A-.M4Y5=IZ1_%V[EZ\\:^'M/U"2RN]31)HF"R_([)$3T#N!M7\2*FU7Q7
MHNB7$4&I7OE2SQ^9$BQ/(9%R!QM!SU' Y[UYOH#W5GX%OK?4O%%A8^0\Z:A9
M7&GK)+O+-NR3("Y;/!QSP.U;>@68@\5^%8I&EE,&@R>6\\?EN!N0#*Y.#M.,
M9-.IE^'IMW;=K_.ROHW&R_\ )M'N$<34DEHM;?*[]?\ (Z>\\;>'[!HEN;\J
MTL2S!5@D<JC<AF"J=@_WL5L6MU!>VL=S:2I-!*H:.1#E6![@UPE^QB\:ZS+H
M6OPZ1?!(FO;74X5,-R F%=6W!@ .#CO6YX/UVVO/"FF2W$5GIC7!:*"WB(2.
M0JQ'[I3C(.,@>A_&N2OA(PHJI3OTO\U?:R^]-Z=MC:G6;FXR\_P=N_\ E\SI
M,XZU@P>-_#ESJ"V<&J1M*\GE(VQA&[_W5D(VD^P-6?%4-U<>$-6AT\,;F2SE
M6()]XL5/ ]Z\UN6^U?#BSMI/%EG)9S1PPQ65KIBFX63*X4#S0=X(Y/'0FJP6
M#IUX<TWUMI?[]$_NTZZBKUYTY6BNE_ZU7ZGJ,6M:?-J5Y8+< 75DBO/&ZLFQ
M2,ALD $>XR*JMXMT1-#BU>2^"6,[;(9&C<&4YQA5(W-T/0<UQ/Q"MGU?5X[7
M1H)+G4+"R,FJ-%)L,EL<'R"1G+/@D#M^-/UN[CO->\):GI&I6^FZ9):RQVES
M-;B2**0@80@LH4X&T<]016U/ 4I1A)MZIM^5DWT3?O;K3;HR)8F:<EII^K_3
MKKOV.ZTG7]+UN"673+M9A"<2J5*-&?\ :5@"OXBJ=EXU\/:CJ*6-GJ223R,5
MC^1PDI'4(Y&UOP)KA[VVO+Z^\4-:ZT-7OET0P2FSLA%$26RJ[A(VZ3:&&,=&
MZ\8KHAJ_A6X\,:!&PCO$,EN+*VMV!D248 ( ((V]_3!J9X*E'5<TK]NFE];I
M7\MM CB)O>R_76W1_P"9T]GJUEJ$5U):3>8EI/);S'8PV2)PPY'./4<5RVM?
M$"QM;[0#97+-9Z@QEE=;25BT.UMNWY>NY>F,X[ 56\/:SI^E:?XLCU"[BMY8
MM7O)&B=P'*N<J0O4Y[8ZUF:5+'!H?PYDGD6-%D?+.V /W3]S6E+!4X3DYIM+
M1>?N2?;R5A3KRE%*+2?_  4CN-5\7:'HMY]DU&_$<X3>T:1O(47^\VT':/<X
MK5MKF&\MH[BUE2:&50R21ME6!Z$&O--*:_L_$'BA)/$MCH\W]HR3O%>6:R,\
M) \MPQ=<KMXQCC\:Z?X=0)!X+M_L\\L]O)++)"TEOY'RLY/RIN;"YR1ST-<^
M*P=*C2YHN[T[V=U?LE^+N:4:\YSLUIK^#]?T1?U7Q;HFBW9M=0O=MP%WM%%"
M\K*OJP13@?6I_P#A(M(_L(:S_:$']G$9%QN^4\XQ]<\8ZYXKE9M;N)_$VN0V
M>HZ1X>CLG19Y[B /<7'R9WG+*-H' )S_ $KFM*EC7PUH=]>R&33(?$<LEQ+(
M@11DL$=EZ*-Q'L":WAET)03=T]+^=TWII:[Z:OS1G+%24FEMK^#MW_1'H]GX
MPT*_L[RYMK[*6,1FN5>)T>- ,[MC*&(P.PIMIXS\/WMM<W-OJ*?9[5!)+,\;
MI&JG@?,P //&!DYXZUA^++_0KM-96T5;G55T&ZW7,#!EBBVGY7(.,D\@8/0]
M*JZ]%%;?#WPE)+'_ ,2ZTN;&2\ &56()C+>HW%2:B&#HR4=)+F=E>W;TUOTV
M_P ZE7J)O5.R_KKIY[G5:3XLT36[HVVFWHDG";Q%)&\3,O\ > < D>XR*A;Q
MOX=34#9OJ:"59?)+>6_EA^FWS,;,^V:R-?OK'4O&7A:/2IX;J\CN7F9H&#E+
M?RR&)(Z DK]:YE;\:3X5N;K1]5L;S1XYI"^@ZQ;J)D;S"3&""26W<@$'M54\
M!2J).S5[63?5MK?E\M+I+?7O,L1.-UIIU^2\_/S]#T/5O%>BZ)="VU*]\N<I
MYACCB>1E7^\P0':/<XK2L[RWU"SBN[*9)[>9=T<B'(85PE[*Q\9:A/HVMKH>
MIM:P/=VVI0JT-PNT[2I)##;DJQ'>NA\#ZE_:GA2WN/L5M9@/)&$M%Q"^UR-\
M8_NDY-<U?"QIT%4C>^E_FK[6^ZS?RV-J=9RJ.+\_P^?Z(FU/QAH6CW;VM_?;
M9XU#21Q0O*8P>[;%.W\<52U;Q"7F\-3Z)>))9ZE?B)W0!A+'L<XR1QRO;!XK
M(;7;BXUS75M=3TGPY!97'ESR36X>XG(4?O#EE&,<*<'I6'X=;=X=\'$,S Z]
M.067:3_K>H'3Z5V4\#3C!3:UZWU6L6^UNG=_(PEB).7*MO\ )I=_T1W7A34[
MO4I=>%[-YHM-7FMH?E V1JJ$+P.>2>3S5[6/$6E:#Y0U2[$+S$B*-4:1WQUP
MB@L<>N*Q_ W^N\3_ /8>G_\ 0(ZKM<6]A\6KB759(X?M&EHEE+*P52%<F1 3
MWR0<>E<LZ$)8B:MHE>RZZ+_A]C6-22I1?5NVIO)XFT5]"_MD:C!_9XZSDX .
M<8P><YXQC-)I'BC1]=F>'3+P231KN:)XWB<+Z[7 ./?&*XC5;S07U*PU&P@*
MZ3!KY:_N>L$DYBP)0<D;0Q +<#-;.HW=IJ/Q/\.?V5+'<36\-R]V\#!MD+)A
M0Q'J^,#\:TE@J:CM+52>MM+*]GIO\UNM"57E?=;I>M^J_I[,I>'O$VKWT'@A
MKJ[\PZI]J^V?ND'F[$8KT'&"!TQ707?CKPW974D%QJ0#1/LD9(9'2-O1G52H
M/U-<5X3_ ./;X;?]OW_HMZ;/KT^I>!=1O5U32M$LI5G1=*@M%:=F)8;&RW#L
M>3A>^?>NVM@J52O;ELKM::;SFELGT7;IN84\1.-/?7S_ ,,?-=SJ]8\5QZ/X
MRL(KN_2+2Y]/DE("AO,DWJ%VX!8G!. .M;>F^(-*U>PEO;"]CDMX"1,S93RB
M!D[PV"N!SSBN"TN[L+3Q#X&DU.2*,'P^JPO*0 )"J8Y/0D;A^..]5O$^-3D\
M:7.A@SV@M+6.Z>W.5ED23=( 1U(BR#BL7@:<W&GJG9:]/CY?O^?D6L1.-Y;^
M77X;_P!:'=Z?XT\/ZI?):66HJ\TN?*#1N@EQUV,P ;\":4^,="&L-I?VTM>K
M,(&B6"1BKG& 2%P!\PY/'O7/>+]3TG4]"T:WT6XM[FZFOK9K".W8%EVN"2 /
MN@*#GTJYX5V0:MXQN?*+N-1.X*,LX6)2!^I_.N=X6BJ3JM27DVKWNE?;;7MN
MMS55IN:A=>OR;[E^7Q[X9AN3#)JBC;)Y9E$3F(-G&#(%V#\ZJ7OC&*V^(EGH
M1E8020'S +9VS*Q38-P&-N&Y(X'<BN,U76I[_P"&-Q=-J^D:;9W$#B'2+&U5
MGY)^0DMP>Y(48Y-=/!-'%X_\.^;(J;]$=5W-C<Q:/ 'O72\%1I)MIO2:M?JE
M_A7X7]3+ZQ.>B?;\7Z_Y>AM:?KMG:Z)>7^I:W'<V\-W+&UQ)#Y(CP^!'C^(C
MIG^*K.D>*-'UV9X=,O!)-&NYHGC>)POKM< X]\8KSN%XK>STN\U ?\2ZW\3W
M37#L/DC)9PC-Z ,1R>E=-J-W::C\3_#G]E2QW$UO#<O=O P;9"R84,1ZOC _
M&LJV"IIRWVD[Z67+?1JW6WENM"X5Y66W3UU^?]6+T?Q$\*RI$Z:LA27&)/)D
M"IGIO;;A/^!8K0U;Q/I&AS1PZE=^7-*N](HXGE<K_>VH"0/<\5P^D6\2?LZR
MA8UPUA/(W'5MS'/UZ?D*LW!'_"16CZ9KG]C:M_9,)?[9"KP7<63@ D@A@<YQ
M_C3E@</[225[1<EOVMKI%V^YB6(J\J;M=I/[_G^J.\T_4;35;&.\TZX2XMY1
ME)$.0><'\<\8JS7)^#O$$-QH$DVH+IUB5OY+42VS"."[DS]^//7<2?4D@UU%
MQ)Y-M+*4:38A;8HR6P.@KRZ]%TJKA;J==.:G!2,&7Q[X9AN3#)JBC;)Y9E$3
MF(-G&#(%V#\ZO:OXCTK0A#_:=V(FGSY4:(TCR8ZD*H)(]\5YGJNM3W_PQN+I
MM7TC3;.X@<0Z18VJL_)/R$EN#W)"C')KHM+N+>P^($,NK2)#]HT.!;*69@JD
M*29%!/?)!QZ5ZM3+Z4(\VNG-=7U=K;/E7?6W-HMSCCB9R=M-;:^M_/\ R+NM
M^,K6.'0=1TS5(5TVZO\ RKF8@;2@1B0=PRIR!Z&MC3O%&D:T;F'3+[=-!'O=
M7B=&5?[VU@"1[CBN-U%]#U+6M);1K;,!\2;IY1S%<3"(DNG)!&0!D8Y%;6K
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MSUT#1TFGF32;%9;A669Q;(&E#=0QQR#WS4ESI.G7EFEI>6%K/;1@!()859%
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZM\&?\
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MK?<*-*4>5/H[_A;\=_O-BBBBO-.L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@":Q_Y"UA_U^0?^C%KU:O,M!LY-0U^UCC&5
MAD6>5NRA3D?F0!^?I7IM?H'#$)1PTY-:-Z?<?,YM).LDNB"O ?CI_P CY:?]
M@R/_ -&RU[]7@/QT_P"1\M/^P9'_ .C9:^YP/\9'S^)_AGFU%%%>^>8%%%%
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M44?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\
M$5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?
M4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_
M /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\
M_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!
MV/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11
M_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4
M?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\
M?4?_ ,11_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\
M/_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_
M\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_
M ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=
MG+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#Z
MYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_G
MT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?4?\ \17444?V
M3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\ $5U%
M%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?4?\
M\17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU
M'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?
M_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\
MS_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P (
M'8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%
M'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_
M ,11_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_
M /?4?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\
M?_\ ?4?_ ,11_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('
M8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\
M('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/Y
MV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N
M8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?4?\ \17444?V3@?^
M?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']D
MX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?4?\ \174
M44?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_ /WU'_\
M$5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\_P#?_P#?
M4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!V/\ S_W_
M /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11_P ('8_\
M_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4?_Q%'_"!
MV/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\ ?4?_ ,11
M_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\ /_?_ /?4
M?_Q%'_"!V/\ S_W_ /WU'_\ $5U%%']DX'_GT@^N8C^=G+_\('8_\_\ ?_\
M?4?_ ,11_P ('8_\_P#?_P#?4?\ \17444?V3@?^?2#ZYB/YV<O_ ,('8_\
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M,C_]&RU[]7@/QT_Y'RT_[!D?_HV6O0P/\9'-B?X9YM1117OGF!1110 4444
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MGN"&8'^!?X5_ ?J35PG R>E(2%4EB  ,DGM6?A]6;G*6 / Z&?\ P7^?TZ@
M2^JMA"4L0>6'!G]AZ+[]_IUT%4*H50 H&  .E*    , = ** "BBB@ HHHH
MBNKF&SM9+BY<)%&NYF/85P6I>*]1OY"+61K*W_A5,>81[MV^@_,UK>.[EE@L
MK0<+,[2-SUV8P/S8'\!7'U\1Q!FE:G6^K47RI;VWU/?RW!PG#VLU?L3?;[\]
M=2OO_ N3_P"*H^W7W_01O_\ P+D_^*KB]0UKQ!-XYET+1#IL4<5BMT9+R&1R
M27*X^5Q[4Z'7=<TOQ/I^E>(X]/FBU,2+;W%BKIL=%W%65B>".A!KY_EQ=K^T
MUM>W,[VM?\CT_P!Q?X.MMD=E]NOO^@C?_P#@7)_\51]NOO\ H(W_ /X%R?\
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M35\VR:Z:2^21NC[<#:P]NU*C4Q-:7+&HUI?5OH.I"C!7<5]QVGVZ^_Z"-_\
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M6-,BA6634;1(V=HU=IU"EUSN7.>HP<CM@TG]M:4-.&H'4K/[$3@7/GKY9/\
MO9Q1[7%?S2^]A[.AV7X&I]NOO^@C?_\ @7)_\51]NOO^@C?_ /@7)_\ %51@
MOK2ZLQ=VUU#-;$%A-'(&3 ZG<.*CL=7TW5"XTS4+6\,?WQ;SK)M^N"<4O;8J
MS?-+3S8>SH_RK\#2^W7W_01O_P#P+D_^*H^W7W_01O\ _P "Y/\ XJLL:UI;
M:B;!=2LS> X-L)U\P'_=SFKI(526(  R2>U*5?$QWE+[V"I47M%?<B?[=??]
M!&__ / N3_XJC[=??]!&_P#_  +D_P#BJR$\0:-)-##'JUBTMP T*+<H6D!Z
M%1GG\*GOM2L=,A$NI7MO9QDX#W$JQ@GTR35>UQ2:7-*[\V'LZ%KV7X&A]NOO
M^@C?_P#@7)_\51]NOO\ H(W_ /X%R?\ Q54/[1LMEN_VRWVW3;8&\U<3'&<+
MS\QP.U.%Y;->M9K<0FZ5!(T <;PN<;BO7&>]3[?$_P TOO8>RH_RK[D7?MU]
M_P!!&_\ _ N3_P"*H^W7W_01O_\ P+D_^*JG;W5O=J[6L\4ZQN8W,;A@K#@J
M<=".XJO>ZWI6F2K'J6IV=I(WW5GN$C)^@)IJMBF^52E?U8.G12NXK\#4^W7W
M_01O_P#P+D_^*H^W7W_01O\ _P "Y/\ XJJ$NH65N(3/=P1"?/E%Y5'F8&?E
MR>>.>.U-L=4L-4C9],OK:\1#AFMYED"GT)!-'ML5;FYI6]6'LJ-[<J_ T?MU
M]_T$;_\ \"Y/_BJ/MU]_T$;_ /\  N3_ .*KD_$_BZWTO0KZXTB\L;J^M'B5
M[<RAR@:54.Y58$<,?QKIJN53%0@IRF[.ZW?2S_5"4*,I.*BM/)?UT)OMU]_T
M$;__ ,"Y/_BJ/MU]_P!!&_\ _ N3_P"*K,;6=,34!8/J-HMXQP+8SJ)#_P !
MSFIDO;62\EM([F%[F%0TD*R N@/0E>H!J'6Q2WE+[V/V='^5?@7?MU]_T$;_
M /\  N3_ .*H^W7W_01O_P#P+D_^*K"N=6$L]E_9>H:8\3W9@N/-FRS84Y2/
M:?\ 6 XX/;-69=:TJ"_%C/J=G'=MC%N]PHD.>GRDYJO:8K^:7WL7)0_E7X&I
M]NOO^@C?_P#@7)_\51]NOO\ H(W_ /X%R?\ Q5<O=^+K.U\<6N@/<VB&6!F<
MO. ZR94)'C/5@V0.I[5;TW5U.GQR:MJ&F>;+/)%&UK-^[?#'"@L>6 '(]0:N
M3QD8J3D]=5J_/_(E1H-M**T\D;OVZ^_Z"-__ .!<G_Q5'VZ^_P"@C?\ _@7)
M_P#%5G6.JZ?JBN=-O[:\$9PYMYEDVGWP>*B?7M(BN)K>35;%)H%+2QM<H&C4
M=2PSD >]9^UQ=[<TKKS97LZ%KV7X&M]NOO\ H(W_ /X%R?\ Q5'VZ^_Z"-__
M .!<G_Q50 AE!4@@C(([URD6O:[X@N[O_A%X;"&QM9F@^V7X=_/=>&V(I'R@
M\;B>?2JIU,34NU4:2W;;%*%&-O=6OD=E]NOO^@C?_P#@7)_\51]NOO\ H(W_
M /X%R?\ Q5<YX=UVZU&XOM.U:T6UU+3V43"(EHI%895T)[$=NHK*@\:W,GCU
MM,>"$:0TSV45T,[S=(BNRDYQCDJ!C.1UK51QKE**F_=5]^F^G?34A_5TD^5:
MNVQW'VZ^_P"@C?\ _@7)_P#%4?;K[_H(W_\ X%R?_%5R'B?7-7L?$F@Z1HGV
M)7U3[1NDO(W<)Y:!A@*PZY/Z57O]<\2^&Y+.YUY=+N]/GN4MY6LDDCDB+G ;
M#,P89ZCK3A'%SC%JIK)72YG=ZM?FF$O81;3AMOHOZZG;_;K[_H(W_P#X%R?_
M !5'VZ^_Z"-__P"!<G_Q55WW;&V8W8XSTS7":CJ_CS3=2TRRE;PZ[ZC,T4;+
M#/A2J%LGY_05%"6)KMJ-6WJWZE5(T::NX?@CT/[=??\ 01O_ /P+D_\ BJ/M
MU]_T$;__ ,"Y/_BJYZRU.YTVSQXQU#2+>Z=G:+R',2&-0N3^\.202<D< $5<
MGUS2;:SBN[G5+.&VFYCFDN$5'^C$X-1*IBD[*;?HWKZ#4*-KN*7R1J_;K[_H
M(W__ (%R?_%4?;K[_H(W_P#X%R?_ !55!<P&U^TB:,P;=_FAQMV^N>F/>JMK
MK>E7QC%EJ=G<&1RB"&X1]S 9(&#R0 3CTJ%6Q33:E+3S97LZ/\J_ U?MU]_T
M$;__ ,"Y/_BJ/MU]_P!!&_\ _ N3_P"*JNS*B%W8*JC)8G  JE9:YI.I3O!I
MVIV=W*G+1P7".R_4 \4*OB6FU*5EYL'2HIV<5]R-7[=??]!&_P#_  +D_P#B
MJ/MU]_T$;_\ \"Y/_BJR)O$&C6YQ/J]C$?-,.'N4'[P'!3D_>!ZCK5JZOK2Q
MM3<WMU#;P#K+-($4?B>*?ML4K>]+7S8>SH]E^!=^W7W_ $$;_P#\"Y/_ (JC
M[=??]!&__P# N3_XJN:L/$)U#QA<Z=;/;S6*6,5S%/$=Q<L[*?F!P1\O85M7
M-U!9V[SWD\<$*#+22N%5?J3P*<ZF*A)1<W=VZOJ*,*,E=17W(M_;K[_H(W__
M (%R?_%4?;K[_H(W_P#X%R?_ !59MIJVG7[(+&_M;DR(9$$,RON4$ L,'D D
M#/J:1=9TQ]0-@NHVC7@ZVPG4R#_@.<TO;8J[7-+3S8_9T.R_ T_MU]_T$;__
M ,"Y/_BJ/MU]_P!!&_\ _ N3_P"*K,NM9TNQ:5;W4K2W:$*9!-.J; WW2<GC
M.#CUJ>*[MY[074-Q%);E=PF1P4(]<],4G6Q25W*7WL/94;VY5^!<^W7W_01O
M_P#P+D_^*H^W7W_01O\ _P "Y/\ XJLVQU?3=4W_ -F:A:WGEG#_ &>99-OU
MP3BHCX@T821(=7L0\S%8U^TIER#@@<\D'CZT_:XN]N:5_5B]G0M>R_ U_MU]
M_P!!&_\ _ N3_P"*H^W7W_01O_\ P+D_^*K.CU73IM0>QAO[62\CY>W693(O
MU7.13;K6=,L;E+>]U&TMIY/N133JC-] 3DT>VQ5[<TK^K'[.C:]E^!I_;K[_
M *"-_P#^!<G_ ,51]NOO^@C?_P#@7)_\54-4KW6--TV2./4=1M+1Y/N+/.J%
MOH">:F.(Q,G:,Y/YL;I44KN*^Y&G]NOO^@C?_P#@7)_\51]NOO\ H(W_ /X%
MR?\ Q549[^TM3$+FZAA,V?+\R0+OP,G&>O'/TIECJEAJD;/IE];7B(<,UO,L
M@4^A()I^WQ-N;FE;U8O94;VY5^!H_;K[_H(W_P#X%R?_ !5'VZ^_Z"-__P"!
M<G_Q59#^(-&CFGA?5K%9;<%ID-R@:(#J6&>/QID>I-%JFJ"^O=.2RM(XG4++
MB6$$$L9LG"@X&T^@-5[3%6OS2^]^7^8N2A_*OP-K[=??]!&__P# N3_XJC[=
M??\ 01O_ /P+D_\ BJRXM:TN>^^QP:E9R76,^0DZE\8SG:#GI3K[5]-TQD&I
M:A:V9DX07$ZQ[OID\TO;8J_+S2OZL?LZ%KV7X&E]NOO^@C?_ /@7)_\ %4?;
MK[_H(W__ (%R?_%55DN(8;<SRRQI"J[C(S *!ZYZ8J"TU73M0MGN+"_M;J"/
M.^6&975?J0<"I]OB6K\TK>K#V5&]N5?<C1^W7W_01O\ _P "Y/\ XJC[=??]
M!&__ / N3_XJN<U+Q':-I=TVB:SHQO(XEE4W5T/*121AGVG(4@\'W%:%UK.E
MV+2K>ZE:6[0A3()IU38&^Z3D\9P<>M:.>+27O2^]^7^9/)0[+\#3^W7W_01O
M_P#P+D_^*H^W7W_01O\ _P "Y/\ XJJ4=Y;2V8NXKB)[8KN$RN"A7UW=,57M
M=;TJ^,8LM3L[@R.400W"/N8#) P>2 "<>E1[;%.[YI:>;*]G1[+\#5^W7W_0
M1O\ _P "Y/\ XJC[=??]!&__ / N3_XJJ=S=6]E;M/>3Q6\*D!I)7"J,G R3
MQR2!^-0VVK:=>W4MM9W]K<3P_P"LBBF5F3Z@'(H5?$M<RE*WJP]E13MRK[D:
M7VZ^_P"@C?\ _@7)_P#%4?;K[_H(W_\ X%R?_%5E+KFDM>+:+J=F;EG:,0BX
M3>74X9=N<Y'<=J7^VM+_ +1_L_\ M*S^VYQ]F\]?,_[YSFG[7%_S2^]B]G0[
M+\#4^W7W_01O_P#P+D_^*H^W7W_01O\ _P "Y/\ XJLZ^U2PTN-7U.^MK-'.
M%:XF6,,?0$D4AU;3EB>5M0M1'&ZH[F9<*S8VJ3G@G<,#OD>M)5L4U=2E]['[
M.BG:R_ TOMU]_P!!&_\ _ N3_P"*H^W7W_01O_\ P+D_^*K*37-)DLY+N/5+
M)K:)MDDRW"%$;T+9P#3[75]-OK22ZLM0M;BWB!,DT4ZNB8&3D@X'%-U<6E=R
ME][%[.AV7X&E]NOO^@C?_P#@7)_\51]NOO\ H(W_ /X%R?\ Q5946NZ3/=);
M0:I923R()$B2X0LRD9#  Y((YS4EGJNGZB\B:??VMTT1Q(L$RN4/O@\4.KBD
MKN4OO8U3H/9+\#1^W7W_ $$;_P#\"Y/_ (JC[=??]!&__P# N3_XJLN'6M*N
M+YK*#4[.6[4X:W2X4R#ZJ#FKU3*OB8_%*2^;!4J+VBON1-]NOO\ H(W_ /X%
MR?\ Q53VVMZK9R!X=0G;U6=S*I_[ZY_(BJ5%..,Q,'S1J._JP>'HR5G%?<>A
M^'_$$>M0LCH(;J(#S(\Y!']Y?;^7\]FO,-$N6L_$%C*A^],L3#/57.W'YD'\
M*]/K]'R7'RQN&YJGQ)V?GYGR^.PZP]6T=F%> _'3_D?+3_L&1_\ HV6O?J\!
M^.G_ "/EI_V#(_\ T;+7U&!_C(\C$_PSS:BBBO?/,"BBB@ HHHH **** +%E
M87>I7(M]/M9[N<@D101EV('4X'-,N+:>TN'M[N&2":,[7CE0JRGT(/(KN/@U
M_P E&M_^O>7_ -!K5@\)V/C'XS>(M/U.6XBBC$DX:W95;<'1<<@\88US2KJ$
MW%[)7-8T^:*:ZL\MHKV"Q^%7A'4YKW2]/\1W,VL6:GS57:4C;IR-OS '@X;\
MJYCP9\.O[=N=2GUN[^P:;I;M'<S*PR77[P!/   R2?;\!8FFTWV#V,[I'#45
MZ7K/P_\ "\WA&ZUSPAK\ERMH3O2[90'VC)4?*I#8Y'!S^.:72OASH%CX5M-:
M\<ZS/8+?;3!%  " PR,_*Q)QSTXH^LT[7^5K:A[*5['F=%=WXI^'D?A_Q!I"
M6UXUWI&JRHD4XQO4$C(R.#PV0>_IQ75:A\*O!>D:Q;6FJ:_?0?;2([6 LF]W
MSR2P3 '( R!SWYQ0\3323[@J,VWY'C53_8;O[3#;_99O/GV^5%Y9W2;ON[1U
M.>V.M>G:=X(TGPQ\8K/2]3NWFMWB6YL=R F23=A4<8(_A;GCH.E:/Q'T[0[K
MXB:0L&I7D6MW%]:PS1PDKY,1.!(C;>&!QCD_2I^LQ<E%+1JX_8OE;9Y%?:?>
MZ9<>1J5I/:3;0WEW$31MCUP1G%5J]ENOA]I&J_$2ZT35=9UFYG6PCN+>:XN5
MD<_,P922O(&5( QWKE/ G@"+Q#K^JVFN2RVUOI:E9V@<!A)N(QD@C'RO^0IQ
MQ,'%R?3]1.E*]D<+17H/A3P!I>M66I:]JVH3:?X?MI76%SCS74'J3C'0@< Y
M.1@4OBOX?Z5:>$U\2^$=4DU#358+*)@-RY.W/ '<@$$ \U7UB'-R_P!7["]E
M+EN>>T445T&84444 %%%% !1110 5]6^#/\ D0] _P"P9;?^BEKY2KZM\&?\
MB'H'_8,MO_12UY>8_#$[,+NS3O+G[+;%U7?(2%C3^\QZ"DM85L;/$D@)&7ED
M;C<QY)-5DD2YNGO96"VUMN6)F/!/\3_T'X^M*BOJ;"2=&2T4YCB88,O^TP[#
MT'XGTKQCO$57U5MT@*60/RH>#/[G_9]N_?BM'I110 4444 %%%% !1110!QG
MCW_C\TS_ *YS_P XZY:NI\>_\?FF?]<Y_P"<=<M7YAG_ /R,:GR_)'UN6_[M
M'Y_F>?WME?7WQ@NDT[59=,=='C+21PQR%AYIXPX(INAP30?$AK7Q?>3W^J0P
ML^DW+A4A>(\/M15 $@'!Y.1]*[5=)LDUI]66'%]) +=I=[<Q@Y QG'7OC--U
M#1=/U6XL[B^@\R:QE\VWD5V1HV^JD9![@\'N*P^O1:Y&M.6U[*Z=N^]GLU?8
MU^KN_,GK>_6W]?J<#X4\,IK-YXGN&U?6+(KK]VGEV-ZT*'E3D@=^>OL*Z/4[
M;2O"_A"YBUV;4-5TZ>94G:\F,[('*KRQ((4'!XY!R1S3KCX<^%[J\N+J;3I/
M.N96FE9;R9=SL<DX#@=:T-+\*Z-H]I<VMC9X@NAB>.:5YE<8(P0Y/')JZ^,I
M5)*7-*VFEDMO.[?IH33H3BK6776[?X6_4Y;6-'N_"6@3ZSX=\472VUK%YJVE
M_(+B"10.$4GD9Z#!/-0ZE9'Q'\2=(\ZXOM-:70S,QLYS%(I+@[2P[<]/:NAM
MOAWX4M+M;F'1XMZ-O57D=T4^H1F*C\JMZUX/T/Q#>1W>KV;33Q1^6CK<21D+
MG./E8=S5QQU&,KMMNS][E2>JTTOKZMDO#S:M96TTN[:?+3[AFE>&HM$NFO#K
M6L78$9!2^OFEC ZYP>_'6N*TR/6_$.FZ_?PZ#!>VOB)W6.:6^$++"H,<8V[#
MTP6!SWKK;;X>>&;24R6]C,CE'C)^VSGY64JPY?T)%;]E9V^G6,%G91"*W@01
MQH/X5 P!S6/UR%.\HWE)VU:MHM>DN]ON-/82E9/1*^VOYKU/+=2U*XU7X364
M%U(T6HV.IPV-R>"R2QR!<\]3C::T/&-AK.F6<,NNZ_?:GX>D<1ZC'##%#(BD
MX#$HF2G9@,'GK77S^$M$N)+MY;+)O)X[F?$K@/(GW6P#@'Z8SWS6K=6T-[:2
MVUU&LL$R%)(V'#*1@@UH\PIQE%PCI=MZ+2]OA>K5G>S]"/JTFGS/6R6[Z7W_
M %.-OOLVE_$;P]>!DCTZXTZ2QMG7_5J^0RC/097@>N*Z76]=L]!MH9;TNS7$
MZ00Q1 %Y'8X  SSZGVIH\.:3_8":))9++IT:A5@F9I  #D<L2>.W/':J^G>#
MM!TJ^6\L[ ?:4&$EFE>5HQ_LEV.W\,5S2JX>IRN=_=TZ:J[:N[Z;Z[FL85(W
MY;:_A_G^!R=KH*ZY\4/%^[4M3L?)^Q?\>%TT._,/\6.N,<>F35JPT1=$^*=C
M&NH:C?>9I<S;K^Y,Q7]XG )Z"NQMM)LK/5+[4;:'9=W_ )?VF3>Q\S8NU>"<
M# /8"G/IEI)JT6IO%F\BB:%)-QX1B"1C..H':M98]M\MWR\BC;S44OS)6&25
M^M[_ (W_ "$TS2;+1[5K?38?)B>1I67>S99CDG))[UQ?B&SO[[XM6,6E:HVF
M3_V0Y,ZP)*2/-Y7:W'IS[5VFF:39:/:M;Z;#Y,3R-*R[V;+,<DY)/>D;2;)]
M:35FAS?1P&W67>W$9.2,9QU[XS7/1Q"I593O>Z:U2>_=._ZFDZ7/!1VU7](Q
MM-\(S1:Y!J^NZS<:Q>6J,EMYD21)#N&&(5!U(XS7&V%HEE\"[_4=/@5+^07+
M-.B#S /.9&PW4?(*]8JEI^DV.EZ6NG65N$M%WXB8EQ\S%FSN))R6/YUK3Q\D
MO?UUB[:)6CS::>;[=R)89-^[V?K=VU_ XOQ?IFC:9X)L+K0H((KBWN+8Z;+"
MH#NQD4<$<ME2Q/K5KPYIVGZKKGBN;6;:"ZNUU!K=A<(&*6XC78,'HI^8^];-
MCX)\/:;?1WEGIJ)-$2T6Z1W6(GNB,2J_@!6'X@T2ZO->N+BY\(P:N& 6"YM[
MW[.63'W)E+#=@^S#':NFGB(5(NDIOJ^9V3U:=M96MIWW=[&4J<HM3:7HKVV>
MNWZ',Z;965[X8\)VF!<63>()@H;YA(@:4C.<Y!P,^M;?B&TNI/B9IMAI]EID
MMO%ISSVUM?%DA,QD^=E"J07"X/3N36_X;\(P:=X>TRUU2..6ZLIWNU,+,J12
MN6)V@8R &(YK5U?0=,UZ&.+5;59Q$V^-MQ5HSZJRD$?@:JKCZ?UAM7<?>_%O
M5:KIZ"AAI>R[/3\$M#SBYT\)'XKL]4U'2])BN([8SPV'FR1P3%QM9@4  ?@,
M!U'6MG3Y)M(\7:7%XBT#3K>[N(Y8;2_TJ0A" NYE:/ .,+P3G';K756?AC1K
M#2I]-MM/B%I<$F>-\OYI/4L6)+'W)J/2O"6B:+=_:=.L=DX38LDDKRE%]%+D
M[1[#%1/'TIQE%W\NGV4MT]-M4^:ZT\RHX>::>G]._;_(\\A@71O"27L^G:9X
MA\.0S"=-0@=H+P#S,[VR!N8'C@C/0UZI<L'T^5EZ-$2,_2LC_A!_#GV_[7_9
M<?F>9YNS>_E;_P"]Y>=F??%;KH)$9'&588(]JYL9BJ==Q<;WNV[^=NEVK]VK
M7[&M"C*FFG_7]?/U/*8M$TV'X -<K9P_:&M/M!GV#S/,W9#;NO' ^@Q5Z=-4
MU'XE7(BM=+O)+?3H&MH]3D<!4;.]T 5@3NX)X["NW_X1[2_^$=_L+[-_Q+?*
M\KR/,;[GINSN_6F:KX9TC6A!_:-F)&MQB*1)&C=!Z!U(;'MFNI9C!RDY7=W+
MY)V\UVL]=F8_59)*UM$OPOY>9YY]AN+3P_K]S&]@3H^J0ZA%::>SM';21@&5
M0651RN3@9 R12RZQ'IOB:;QTTA:SN+BYL%(/RO%'"#'CZR0M^=>D66AZ;IVD
M-I=E9QPV3*RM$N?F#=<GJ2?4\U5?PCH4GAZ'0WL%;38&#QP&1_E().<YR>2>
M_>J68T6WSIM/3I\+23^=TFOGJ)X6=ERM:?G?3Y:V&>#-.DTOPAI\-QG[0\?G
MW!/4R2'>V?Q8US@8:MJFNRZ'H.D&**Z>"]O]6F9M\B !@$VDA0,=P.M>@5A7
M7@OP_>ZE+?W.FJ\\Q#2_O'"2D="R [6_$&N*CB8*I.I4O>7;UOM=?UT-YTI<
ML8PZ?UV9YYHMK!JWA;P!;WJK<0/?W(*,"595,I P>WR@8/;BMCQ)"=*\7:NV
MB0BVFD\+S2;;==NYUD 5L#^( G!KLK?PQI%HMDMO:;%L9I)[91(^(G?.X@9Z
M'<>.@SQ5HZ79MK U1H<W@MS;>9N/^K+!BN,XZ@<XS774S&#J\Z3Y?>T]9-_Y
M&,<+)0L]]-?16/._$^DZ#;_"*PN+&"W5E%J;>9% >1F=-V2.22-Q(]1GM7I5
MXTJ6,[6PW3+&QC&,Y;''ZUS\GP\\*RLQ;24P6W!!+(%0Y#910V$Y'\(&>G2N
MFKDQ6(A4C&,6W9R>OG;3=]C:C2E%MM):):>5SQO3].O;OX7274]KX=^RSPR2
MSZC<32FX63)R[$1D[PW8$\C%:/C%KR"QT*ZTBXDE\3OIQ6>2U0DRV_E9D<@X
M/#<KG!W'IFNSF\#>&[B_:\ETN-I'D\UUWN(W?^\8P=I/U%:<.D6-OJUQJ<4&
M+RX18Y)6=F.Q>B@$X4>PQD\UW2S*E[3VB3>K=K::Z6>KT[[7LM%NN=82?+RM
M]E?TZ[?UW.+N(],BL/ JZ#@V'V]#">[ Q/DM_M9SGWS67-8M!INN7D&GZ3XD
MT-[JXFN6D+07<9!)=2Q'.W'!X/IVKO;?PKHUJ(%@L]BV]TUY"HE?;'*P() S
M@#D_+TYZ5#=^"?#M]?R7ESIB-+*V^4"1U25O5D!VL?J#40Q]&+UYK?B_>;Z-
M.^NZ>_0J6'FUT_I6[?A8Q(39:C\1M"OH+=?+N-%>=/,0;OO1E2<_Q 8YKF[>
MR@U'0?#-K>1B6"3Q'<;T89# -*<$=P<<BO2[WP_IFH7UG>75MFXL3FWD21HR
MG(./E(R,@<'(J.+PSI$$=K'%:;5L[EKJ >:YV2MG+=>?O'@\<U,,?3A%6O=?
MA;FZW_O(<L-*3=[?U;_(YC5[==+\?&31K=+>:30;D[84"[V5E*<#J0361J&D
MZ%_PH=+PPV_FM8I/]IP#(;AL;OFZY+$J>?45Z/-IEO)J2ZDL2_;XH&ABE8MA
M58@D%0<'D#W]Z\ZO?!E[JMM-9'PE:V%W<MB;4$O=UM'D_-)'#N)#$9Q\HZ]:
MWPF)A/DYI<O*XMNZULWW:NK/I=^1G6I2CS65[W[];>7]=STRT_X\8/\ KFO\
MJY/X8,MMX1_L>5O].TRYF@N4/#!C(S _0@C!KL(T$<:HO10 *R-4\):)K-Y]
MKO[+=<[=IFBE>)V'H60@D?6O*IU8<DZ52]FT[K757Z77=]3LE"7,IQW6GWV_
MR*FJ^--/L+?7/*W22:/ 'F; \OS&!VQ[O[V< CMFN(FTCQ3;_#R&W&A0BZLY
M?[3%[]N#2&8,9"WE[.I!*XW5Z%_PB>A_V.NE+IT:6(E68PH2H=P<@M@Y;D#K
MG.*V" 1@C(-=-/&4L.DJ4;ZIZ^2TV?F[K5;;F4J$ZK]]VTZ>?JO0\XUV[?Q)
MXG\ WFE7KV+7D-Y(DZ(KM'^Y4D88$$]5YHO[2\LO&VE6WC/5;G5-,FE#6$A2
M.&-+E?NK*J*-Q/\ "<]>,=:ZZR\):)I\FGO9V7E'36E:TQ*Y$1E^_@$XY]#T
M[8JYJ^CV&NZ>UEJMN)[=F#;=Q4@@Y!!4@@_0UI]>I1<807N)-;+F5Y2::>^B
M:Z]_4GZO-IRD]6T]W;9+5?(S'UCQ&/$/V-?"V[3?-"_VA_:$8^3N_EXW?A57
MQ3_R-GA+_K]E_P#1+5U2J%4*,X P,G)_,U5NM,M+V[M+FZBWS63F2!MQ&QBI
M4G .#P3UKBIUX1FI<MM&M+ZW35W=O\/N-Y4Y.-KWU3U]?)'+^*;&WO\ XB^$
M(KR)9HE6]?RW4%20B8R#Z'GZ@5D/::A<_$[68;+3]'N!9VUNMI#J+,@BB9<L
M8U5&&"Q()XZ 5W\^F6ESJ5IJ$\.ZZLQ(()-Q&P. &X!P<@#K575_#.D:[+%+
MJ=F)9H05CE21HW4'J-R$''MFNJCC80C&$KV47'T?,Y72NNFFZZF53#RDW)=[
M_A;M\SS8V[0Z.VGW4]B=,F\30Q75O9.YAMU(R\6YE7"[PO X&:Z76-.TNQ^)
MWA)K*W@MKF0W0=(4"[D$#8) ]"2!]36OJF@I:>$SI>@Z18SVZL-]C/E5E3.6
M ;L_<,<\UA:#X3D7Q58:F- _L2WT])#^^O/M,T[NNP#.YL(H+<9ZGI79]9IU
M8RJ<UM)JUUK>-E=7O?Y/UTN8>RE!J-K_  ]]+/T_R-_QM=V-IX6G_M.S:^AF
M>.%;59#'YKLP"J6R,#/7V]>E<EJ,%]:>,/"K7VGZ-IKM>%8HK!F:79Y9# G:
MHV]!@#TKT/4=-L]7T^6QU*W2XMIAAXWZ'_#ZUE6W@GP_9RPRP:?B:"59HYGG
MD>164$#YRQ./F/RYQSTKBPN*I4:7+*]_>]-5;NDO/1W[F]:C.<[JUM/P=^WZ
MG.^%M#TV\M/%MQ>64%Q+-J][&SRQAB$#<*#V&23]36;X>2+4)O MOJX$UJ-,
MED@CFY1YUV@<'@D)G'I7HUGI-EI\5U':0^6EW/)<3#>QWR/RQY/&?0<54E\*
M:+/HEOI,M@K65KCR$+MNB(Z%7SN!]\YK3^T(N4N:^NWDN5KOYK_,GZLTE:VG
MXZIF#H=I8V7Q8UN+3HXXE.GPM+'%PJN6;/ X&1@_CGO4WBV*&\\8^%;+4%62
MPEFN'>.091Y5C!C!['JV!WK9TCPMHV@W,EQI-D+>:5!'(_F.Q< D\[B<G)ZG
MGWJKXOT^YU'3X(HM(MM7MQ)NGM9)/*DQCAHWR K ^O4'J*A8B$\5&2;MRVN[
M)_#:^]O-:_,;IRC1::ZWT];_ -:',ZK;P:5\0M6D\/Q)#>_\(S<3&*!0/WN]
M=C8'\1P/R%8?]EWC?"^WG:#PY:VA@CF74S/-YZRY'[PD1D^9NZ@$]Q76^$O#
M$MEXEN-8DTE='B^R?98K<W/GRR$N&:21\G)^50.3P*UE\#>&TU 7B:7&)5E\
MX+O?RP_][R\[,^^*[7CJ5%J#;=N771[7TWMU\[=F8?5YU$Y6M>^GK\O\C$TS
M3+;4/B?J5QJ<$-S/!IMKM+IE0S;MQ (XZ>F<$USTT4,.CWFFM^YTD^,OL]Q&
MO"+ 0K;#Z+OQ[<UZC%IEI#JEQJ,46V[N42.63<3N5<[1C.!C)Z"H!X>TK['?
M6K62/!J$S3W4<A+K([8R<$\?='3&,5RPS",97=[6BO2V]OQL;2PS:TMU_'^M
M3F]?LK'3/&7A:32H(;6\DN7@9($"%X/+)8$#J 0OTKGK/1M//PB\17CVD+W,
MDEY(960%@4D8+@]1C&:[[2?">B:)=&YTVR$<Y38)9)'E95_N@N20/88%3)X>
MTN/1)](2UQ8W'F>;%YC?-O)+<YR,DGH:(X^$(QC%MV<=>K2;??S5M0>'E)MM
M+6_XI+MY'&ZKI]GI:^!I;"UBAE-_"C2*@#,'C.[)ZG/4YZFL[0K+4]2M]>N9
M=.\/WADOITO)-2ED$J!3@(<(=JA<8P>!7H]SHFGWBV(N+?>-/E66V^=AY;*,
M \'GCUS5'4O!?A_5KU[N_P!.5YY0!*R2O&)<=-X4@-^.:JGF%/DY9WOWW^TW
MW7?ON3+#2YKQMZ?*W9D7@$2KX#TM9[N.\*Q%5GCW[70,0F-ZJ>%P.0.E<EI5
MKJVI>(/%$PT[0[Z1=1D@<ZH[B1(0!Y:@!& 0KSUYY]*],AACMX4A@C6.*-0J
M(@P% Z "L?5?!^A:W>&ZU&P$D[)L>1)7C+KZ-L(W#V.:PHXR$:M24EI/YVUO
MW7YHUG0DX12Z?Y6\SS^RTZ*]TWP;87TUMJ%F-3N!'Y1=XS&JN0F74%@"-O3!
M QTK8UJ'^RO&^JMHL*V\S^%YY0L"[=\J. AP.XSBNS.A:;G3]MHB#323:*A*
MK$2NW@ X/!/6EGTN!M1?5((D&I"U:VCFD+%0A.[!4'!&X ^OO6TLPC*=];6E
MITNY-_Y7,UAFHVZZ?@K'G/B'2-!B^!L5U#!;K(+2&2*X51YC2MMW?-U).2#^
M/I5O7?\ C\^)'_8-MO\ T5)5:Z\$W.K6QL&\(V^F33R+]HOEOM\$8W NT,62
M5) ('RCKUKT"?P]I=R^I-/:[FU2)8KP^8P\U5!"C@\<,>F*Z:F*IT4KR<KMO
MH[>]!]&_Y7_DC*%&<WHK:+OVDNWFCCM;T;3]+\'>&Y;&TBAF@OK(K,B /EF
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M7Q=T37'B T^;4+*!)-XR7W9QCKT4UY%?:G?ZG<+/J5[<7DRJ%62XE:1@ 2<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\(7K/]ZP_P"_[_\ Q%=_11_J[@.S^\/[3Q/?\#@/^$+UG^]8?]_W_P#B*/\
MA"]9_O6'_?\ ?_XBN_HH_P!7<!V?WA_:>)[_ (' ?\(7K/\ >L/^_P"__P 1
M1_PA>L_WK#_O^_\ \17?T4?ZNX#L_O#^T\3W_ X#_A"]9_O6'_?]_P#XBC_A
M"]9_O6'_ '_?_P"(KOZ*/]7<!V?WA_:>)[_@<!_PA>L_WK#_ +_O_P#$4?\
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M]_W_ /B*[^BC_5W =G]X?VGB>_X' ?\ "%ZS_>L/^_[_ /Q%'_"%ZS_>L/\
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M_P 17?T4?ZNX#L_O#^T\3W_ X#_A"]9_O6'_ '_?_P"(H_X0O6?[UA_W_?\
M^(KOZ*/]7<!V?WA_:>)[_@<!_P (7K/]ZP_[_O\ _$4?\(7K/]ZP_P"_[_\
MQ%=_11_J[@.S^\/[3Q/?\#@/^$+UG^]8?]_W_P#B*/\ A"]9_O6'_?\ ?_XB
MN_HH_P!7<!V?WA_:>)[_ (' ?\(7K/\ >L/^_P"__P 11_PA>L_WK#_O^_\
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MN [/[P_M/$]_P. _X0O6?[UA_P!_W_\ B*/^$+UG^]8?]_W_ /B*[^BC_5W
M=G]X?VGB>_X' ?\ "%ZS_>L/^_[_ /Q%'_"%ZS_>L/\ O^__ ,17?T4?ZNX#
ML_O#^T\3W_ X#_A"]9_O6'_?]_\ XBC_ (0O6?[UA_W_ '_^(KOZ*/\ 5W =
MG]X?VGB>_P"!P'_"%ZS_ 'K#_O\ O_\ $4?\(7K/]ZP_[_O_ /$5W]%'^KN
M[/[P_M/$]_P. _X0O6?[UA_W_?\ ^(H_X0O6?[UA_P!_W_\ B*[^BC_5W =G
M]X?VGB>_X' ?\(7K/]ZP_P"_[_\ Q%'_  A>L_WK#_O^_P#\17?T4?ZNX#L_
MO#^T\3W_  . _P"$+UG^]8?]_P!__B*GMO ]\\@^VW<$*=_(R['\2 !^1KN*
M*J/#^7Q=^5OYL3S+$M6YOP*FFZ9:Z5:"WLX]BYRQ/+.?4GN:MT45[D(1A%1B
MK)'GMN3NPKP'XZ?\CY:?]@R/_P!&RU[]7@/QT_Y'RT_[!D?_ *-EKT,#_&1S
M8G^&>;4445[YY@4444 %%%% &AH>MW_AW5H=1TJ;RIXCZ95QW5AW!KT0_&:U
MGFBO+[P?8W&H1#Y;HRC<I]LH2/SKRNBL9T:=1WDBXU)15DSJ=8\8:EXQ\5V%
MUJ11$BG58((QA8@6&?J3@9/M7K/Q&\<1>%M:L8+S1;;5H'B\Z-9B%:*0,1N!
M*MV]J^?T=HW5T8JRG(8'!!]:LW^JZAJLB2:I?W-ZZ#:K7$S2%1Z L3BLIX:,
MI1[(N-5I/NSL&\97OC/XG^'[N\C6"*&_MTA@0DB,>:I//<GN?85WWCOXAQ^%
MO&"6MUH-KJ9BA2:VF=@DD+-D'!*MZ=L5X3#-+;SQS6\CQ2QL'21&*LC Y!!'
M0@]ZFOM0O=3N//U*[GNYMH7S+B5I&QZ9)SBB6&A*2[) JTDGW9MZIXYU?4O&
M4?B3>L%W 1Y"(,K&@S\ON#DY]<FNP'QK!87C^%K(ZJ(O+%[YG(_#;NQGMNKR
MNBM)8>E))-;$JK-;,[+PY\1;O1O&=]XCU&U_M&YO86B=1+Y0&60C!VG@! ,5
M@2ZU*?%3Z[;QK%-]M-Y'&QW!6W[P">,\_2LRBK5."=TO(ESDU8] \4?%%?$4
M-M)#H-O9:C;SQS)?>8)'!0DJ/N XR3P2:U)?C89F@N7\,69U&)=HNVER5'\0
M7*Y7//<_C7E=%9?5J5DK;>I?MIWO<[G4OB1_:'Q#T_Q1_97E_8XA']F^T9WX
MW\[MO'W_ $[54F\=>=\31XN_L[&'5OLGG^D0C^_M]L]*Y&BK5&FMETM\B?:2
M?7S.[M?B5]F^)%YXL_LG=]JA$7V7[3C;A$7._;S]S/3O5?P_\1;CP_XRU76X
M;%98M3EDDEM6EQMW.6&&QU&2,X[GBN,HI>PIVM;I;Y![2>]SU3PX-3\9_$*P
M\2^'-%M=*LK&18KD),FT#DN<  DLK$<+U[U2^-.OKJ?BZ/3H'#0Z;'L;'_/5
MN6_(!1]0:X6QUG4]+CD33-1N[-)/OK;SM&'^N",U39F=BSDLS')).2341H6J
M*?1*R*=2\.7N)111749!1110 4444 %?5O@S_D0] _[!EM_Z*6OE*OJWP9_R
M(>@?]@RV_P#12UY>8_#$[,+NS:HHHKQCO(+RV^U6S1AMCY#(X_@8<@_G265R
M;JV#.NR524E3^ZPZC_#VQ5BJ%Q_H5\MV.(9L1S^QZ*_]#]1Z4 7Z*** ,]XY
M-,8R6J&2U)R\"C)C]T]O]G\O2KL4L<\2RPN'1AE6!X-/JC-;RVLC7%@N[<<R
MV^<!_=?1OT/?UH O45%;7,=U")86RO0@C!4]P1V-2T 5[Z^@TVRDNKM]D48Y
M.,DGL .Y)KCKCQQJ$DI-E;6\,783@NWXX8 ?K5GQY*V[3H,_NV\R0CU*[0/_
M $(UR=?$9YF^(HXAX>@^5*UWWOJ>_E^"I5*?M*BO<W?^$TUG^[8?]^'_ /BZ
M/^$TUG^[8?\ ?A__ (NO+=7\8>(]'EA$_A*,QW%VEK XU1?G=SA>-G&?TJ;4
M?%VM:/H,E_JOAI()OM$4$,"Z@K^:7.,[@GRX..W>O-6*S9VM4WV]Z/\ F=7L
M<$KWCMY2/3/^$TUG^[8?]^'_ /BZ/^$TUG^[8?\ ?A__ (NO-_[=\8_]"7#_
M .#A/_B*OZWXD&F7]OIEC92ZEJERADCM8F"!4!P7=CPJYXSSD]JS>.S3F455
MO?LXO;O9Z?,KZM@[7Y/P9W/_  FFL_W;#_OP_P#\71_PFFL_W;#_ +\/_P#%
MUY_9>*+E=;@TKQ!I1TNYNE8VKK<":*8J,E0P PP'."*M>'?$']O_ -J_Z-]G
M_L_49K'_ %F[S/+Q\_08SGIS]:4\PS2"<G4=EYI[Z=-_D..%P<G91_,[;_A-
M-9_NV'_?A_\ XNC_ (336?[MA_WX?_XNN,M=;^T^*+_1_L^W['!%-YV_._?N
MXVXXQM]>]2:[KEIX?TPWM[YC NL<442[GFD;A44=R:C^TLSYU#VCN[6VZ[%?
M5,)RN7*K+U.O_P"$TUG^[8?]^'_^+H_X336?[MA_WX?_ .+KS:?Q7K.G6WV[
M6/"\MMIZ\RRPW:320K_>:, <#J<$XJ;7_%LNFR:-'HNGIJSZN6\C%T(5("AL
MY*D'(/M6RQF:N2BJE[WZQMHKO79:>9G]7P23;C^#_(]#_P"$TUG^[8?]^'_^
M+H_X336?[MA_WX?_ .+KS5?&&IV.H6<'B;PZVF07LZV\5S'>).HD;[JL  1G
M'6I+GQ9J,^J7=GX;\/R:JMC)Y-Q.]TENBR8!*+D$L1D9X%'US-K_ ,3SO>-N
MV^WXA]7P5OA_!W^[<]&_X336?[MA_P!^'_\ BZ/^$TUG^[8?]^'_ /BZXKP]
MX@37H+@/:RV5W9S&&YM9B"T;X!ZC@@@Y!%;%<]3-<QIR<95'?Y&L<%A9*ZC^
M9N_\)IK/]VP_[\/_ /%T?\)IK/\ =L/^_#__ !=>8GQ?KEUK6IV.B^&4OH].
MG\EYFU%8MQQG[I3W]:T_#_B?^V+N[T^]L)M,U.S"F:TF8-\K=&5APR^XK>>-
MS6$>9U.SWBVD^Z6JW,XX?!R=E'\SN_\ A--9_NV'_?A__BZ/^$TUG^[8?]^'
M_P#BZPJPI/$-P=9U;3++3?M-QI]K'/$OGA//9]V$Y&%^[UR>M8PS3,JE^6H]
M/3O;]326#PL=X_F=U_PFFL_W;#_OP_\ \71_PFFL_P!VP_[\/_\ %US\+.\*
M-+'Y;LH+)NSM..1GO3ZS_MC'K_EZ_P "OJ.&_D-W_A--9_NV'_?A_P#XNC_A
M--9_NV'_ 'X?_P"+K"HH_MC'_P#/UA]0PW\AN_\ "::S_=L/^_#_ /Q='_":
M:S_=L/\ OP__ ,76%11_;&/_ .?K#ZAAOY#=_P"$TUG^[8?]^'_^+H_X336?
M[MA_WX?_ .+K"HH_MC'_ //UA]0PW\AN_P#"::S_ ';#_OP__P 71_PFFL_W
M;#_OP_\ \77"1>(I[ZQUB32-,:[N=-O&M%MVF6/SV4(2=QX4?,>OI[UO5I/-
M,RI_%4?X?UU)C@\++:/YF[_PFFL_W;#_ +\/_P#%T?\ "::S_=L/^_#_ /Q=
M85%9_P!L8_\ Y^LKZAAOY#=_X336?[MA_P!^'_\ BZ/^$TUG^[8?]^'_ /BZ
MPJ*/[8Q__/UA]0PW\AN_\)IK/]VP_P"_#_\ Q='_  FFL_W;#_OP_P#\76%1
M1_;&/_Y^L/J&&_D-W_A--9_NV'_?A_\ XNC_ (336?[MA_WX?_XNL*BC^V,?
M_P _6'U##?R&[_PFFL_W;#_OP_\ \71_PFFL_P!VP_[\/_\ %UA5E>)-<7P]
MH<NH&W:Y972..%&"EW=@H&3TY/6KAFN8U)*$:CN_0F6"PL4Y..B]3LO^$TUG
M^[8?]^'_ /BZ/^$TUG^[8?\ ?A__ (NN8TZ:\N+".34K1+.Y;.^!)O-"\\?-
M@9XP>E6JF6;YA%V=5_@-8'#-7Y/S-W_A--9_NV'_ 'X?_P"+H_X336?[MA_W
MX?\ ^+K"K,\.ZU'XBT"VU6")H8[D,RHYR0 Q'./I36;9BXN?M'9:=.M_\F+Z
MEA;\O+J=A_PFFL_W;#_OP_\ \71_PFFL_P!VP_[\/_\ %UA57OIKBWT^>6RM
M?M=PB%HK?S!'YC=EW'@9]:2S?,&[>U?X#>!PR5^3\SI?^$TUG^[8?]^'_P#B
MZ/\ A--9_NV'_?A__BZY^%G>%&EC\MV4%DW9VG'(SWI]+^V,>O\ EZ_P']1P
MW\AN_P#"::S_ ';#_OP__P 71_PFFL_W;#_OP_\ \76%11_;&/\ ^?K#ZAAO
MY#=_X336?[MA_P!^'_\ BZ/^$TUG^[8?]^'_ /BZPJ*/[8Q__/UA]0PW\AN_
M\)IK/]VP_P"_#_\ Q='_  FFL_W;#_OP_P#\76%62=;QXQ30OL_WK!KSS]_3
M$@3;MQ[YSG\*N.:YC._+4>FO0F6"PL=X_F=G_P )IK/]VP_[\/\ _%T?\)IK
M/]VP_P"_#_\ Q=85%1_;&/\ ^?K*^H8;^0W?^$TUG^[8?]^'_P#BZ/\ A--9
M_NV'_?A__BZXSPQK?_"1^&K/5OL_V;[4I;RM^_;AB.N!GIZ5IR.(HGD;.%4L
M<>U7/-<QIS<)5'=.W0F."PLHJ2CH_4Z#_A--9_NV'_?A_P#XNC_A--9_NV'_
M 'X?_P"+KSN?QFB>"K37X+"25KUHTM[7S I9G;:H+=!]:WK"6ZFL8Y-0MDM;
ME@=\*2^:$YX^; SQCM5SS',Z<>:51K5KINM_^'V)CA,))V4?/J=-_P )IK/]
MVP_[\/\ _%T?\)IK/]VP_P"_#_\ Q=85%8_VQC_^?K-/J&&_D-W_ (336?[M
MA_WX?_XNC_A--9_NV'_?A_\ XNL*BC^V,?\ \_6'U##?R&[_ ,)IK/\ =L/^
M_#__ !='_"::S_=L/^_#_P#Q=85%']L8_P#Y^L/J&&_D-W_A--9_NV'_ 'X?
M_P"+H_X336?[MA_WX?\ ^+K"HH_MC'_\_6'U##?R&[_PFFL_W;#_ +\/_P#%
MT?\ "::S_=L/^_#_ /Q=859.N:W_ &*^EK]G\[^T+^.S^_M\O<&.[H<XV]..
MO6KAFN8U)<L:CO\ (F6"PL5=Q_,[/_A--9_NV'_?A_\ XNC_ (336?[MA_WX
M?_XNL*N>7Q'=Q7V@V6I:5]DNM6,PDC^TA_LYC0OU PV0/;&:<,TS*I?EJ/3T
MZ)O\D_Z:%+!X6.\?S]#OO^$TUG^[8?\ ?A__ (NC_A--9_NV'_?A_P#XNN%O
M/$4^EZ8MUJFF- \E\MI%$LRON#/M60D= 1SCJ.E:45Q=OJEQ!+9>7:1HC177
MF@^:QSN79U&,#D]<TY9GF45S.J[>JZ6V[[] 6$PC=E#\SJ/^$TUG^[8?]^'_
M /BZ/^$TUG^[8?\ ?A__ (NL*BLO[8Q__/UE_4,-_(;O_"::S_=L/^_#_P#Q
M='_"::S_ ';#_OP__P 76%69IVM1ZEJNJ64<3(=.E2)W8_?+(&X'IS51S;,9
M)M5'IOMZ$O!85-)QW.P_X336?[MA_P!^'_\ BZ/^$TUG^[8?]^'_ /BZPJ*G
M^V,?_P _65]0PW\AN_\ "::S_=L/^_#_ /Q='_"::S_=L/\ OP__ ,76%11_
M;&/_ .?K#ZAAOY#=_P"$TUG^[8?]^'_^+H_X336?[MA_WX?_ .+K"HH_MC'_
M //UA]0PW\AN_P#"::S_ ';#_OP__P 71_PFFL_W;#_OP_\ \76%11_;&/\
M^?K#ZAAOY#=_X336?[MA_P!^'_\ BZ/^$TUG^[8?]^'_ /BZPJS+_6H[#6])
MTQHF>34WE57!P$"1ER3Z] *J&;9C-VC4?5].BN_P)E@L+%7<3L/^$TUG^[8?
M]^'_ /BZ/^$TUG^[8?\ ?A__ (NL*BI_MC'_ //UE?4,-_(;O_"::S_=L/\
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M_AGFM%%%>^>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MII(U<J) -GRG';.#COBNCT/P]::#'/\ 9GGGGN9/,N+FYDWRS-C +'CH.@
M%2W&C6]QKUGJ[O*+BTBDBC4$;"'QG(QG/RCO7&\7%8F5:.FC5_/EM?=O?K>_
M4W5%^R4'W_6YQ&C>$=(O/%'B;2+J&273+*6$VMFTS^7"9(@SLHSUSC'IVZU0
MT?4+75?A_P"%H-934M4NIO.\NPM9!_I(C9DS*21\JC'4CGUKT:RT:WL=8U+4
MH7E,VI-&TRL1M78FP;>,C@<Y)K$A^'NF6VD:98V=YJ%M)I9D^S7D,JK,HD8L
MRD[=I!STQ74L=3G_ !)/[-O50:?WRM>VKWW,7AY1^%+K_P"E)K\-CE;&*33=
M8\1Z=#I;:-:R:"]Q]@^TB50^67?\I(4D<8![9[TRX\/V6D_"O2_$-J)%UB&&
MRF2\\UBX#-&-G7[@5L;>G%=G;^!M.MKN[NA=7TMQ>V;VES+-,':56_B)(X8=
M!C  [5;NO"]E>>$8?#LLLXM(8H8E=67S"(BI7)QC/R#/'KTJI9A3YXN+=KQY
MM]4E9[MM_-ZB6%ERM-=';]#-T(_\7*\6?]<K'_T!ZXO4M/L[_P 'ZS-<P1S-
M'XIE$;GG >X0-CZCBO0M3\)6NHZP=3AOM0TZZ>,13/93^7YR#H&!!Z9/(P?>
MH(? NE6^@S:1#)=+:RWHO?\ 6 LKAPP4$C[N5 YR<=ZSHXRC3DJBD[^YT_E5
MG]Y4Z$Y)QMI[WXZHQ-9T_0WUU=)MM#OM;DLK55&G12*EK:J22"=S*-Q_'@=J
MPK6\OK/PKJ>E1-+IL3:_%8!4N#(;.*39N57]N1[9-=]J/A*VOM9?5(+_ %#3
MKJ6-8YVLI@@F5>FX$'D=,C!J.U\"Z+:Z7J.G!)I;/49!++%+)NVN !N#?>SE
M0V22<\U=/'48TTIMOX7K=ZIZ];=[::]6*6'J.3:TW_X'G_6A2/@?0=/U2V%H
M\=E;W,;P7.GLY*WXQD9!;[RXSD9/6N1T:QM;3X;>$+BWA2.2YURT>=QU<B5@
M"?P%=_IOA&UL-3BO[B_U#4[FW0I;O?3A_(!&#M  Y(X).3[U7A\!Z9#X=DT0
MW-])9&020*\PW6I!W#RV !&#SSFIACHQ7+.HY:Q?W<U_7=;]K=$$L.V[QBEH
M_P!/\GM_F1:Z1_PLSPF,C(BOB1_P!*X[2O#^GK\'M2UEH-]^]M>A9F8DHN^1
M=HYP!P3]2:[JR\%VEIK=IJ\VH:E>WUJKHLMU.'W*PQ@@*  .<8QR3G-3P>%+
M&W\'R^'$EN#9RI*C.67S )&9CSC'5CCBICC*=*G"$)/1QOTNDYM_^E(;H2G*
M4I+>_P"44OR9RBZ+::Y\0[*#4E:6U3PW"[0;RJR'S6 W8/(&3P>,X]*HW#S:
M/I?B+1=,N9K6T&L6UK"5<DVT<P3>$)Z#DX],UZ!;>'[6TUM-4CDF,Z6*6 5F
M&WRU8L#C&=V3ZX]JS-;\/6L&DZY,FG3:N=3=)+BS\T*3M"KF,XX( W 9Y(ZB
MKIXV$JBBW>/NV72ZDN^FUQ2P\E%M;Z_=8Q=8\+Z5X?U_PN^CQM:B34E22%9&
M*RD1OAR"3EAR,]?F[]NP\0W5K9>';ZXO[J:TMTA;S)X#B1 1C*\'YN>/>N%L
M-&DU/Q3HL]O'XBECTZ4RRW6M@H(UVD"- 0-Q)QDX/ ZUZ#JFFVNL:7<:??Q^
M9;W"%)%SCCV/KWK#%R2G2563E;=]?B??R[_D:45>,^16OMVV/+;^SCTQM&U'
M2?#-YH[?VA;Q_P!H7-VHFF5F *N@9BVX==V*VM&\+:9K_B+Q5)K$+72+J)2.
M)I&"QGRURP /WN1SU&.*UW^']C<1P"^U75KUK61)+9[BY#>258$8&W!Z8)()
MP3S6YINC6^EW6H3V[RLVH7'VB4.00K;0N%P!QA1US6];,(^S:IR?-:U]>Z>[
M;??MZ&<,,^;WEI\NS['G.E2S:YHO@S1=4N9I;.\DO1<YD(:<0,PC1F!!(QU]
M=M;6EZ/9Z)\7A;::&BMVT-W6WWEEB_?H#MST!QTZ9S6RO@G3%\.VND"2Z"6<
MS3V]RLH6:*1F9MP8 #^,CIC'7-.TCP;9Z1K[ZR+[4+R^DMS;R27<P?<I8-T
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MQ\IP>5RV<=.*RM1NKCPMI?C33]">2""UN;1+51)_Q[B=4W[2?N]3CL"<UC#
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 36/_(6L/\
MK\@_]&+7JU>4V/\ R%K#_K\@_P#1BUZM7WO"W\"IZ_H?-YO_ !8^@4A 92K
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M%?.SFYR<I=3U8Q459!1114%!1110 4444 4)?]!U 3CB"Y(27T5^BM^/W?\
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MMG>.TD]E;W.V%W;JV,$CGG ./:N@TVPBTO2K33[=G:*T@2!&<@L550H)QCG
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M]G9I>_(_P[W_ #']:P=K<R_K0\]LO!%E:WUI<W.H:EJ(LCNM8;VX#I"V,!@
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M_P#Q%9_V/C_^?3+^OX;^<PJ*W?\ A"]9_O6'_?\ ?_XBC_A"]9_O6'_?]_\
MXBC^Q\?_ ,^F'U_#?SF%16[_ ,(7K/\ >L/^_P"__P 11_PA>L_WK#_O^_\
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M_O6'_?\ ?_XBC_A"]9_O6'_?]_\ XBC^Q\?_ ,^F'U_#?SF%16[_ ,(7K/\
M>L/^_P"__P 11_PA>L_WK#_O^_\ \11_8^/_ .?3#Z_AOYS"HK=_X0O6?[UA
M_P!_W_\ B*/^$+UG^]8?]_W_ /B*/['Q_P#SZ8?7\-_.85%;O_"%ZS_>L/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %:^MVG@#0D+/$V^)C_>';Z$9!]C3[6Y6[MDF3C=U
M4]5(X(/N#D5-5!O]!U(-T@NVP?\ 8E['_@0X^H'K0!-J&H6^EV;7-V^V->
M,EB>@ [FN6?Q[)N/E:4"O8O<[3^04_SH\>NWG:;'GY2)7(]QL _]"-<K7Q6<
MYSBL/B70H.R5NB=[J_4][ X&E5I>TJ:W.I_X3VX_Z!,?_@6?_C='_">W'_0)
MC_\  L__ !NN6HKQ?[?S'_GY^"_R._\ LW"_R_BSJ?\ A/;C_H$Q_P#@6?\
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M )^?@O\ (/[-PO\ +^+.I_X3VX_Z!,?_ (%G_P"-T?\ ">W'_0)C_P# L_\
MQNN6HH_M_,?^?GX+_(/[-PO\OXLZG_A/;C_H$Q_^!9_^-T?\)[<?] F/_P "
MS_\ &ZY:BC^W\Q_Y^?@O\@_LW"_R_BSJ?^$]N/\ H$Q_^!9_^-T?\)[<?] F
M/_P+/_QNN6HH_M_,?^?GX+_(/[-PO\OXLZG_ (3VX_Z!,?\ X%G_ .-T?\)[
M<?\ 0)C_ / L_P#QNN6HH_M_,?\ GY^"_P @_LW"_P OXLZG_A/;C_H$Q_\
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M!9_^-T?\)[<?] F/_P "S_\ &ZY:BC^W\Q_Y^?@O\@_LW"_R_BSJ?^$]N/\
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MGMQ_T"8__ L__&ZY:BC^W\Q_Y^?@O\@_LW"_R_BSJ?\ A/;C_H$Q_P#@6?\
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M )^?@O\ (/[-PO\ +^+.I_X3VX_Z!,?_ (%G_P"-T?\ ">W'_0)C_P# L_\
MQNN6HH_M_,?^?GX+_(/[-PO\OXLZG_A/;C_H$Q_^!9_^-T?\)[<?] F/_P "
MS_\ &ZY:BC^W\Q_Y^?@O\@_LW"_R_BSJ?^$]N/\ H$Q_^!9_^-T?\)[<?] F
M/_P+/_QNN6HH_M_,?^?GX+_(/[-PO\OXLZG_ (3VX_Z!,?\ X%G_ .-T?\)[
M<?\ 0)C_ / L_P#QNN6HH_M_,?\ GY^"_P @_LW"_P OXLZG_A/;C_H$Q_\
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MXQ]HA6=),#&3F/##V(Y__56!73^/(T74-.D"@.\4H9NY *8_F?SKF*_,,_\
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M./$)L9TG6#PR\3M&P9=P=R1D>FX?C6D\!%5G;;5Z;)J;C;;:UMR8XEN'W?\
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MY'K$NLV$.HRV,URJ7$-M]JD# A4BR1N+8VCD'C.>*HZ;XRT#5[U+2PU!9)Y
M3&KQNGF@==A8 -^&:\_U&2X\2^!?$WB2V1PM]-!&@5=Q%M"5WX'<9,A(SSBK
M^H-)?77A^.;Q9::COOHI;2'3]-4/\O).1+\J8R"<<9Z5UK+J2C:<G?5/?1J*
M;VB^KMNMM^V'UJ;>BT_--V[_ .>Y=F\3:NECJ4BW>'A\3I81GRD^6 F/*=/]
MH\]>>M=[)(L43R/D*BEC@$\#V%>67'_(+U?_ +'./_T**NU3_A,?^$A^?^P_
M[&\T]/.^T>7V_P!G=^E9XNA#E3C9;^5](E4:DKN]W_P[.3LO%]SJXUR]?Q/+
MI=O:W1B@0:472.(2HJL2R9+-G:5SD;LX&*[&_P#&6@Z9?SV5[?;+J#87A6&1
MW^8$C 526X&3C..^*X6__P"2<>+O^QCD_P#2N.NHT.)&^*/BJ8J#(D%DJMCD
M HQ(_P#'1^5;XBA0<93::4;Z*RV]FM^7^\][_G>*52HFHWU=N_\ >\_(VAXE
MT8Z$-9&H0_V>>D^>,YQC'7.>,=:BTKQ9HNM7CVFGWA>Y1-YAEA>)BOJ Z@D>
MXKAH=4&DZ/?)';63-/XKN((9;Y,P6K;R1(?0C''3KUJS%<SR_%;08KO7;;5I
MXX+DN+6W6-( 4&%R&8DG'0GC XYK)Y?32GOHI->B5^WRW7D5]9E>/RO\_G^C
M.D_X6'X6*HPU9=C$@OY,FU#N*_.=N$Y!^]C/7I6EJWB+2M#CA?4[Q8O/.(45
M6D>3_=502?P%<5H5O$OP'U,B-<R6M^[\=6#2@'Z_*/RJ31[B"R\::-<:M(D4
M=QX<ACLY9F 7>"#(H)_BP0?I1/!4.:?+?W7)6NKNW;33SWT''$5+1O;5+Y7^
M9U\/B71KC0WUB+4(?L$>=\S$J$(Z@@\@\C@C/--TGQ3HVN7#P:9>B29%WF)X
MWC<K_>"N 2/<<5P?BN?3;R,W6@-]FMH->@?4;_R_-@9]F!)MW895)4-TYYYZ
MU:N([J]\8Z4A\30:I?Q07$D*V-BJ!$:/;^\<2G:I)&.#R*/J%%T^9MIN[UZ6
M5[.R:_%:6=N@OK,^:UD]OGZ:_HS8\2>/-*MM'U:+2M50:E;02")A&2@E52=H
M8C86&/NY/TKJ-.E>?2[6:4[GDA1F.,9)4$UYG)JFB0_ B2QFFMXYX[0V[VKD
M"07(/(V]=V_YOUKTG2?^0+8_]>\?_H(K'&4(4:5HQ:M)J[ZV2\EIY:^II0J2
MG.[?1/3YF7>^.?#FGW4MO=:B \+;)2D,DB1MZ,RJ54_4U/J'BS0]+D@2^U".
M,W$/GPX5F\U,@94J#DG(P!R>U<.^O3ZAX:U6[35-*T&R\R>,Z?%:J]Q(V2"&
MRP&]CV"GK4OA2))==\&M(H8Q>'F9"1]TY09_(FNAY?2A!RE?2]U?JE?^6WW<
MQDL3-RLK:V_.W?\ R.YTWQ'I.K6,]Y8WJ/!;DB=G!C,1 R=P8 KQZBN;U;QY
M8W3:5'X<U,-+/JEM#*IA(\R%GVMMWKR.@W+T]:P_$]O++<?$)+6-F/D:?)(L
M?!9!DR?^.*:T?&&L:'?CPE'I]U:SR/K-H]NL3 LL>[!.!T'0?7'I3I8.E&<9
M6;3]-/=4M=-=_+:X3KS<6KI6_'5K37R\]SK_ !)=SV'A35KRT?RY[>RFEB?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD>U6OM5O_P ]X_\ OL4?:K?_ )[Q_P#?8IJ51.Z;"T'V)$18T5(U"JHPJJ,
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MP])\NYC_ ++LMEVVZX7[.F)CZN,?,>3UJS]JM_\ GO'_ -]BC[5;_P#/>/\
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M:0VT,=L%VB%(P$QZ;>F*BL=)T[2]_P#9FGVMGYAR_P!GA6/=]< 9J;[5;_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>sangamo-2022cdagraphicceo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sangamo-2022cdagraphicceo2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@?K< TS_ (>2?#3_ * /BS_P$M?_ ))K\WJ*^G_L+!]G]YXW]I5_+[C](?\
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M\WJ*/["P?9_>']I5_+[C](?^'DGPT_Z /BS_ ,!+7_Y)H_X>2?#3_H ^+/\
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MXL_\!+7_ .2:/^'DGPT_Z /BS_P$M?\ Y)K\WJ*/["P?9_>']I5_+[C](?\
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M\WJ*/["P?9_>']I5_+[C](?^'DGPT_Z /BS_ ,!+7_Y)H_X>2?#3_H ^+/\
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M%%?0GEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !72_#OX;^(OBIXF@T#PQILFI:C(I<JI"I%
M&,9=V/"J,CDGJ0!DD \U7VQ^R'))X/\ V5OBWXMT<>7XBC^T1QW"*"\8BME:
M,CZ-([?AWKAQF(EAZ//!7;:2]6=.'I*K/EEMO]QPVK?\$[OBGINE2W<%QX?U
M.9%W"QM+V03/[ R1*F?JPKS'X1_LY^*_C%XPUKPSISV.CZMH\;27<.LM+#L*
MR"-DPD;G<&/0@=*Y7PI\3O%?@CQ1)XBT37KVRUN0.);SS/,>7<"&W[\A\YS\
MP/(!Z@&OJ;_@GIKNH^*/C)XWU75[V;4-1N]*\R>ZN'+N[&:/DD_Y &*XL14Q
M>%H5*DY)V6FEM;]NQT4XT*U2,8IJ^^I@?\.V_B9_T'/"?_@7<_\ R/7A>L_!
M?Q1IGQ5N_AY:6BZWXDMY_L_E::6=';:&)#,%PH!R68 #!)XKWBX_8_\ AI)<
M2LW[1GA1"SDE2MMQST_X_*ZK]A'PSIWA?QI\7+VRNK?7;C08!:6%_$!MN8]\
MQ+IAFX?R8SP3P>M<ZQTZ=*=7VG/9;<CCJW9:LU^KQG.,.7EO_>3.%7_@G3\4
MCIGVHWGAP3[-_P!B-[+YN<?=SY6S/_ L>]?.OB_P=K7@'Q!=Z'X@TZ;2M5M6
MVRVTX&1GD$$<,".0P)!'0UH3?%#Q7/XZ_P"$Q?7KT^)?/^T#4/-/F!LY ';;
MVV?=QQC'%?4?_!1"U@U"V^&7B22%(=5U'3Y4N=HP=H$+J#WP&E?'U-=<*N)H
MUZ=*O)24[[*UFE?YHPE"E4IRG337+;YW/C2BBBO8. **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /N?\ X)AL?^+E#/'_ !+#C_P+K[IKX6_X)A_>^)?TTS_V[K[IK\QS
MG_?JGR_)'V& _P!VC\_S84445XIZ 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?*'_!23_DAV@_]C'!_Z2W5?F]7Z0_\%)/^2':#_P!C'!_Z2W5?F]7Z/D7^
MYKU9\GF7\?Y(****^A/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O>OV6_VB[+X-W&M:#XF
MT]]7\$Z_'Y5];Q*&>)BI0N%) 92I*LO4C!!XP?!:*PK488BFZ=1:,TIU)4I*
M<=S[%TS_ (9(\"ZI-XDMM3UGQ7+&K/#X>N[262 $C[H$D**V,\>9(1WY/-8?
M[*OQS\ ^ ?C+XU\0ZNL7@KP]J=HT5A8PQ7%TL7[U"$RBNV=H)).!G.,# KY6
MHKA>7PE"4)SE+F5M7^6EOP.GZU)2C*,4K>1]82_#_P#9)FE>1OBAXK!9BQQ:
MR=_^W"N7^&WQL\,_LU?';5;OP7<WWBGX?7426LC7 V7,T>U6+@,D?SH^X %5
M!&1GG=7SO16BP*<90J3E--6LVOT2)^L.ZE"*BUV_X<^S)&_9&G\4?\)>VJZN
MCE_M1\,"TG^RF3KLV^3Z_P /F[.WW>*\5_:>_: E_: \<0:A!9R:;H>GPFVT
M^TF(,@4G+2/C@,QQP"0 H&3C)\=HHHX&%*:J.3DUHKN]O053$2G'D223WMU"
MBBBO1.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /N?_ ()A_>^)?TTS_P!NZ^Z:^%O^
M"8?WOB7]-,_]NZ^Z:_,<Y_WZI\OR1]A@/]VC\_S84445XIZ 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 >@?!7XU:Q\"?%%QK^A:=I=_J$UJUH#JD4DBQHS*Q*A)$P3M
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MG[?'Q0\8^'+C1U.DZ$MPGERWFDV\D=P5(P0&>1PN?50#Z$5YY\#_ -H+Q3\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KP;XY?L<^"OC5?2:NWG>'O$4@^?4+!
M5*S'L98SPY]P58]R<"O>:*WHUJF'ESTI69G4IPJQY9JZ/A;_ (=AG_HI8_\
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M ((?_NFONFBC^V,=_P _/P7^0?4,-_+^+_S/A;_AV&?^BEC_ ,$/_P!TT?\
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MMC'?\_/P7^0?4,-_+^+_ ,SX6_X=AG_HI8_\$/\ ]TT?\.PS_P!%+'_@A_\
MNFONFBC^V,=_S\_!?Y!]0PW\OXO_ #/A;_AV&?\ HI8_\$/_ -TT?\.PS_T4
ML?\ @A_^Z:^Z:*/[8QW_ #\_!?Y!]0PW\OXO_,^%O^'89_Z*6/\ P0__ '31
M_P .PS_T4L?^"'_[IK[IHH_MC'?\_/P7^0?4,-_+^+_S/A;_ (=AG_HI8_\
M!#_]TT?\.PS_ -%+'_@A_P#NFONFBC^V,=_S\_!?Y!]0PW\OXO\ S/A;_AV&
M?^BEC_P0_P#W31_P[#/_ $4L?^"'_P"Z:^Z:*/[8QW_/S\%_D'U##?R_B_\
M,^%O^'89_P"BEC_P0_\ W31_P[#/_12Q_P""'_[IK[IHH_MC'?\ /S\%_D'U
M##?R_B_\SX6_X=AG_HI8_P#!#_\ =-'_  [#/_12Q_X(?_NFONFBC^V,=_S\
M_!?Y!]0PW\OXO_,^%O\ AV&?^BEC_P $/_W31_P[#/\ T4L?^"'_ .Z:^Z:*
M/[8QW_/S\%_D'U##?R_B_P#,^%O^'89_Z*6/_!#_ /=-'_#L,_\ 12Q_X(?_
M +IK[IHH_MC'?\_/P7^0?4,-_+^+_P SX6_X=AG_ **6/_!#_P#=-'_#L,_]
M%+'_ ((?_NFONFBC^V,=_P _/P7^0?4,-_+^+_S/A;_AV&?^BEC_ ,$/_P!T
MT?\ #L,_]%+'_@A_^Z:^Z:*/[8QW_/S\%_D'U##?R_B_\SX6_P"'89_Z*6/_
M  0__=-'_#L,_P#12Q_X(?\ [IK[IHH_MC'?\_/P7^0?4,-_+^+_ ,SX6_X=
MAG_HI8_\$/\ ]TT?\.PS_P!%+'_@A_\ NFONFBC^V,=_S\_!?Y!]0PW\OXO_
M #/A;_AV&?\ HI8_\$/_ -TT?\.PS_T4L?\ @A_^Z:^Z:*/[8QW_ #\_!?Y!
M]0PW\OXO_,^%O^'89_Z*6/\ P0__ '31_P .PS_T4L?^"'_[IK[IHH_MC'?\
M_/P7^0?4,-_+^+_S/A;_ (=AG_HI8_\ !#_]TT?\.PS_ -%+'_@A_P#NFONF
MBC^V,=_S\_!?Y!]0PW\OXO\ S/A;_AV&?^BEC_P0_P#W37J'P=_8-\$_#75+
M?5M9NYO&&JVYW1?:X5BM4;/#>2"V2/\ :9AWQG%?3-%95,TQE6+A*IH_1?DB
MXX/#P?,HA1117E':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^>O[=
M?A?_ (3C]J[P!X<^T_8O[8TW3]/^T^7YGE>;?7$>_;D;L;LXR,XZBM[_ (=?
M?]5+_P#*#_\ =-'[5W_)]'P=_P"X-_Z<YJ^[*^FK8VOA</05&5KQ[+OYGD4\
M/2K5:CJ*^I\)_P##K[_JI?\ Y0?_ +IH_P"'7W_52_\ R@__ '37W917#_:^
M-_Y^?@O\CH^HX?\ E_%_YGPG_P .OO\ JI?_ )0?_NFC_AU]_P!5+_\ *#_]
MTU]V44?VOC?^?GX+_(/J.'_E_%_YGPG_ ,.OO^JE_P#E!_\ NFC_ (=??]5+
M_P#*#_\ =-?=E%']KXW_ )^?@O\ (/J.'_E_%_YGPG_PZ^_ZJ7_Y0?\ [IH_
MX=??]5+_ /*#_P#=-?=E%']KXW_GY^"_R#ZCA_Y?Q?\ F?"?_#K[_JI?_E!_
M^Z:/^'7W_52__*#_ /=-?=E%']KXW_GY^"_R#ZCA_P"7\7_F?"?_  Z^_P"J
ME_\ E!_^Z:/^'7W_ %4O_P H/_W37W911_:^-_Y^?@O\@^HX?^7\7_F?"?\
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M_P H/_W37W911_:^-_Y^?@O\@^HX?^7\7_F?"?\ PZ^_ZJ7_ .4'_P"Z:/\
MAU]_U4O_ ,H/_P!TU]V44?VOC?\ GY^"_P @^HX?^7\7_F?"?_#K[_JI?_E!
M_P#NFC_AU]_U4O\ \H/_ -TU]V44?VOC?^?GX+_(/J.'_E_%_P"9\)_\.OO^
MJE_^4'_[IH_X=??]5+_\H/\ ]TU]V44?VOC?^?GX+_(/J.'_ )?Q?^9\)_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVW_@V;_Y'H_X:8U#_H4[;_P;-_\ (]>/T4?Z_<1?]!'_ ))#_P"1#_5O+/\
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M\?HH_P!?N(O^@C_R2'_R(?ZMY9_S[_%_YGL'_#3&H?\ 0IVW_@V;_P"1Z/\
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M'O$3DE]8_P#)(?\ R),N&\L46U3_ !?^9]R4445_6Y^,!1110 4444 %%%%
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M3Z/C%_W&?_3G#7W97L9I_'C_ (8_D<&#_AOU84445XYWA1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JGK/_('OO^N$G_H)JY5/6?\ D#WW_7"3_P!!-7#XD1/X
M6?<E%%%?WP?SD%%%% !1110 4444 %%%% 'PG^RC_P GT?&+_N,_^G.&ONRO
MA/\ 91_Y/H^,7_<9_P#3G#7W97L9I_'C_AC^1P8/^&_5A1117CG>%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?4****\<[PHHHH \(^+'_)=/!W_;G_Z5/7N]>$?%C_DNG@[_ +<__2IZ]WH
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M&*@;< @].Y%>2Z3\0O%4.GQ:+8ZI.('Q#%$JJ7&> JL1N'M@\=JM_$CXD?\
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M%[:IMNWEN]3UO2/%ECJ7A'Q]/-<V]I<:A*TL-K+*JR,".  3DGZ5G0ZM8?\
M"CWL&O8%O3>AOLPD4R[=XY"9STKS6BN5\2UY1M.";]G.FWWYY.3?K=F_]E4X
MN\9-+FC+_P !5DOP/>="UV3[)9P7/C#P_KFA.B^?%K"B*Y51U4)D[CCNQ/XU
MY#XUDTF7Q1?MH:[-,+CR@ 0.@R0#R!G.*Q**QS3B"IFF%AAITTN5WNW*3VM9
M.3;4>MKO6VNA6#RV.#JRJQE>_2R2]6E97\[(****^4/9"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "J>L_\ ('OO^N$G_H)JY5/6?^0/??\ 7"3_ -!-
M7#XD1/X6?<E%%%?WP?SD%%%% !1110 4444 %%%% 'PG^RC_ ,GT?&+_ +C/
M_ISAK[LKX3_91_Y/H^,7_<9_].<-?=E>QFG\>/\ AC^1P8/^&_5A1117CG>%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]_UPD_\ 035RJ>L_\@>^_P"N$G_H)JX?$B)_"S[DHHHK^^#^<@HHHH ****
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MO&_QEL]>TKQ->:CXD:V:UL[![>2.WC14.=@:%><;SRQZGVP >Y4444 %%%%
M!1110 5\;>(_^1K\1_\ 87OO_2F2OLFOC;Q'_P C7XC_ .PO??\ I3)7XIXI
M?[CA_P#&_P C[SA'_>JG^']44****_F\_5 HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J>L_\ ('OO^N$G_H)JY5/6
M?^0/??\ 7"3_ -!-7#XD1/X6?<E%%%?WP?SD%%%% !1110 4444 %%%% 'PG
M^RC_ ,GT?&+_ +C/_ISAK[LKX3_91_Y/H^,7_<9_].<-?=E>QFG\>/\ AC^1
MP8/^&_5A1117CG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?1\8O^XS_P"G.&ONROA/]E'_ )/H^,7_ '&?_3G#7W97L9I_'C_AC^1P8/\
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MGD\1GGN#72^!_CZGC/XOZ'X<\(V[)X0%BR3026BQ&!D5R"FT_*HQ&N.G/TH
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M@#;?]_V_PH_XA1QA_P! ?_E2E_\ )A_KID?_ #^_\EE_D?1%%?.__#4FH?\
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MR_R/HBBOG?\ X:DU#_H VW_?]O\ "C_AJ34/^@#;?]_V_P */^(4<8?] ?\
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M%%%>.=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIS.XLKC)M;Y6 S'*/7CANV3TSD ':LP4$DX Y)-8,?A;PUJ&O1:]#ING2ZQ
M3MU"&-/.!*E3EQR>"1SZUX9\2OB)/\2O!Q\-3:3?Z=XHLKZ&75_"ZL5GO;92
M3(MNP_UJGAAMR<#.".3!\*=#M#\6-'OO!7@G7_"&BV\%PFL2:LTJ1SY7]VH#
MNV2&P< ]\XXS0!],T444 %%%% !1110 5^/G[37_ "<#X_\ ^PO/_P"A5^P=
M?CY^TU_R<#X__P"PO/\ ^A5[60_\C1?]>Y_^E4SS<S_W3_MY?E(\RHHHK]./
MD0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "M/PO_R,ND_]?</_ *&*S*T_"_\ R,ND_P#7W#_Z&*\S-/\ <,1_@E_Z
M2SJPO^\4_5?F?M[1117Y4?;!1110 4444 %%%% !1110!\)_LH_\GT?&+_N,
M_P#ISAK[LKX3_91_Y/H^,7_<9_\ 3G#7W97L9I_'C_AC^1P8/^&_5A1117CG
M>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\)_M7?\GT?!W_ +@W_ISFK[LKX3_:N_Y/
MH^#O_<&_].<U?=E>QCOX&'_P_J<&'_B5?4****\<[PKR+]ISP)KOQ"\ V>G>
M'K'^T+V/48YVB\Z./"!) 3EV ZL.^>:]=KS#]HKXB:C\-?AS+J.D.L6IW%Q'
M:03.@<1E@Q+8/!.%.,\9]: /./#?@_XG^*/C9X8\5>,/"]GI]IIL+6[/9W,1
M15V2;6*^<[$[G[>U=7JGA/5-9_:DTK7(M-N;?2=*TLQS:@R%8II"L@"J?XL>
M:.G]T^E<!K?C_P",/P^CL_"FJSV6K:WXC"+I6I0%-]LY<!T8;%!(W#DC SD$
M@8&W\-M:\=_#GXSV/@CQ=KW_  D-MJUFUS#*TC2F-@K'(9@&'^K<8Z<@]: /
MH^BBB@ HHHH **** "OQ\_::_P"3@?'_ /V%Y_\ T*OV#K\?/VFO^3@?'_\
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M/!=K'I-EKKB.33X5*1,'C\V.5$_@^7(*C Y7 '.?6M.^&?P^\(^// 'PAN/
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M\)_M7?\ )]'P=_[@W_ISFK[LKX3_ &KO^3Z/@[_W!O\ TYS5]V5[&._@8?\
MP_J<&'_B5?4****\<[PKCOBQ\.+;XJ>#+K0KBY:S=V66"Y5=WER+T)'<<D$9
M'!KL:* /G&U_95U?5H;J]\3^,[K4O$$-ND.DWD;R?Z&R-N5R2=QYXQQC<QY.
M"-GX9?!/Q=9?$A?&7CS7K76;^TMVM[-;8LV,@KN.44 !2W ');)]_=:* "BB
MB@ HHHH **** "OQ\_::_P"3@?'_ /V%Y_\ T*OV#K\?/VFO^3@?'_\ V%Y_
M_0J]K(?^1HO^O<__ $JF>;F?^Z?]O+\I'F5%%%?IQ\B%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>I?#6\N_@7XNTWQ3XQ^&]SK>F/'(
MEI::U;M;02R8!#JTD3JQ4'/ XR#D5Y;7W/X+_:>^$/Q>^%>D>%_C3:M'?Z4L
M:^>UO<-'.R#:LB/;_.C%?O#@$YZ@X'G8ZI.G!6IN<7H[;V\CKP\8RD[RY6MK
M[%3]L?1#\8_@WX6^,>E:K?+I2QI&VA7FSR[82,$9H]H!W>8H5B=VX;2" N#\
MZ_#6\N_@7XNTWQ3XQ^&]SK>F/'(EI::U;M;02R8!#JTD3JQ4'/ XR#D5ZO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M72-1BU:6QN/%RZ^MP+J1'G5K?[(KE4VE"N\<'RNOS57UJCS*,9)MNVC7^?\
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M#D<C"\]JUCC,/.'M%45KVWZD2P]6,N5Q=SR6BM_POX!\1>-/%"^'-%T>ZO\
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M=E?"?[*/_)]'QB_[C/\ Z<X:^[*]C-/X\?\ #'\C@P?\-^K"BBBO'.\****
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MZ^X?_0Q7F9I_N&(_P2_])9U87_>*?JOS/V]HHHK\J/M@HHHH **** "BBB@
MHHHH ^$_V4?^3Z/C%_W&?_3G#7W97PG^RC_R?1\8O^XS_P"G.&ONRO8S3^/'
M_#'\C@P?\-^K"BBBO'.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T_"_P#R,ND_
M]?</_H8K,K3\+_\ (RZ3_P!?</\ Z&*\S-/]PQ'^"7_I+.K"_P"\4_5?F?M[
M1117Y4?;!1110 4444 %%%% !1110!\)_LH_\GT?&+_N,_\ ISAK[LKX3_91
M_P"3Z/C%_P!QG_TYPU]V5[&:?QX_X8_D<&#_ (;]6%%%%>.=X4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?"?[5W_)]'P=_[@W_ISFK[LKX3_:N_Y/H^#O\
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M?^AVU_\ \)F#_P"3ZV:*/[*I?S2_#_(/]=<T_N_=_P $QO\ A2?@G_H=M?\
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M5(QAS)65E"$7*VOO-:['R.\C2.SNQ=V.2S'))]:;7U/XTU*7XF?!#QUJ>O\
MD37^A:W+!I]RL*HT4:R1@1@@<@AR/?C.2*^6*^SR_'/&PFY0Y7%V:O=;)Z.R
MZ/L?F><96LKJ4U"ISQJ1YDVN5[M:J[ZI]6%%%%>J?/A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !74_"G_DJ/@[_L,V?_ */2N6KJ?A3_
M ,E1\'?]AFS_ /1Z5RXO_=ZG^%_D>AE_^^4?\4?S1^D5%%%?S(?W0%%%% !1
M110 4444 %%%% 'PG^RC_P GT?&+_N,_^G.&ONROA/\ 91_Y/H^,7_<9_P#3
MG#7W97L9I_'C_AC^1P8/^&_5A1117CG>%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'PG^U=_R?1\'?\ N#?^G.:ONROA/]J[_D^CX._]P;_TYS5]V5[&._@8
M?_#^IP8?^)5]0HHHKQSO"BBB@#PCXL?\ET\'?]N?_I4]>[UX1\6/^2Z>#O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'PG^U=_R?1\'?\ N#?^G.:ONROA/]J[_D^CX._]P;_TYS5]V5[&._@8
M?_#^IP8?^)5]0HHHKQSO"BBB@#PCXL?\ET\'?]N?_I4]>[UX1\6/^2Z>#O\
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MG(E27,VDK7BXZ12C9M--WMIN>K^'_@+X-U2[33+[P5/HL,UL3!?:CKN-1E;
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M/_)4?!W_ &&;/_T>E?3XO_=ZG^%_D?#9?_OE'_%'\T?I%1117\R']T!1110
M4444 %%%% !1110!\)_LH_\ )]'QB_[C/_ISAK[LKX3_ &4?^3Z/C%_W&?\
MTYPU]V5[&:?QX_X8_D<&#_AOU84445XYWA1110 4444 %%%% !1110 4444
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MJ7_?F/\ ^.4?\+LT#_GVU+_OS'_\<KQ&BC^U,V_Z#)?^ TO_ )6'_$&>!_\
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M"?YP/T3@K_?*O^']4>44445]0?L(4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK=;73Z6/ENBBBO0/O HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K8\&_\C?H?_7]!_P"C%K'K8\&_\C?H?_7]!_Z,6O/S#_<ZW^&7Y,SJ
M?!+T/W@HHHKQ#^7@HHHH **** "BBB@ HHHH ^$_V4?^3Z/C%_W&?_3G#7W9
M7PG^RC_R?1\8O^XS_P"G.&ONRO8S3^/'_#'\C@P?\-^K"BBBO'.\**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** "BBB@ K8\&_P#(WZ'_ -?T'_HQ:QZV/!O_ "-^A_\
M7]!_Z,6O/S#_ '.M_AE^3,ZGP2]#]X****\0_EX**** "BBB@ HHHH ****
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MB_\ ]$\UW_P%-?M#11];QW\\/_ '_P#)A_KKC/\ GU'\?\S\7O\ AE'XO_\
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M,H_%_P#Z)YKO_@*:_:&BCZWCOYX?^ /_ .3#_77&?\^H_C_F?B]_PRC\7_\
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M***\<[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M::_Z+%_Y<^I__&J/J-#_ *"(_B'UBI_SZ9]V45\)_P##*/[37_18O_+GU/\
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MT$1_$/K%3_GTS[LHKX3_ .&4?VFO^BQ?^7/J?_QJC_AE']IK_HL7_ESZG_\
M&J/J-#_H(C^(?6*G_/IGW917PG_PRC^TU_T6+_RY]3_^-4?\,H_M-?\ 18O_
M "Y]3_\ C5'U&A_T$1_$/K%3_GTS[LHKX3_X91_::_Z+%_Y<^I__ !JC_AE'
M]IK_ *+%_P"7/J?_ ,:H^HT/^@B/XA]8J?\ /IGW917PG_PRC^TU_P!%B_\
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>sgmoproxycardp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmoproxycardp1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$817AI9@  34T *@    @ ! $[  (
M   :   (2H=I  0    !   (9)R=  $    T   0W.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N;F5T=&4@
M36%K82 H0V]N=')A8W1O<BD   60 P "    %   $+*0!  "    %   $,:2
MD0 "     S0V  "2D@ "     S0V  #J'  '   (#   "*8     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=23W_KH-YAB7)2<M?1=K=NQRMCX)^Q1V:?VAO^RI$N?)QNV&W/\ >XS]G_\
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M?0-%?-GAW]JZ1KY(_%7A^-+9CAI]/D.Z/WV-][_OH5T_P[_: F\=_$A?#O\
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M ]017S?XR_98GGU1KGP/JMK#:RL6-IJ+./)]E=58L/8C(]37L'Q5\6ZMX(\
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M3K5I7AM(5A1IGWN0HP,MW/O5N@ HHHH **** "BBB@ KRSQ%_P BOXF^L?\
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MR,9K'?2]1O;>-;V*QC>"6V:/RV+'$<@9SN*@C(& N/QYXB-F]3CI0IR5YO\
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MR2.P.>7=G/.!G[W7 ^E:%2]SSZBBIM1=T%%%%(@**** "BBB@ HHHH ****
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MGAPH''(8'L16QHMQ<7>@V-Q>;?/EMT>38<@DJ#GH/Y4.+1G4P]2E&\U;^O\
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M5#0-**095VVL6#&X<F4D[CN.?GY .#GI5B_T:RU*:.6[C=F0;?EE9 ZYSM8
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M>=:?:,8\O=L;=N[9SY6<_C5UKZZT_P $V;VD@@1Y_+6;<JB*$NVP@N"H&W:
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MC-.3Q#I<DT"K*V94#*YB8*N02 S8PI.T\'!XK 32=2CN;"8V4K#2!LVATS=
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M@W[U8MOXCRV_,4ZE.%TEU_S+Q> P?M(0I2Y>9/N]5)K\;6^1O6?BB'4O$/\
M9+V.,/<KYC.&'[EE7.,=]WX8K?\ L\.<^3'G&/NBN'O? NI3WEW/;WL$1F-T
M4.Y@5\V1''0=@A!^M,M=$U+6DO9K6]$2K=WL #NW!^VJX/';;&P_&LG&+5TS
MAJ8;#32E3J66SW??4ZO[7;+XD32A9H'-H;KS0!QAPN,8]\YK-D\0VJ>'HM5_
MLU")+[['Y>1D?OS#NSCVSC\*S$\%:JLS2F_B+ECAM[Y"F\6?&<?W%*_7VIK^
M!M2943[9!Y:RB39N;&?MC3YQCKM8#Z^U"4.Y4:6#5KU.JOOMK?[]/N.W^SP\
M_N8^>ORCFD%M .D,8_X *Q?#>B7ND22F^NEG#P)&,,QPPFG<GG_9E0?\!^E;
M]9O1Z'E54H3<8RNNY$+: '(AC!]=@I?LT&,>3'C_ '!4E%(RYGW$ "J H  Z
M =J6BB@04444 %%%% !1110 4444 %%17,)N+2:%97A,B,@DC.&3(QD'U%>#
MQ_$?Q%IE]#IVNRW;-X9EE&I-"0&U%B^V"/)&,'.?< FCK8.ESWVBO.F^+20:
M'?75_H5S::AI]]#9W6GR3+E#+]U@X!!'7\J;JWQ<_L_4KNPL_#\]]=0:JNF1
MQI<*IE<J6!&1QTQBC^OR_P T']?U]QZ/17+Z]XQE\.^$;'7-1TB5/.EA2YMO
M-&ZU$G!).,':2!VZUCWOQ5BMVO8K719[RXCU;^R;.&.90;N4#+$$C"@9')SU
MH_K^OO ] HKQV[^)NL:SXH\*/H>C7RQM<74-Y8FY1#),B$-&V>NP$/GH<CN*
MZ.Q^+%G?>*X],&EW":?<7KV%OJ?F*4EG7JNP?, >@;_Z^ #OZ*XOQO\ $&7P
MCJMEI]KH<VK3W<$UP%BG6/8L8RQY'ID_A5/PQ\5%\275Q$/#][:@:<VHV>^5
M&:ZB5MIP,_*=W R?RHW ] HKQ?Q+\6=1U7P'KZZ7I5SI>HV8AWRQ7L;F**1C
M^\#KWR-N!R-V>U:4/C7Q+_PM6R@U'0[JRL?[(,D]LU[&R1+YB[KAL==N-N.O
MIU-']?A</Z_+_,]6HKS"W^-EI);7-Q/H5W;PFSFO-/=YE(O$C)W=,[#QG!_P
MRC?&&^1=.B;P9?"]U(&6VMOM4>980JL'4XY)R0%ZG% 'J%%9.L>)M,\.Z(FJ
M^()CIULQ56\U"Q1F'"G9GGMQQ5?3/%FD^)O#M[J7AJ^%W#;AT,JQLNV0)NQA
M@,]12;LF^P+6QO45Y+\+OB9<WNGZ;I/B:UNDGFLIKN/4YY0XN51V+' Y4 9'
M_ :MV_QLM)+:YN)]"N[>$V<UYI[O,I%XD9.[IG8>,X/^&6] 6IZ?17F3_%Z[
MCL;)G\(7@OKY7GM[/[5'E[=4#F;=T .< =3@_2HM2\>7=GY?CI!<S>&9=-CB
MMK-9%0RW3RD'<#]W: 03TZ8S0&YZE16#I.N7FK^$I=3N=+GTBX$<A$$SK)]T
M'#!EX*GL>_TP3YQX"^+KVOANU@\7VEX'^P3WL>HRRA_M@1VR .H_NC/IVHZM
M?U_6@'LM%>81_&A(U5=4\.7=A,6MY/+EF5LVTQP)@0.Q*Y7WJ[H/Q:LO$6KV
M>GZ?ITAEN=0GL^9A\B1('\TC'0@]/;K3LP/0J*\[\=^(]>TGXB>$[+2-/N+J
MVG,[2117*QK=-L(VG/\ <'S\\'/J*DL_BQ:W?BB*P&CW2Z9<7[:=;ZKO4QR7
M"_P[>H!/0_\ U\):@]#T"BN5\1>.(?#?B*+3;RR<Q3:?/>I<B0 $Q*6:/&.N
MT9SGOTKEK?XW03"*X?P[>+IZ&!;Z\6966T:;E 1C+<8R1C'3TR+4#U.BO(+K
MXE:IX<\?^+&U;2[N?3;7[/%!$MRF(F(81[5_Z:GGU '/05:\2_$2[U+X7>([
MJP@N=#UO29H89X3(KM$6E3!5UX8%2>GO1N.VMCU6BFQDF-2>I S3J"4[JX44
M44#"BBB@ HHHH \\\4R6X\1W DTK1[A@%S)<Z?;2R'Y1U9[I&/XJ/QZUD>;:
M_P#0"\/?^"FS_P#DVM?Q3IGB"X\1W$NG:1K%S;L%VR6WB!;6,_*,XC(XY_/K
M61_8OBO_ * 'B'_PJT_PKL@WRK5?A_F?98:4?8P]^.R^U'MYR/1?#+(WARU,
M<%O N&Q';1)'&OS'HJ.ZC\&/]*U:RO#,-U;^'+6*_@N+>X4-OCN;H7,B_,<9
MD'WN/\*U:Y9_$SY3$?QI^K_,****DP"BBB@"O=V%GJ$:)?VL%TD;B1%FC#A6
M'1@#T/)YID>E:?")Q#86L8N$6.8+"H\U%7:JMQR O !Z#BK=%.[+52:7*GH1
M/;026C6KPQM;LGEF$H"A3&-N.F,<8HM[2WM%9;6WB@#MN81H%W' &3CO@ ?0
M"I:*0N:5K7"JQTZR,$T)L[<Q7#F2:/REVR,>K,,<G@<FK-% E)K9D9@A-RMP
M8D,ZH467:-P4D$KGK@D X]A1]GA^TBY\F/SPGEB7:-VW.=N>N,\XJ2B@.9E/
M^Q],W9_LZTSZ^0O]_P ST_O_ #?[W/6K'V>'[2;GR8_/*>69=HW;<YVYZXSS
MBI**=V4YR>[(;2SMK"U2VL;>*V@3.R*% BKDY. .!R2:ADTC39;IKF73[5YV
MD24RM I8N@PC9QG*@D ]1GBKE%%V"J33;3U94ETK3Y[C[1/86TDV])/,>%2V
M],[&R1G*Y.#VR<5+'9VT-U/<PV\4<]QM\Z54 :7:,+N/4X' STJ:BB[#GDU9
MLKW%A9W<T4MU:P320AA&\D88H&&& )Z9'!]11;:?964DDEG:06[R*BNT42J7
M"#"@D#D <#T%6**+L.>5N6^A5_LRP^V+=_8K;[2CLZS>4N\,RA68-C.2H )[
M@ 5:HHI"<G+=E$Z)I3>;G3+,^<7:3-NOSE\;R>.=VU<^N!GI3X=*T^VNFN;>
MPMHIW9W:6.%58LV-Q) SDX&?7 JW13NRO:U&K<S*L^EV%U<&>YL;::9HQ$9)
M(59B@;<%R1TW ''KS22:5ITQ<S6%K(9"Q<M"IW%EV,3QSE0%/J.*MT478E4F
MMFRL-.L5>U=;.W#6:E+8B)<P*1M(3CY1@ <=JEG@ANK=X+F))H9%VO'(H96'
MH0>"*DHHNQ<TF[W"HX8(;=66WB2)6=G8(H7+,<ECCN2<D]ZDHI"N[6"BBB@0
M4444 %%%% !1110 4444 %%%% !1110 4444 %>7^)OAIJNMZIXKO+>XMHFU
M&6QN-/+.?OVZD$.,< YXQFO397,4+R!&D*J6")C<V.PSQFN7TKXD>'-6N(H4
MO!:M*D>S[4Z1YD?/[D MDR+CYE XR.>:%OH'0XZ[^''B76O#?B"\U26QAU[5
MKNWNH[>)V,,?D<*A8CN"?7MSZ1V'PV\52^((=8U8Z9',^OQ:I/';S.55%0AE
M7*]<GI^M>KV^I6-U-Y5K>V\TFTOLCE5CM#%2< ] P(^HQ6>GC#PU+J L8M?T
MQ[LR^2(%NT+^9_=P#G/!XH7E_6W^2!ZK4;XRT$^)_!NJ:.C*LEU 5C9C@!QR
MI/MN K@(/AEKNE^"?#YL)K2?Q%I&H/J$HED;RKEW)W MC.<!1GCH:]&B\4:#
M/>3VD.M:>]S;EA-"MTA:,J"6R,Y& #GTP?2K,FJZ?%%%)+?VR1S1F6)FF4"1
M NXLISR .21VYHVU'Y'E]K\/?%NER:'JEG)ID^K1:G=WUZLKN(D-P@0XP,MM
M ]N:3PW\*KO0O'9N)=*T:[T]+U[R+4I7D^U("250*,+D'!R1CK7;ZI\0?#6E
MV<EPVKV=P(KB*WE6&YC)C:1@ 6^;@ 98^RGTK8AUG3+C4WTZ#4+62]2,2M;)
M,ID5#T8KG..1S[BFO(3\_P"OZN<MXN\(:CKGC'3=5LGMQ!:Z?>6SB1R&+RQE
M5P #QGK7*I\*=?.C0V1O+2"1/#;:69(Y&/[XW'F>@^4J,$^_2O3I_$>BVM[<
M6ESJ]C#<6T7G3Q27"*T4?]Y@3P/<UE3^/M&6]LH+&>*^CO$+I=0W,0A $J1G
MYV8 D%QP,DXP,GBDET7];_YL?G_73_)'G%A\)O$2>&?$MM)::/83ZI8VT,$%
MG*VS?$P+%LKP6QU&>3737'A?Q=?^*]+U6\32E%QI+Z;J@CD?$2-(6)C!ZMMP
M 3QG/:NO3QAX:DL&OH_$&F-:+*(6G6[0H'/1=V<9]JNZCK&FZ/9K=:K?VUE;
MLP59;B544D] "33>N_\ 7]7%_7]?<>-Z1\'=7LM'U/39=*T%)?L4UO:ZFDLO
MG3N_ +#HHVD@\5O^-? GB#7/"&BZ+966BW/V2SCA>>XDD2:VF"A3)&P'W>.0
M>O'%>AVVM:7>:E-I]IJ-K/>0*'EMXIE9XP<8+*#D=1U]:SM$\;:'KJ2_9[^W
MBGBN6MGMI9T$BN'9%!7/&[:2!W%+?^OZ[A>VO]?UH:6F64EKHEE9W\WVR:""
M..69QGS750"QSZD9J2ZM1)IUQ;VZHAEC91Q@9(Q56\\2Z'I]A'?7VLV%O:3,
M4CGEN45'89R Q.">#P/0U3L/&FB7VJZGIWVZ""YTYR)8Y9D!9 BN90,_<PW7
MV-#]ZZ!:6.&\._"[5["Y\-C4IK7R-/TJZL;KR9&+%I6?!3*\C#CKBL?2/@[J
M]EH^IZ;+I6@I+]BFM[74TEE\Z=WX!8=%&TD'BO5QXO\ #;1VD@U_3=MZVVV/
MVM/WQSC"\\\\<=ZNVFKZ=J%U<VUC?VUS/:-LN(HI59HF]& /!^M#U_K^NX+3
M^OZ['FGB_P"&6HZI:^&;JUL]-U2ZTFP6RN+*^D=89/E W*RX/!R>W:NFO?#5
M_#\,X=!TK2]#DF6)5FL;CS/LK#.7"G[PYY!/0UJV?B_1;JXCM9=2L;>^E>14
MM&O(FD8(S+D!6/\ =)]L$'!!%5Y_'_AN*33!#JMG<QZE=M:130W,91752QR=
MWT''=U]:>^@+3Y&;\/\ PEJGAOP!/I&J31&>9YGBACD9X[97'$88\D Y/XFN
M,7X-ZU<Z5HMC>75G&MGH]S93/'(Q_>.[,A'R\KR,].]>HMXO\.)8&^?7M-%J
M)O(,YNDV>9_<SG&?:FR>+-)7Q1::!%<QSZA<*[F.*16,2JN[+#.1D=.*6[_K
MM_DPV_KS_P SSC_A6GBG6]+U:3Q#-I\%\VDQ:78);NS+B-U<2,V.,E!T'<].
ME7/ OPEN?"OCBVUBXF@D@ATM(ML;DM]J*A9&P1]TC=SUYZ5V.N>/-!T33[RX
M^WVMU+9S1P2V\5U&'21VV@-N8!>Y.>@!]*T;_P 2:-I'V<:QJMEI\EPN8DN;
ME$+^N,GG&>HHOU_K^M0\OZZ?Y&!XVT'7M0\1>&M7\-"R>;2YYO,6\=E7;(@0
MM\O)P,\?2N8TSX;>([3Q!9Z?-/9?\(Y8:RVKQ3!F,\C$Y6,KC P>_OWZ5Z'_
M ,)5H'E64O\ ;5ALU!MMHWVE,3G.,)S\W/''>LR#QW93W-S ("C6LL22,]U
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M1TE%5--NVO;/S)%"R)(\3@=-R,5)'L<9JW4G+*+BW%] HHHH)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\PU#X::D;R_;3%TQ(]4>Y2<L65H4EE202+A3N<!,;>.<<\5Z?10M)<P
M/56.)\)>%=8T;Q)-=:B;,VD<$MO T,S-)('N&F#,I0!>&Q@$\BLN/X<:HBI^
M^L=XN$E+!VY"W[7./N_W#C_>]N:]*HIIVL^W]?J*VC7<\3U_X<>))[Q[R^N_
M-N;FYBM8YX+B29VC>219&*,@6%/*E8;5) (SU-=]X[\'3^)M!LK'2IXK22VF
M W.2!Y#(T<BC /)1CCW KKJ*2T27]?U_F4VW+F/*V^'&NH@6#^S0-/=?L8$K
MK]J7[8MP?,.P[" NT8W<DFMW2?!=W9?$"ZUJ[$<L$DTES#(MY(#$[QJC)Y.W
M:?NGYMV>G'%=O133:_'\=R6DSS+Q%\.M:UB\U2*WDT^.VN);BZAG=W$C/+ (
MO+<!3A1C.X$Y^7CBH-3^&&L7FKM=07-@L9NY)P&D<':T\,@Z)UQ$WXD?AZI1
M26EO+0?_  YY*_PKUA;>U(ELYGMX;>)H$NY(!*%M3!)^\5"0,G(X.1D'%=5X
MC\+7UQIFC)HD5G))IB/"+>]E;84>$Q9WA225SGD<C/3-=A11+WKWZ@M+6Z'+
M^!O"UQX4L+VVNIX[CS9T>.1"<E5@BC^;(X.8R<<]1S7$:KX#URST#5KF7[.+
MBUBE;36L6:6225KO[0C%2@VD'"X^;J3TKU^BG)N3N_ZZ M%8\Y\1^&=1MM'\
M):1H5G'=O:>9!(TS,L:@VLB%W8*V.6STY)QQFL^7X4ZHUC);)>61&9=CN6)8
M-;0Q+N&WNT1SST/?I7JU%%W=ON*VWD>6S?#C7+^XO;VX?3H)[Y)2T"2NR0LT
MMNP ;8,C; 23@?,W3O6YX*\%W/AS6+VYO0DN1(D%PMY(Y='E,F#$5"I@GLQR
M<GO7;447M;R"V_F>6V?PRU:WNII9I=.F5[V.X"&1\%5FN7*GY.XG4?@WMFS#
MX(\1_P!C:?;226:BSU!WAMVNWD$%LUNT.T2F,,Y4L6 (Z87/&:])HI=&N_\
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MW>_W U??M8K6#7K6I.IQ013[WPMO(77;N.TY(!SC&>.M6:**0PHHHH ****
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M.;\5^-]47X2V_B71X)+&]DN(08'4,?\ 6[67YAT.#@X!P>U<OH_QLOY=;O\
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M:%9O9'EUOLZ6T7S\PHHHI& 4444 %%%% !1110 4444 %%%% !1110 4444
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M#TK2/^0)8_\ 7O'_ .@BJGA__F)_]A"7^E9,/BS4(($AB\ ^)5CC4*HW61P
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M6N(D622(>(+[<JL2%)'G=]K?E0M&)ZHX'7OB%?W?B!;;3;^WN(%NUDCM+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/UOP[XEB\7#6--L[RYA%X\DL4-XH,L0:#8 K.%[2\<=\]1GTZBEU3[#[^?\
ME;^O,\<T_P #^*4M[&XN;>[%]'$#(3J .'4VVWH^#PL_Z^HS#<^#O%C7DGV.
MQU"SL_-<3)%=1LTLC/,5GC7SE4 "2/J001]T[:]IHIMWL'<XJY\.ZF-!\2M
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M<$DD%AR,=#FCO_7;_@@NAT&O?%30-*T_47L)C?75I;F6.-(W$<S8!VB0*02
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $=Q@VTNXX&PY..G%>90O#?>%[*T@L;V]@@M8DM)Y_#PN%4C[S@,W.X;1
MC/&.IKTVY_X]9?\ </\ *O#HFM[BZ\.7HU]+..PM;9+BV>.?=N1LL/E0@\<=
M:T@CZ')Z7M(S?9I[7Z/R?H:$FH/$NEQ):VFJV):65X+BR2SM[>-'*.7B^=5;
M>1^\ZC)'\1K/NAJNK>$[/51JEA?-:11O-=W=LH>!E;<L7V@DEGSU7C[P]:T=
M02WU;X;RVBK<K-&UWJ,,L:8#J)RNQL\X/F X]JGDT.QGE@:\L/.<S7?VJ)F=
M2[1P!U$H4A-^[^Y\O3%:'T$*E.G[S5FI2Z)Z1N_)*Z>ZMJE>Y%?Z7//)H&L:
MTW]H0+<1$V4.DJB2^>ID;;AB)#D<\=379^#M-M;.Z+2QN^L);"&]N4.Y&;>6
M"LW>0 KG/.-O;%<.GA33UGAGEDU&2Q:R$MYLD.-,D<*T94'D@*6'&X^M=IX7
M@O\ 2?%,FDS7&^T.FI<K$BY1',C+PQ&X\*/O$GGZ5,MCS<PDI8=QA/9;6Y=+
M[:>M_/1WVOV=>36?@C5[>:&2UTRXMI;2_D=)/MBC>K7R2;AB3E3#N&&P>#QD
MC/K-<':?$5H--O7U6RV7%M\\9\Y$6X1II(UV\\$>6>.IK%/EDI=CY#=<HGA+
MP]KULNOIK,URLMVKQHTC*8I&+2$2(1(S=&4'*IP ,<5A67A3Q-?Z=,D^FR:'
M,DFF6T7DW$4AVVY.^=>JC[W ()PHXKL]!\7MXCT:[U&ST^2WMHH0\4LSJ=[&
M,/C:#Q@,*PU^*L-EH=O+JVG3+?959(ED0!OW"S%U.><A@ O7)Q[T[-.WI^>@
MG[WSO^E_T$3P_JUOX7\-6MSI=U="UDD.HVMO>+&[RL&Q+NWJ"N\EL9R-PXXQ
M64/#GBE8[TSV%_-$9HC=P"^4F_Q-(S/'F3"C8R##%<@8QQ6S-\2S8WFJ1RZ?
M+>I:W'6 JOE0D1*I()R27D/3L#Z5I>$OB-I7C/4IK32(ICY",[R-C&!M /T)
M9@#_ +#4K<SO\_Z_K\@NDOP.7T7P[XIT;4M&N)[.]DBL=-@06]M+$0&2)E>%
MBTP'+,#D*P.!R,5U>NV>H)XNLM1M=&&K6\EFUI(AE11 QE1][;C]W"G[H)RH
MXYR.KHIMW=_7\?\ APM=?UT/+K/PMXBGFNHKZVNTADGA%R7O@5NB)W9I4P^5
M7RV48X)QC'%1>#/!6KVEW FNZ==(!=1W%S,]Z&64BT51G;(2Q$JG.1CD'D=/
M5J*(OE32'+WCS#P_X:\1P^.;*^O[2Y2WMY93<RS7:R+-(1/B5%WD@%7C7& >
MV/ES4VL^&?$3:QJU[IT5PWVB.Y"A;P /S 8E"EL _++C@8R<XS7I-%):?=;[
MQ-79X])X-\3ZF9[N[L;V*2:YG>.)]04,D3+<E5.R0KPS0="<8'8'%B7POXK>
MZU8V-I<VES/:R[[EKM=ERS) %50LF0P*2C)"XSUYKUFBCJQO6S.'\+^&[^&]
MTRXU5+LQ6UO.R+<R!3#(TH*KL21P<+D#EL#BJ=OHNOP:QH$\EG>3M!<7 N"]
MPAACB>9V#'$@;>%VXPK @[2!V]$HIWU7D*V_F>=>(_#/B#4K;5$MX[AB]Y<S
MVNR["=;4+$00PQ^]'0]#R?6I?&GAB_U?5[2>WTZ:[+:3<6CRI.J".1FC*[LN
M." XR >2/J/0**$[6\O\K!;1KO?\7<\O\.>%?$VG^-XY;TWB:=#/*;8K.LJ)
M#OFQ&^9<@$.A&$;HN2-M7?%OA_6-2\37QL+"ZN+:[T\P/)+.BQ(0.!'B0$$D
MD$,F.A##'/H=% WK?S/)++PSXPM_$\*QVUQ!:6TEV+>X^U*R"%Q/Y08F4L<%
MH\*%X&,G(P*6B>#O%46O6]RUCJ&FV;W$;D"XCED214@#R/\ OP-K&-QGYC@G
MY?FKVBBA.SN$M;G!^ ]#U;3O$6K7>KV,\#30I$UQ+.D@N9%FF8NH#$A=KI@$
M#TQQ7>444@ZW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *YH_#_P .E+A1:W -Q()&<7LP="&9@$;?E!EW.%('S&NEHH SM,T#3-'T
MMM.TVV\FT8;3'YC-D;0G4DG[J@=>U9L'@'P_;6<=M!;W,8CF\Y)5OIQ,IVA,
M>;OW[=@"[<XP,5T=%.[O<# N?!&@7FI"^GLF-QYWG.PN) )&^4_.H;##,:':
M01E<XHL/!'A_2BITRQ:T*B(9AGD4D1L60'YN1ECD=\X.>*WZ*2TV **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IDTR6\$DTS!(XU+.Q[ #)-/K+\3?\BEJ_P#UXS?^BS0!
MSUM\1Y;^VCNM-\%>*+NTE&Z&=;>!!*O9@KS*P![9 J7_ (3O4/\ H0/%7_?N
MT_\ DBD\.Z/KC>%]*9/%$R*;.$A190G:-@XSBM+^Q=>_Z&N?_P  H?\ XF@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWN9XC)"L5S"!&8YU4$+N+*67 8\J5[>E6/#GAVW\,::;6"\FN(?E$9G6,&-
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MR53?MY(Y(!Q].U<MKGQ09)+)_#UO-=)<2B(1M!'B0"XBB9U<RC'WRH&.IR2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %9GB4%O"FK*H))LI@ ._P AK3H(!!!&0>H-
M 'G?AGX<>%-0\)Z3=I_:,HGLXGWQ:[>;6R@/&V;&/IQ5RR^&6@30NU[8ZI;.
M)7547Q%>R;D#$*V?-&,C!QVSBM=/ /A6)2L.AVD2;BVR-=B@DY. .!R33O\
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MBT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1102 "2< =2:
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M-HL*:1<WG[ME EECY53GKGIQS7,>./B'KRS:=-I>H7EI/;V-E-=QK+$D)>8
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M0.N+>:4,&,[CK$!C;WKJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO%(S!0S#RU9&09Y#;QS]?K2336GE^ ]G]_XF:/#7BE'U8I]J%Q)<1S6]PDL
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MLG.=L@&T@]&QQQBNJ2Y\6>'(_)N[%O%%G&,1W5I)'%>8])(W*QL<8^967/\
M<%1S:G8>>;NW\#:E=7X;/&GPH^[IGS)&5?QW4 9?@_5$\=^(U\:QP-8Z/IMG
M+8623D+(TC,IG=U_@"^6J 'DX8XQBMGP:?[8U#5O%93$6J-'!8,1R]G#NV/U
MZ.[RN.F59,UC1^ [WQ!XDO-6UY?['TZ^"B[T6SN2XU#:!M:X884''RE4^\
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M/( .0%XXP>1Z'I2Q>%=!@U-]1BT>R6]DF^T-<"%=YDP1OSZX)Y]SZUXRNO\
MC:U\:7]E9ZM=7<&EW#6;"ZN[=-\(C),AC8AW?^(,H/ Q3=%\;^(].\.:C=+K
M\NKS2>'EU#,P5S9SF81X&!V4[L'TYH6NO]=PMT_KL>TS>&-#N=9.K7&DV<FH
M-&8S<O""Y4C&,_3CZ<55C\/>$[FX>UBTS2Y9K)(XWB6)"T"@[HU(_AYY _&O
M(H==\07?B6S\+VOC*\N;22^@3^TX&0R,)+<NZ;@"#AAQW&:6ZMM9TO6_'/\
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M[S!R-W'.#ZU8ETC39YGEGT^UDDD0([O"I+*,@ DCH-Q_,UQ?_"\OAU_T,/\
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MHJ1HH5448"@= !7 _P#"\OAU_P!##_Y)7'_QNC_A>7PZ_P"AA_\ )*X_^-T
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M^AA_\DKC_P"-T?\ "\OAU_T,/_DE<?\ QN@#T"BO/_\ A>7PZ_Z&'_R2N/\
MXW1_PO+X=?\ 0P_^25Q_\;H ] HKS_\ X7E\.O\ H8?_ "2N/_C='_"\OAU_
MT,/_ ))7'_QN@#T"BO/_ /A>7PZ_Z&'_ ,DKC_XW1_PO+X=?]##_ .25Q_\
M&Z /0*S3X=T8W1N3I5GYYN!=&3R%W&8# DSC[WO7(_\ "\OAU_T,/_DE<?\
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MTZ9Y^O-)-X+\-7&G6EA/H5@]I9-NMX3;KMB)Y) QW/7U[US7_"\OAU_T,/\
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MU_7<%9I_UV_S.YC\'^$YHEDB\.Z,\;J&5UL8B&!Z$';R*=_PA?A;_H6M'_\
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MKX*="E[23ZM?=U_,X_\ X02__P"@5X'_ /!$W_QRC_A!+_\ Z!7@?_P1-_\
M'*G\9"Z.N+-+;:D^EVMF7EDLYO*PQ;DY[X Z>]9TFJK=>(9[J6XU%+2SFMXX
M+F%_W4*$#&]2?FW$\\=*J-+F5SLHY3*K3512W5^]M4DM]W?;[KEK_A!+_P#Z
M!7@?_P $3?\ QRC_ (02_P#^@5X'_P#!$W_QRKNMZ+'-XJL8;6]ODN+N5IY@
M+@[$B3KA?<D#\36;IMY.?&T9:XNBSW\\;W+.QMID .V)1TW#CCV/)I1IW5TR
M:>6JI2]I"?V7*UNU_/R?^1+_ ,()?_\ 0*\#_P#@B;_XY1_P@E__ - KP/\
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M<-OE=+N50Q^@;%<[X@^%7Q.U'Q-J=[IGC".WLKF\EFMX3J=RGEQLY*KM"8&
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MYR6?G)XX' KKAHUDNOMK(B/VYK?[,9-YQY>[=C'3J.M>8_\ "GOBS_T.\?\
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M $.\?_@VN_\ XBC_ (4]\6?^AWC_ /!M=_\ Q% 'KE%>1_\ "GOBS_T.\?\
MX-KO_P"(H_X4]\6?^AWC_P#!M=__ !% '?:[IU_'J=MKFAHLMW;H89[5WVBZ
MA)SM!Z!P1E2>.2#UI(/&>ER!EN8K^RF3[\-S8RJRGZA2I^H)%<%_PI[XL_\
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M'_"GOBS_ -#O'_X-KO\ ^(H)/7**\C_X4]\6?^AWC_\ !M=__$4?\*>^+/\
MT.\?_@VN_P#XB@#URBO(_P#A3WQ9_P"AWC_\&UW_ /$4?\*>^+/_ $.\?_@V
MN_\ XB@#V;3?^0A%^/\ (UO5XYX$^&WQ#T#QM8:GXB\4I?Z;!YGG6XU&XEW[
MHV5?E=0IPQ!Y/:O8Z0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "H+Z::WL)YK2W^TS1QLT<._;YA X7.#C-3T4GL!YCX(
M^,3^-_%!T:T\,W%J8E9KF:6X!$ ''(V]<X&*Z!/'L4WC!?#\-CF<SR1;WN43
M(3;N*J>6(#9P.< UKZ1X7TK0M3U2_P!-MA%<:I,)KEAW8#''H,Y/U8U#IWA2
MST[Q)=:U%+,\]R9"R/C:N\J3CC/\ _,U2M=7[?B*5];=_P #%O?B5#;:U)I%
MOI4]S?I<O;>4LJJ"P9 G)Z!@^[V"FEB^(Z3:EI<$6D3_ &?4DA>.=I5&P2-L
MP5ZY#9!^E7M2\!:;J&K7^J1SW%IJ%ZT#_:82NZ)H<A64%2.AP0<@X%"^ M,C
METMH9KA%TR*&.%=P.X1OO!8XY)/6E'I?YCEL[?(Q[?XMZ=>K,EE8337,<OD>
M2957]YYK)@L> ,+NSZ&KFK_$>#2;K1[8Z;)+/JT"211"XC#!F8*$QGYCEAG;
MG !/:HV^%.C*9Y+>ZNX+F94S.I0D,LC.&P5()^<K@@@BK4_PXTN:31PMU>1P
M:3#'"D*E,3!'5UWDJ3]Y0?E*T+I<'Y#;?XAVMSX'U'Q0FGW"V5B#\KD*TFT#
M?@=MK$K]5-5[#XJ:-J6LVMA:QR.MUJ$MC%.K J2D:-O^A+JOUK;?PE92>$;C
MP\\LQM+@R%V.W=\\AD(Z8ZDCITKG-.^#GA_2[B.:TGNT>"6.6W(9?W+JR$E>
M/XO+ .<]335N;78.GF=#X9\5P^)I+M(;5X/LNW)=@=V6=?\ V0_G536/',>D
M:MJ%D=/DE%A;+<22><BDACQA2=Q';< <'CWJ"V\!2Z4]R^A>(+ZR-PH61#'$
MZG#LV[E-P(WL!@@=,YJSK_@:U\1:H;N^U&]""(QQVZ&/9&2,%@=N[D=B<9YQ
M2ZBUL9TGQ0LK;3)M2O-/F@L4N8H4F,J$NCR,GF%0<J 5S@]B*V6\6P_\(+_P
MDR6KO%Y/FB .-QYQC/2LN+X7Z,C7(EGNIXYYHW\N0IA(T9F$7"Y*Y=N3DXP,
M\5:T_P #I9^!9_"TFI7,MHX*02X4/!'QM4<8.,9R1W-'0;WT,VU^)POKK4+:
MTT9VN=-A>6Z@>\B61-C,K@+G+ %3\PXY'K4EO\3K*6+4Q/I\\-QI]I#<M")%
M;S/-QM0-TS\R9]-XJSI_P]M],N+Q[;6-0*:A"\=Y'((6^T,V_,A;9N#9<G"D
M#IQCBH(OA9HT37#K<W@ENH7AFD#J&=3LV]N"GEKC]<T==0]"6V^(=NVMP:-J
M%BUAJ<TT<7V26=#)APYW@ _,H\OJ/[PZ=*CUOXH:3H.LZAI]Y#*?L$ELDTJD
M;0)C@G_@.5)_WA5VR\"VUM=Q7=SJ5]?723Q3M/<LI9V0.!G"C /F'@=, #I5
M.\^%VB7VM2:G<2W+33SO+<#<NV<%E(1AC[HV #'.">:.H=!=)^(UMJFJV5K_
M &=-%#>>6J7)D5E61U=E4CKR(VY^E4=6^+5EI.MW6FRZ>2]O/Y'F-=QHN04&
M7+'Y!^\'+<'!K1T;X;:9HNH65Q#>7LL=C'&L-M(R>7N1617.%R6 =AUQSTS3
M-0^&EA>ZM-J<&HWME>33F=I(1&WS;D9>'0@@%.,@_>-/3F\@UMY_\/\ \ F7
MQO.FJR65[HLMN8[BWMVD^T(XW3?=Z>W-8-W\:=/L[=)Y=*G*/;+<;5G0N,H[
M8V]2,(>>G(KIKWP9#?17)DU*\6[N'MY?M:",.DD(PK@;=N3U(QCT K+F^$^B
M2)$L=S>1>5"D 967)1492#\O?=N/N!C%) 7#X]AG\(3>(=,L)+VVBN3#M655
M++NVAP3V)(X]ZHWWQ3T_3Y+RWGMA]MLA,9[47*;XQ&J')] =^ >GRFMBV\$:
M99>%[K0;1YHK.YN&N#@C*%I ^U>.F1CZ56U/X>Z=J9NVDN[J)[F2>1GCV94R
MA <94]/+&,^IHZ_+\0(=>^(EOX=T'2]3OK(,FH;BJQ7<;  +N!5\[7)'0 \Y
M%0'XEJ]A=W4&B7+K"J31!ID7SH6D:,2#T^=<;3S@@UH:WX&B\0Z38V.JZO?2
M&UWAIU2%7F5U*E6 CV@;3CY5!]\\U%:_#K3;6SOK9;R\DCNE2)-[*?L\2R&0
M1I\O3<Q.6R>1SQ0'3^OZ_I%.3XD36]K*]UX=N4FBFFC>%+F-R!"F^5L]#M&,
M#N35CPM\2M+\6:RFFZ?$XF-O-/)N8?NQ'*(\'W;.X>U6-3\ V.IV\L;7UY;M
M+=33O)"RABLR[9(^5(VE>/4=0:B\,?#;1?">NRZKI;3>?+&\;ARN&#%3V';9
MQ]31'S_IV_S!^7]:F4OQ>M9)9X8=&N9IX \C)'-&?W2;][9SP1Y9^4\G(I]Y
M\6+>#4;NUM-(FNS;$G<EP@RHV?,5/*@^8N,]>?2M2[^'>F7.C0:?'<W5KY3S
M%IX-@DE67/F(Q*D$$-C.,C P::_PWTHW=Y/%<7,)O 5E5"N"NZ-E'(_A,?'^
M\:%OJ#VT(9/B1##J;V4VDW :WF$=XZR*1;@NB!O]KYI,8'8$U+H'Q&T_Q"VH
MK9VTBOI\,LDRLPR"CLNW\0H(/H:?<_#S3KK6'U![R\4S7/GW$*LNR<;D<(WR
MYVAHU/!!ZC.#4FD^ -*T:YOKBTDG\V_M3;3LQ'S L[;NG7Y\?0"EKR^8=2KX
M;^)6G>)-=72;>UEBNL%G5V!VKY:.#[@[R/JIJ&X^)L&FQ32ZUI_]G1QSSVX>
M:[CP\D49<J#ZG  ]2:NZ)\.])T+6K;5+62X>ZMXWB#.5^965%P<#MLR/<FI[
MOP/87GF^;/<?O9KF8XV\&>/8W;L.1[TY>7;\11OI?O\ @1Z/XWCUB75A#9A(
M]+CW2'[2C.3L# %!\R@C.">#@UA3?&+3+2RLKF^LFC2^MFN+<Q7,<H=5=5*Y
M4X##<W';80:Z/2_!Z:4=1CAU2\DM+]"'MG2+:C%0NX,$#9PO0DCD\5D7/PJT
MS4=.M[/6-2OK];6)(8'D$2-&BNK #8@'\.,G)PQH]/ZW_P" "OU_K;_@E^V\
M<9L[.XU+2+FP6[$KJ)'5OW:0^;O&.N1QVP0:IV_Q(2<VD)T:XBN[BY2'R9)X
MU"J\:R*V\D*25887.<@CMS,_P]5]+M+,^(-58VKR;)G,3MY;Q^68L,A 78,<
M#.23G)IO_"M;,Z2;%]8U)DDF62X<F(M.J*J)&?DX"J@ (PW4YR:>E_+0%>VO
M]?U_D5#\4H_L)O$TB2:!9IXF\F[C=E$*LTA*Y^4A5SM."<BK6M?$>UTB\U&)
M;+[3'I]BM](RW**[1L."L9^8CH,]!D4V3X9V\]HEG/KNIM:QRRND2B!=J2AA
M)'N$>2&#$9)+>A%7=2\#6^H7UY*NI7=M;7MO';SVD21;&5!A<%D+#'L0.*0&
M?;?%+3[RZMX;2SEE%Y*([1PXQ-^^6,GV #!OI4NG?$>VO@)'LC';F6XB\Q+E
M)"IA1G?<HY4X7H<'Y@:LV'PZT33KG39K=9?^)9>7%W;(2"%:8'<O3H,\?055
M;X<*;>.!?$.I)%#+*\2B*W_=K*&$B?ZO)!#GDY(XP10_ATW'U\BI=?%BVLM/
M2XN]'N(9-^)(6G0%4\D3*P.<,2A^[USQ70^$_%*>*[.XNX+800PS-"#YZ2,6
M4D$,J\H>AP><$53TOX?:;IMQ:SRW-S?36\QE#W6QM_[H1(I 4#"JHQWR,DFK
M>A>%I="94AUN^FM%E>1;61(0@WDDC*QAB,MGDYX':F[=!:G%ZU\:+C1O'+>%
MG\)W,U\9UBAV70 F#?=8?+T(/X<^E>IJ6**7 5L<@'.#]:R;GPOI5WXJL_$4
M]L&U*SA>&&7T5OZCG'IN/K6O27PJ^XW\6FP4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &:)];^U1J=/T_R#L\Q_M[[ER!NP
MODX.#G'(S@=,X!'/K9M9VFT_3TG7;Y*+?NROS\VYO)!7 Z8#9]NM:5%5==C;
MVD?Y%^/^?4RGN/$ 2/R],TUF*YD#:C( K9/ /D'(Q@YXY)&.,EYGUO[5(HT_
M3_(&_P M_M[[FP#MRODX&3C/)QD]<8-6X\;>%;2YEM[KQ-H\,\+F.2*2_B5D
M8'!4@MD$'C%1_P#"?>#_ /H;-#_\&4/_ ,51==@]I'^1?C_F7O/UO[#N_L_3
M_M7F8\K[>^S9C[V_R<YSQC;C'.>U GUO[5&IT_3_ "#L\Q_M[[ER!NPODX.#
MG'(S@=,X#]/UW2-6MVGTK5;*]A5MC26UPDBAL XRI(S@CCWJU]JM_P#GO'_W
MV*+KL'M(_P B_'_,I1SZV;6=IM/T])UV^2BW[LK\_-N;R05P.F V?;K3'N/$
M 2/R],TUF*YD#:C( K9/ /D'(Q@YXY)&.,G0^U6__/>/_OL4?:K?_GO'_P!]
MBBZ[![2-_@7X_P"92,^M_:I%&GZ?Y W^6_V]]S8!VY7R<#)QGDXR>N,$\_6_
ML.[^S]/^U>9CROM[[-F/O;_)SG/&-N,<Y[5=^U6__/>/_OL4?:K?_GO'_P!]
MBBZ[![2/\B_'_,I"?6_M4:G3]/\ (.SS'^WON7(&["^3@X.<<C.!TS@$<^MF
MUG:;3]/2==ODHM^[*_/S;F\D%<#I@-GVZU=^U6__ #WC_P"^Q1]JM_\ GO'_
M -]BBZ[![2/\B_'_ #ZF>]QX@"1^7IFFLQ7,@;49 %;)X!\@Y&,'/')(QQDO
M,^M_:I%&GZ?Y W^6_P!O?<V =N5\G R<9Y.,GKC!N_:K?_GO'_WV*/M5O_SW
MC_[[%%UV#VD?Y%^/^92\_6_L.[^S]/\ M7F8\K[>^S9C[V_R<YSQC;C'.>U
MGUO[5&IT_3_(.SS'^WON7(&["^3@X.<<C.!TS@7?M5O_ ,]X_P#OL4?:K?\
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M<>(/(4KIFFF4L0RG49-H7 P0?(Y).[(P,8')SQH?:K?_ )[Q_P#?8H^U6_\
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MO/+M=!L]>$^4;\8YP01GICFGW?@+P]?R1O>6DLQCB6(AKF3YPH(4M\WS, 2
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M8A<?,0TF,9'W3]*ZC1_"FDZ#>3W.F021R3KL;?.[@+N+;5#$A1DG@54'P_\
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M1,%LKPP"$S@#YR%'\.[@'J>:OZ?X6TK3!?\ V:*8G4%"SM+<22,R@$!06)(
MR<8]:KZ?X,T[2I[)["6\2.S8LD,EU)*GW"@&&)P #T'?'I2&5#JFJVWQ(ATV
M:Z+V%U#(Z1O:A%!4 @(X)+-U)S@8I-<\=1Z+XH@T@V:W E0EI$FPT;;&8 KM
MQR%ZYSST-6KOP/I%UK"ZF%GBNA<+<$K.Y4L""<*3M&[ !P.1]34U[X/T;4-:
M_M2ZMY&N>,XG=48A2H)4'!.UB,XI:V0]+G%WOQ/U*[LY(+#2?L5T@@FDF:Y6
M010R-%M(!7YB1)C';KDUM>(_&C67CC2=!L+FWBW7$8O?,9=Q5\[44'GGJ2.G
MRCO6A/\ #SPU/<).;*1)%6-,QW4J[E0*$5ANY V+P>XSUK:N](L+^>">[M8Y
M);>59HWQAE=>AR.O7H>*KJO471^A<HJM86$.FVOV>V\SR][/^\E:0Y9BQY8D
M]35FD 4444 %%%% !1110 4444 %%%% !71VO_'G#_US7^5<Y71VO_'G#_US
M7^5 $M%%%( HHHH **** "BBB@ HHHH R+74[J3Q;J6F3B$6UO;6\T+*#O)D
M,@8,2<?\LQC K O?&E]HWB'4;;4(X+NUAD'E);PF.1(PBNS,S.0Y&\  *N>O
M%=;+IUE/<">>S@DF!0B1X@6!0DJ<]>"S8],GUKGM:UKPC#=-_:45E<W$%U&9
M2T*LT4F,"0DCD@#&1DC@475T#ZE?Q-X[?1KC4;6VTVYD-C LDEWY3-$A.#M)
MZ?=/'/7C%.L_'-QJ5NWV;0[F"X6U>X9+H^5M4 [" P!8,1U &/>G:MKO@Y8;
MG5KB&SOYDM [LMN))&B+#"DD>O\ "3QZ5"^K^!;"PAN+*UTZ3[+(8;>*WM5#
M(S_>VC V@YY/2IL]?Z[_ / "Z*]WXRUR"PLY4L+?=-HZWKY?I*71<?3#?K[5
MIZ'XW77-8CL8M)O(P8=TL^TM'$^,["P&.@X.>?2K%Z_A33)8[6^MK&!K2V)B
M1K48CBR,A?EQC.W@>W%5])U?PI>:W(^CP69FM[/>][' J!(]W*;L ]221V[\
MU3:;T\_U_KY$I-+7R_3^OF4U^(K2:DUA'H-])<QLXECC!8P@?=+_ "_+GWXP
M002#56S^*MOJ23S:?HU[/:Q+E;E0?+)S@ MC"Y[9/X5J:?/X',]O/IMMIB3"
M1FA>.T",KMP2/E!!.,?A67J/B/P7I#K+#HMM,JV<A$D-HBE41\>5M(!^]VQ@
M=:2VU*?D:MWXW6UTG2[XZ=(XOBV^,2@&$*0&.?XNOMFLF7XI@7+16^B32C8)
M58W*KN1MVT]."=IX[5K/XA\*K;I%J<=G:K$[K%#-&K8Q@G  .,D]."34V@1^
M&-:M7N]-TBSC:8^;*&LU5B6)PS<<DX)HUW0&4/B-'!<L)[.2:W+N?-3"F- /
ME&W^(\>U-;XER^3#Y?A?5Y)I(VE>);=\HF<*WW<E3ZX'MFNN71=+5@RZ;9@@
MY!$"\?I55_"7AV2WA@?0=-:&#<(HS:(5CW?>P,<9H Q?$/C*YTVUT&]L+>&X
MMM1;,NV0'@IE55NG+$?-Z#I5O2_&:ZE;W]RU@\-OI\!DF8R!FW#.5 '7[IYS
MZ5M2Z1ILUG':3:?:R6T2&..%H5*(I&TJ%Q@#'&/2GV^FV-G"T-I96\$3($9(
MXE4%0, $ = .,4Y=; MU<X:Q^(E\VJF*]T]=C)-*8XW&8HX^2=W\1VYX &3W
MJ6[^(E])H<T^G:#/%=QVYG9+P^6$7=A6 8 N#ST Z=ZZVT\/Z-8;/L.DV-OY
M:LJ>5;(NT-]X# []_6H3X5\/FWB@.AZ<8H0ZQI]D3:@;[P QQGOZT(6NIC/X
M\/\ :G]GQ:4[SM/Y$>9U"LP;8^3C@!C^(YJ;5O&\6D:S<V,UD[+!%O$P?.]]
MH8)M +<YP, G.!BMN+1-*@N6N(=,LXYW96:58%#,5&%).,Y Z>E.NM'TR]:1
MKS3K6X:08<RP*Q88QSD<\4M;>8_M>1QEE\5(KK9)-HUQ!;,I9I#*"RX!R-A
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M=KYEA'8/IR()%#.LD4C,^">@D\L<\\<42T;L..JU/16N8$M?M+SQK!MW^:7
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M2]+Q",I(0=F\C.[9SC/ZT?U^ KGIU%%% PHHHH **** "BBB@ HHHH ****
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M[I?Q \/:%XMC\.-:ZS]IP^F+.77R8M_5R ,DKV/?I7I%>?\ B_\ Y+/\.O\
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M*C1_:F22W6>-EBR'W %4!!^\<CV]ZCL/#'@W5))SI\JZA-;K]DFECU.6:2(
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M44 %%%% !1110 5YO#\.?%>EZEJ\WAWQ]_9EKJ>HS:@]M_8T4VQY#D_,[$G
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MFF-.'?SHMG1P0<$+W'?K0!Z17G_Q7_YDK_L;;#_V>O0*X_XC>&M8\2Z;H_\
MPCLEC'?:9JT&HI]O9Q$WEA\ [ 2>6'''&>: .PKS_P#YN2_[E+_V[H_XO#_U
M(_\ Y-T>&O#7C'_A9,GBGQC)H?\ R"3IT<>E--_SV$@)$@_WN<^G% 'H%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445%<7,%I
M%YMU-'!'G&^1PHS]30!+134=)8U>-E=&&593D$>H-.H **;++'!$TDSK'&HR
MSN< #W-.H **CBGAGW^1*DGEN4?8P.UAU!QT/M2F:(3B R()64N(]PW%0<$X
M].1^= #Z*9)+'"H,LBH&8*"S8R3P!]31%-'/&)()$D0YPR,"#@X/(H ?142W
M4#V[3I/&T*[MT@<%1C@\].,'/TI\<B2QK)$ZNC@,K*<A@>A!H =1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&5EN+PRHK@QA-J[B%XW]!]>U5=7U/XMZ+HE]JETO@MX+&WDN)%C%V6*HI8@
MD#.!ZBNX\,:G-K7A'2-4NEC2>^L8;B18P0H9XPQ !).,GU-$=!25S4HHKE?'
MOVK^R[4::;\7@N4:+[&LYS@C(8Q\#(Z&3*>HH&=517%^.WO;S0=/OM$75%DC
MO 66V^T1N(\-N+1H5+ $ @$<\>O,=_KOB6'0="DM[.=[NYN0+D_97XB#XRR!
M&*EE(.#M YR1C%"U^\'^ESN**\EL_&GBN[U<P6WG7"E"\:#36 ;YF5OFQT4
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MCY^0<YS5.37O&DFGMYZ2QR2WC0^5:Z?,98U((^\T83:I(.[=R,D,2,$OI?\
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MBCL8[[3-6GTY_L"N(F\L)DC>23RQYXXQQ5)V=R9*ZL=A1112&%%%% !1110
M5ROB3Q7<:%KMM;+#"]JT7F3.VXN,EA\H'IC-=56%X@\8:5X:N[2VU-W$MYN$
M"1@,SD=@N<G/3@8Y&<4GNA]&</8?$_5=27<^GZ>UMYACE&[<64-@XVLR_=[9
M/-+<_$/4);,M':V.FR27)MHY_.1V"JP_<[025DYZ-COA:[*Z\::?9.8Y;6^W
MJJ;D6W.5=AN$9Y^]MRV.F!UJJGQ$T-[OR42[*\L)O(_=GY2<YS[8^I%%U<6M
MM2KKWCB^TK7]2L8+*V:*QLC<!IKA5>0[<C"9W,"?DR%/S'KVK&TOXHZCJ%K)
M-/::;9Q[XXS/+= );ENOFKG> >@)"C-=*/B'H6ZU#F:*2Y,BI'(JAP47>1MS
MG[N#D9'(SBH%^)&D74<RV<<WVM.3#<1["%R!N.,\?,!GU--:,&U8Q-4\?W[>
M+$TNUN+.WC@-P)P'R[[8F,8&>A.,CCFGR?$;5+:SO%&GPO)8FWB>:>41H6E4
MNK%F*J/EQDY RP^E;X^(6BD$B.[W>;LV^1SCCY^OW>0,]?:K6J>,]+TG4)K*
M\CN3)$@8E(MRL2,A0<]<<_A26BW#J<UXG\<:M";O3]/CM[2Z^QK("7WR1$H'
M,@Q\I0$E >F[\JJIXNUK2O$.IPZC>VSQ+<+!')<'9!;K\OS.0,^V<]6KI8_B
M%H\B0MY-\K3S1P1J;<DLTF=G0]#M;!Z?*:M1>,])GTB_U&,S&WT_ N,IRC=U
MZ]1QG/ S3V=Q6;5C 7Q[JMQXLNM*@M-/B@MS(3+-<KG$:[LD!LJ&ZAF &/6K
MUIXQM;OP5+XAS9RW]I$RN(MK>42^W;G=C:2HYW;3C.<<TR7XDV%GIMW?7]E<
M6ZQWGV2!6*!IVV!AC)Y)W=!FBW^(>@QB,7$$EO?W%G'=2P)$"QRH(7W.",9X
MQ^5+[/W?E?\ (=U?^O3\Q_A;QK+KVK6]I<K:1&?3ENU2&42-GC=G:QVCYAC/
M4$$$\XYS3?B9JMUXHGM1'I\L+C<$>[2'[. IRI+,"67JP )'H*Z*+XH^'7NH
M[>0W4$T@.$EAVG&,COWY ]P>E7-(\96VMZY#8V5C<+');R3--*FW8RN%VD>X
M;.?<4_B>GG^H-I+7R,$_$>ZDTVSF@_LX2S0,Y$KL!+()3&4BP2&VXR2"01R#
MCFH+CQOJVE>)'@F>*\ :6,V8.'D8,!F+C.!UP<X'>O2\#CCITHI=;^H=+'FU
ME\0-3U2]T.W<65G]LG4L8KA)?M";B,)M9@,8^89)''3-:'ASQ9?:GJ\.EW<,
M,MM-&X:1SERV"W/&",<8Q7<!0,8 XZ<4M,6M[GE]CXUUNS>T>=[:_CVSI-!"
M-IW"9U4#'1@% P>U=GX/URY\1>'H]0O(8(G=V"_9YTE1@.^59@/0C.>*W>G2
M@  8 Q0M%J#WT"BBB@84444 %%%% !7G_A#_ )+/\1?^X9_Z3M7H%>?ZC\/_
M !%_PFFL:_X:\:?V+_:_D>?!_94=Q_JHPB_,[?[QX Z]\4 >@5Y_\#?^2,:%
M_P!O'_I1)1_PB'Q%_P"BH_\ EOV__P 570>!O"__  A?@NQT#[9]M^R>9^_\
MKR]^^1G^[DXQNQU[4 =!7G_PH_YG7_L;;_\ ]DKT"O-X?ASXKTO4M7F\.^/O
M[,M=3U&;4'MO[&BFV/(<GYG8DX  [=.E 'I%>?\ P-_Y(QH7_;Q_Z424?\(A
M\1?^BH_^6_;_ /Q5=!X&\+_\(7X+L= ^V?;?LGF?O_*\O?OD9_NY.,;L=>U
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M+_W#/_2=J] KS_4?A_XB_P"$TUC7_#7C3^Q?[7\CSX/[*CN/]5&$7YG;_>/
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M>Q@]\Y'MTJU<>#],O=<NM3U!9+B2=458S*ZI'M&,@ XR?7&<<=*WJ*!G/?\
M"">'?ES8,=DXN$S<2GRW'W2OS?+C)P!P,G&,FI]/\,VECIM_9[GVW]W+=3/
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MR> ]4\$:Y86.N^;=76G7$,,?V.==[M&RJ,E !DD<FNW\ _\ )-O#7_8)M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVO<?W(_R/^- &S16-_:]Q_<C_(_XT?VO<?W(_P C_C0!LT5C?VO<?W(_R/\
MC1_:]Q_<C_(_XT ;-%8W]KW']R/\C_C1_:]Q_<C_ "/^- &S16-_:]Q_<C_(
M_P"-']KW']R/\C_C0!LT5F6FI33W21NJ!6SG /I]:TZ "BBB@ HHHH ^,M<D
M2+XXZC)*RHB>(Y69F. H%R<DFN[^.^J:9<Z3I]I9:A:/<1ZA<RO:VMT+C*OR
M)&/)0G/W>!\QQP*Z/7_V<O[<\2:GJW_"4^1]ONY;GRO[.W>7O<MMSYHSC.,X
M%9__  R[_P!3?_Y3/_MM#U5BD[._]?UJ+\#)S;?#75)PC2&*_E<(@R6Q#&<
M>M8.F0>)O#4<B7=GJ*K>(]X?L22R?O)H)%PP &&#A,CG!YKV#P!\,_\ A!M
MGTW^UOMWFW+7'F?9O+QE57&-Y_N]<]ZZC^QO^F__ (Y_]>CN*YX/JV@W5WK]
MI]JMM6:6\M]++RQF; VOB4EAPK#@\\C)/<TRW'B8?8UF_MPWBI$MJ?WOE^2&
MD$V_MG&W[W/W<5[W_8W_ $W_ /'/_KT?V-_TW_\ '/\ Z]-N_P!Y*T^X\9M[
M>^TG3+.6>'6KM)/#SRW,0FG:1KEFB^7.<JW7@<@9K/\ #=MKZ^)M*#7^KF!1
M&P>Y@NBKY+&9#NX SA<N/[I%>[?V-_TW_P#'/_KT?V-_TW_\<_\ KT[ZW_KK
M_F%M+'CGA*UN9O$VIRZK:ZI+*^GSQ7AG23#OY[82,M\O*;<!>*I6YUJ/PE/:
M:);:@D=MJ-JMG,]H8+ATS\R2 #Y@F -W0BO</[&_Z;_^.?\ UZ/[&_Z;_P#C
MG_UZGI;^M[CZW_K:Q\[V@U34FDM+2XUXI$H:=&FG61)A:.Q!R<@&4#CH>U+J
M,7B369K^&XM=4&_3)$DB(N")"D:,IR3LRS G:H!R2#G->_67A2RTY9%L$AMA
M+(9)!%"%WL>K'!Y-6?[&_P"F_P#XY_\ 7IWUN"TMY'BFHW.IQ7D%KI46N"WF
M6SD@)2<[45)!(&8\@Y*Y!Z\57NM-\06UKX:6UNM6A$UHDTLC_:)V6[8INW!2
M2/ESPWR@;N,U[G_8W_3?_P <_P#KT?V-_P!-_P#QS_Z].^M_,5M+'F/@87YO
M?$%O,VI8\W,5]>+*N2Q;@1R< KQDK\I&WBNETS3M5M+HR:AKDFH1%"!$UM'&
M <CG*C/KQ[UU/]C?]-__ !S_ .O1_8W_ $W_ /'/_KTAGC^J:)<72:Q!]DN4
M2X\2VS!H49&\K;%EU8<@#GYATQ7-./$<=M')<_V]*85M]EN@N!YY#2C;O3E6
MP4()R.F<U]"_V-_TW_\ '/\ Z]']C?\ 3?\ \<_^O1?2WI^"2_0.IYI\1VO!
MI>G362ZBTD<^XVMF)1YW& I>+E#D\$\9'.:Y""/Q-B_DU*?6/)-T@U&"**??
MY?G<E'Z?<P,1_P )'O7O7]C?]-__ !S_ .O1_8W_ $W_ /'/_KT=;ATL>(W5
MA=0>,[:ZL8==_P!)732DDWG$E%EQ()>P(&W(;U)[FJOV?Q!=WXMV.NH9;I$U
M-M\JJ&-U@&,C@#RNI7C&,U[Q_8W_ $W_ /'/_KT?V-_TW_\ '/\ Z].^P,\J
M>VU:Z^&FBVLS:DMR]]#%<,CR+,(O.()+#Y@-O<]JP-,/B#2HC-.-:EA5K*XF
MW^=*YQ*XD !Y/R!<J.V*]T_L;_IO_P".?_7H_L;_ *;_ /CG_P!>E<.ECYVO
M[77-0TT0S0Z[>2W.FRAH9%N(Q"5WL#_=<'Y1M/S9Q]*[KQ3;QS_#W25@@U&2
MV2ZM7=0LK7"QAP6/_/3(&>>M>G_V-_TW_P#'/_KT?V-_TW_\<_\ KT >&Z!#
MXI;Q-H_V^XU.&%5C,/G13N'AW/N5\?*"5V F09^[6IXQ_M;_ (2'5/LO]N>?
M]D3^S?L&_P G&UO-W;?ESTQGG.W%>O?V-_TW_P#'/_KT?V-_TW_\<_\ KT >
M!M9ZW=RR&SD\01Z?")'L,RSHY3SH5&[^(\-+@-SCGM4=U)K44ECI_FZR+N..
MY%E&CS%BRW2B-G]5"9&6XQCVKZ _L;_IO_XY_P#7J(^'(#>"[)C-PJ&,2F(;
M@I.2N<],@''M33M871GACV?B..'1H;=[^QA\VZ96C@F8+,;IB"RQ]BF3\P*X
MS5.WTS7+*\@L[%]7LHX[RX!<Q7,B>=Y^5("\$&/G)RI^8]:^A/[&_P"F_P#X
MY_\ 7H_L;_IO_P".?_7I)V&];GD?@2"]/C:[N=0BU'[3]CDCNI;M)-GF?:"0
M$+?+C9M.%XK+ETR]TSPXBB/64M9-3O6G6U:4R%OF$!P/FVEMIXX)P37N']C?
M]-__ !S_ .O1_8W_ $W_ /'/_KTNEOZWN.^K_KI8\Q\$:7J=S::O/KTVH1W\
MQ%MF69PJJ88R612< [RWS#WKD;:3Q!>^'HK_ %6;5I;=KF2UD6P>1FS##Y<3
M_+S\TH))'!.,U[Y_8W_3?_QS_P"O4-IX:M["U2VLRD$*9VHD> ,G)[^I--ZB
M6AXWI%UXD.J16>HIJHN(TN)9V*2>6=UJFT!ONYWAL#L:UI;+5=+^%-A>::=1
MEU2W%O?2PR2R223/\OF1D$YQ@GY>G'2O5/[&_P"F_P#XY_\ 7H_L;_IO_P".
M?_7H>OX?@):'AEQIOB 7-E83R:S-=26]LL;J\GE%&5OM0<C@') ^;D?+BJ\5
MIK<>D^%[?3GU:QACMMK%X;ERET' ;*KSMQNQN&S&<5[W_8W_ $W_ /'/_KT?
MV-_TW_\ '/\ Z].^O]?U_P $.AY%XCL;^W\6>(KK38M2%Y<Z3$;66V\PH2I8
M2 8^7<!C /.3D<FK%E_:W_"M]<_LO^TQ^^D_LWSM_P!I\C"]-_S9^_C//2O5
M?[&_Z;_^.?\ UZ/[&_Z;_P#CG_UZ70?6_P#6QXG9_;_^$FL?[,'B+R//M_L7
MVSSMGV?<WG[]W&,;<;N<;<55=M?U&^AL'&N1QQRI!<N!-&"#>$DJXZ_NV'(/
M KW;^QO^F_\ XY_]>C^QO^F__CG_ ->CJA6/%O!RW.C:U<:GK=KK,LS:6A4^
M7-+OV22*5(Z%MNS //.>Y-;7B[P[<>)_%EC;(\EM9RZ9.D\_V??@%XSLYX5C
M^?!XKT_^QO\ IO\ ^.?_ %Z/[&_Z;_\ CG_UZ=];_P!=1^G];'@HL/$-M:Z)
M:VCZA8VZ27.QD@F?;+]J8@LL?JG.6!7&:ADEU^Z?79+@:Q:1N%D\E(KMUWK*
MWR%LYP5 &Z/  Q[U] ?V-_TW_P#'/_KT?V-_TW_\<_\ KT@/&_!@\0R^-%FU
M1M2M(_*R;6Z6>0>48EV*9#\FX-GDX8D-FL_7_P"UX_%]]=Q6>K75Y ]T$VB8
M1) T2B,H5X!^^?E.XD5[I_8W_3?_ ,<_^O1_8W_3?_QS_P"O0]0/!O#UCJPU
M33[VZBU5YU@OH+.0K.JJP96B#!R2%(+8WGG SG%=)X _MFV\-ZI-?/>W<PC#
M);7,<R/YP0[P&DY.6X^7@$'%>J_V-_TW_P#'/_KT?V-_TW_\<_\ KT=+!UN?
M/5C!XCO[-XI3K21&:24;#=1D-]E9L9<EB/, '7!/3K6WX9BU2?Q[IMQJ\6J/
M=Q^;YLEPDGDI$;=-F"1L!+;\]\YS7M7]C?\ 3?\ \<_^O1_8W_3?_P <_P#K
MT[ZW$];'BVHG6$^(-PEFNL3PR7]L[2XG2.%!,@*;?N,N Q#+VW9S60AU:]UX
MZ<]QK:W,LD?V]/-F3;F[VED[!?+QRO&*^@/[&_Z;_P#CG_UZK6_A2RM;NXNK
M9(8KBY(,TJ0@-(0,#)SS26EO(;UN>5ZA;WL_PIT=-3BU":6*^A-P%61K@1K,
M<GCY\A0.>M<_:6_BN6^LUO)]4CC%K^X62*>3S(OGW*^/E!(V EQG[M>^_P!C
M?]-__'/_ *]']C?]-_\ QS_Z])ZJP'A<5GKK/HUD@U>WG-E8Q6WE^8D,<7ED
M7&_' 8<?>YSC%.\%7/BNV\0VUQXG35&M'CWJBQRN!(S" !AV "E^>F<]Z]R_
ML;_IO_XY_P#7H_L;_IO_ ..?_7JN;5ON*VEC+HK4_L;_ *;_ /CG_P!>C^QO
M^F__ (Y_]>D,RZ*U/[&_Z;_^.?\ UZ/[&_Z;_P#CG_UZ ,NBM3^QO^F__CG_
M ->C^QO^F_\ XY_]>@#+HK4_L;_IO_XY_P#7H_L;_IO_ ..?_7H RZ*U/[&_
MZ;_^.?\ UZ/[&_Z;_P#CG_UZ ,NBM3^QO^F__CG_ ->C^QO^F_\ XY_]>@#+
MHK4_L;_IO_XY_P#7H_L;_IO_ ..?_7H RZ*U/[&_Z;_^.?\ UZ/[&_Z;_P#C
MG_UZ ,NBM3^QO^F__CG_ ->C^QO^F_\ XY_]>@#+HK4_L;_IO_XY_P#7H_L;
M_IO_ ..?_7H RZ*U/[&_Z;_^.?\ UZ/[&_Z;_P#CG_UZ *NF_P#(0B_'^1K>
MJA;:9]GN%E\W=MSQMQV^M7Z0!1110 4444 >;>)?$'B/3_B*+33V:339%B0(
MHSY<WE3.!C'(;:/Q4>M0Z-JE_JEE;M#X@O+FW_M*VB%S&R@OOA5I8R=N/E?/
M'\.2O:ND\1>)]2T2^OA':VLMK:V!O 6=@[?-MVXQCK^E.A\2:@/&QT:>UM1:
MM)M26-VW\Q&0$@C';%$>_P#6C%)]/E]__#F=X)UZ2^G>*XUVQN+EKV>.2T:\
M$TP12^T! %\IN.5.[(7.?3*TC7=6T[6;&_\ $>MQVVCWMU/"@N[A "RF;')
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M?ER,<]LYIVC>)==D\2Z)_:5_+':RV\)GDD95C<F&5R&39PSA V<C&TCZ^JD
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MY;>&?&@5[PQZ@+\V5S!;RR7I)B#/&R@@W#'D>8!ER0=N2N 0+M_7]7!]^_\
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MOR:UZ\FU*Q\1:4-<CT74)U@TA[:'2X?.?:YDV;HV&<' ("^F>U+J5KXIT_\
MMS[!J]W-_9;VT5AYMS(WG/+L\Q7Y^8C(QZ;J-_Z_KN%K=#U975P2C*P!(.#G
M!'44DT\5O'YD\J1(.-SL /S-<UH>CW<']M0)<WEFDLD2177RM*[I$BO*/,5@
M=Q&,D'.">^:37O#=_?>'H-._M&XU*3[?#*]Q>10%D0."?E5$0@ 9Q@GZTGY>
M07TN=-'-',&,4BN%.#M8'!QG'ZBGUY-:>$/%GA_4(+;0GN$TRVGD:)1(I$H
M0#S,2H &52N=KE>H53@U9T?2_&T,EKYZ:EO!N IN+P>5$&3Y&8?:'9B&X"MO
MX/5<8HZ7'UL>H4R26.+;YLBIN8*NY@,D] />O-OL?B2S\ 6MMJLNK7%_-J*
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MU/WCC_P<_P#V%>@44 >?_P#"J/\ J?O''_@Y_P#L*/\ A5'_ %/WCC_P<_\
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M (.?_L*] HH \_\ ^%4?]3]XX_\ !S_]A1_PJC_J?O''_@Y_^PKT"B@#S_\
MX51_U/WCC_P<_P#V%'_"J/\ J?O''_@Y_P#L*] HH \__P"%4?\ 4_>./_!S
M_P#84?\ "J/^I^\<?^#G_P"PKT"B@#S_ /X51_U/WCC_ ,'/_P!A1_PJC_J?
MO''_ (.?_L*] HH \_\ ^%4?]3]XX_\ !S_]A1_PJC_J?O''_@Y_^PKT"B@#
MS_\ X51_U/WCC_P<_P#V%'_"J/\ J?O''_@Y_P#L*] HH \__P"%4?\ 4_>.
M/_!S_P#84?\ "J/^I^\<?^#G_P"PKT"B@#S_ /X51_U/WCC_ ,'/_P!A1_PJ
MC_J?O''_ (.?_L*] HH \_\ ^%4?]3]XX_\ !S_]A5?X<PWFE_$#QKH5QK6J
MZM:Z=]@^SOJ=V9W7S(G=N3@#)/8#H/2O2*\_\(?\EG^(O_<,_P#2=J /0*\8
M^''@V\\8?#_3==U/QSXQBNKKS=Z6^KE4&V5T& 5)Z*.]>SUY_P# W_DC&A?]
MO'_I1)0 ?\*H_P"I^\<?^#G_ .PH_P"%4?\ 4_>./_!S_P#85Z!10!Y__P *
MH_ZG[QQ_X.?_ +"C_A5'_4_>./\ P<__ &%>@44 >?\ _"J/^I^\<?\ @Y_^
MPH_X51_U/WCC_P '/_V%>@44 >?_ /"J/^I^\<?^#G_["C_A5'_4_>./_!S_
M /85Z!10!Y__ ,*H_P"I^\<?^#G_ .PH_P"%4?\ 4_>./_!S_P#85Z!10!Y_
M_P *H_ZG[QQ_X.?_ +"C_A5'_4_>./\ P<__ &%>@44 >?\ _"J/^I^\<?\
M@Y_^PH_X51_U/WCC_P '/_V%>@44 >?_ /"J/^I^\<?^#G_["C_A5'_4_>./
M_!S_ /85Z!10!Y__ ,*H_P"I^\<?^#G_ .PH_P"%4?\ 4_>./_!S_P#85Z!1
M0!Y__P *H_ZG[QQ_X.?_ +"C_A5'_4_>./\ P<__ &%>@44 >?\ _"J/^I^\
M<?\ @Y_^PH_X51_U/WCC_P '/_V%>@44 >?_ /"J/^I^\<?^#G_["C_A5'_4
M_>./_!S_ /85Z!10!YO\.8;S2_B!XUT*XUK5=6M=.^P?9WU.[,[KYD3NW)P!
MDGL!T'I7I%>?^$/^2S_$7_N&?^D[5Z!0 4444 %%%% 'G_PH_P"9U_[&V_\
M_9*] KS_ .%'_,Z_]C;?_P#LE>@4 %%%% !1110 5A>+]1N+/11:Z:^W4M2E
M6SLSD91WSE^?[BAG_P" UNUR^GDZ[XZO-0.39Z*IL;;T:=L-,_O@;$!['S!0
M!O:9IUMI&DVNG6*>7;6D*PQ+Z*HP/Y5:HHH **** "BBB@ KF?%O_$UN=/\
M#$?(U%S+>\CY;2,@N#_OL4CQZ.WI73$X&3P*YCPD/[5N]0\42?,-1<0V7.=M
MI$2$(_WV+R9]'7TH Z<# P.!1110 4444 %%%% !1110 4444 %%%% 'G_\
MS<E_W*7_ +=UZ!7G_P#S<E_W*7_MW7H% 'G_ ,#?^2,:%_V\?^E$E>@5Y_\
M W_DC&A?]O'_ *425Z!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7G_A#_DL_P 1?^X9_P"D[5Z!7G_A#_DL_P 1?^X9
M_P"D[4 >@5Y_\#?^2,:%_P!O'_I1)7H%>?\ P-_Y(QH7_;Q_Z424 >@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y
M_P"$/^2S_$7_ +AG_I.U>@5Y_P"$/^2S_$7_ +AG_I.U>@4 %%%% !1110!Y
M9\.O$^@Z+<^,[?6-;T[3YV\57TBQ75W'$Q4E!N 8@XR",^QKL_\ A/O!_P#T
M-FA_^#*'_P"*J2X\$^%;NYEN+KPSH\T\SF2262PB9G8G)8DKDDGG-1_\(#X/
M_P"A3T/_ ,%L/_Q- !_PGW@__H;-#_\ !E#_ /%4?\)]X/\ ^ALT/_P90_\
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M*'_XJC_A ?!__0IZ'_X+8?\ XFC_ (0'P?\ ]"GH?_@MA_\ B: #_A/O!_\
MT-FA_P#@RA_^*H_X3[P?_P!#9H?_ (,H?_BJ/^$!\'_]"GH?_@MA_P#B:/\
MA ?!_P#T*>A_^"V'_P")H /^$^\'_P#0V:'_ .#*'_XJC_A/O!__ $-FA_\
M@RA_^*H_X0'P?_T*>A_^"V'_ .)H_P"$!\'_ /0IZ'_X+8?_ (F@"GJ_B[P?
MJNCW=A_PFFCVPNHFB,L6I0[D##!(RW7%6+?QMX)M+6*WMO%&@QPPH$C1=1A
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M#9H?_@RA_P#BJ/\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B:
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MMA_^)H /^$^\'_\ 0V:'_P"#*'_XJC_A/O!__0V:'_X,H?\ XJC_ (0'P?\
M]"GH?_@MA_\ B:/^$!\'_P#0IZ'_ ."V'_XF@ _X3[P?_P!#9H?_ (,H?_BJ
M/^$^\'_]#9H?_@RA_P#BJ/\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\
MX+8?_B: #_A/O!__ $-FA_\ @RA_^*H_X3[P?_T-FA_^#*'_ .*H_P"$!\'_
M /0IZ'_X+8?_ (FC_A ?!_\ T*>A_P#@MA_^)H /^$^\'_\ 0V:'_P"#*'_X
MJC_A/O!__0V:'_X,H?\ XJC_ (0'P?\ ]"GH?_@MA_\ B:/^$!\'_P#0IZ'_
M ."V'_XF@ _X3[P?_P!#9H?_ (,H?_BJ/^$^\'_]#9H?_@RA_P#BJ/\ A ?!
M_P#T*>A_^"V'_P")H_X0'P?_ -"GH?\ X+8?_B: #_A/O!__ $-FA_\ @RA_
M^*H_X3[P?_T-FA_^#*'_ .*H_P"$!\'_ /0IZ'_X+8?_ (FC_A ?!_\ T*>A
M_P#@MA_^)H /^$^\'_\ 0V:'_P"#*'_XJC_A/O!__0V:'_X,H?\ XJC_ (0'
MP?\ ]"GH?_@MA_\ B:/^$!\'_P#0IZ'_ ."V'_XF@ _X3[P?_P!#9H?_ (,H
M?_BJ/^$^\'_]#9H?_@RA_P#BJ/\ A ?!_P#T*>A_^"V'_P")H_X0'P?_ -"G
MH?\ X+8?_B: #_A/O!__ $-FA_\ @RA_^*KE_ -_9ZI\6OB%>:9=P7EK)_9N
MR>WD$B-B!@<,,@X((_"NH_X0'P?_ -"GH?\ X+8?_B:T-+T#1]#\W^Q=)L=.
M\['F_9+9(O,QG&=H&<9.,^IH T*\H^#?B[PWI?PET:SU/Q#I5G=1^?O@N+V.
M-US/(1E2P(R"#^->KUS_ /P@/@__ *%/0_\ P6P__$T '_"?>#_^ALT/_P &
M4/\ \51_PGW@_P#Z&S0__!E#_P#%4?\ " ^#_P#H4]#_ /!;#_\ $T?\(#X/
M_P"A3T/_ ,%L/_Q- !_PGW@__H;-#_\ !E#_ /%4?\)]X/\ ^ALT/_P90_\
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M_P"A3T/_ ,%L/_Q- !_PGW@__H;-#_\ !E#_ /%4?\)]X/\ ^ALT/_P90_\
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M>%_.O;JXMK:R+3E_OC:59D4"3(7[P(8_\"/(-/OM"O[G4I;E9H7C>-(3#(6
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M1_Z)K6G\,?\ #+\T>E1_W2/_ %XG^@^;_D%W?_8[UV?A3_DIOC/_ 'K7_P!
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MF2^%=)FM8+=X) D.[!6=U9PQRX=@<N&/)#$Y[UL44^9]R_K%9._.^^[$ "J
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M8\9QP_M0KETHXG>,(Z=_5^?0OR:9K5K#=6\$US<^=%'Y4OG'$3>8Q8?-+O\
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MA1APW) )Z#TJH.TD_-'5@9QIXNE.;LE)-_><YIG_ "6*+_L7D_\ 1@KD9/\
MDX\?]?(_]$UZ-9^&KRW\?)K;R0&V72ELB@8[]X8'.,8QQZY]JPF^'^JM\6?^
M$H%Q9_8O.$GE[V\S'E[>FW'7WKJA.*E=O[+_ #/H,-C*$95'*2UH\OS[')^
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M; 7=K>/.[F1_+*G=P#LSGD=J(5(*]W]J_P A8#'8:G3BIS2_>N7RY7J-TO\
MY"/PT_Z\[C_T4*R-/_Y$?P?_ -C&/_1C5V]GX-U"WNO"$KS6Q70[>6*YPS?.
M60*-GR\C/KBJ%KX U6#PYH.GO<69ETW5A>S,';:R;B<+\O+<]\#WI>TC??K_
M .W2,EC</I[ZW_6M_P#)+[SGOCQ_Q^:+_P!<YOYI6?X\_P"2G^'_ /KA9_\
MH9KMOB7X$U/QE<:>^ESVD0M5D#_:'9<[BN,84^E5?$OPZU;6?&.EZM:W%DD%
MG% DBR.X8E&R< *1].:=&I",8)O:YO@,?A:>'H1G-)QC43\KM6^\1_\ D/\
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M8P0QW-^9Y/OS3;CT0Y5,,_A@U\_Z_IF%-XRAA63-KO:.V69@DF?FW ,F,9R
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MQU''-)8>*S>:+>:A)9>4+=%*H9"-Y(R%RZKCDCGE3D$$UM-86;11QM:0&.(
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M+U-6E8@0[(BP &[=Q(01M^;@G(Z9XKKXY%EB22,Y1U#*?4&@!U%%% !1110
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M?C_QQ?\ "@#K**Y/^V]0_P"?C_QQ?\*/[;U#_GX_\<7_  H ZRBN3_MO4/\
MGX_\<7_"C^V]0_Y^/_'%_P * .LHKD_[;U#_ )^/_'%_PH_MO4/^?C_QQ?\
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M_'%_PH_MO4/^?C_QQ?\ "@#K**Y/^V]0_P"?C_QQ?\*/[;U#_GX_\<7_  H
MZRBN3_MO4/\ GX_\<7_"C^V]0_Y^/_'%_P * .LHKD_[;U#_ )^/_'%_PH_M
MO4/^?C_QQ?\ "@#K**Y/^V]0_P"?C_QQ?\*/[;U#_GX_\<7_  H ZRBN3_MO
M4/\ GX_\<7_"C^V]0_Y^/_'%_P * .LHKD_[;U#_ )^/_'%_PH_MO4/^?C_Q
MQ?\ "@#K**Y/^V]0_P"?C_QQ?\*/[;U#_GX_\<7_  H ZRBN3_MO4/\ GX_\
M<7_"C^V]0_Y^/_'%_P * .LHKD_[;U#_ )^/_'%_PH_MO4/^?C_QQ?\ "@#K
M**Y/^V]0_P"?C_QQ?\*/[;U#_GX_\<7_  H ZRBN3_MO4/\ GX_\<7_"C^V]
M0_Y^/_'%_P * .LHKD_[;U#_ )^/_'%_PH_MO4/^?C_QQ?\ "@#K**Y/^V]0
M_P"?C_QQ?\*/[;U#_GX_\<7_  H ZRBN3_MO4/\ GX_\<7_"C^V]0_Y^/_'%
M_P * .LHKD_[;U#_ )^/_'%_PH_MO4/^?C_QQ?\ "@#K**Y/^V]0_P"?C_QQ
&?\** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>sgmoproxycardp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmoproxycardp2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$817AI9@  34T *@    @ ! $[  (
M   :   (2H=I  0    !   (9)R=  $    T   0W.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N;F5T=&4@
M36%K82 H0V]N=')A8W1O<BD   60 P "    %   $+*0!  "    %   $,:2
MD0 "     S$Y  "2D@ "     S$Y  #J'  '   (#   "*8     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M       ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A
M,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)
MBI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9
MVN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH :\L<6/,=4STW'&:$D20L$=6*G# '.#
MC//X$'\:XGXJ:78:CH.F&_LX;DIJUHBF6,-A7F17'/8C@^M<!J&L:UX3USQ$
M_ANZ:."2]NXTL5@1HXS%;0D.HVYR >G3"]*%JF_7\+?YAV_KO_D>[U&+B$HC
MB6,K(=J,&&&/H/6O/=&U\R?"+5M2\63P:S9P"8;H9TD,\0 PK.@ W9)&0!V-
M>9SQZ%'H[O+=VD\-Q87<UA#8DF"TU!FB*PQ8_C5=O/4Y8]Z=M; M5<^D%D1G
M9%=2R8W*#ROUHCD26,/$ZNAZ,IR#7B'A[5/"Q_X2C6[F.T1(-/E@N=*A;]]=
M[7'F32^A9\*OH#70>&M0L- ^#>M:II-Y:3$^=/Y.GG,-K,Z@+"GTROU))I/1
M-^0+5I>9Z@&#+E2"#W%+7@.D:KXAT+P99^&X;^ZT>^TZ\O(YUQ%))L6V:X0$
MX9<$Y&1VJ63QUXK2.XU :W*5D69!;B"/9%LMH9=X^7.<R'J2,4[:M?,5]O,]
MYIHEC9=RNI&[;D'OG&/KGBO"=6^*&J27R_V3K1,7]J2&"0/"L4\'FQHJ &,M
M(0"W *\'.3BK^J6]S=? >*WL#MNI-;982.SF^?;^N*2V4N__  /\Q];?UU_R
M/: P)(!!(ZCTI:^<;+Q3XFLK*^U 74>ESZQJ0N;B=F5$A#6PDB0NZL #P.F3
MC ZUU>C^)?%6M^+-1TS4-2MXU:TEB>TBDCW >0"LL2;=S9=L[LD$'IQ0]+^2
M_0.WF>P1SQ2L1%*CD*&(5@>#T/T.#^5/KY]\*:O?0^'XX-%UDQR2IHUH;R*"
M$R1>8\B.F=GS;?N@-G&/K6EHGCO7KO7-#@OO$#)+)<6L M/*C'VR-WE$DA^7
M)(V*,KC&?>J<;.WG85]'Z7/<*B6Z@>%IEGC:)20SAQM&.#D^U>8>,_$VL6OC
MJ73;75Y+3FVBM[%(D_TF.4/YTN2"24P""#@8YZU4CTC3T_9]TF'4-3ALXF,5
MP);N$&%W+;@DH0#*'H2?Q)J?L\Q5M;'KH=2VT,I;&<9YQZTZOGFSU][+5EO+
M+47\-P7]CI\1AC",D%OYLD<DB%U)VKC(8]/,YSQC?G\7:I>Z3I$>K^(6TV"Y
MT^X=)OLR?\3)Q-Y:(<K_ !1G/RX^]NZ"B6BN+K;T_$]D$\3+&RRH5E_U9###
M\9X]> 33G=8XV>1@J*,LS'  ]:^<M*U?5[[PGX?$FISV6I:9),8!'''^XA33
MR\6W(.0ZCDG/4XQBK/B'QEK6K:+J$%[JAE>XMI$N-,\E56*$6Z2)..-PW.2,
MYP<X'2J<?><1)[>9]"%U!4%@"QPH)Z]^*6O!O%/BC5H?&5S=6NI&34=,:]CM
MM/\ +4_9XA FV7;C<<[F.3D?+TXK7\-:_P"(]7U*U@N?%*);065U=BXMWAG6
M81O&%\U@F#C<V=H7( J=_P P3T/8J8\T43HDDB(TAVHK, 6.,X'KQ7EV@^+]
M6F^$.N:E%J4NH:GI[O&;LK'+&#A"6C** Z ,6Y&1T.<5G>&9[GQ#\2M(FNM9
MEU2UT\WJV5VT<1%PB^5\V0N,Y<C<N/N#WII7E8?2Y[&)$,AC#J74 E<\@'VI
MU>):UK.G>$_'VOWEA)'?WUQ%,[3Q+MN]-<*HPV]2K1'@@D$#GKWS;7QSXJN-
M.BFC\028LTGE)C\F9;@)=11J&?8-PVR'E0N:4?>L@EHKGO\ 17BWB#Q_JVE>
M+=40ZW,ODRW4/]FQ)$##&D2&*7YD)Y9R23D8'3BLJT\:^*[ZPA,/B22/[,D[
MF2(0SB<+=11+E_+ ;Y9#R ,X'%"UM;U!Z:^=CWZF&:,2;#(H?^[N&?RKQ'P]
MXX\13>(K6RO-=DEF@U*.RBM&AC!OH3/*DDK87)**B\K@#'/6NH\6Z+IDWQ.A
MNIM/MGN#H-Y,96B!;>AC"-GU ) /;-#T5_7\%<?6W];V/1TD26-9(F5T895E
M.01Z@TZOG>T\6>)]$\-V&F6NN&.U6&T9;J?RHA;A[7S%BWE" NX <C)QC/-=
M'<>*O$%OX<UK5-0UR=)1?Q:=%';O!';VY:.-V?S&C; Y8;CGJ/K3DK-KM_7Z
MDIW2?<]EHKP.P^(?B:>?3I%UMIKQK>T:/3A%&PNP_FB1\!=QQL0Y! Y]ZDTW
MXB^(+;14O=6\06Y@D\T&7S(G:.8VKL(WVJ F)-NU2,CD$G%)Z)OL/JEW/=6G
MB3.Z5%PP4Y8<$]!]3D?G3Z^?[;5+VVTO5[LZA]LU236M.N?L<\$3\O'$PD"[
M<@DG:"/[HQSS6I>^-;VV\#:9J</CAKIVN5:]6..!)U)B5FACW)M<JS9V'DCY
M<\57+^GXV%>Y[6S!5)8@ =2>U+7%^.-5L]9^$7B"[TV<3P?8YDW@$?,O##GT
M((_"N&TKQAXH@T75[DZM+=-_9D]S KVZ$6ICNVA!4*H) 09YSTJ1]$_ZZ?YG
MMM!.!D\"N;\&ZYIVI:>;.S\2+X@N+<;GN"JJY0LP7(4 '[I&1UQGO7EEKXR\
M:W?BF?1+V9OLBS7-L\KPQD/]F5WDR-O1E>(4GH"U5SW)+JWD"F.>-PQ 7:X.
M21N 'X<_3FGK(CLRHRL4.& .=IQG!_ @_C7A/PZD,U_X:E8(&?5Y&(1 B@G2
MTZ*  ![#BC5/$^K^'O%?BD>'=19[A[VZ>;3Q&CB)5@B*SXQN!SD<DCCIUJY1
MY7;RO^7^8D[_ ->O^1[L[K%&SR,J(H)9F. !ZDTZO)[C4M0U;X!^()]4OX-0
M94E2&YAF24L@*XW,@"E@<C@#M6%<>,?%UEJL&E)KB;;:\GACN;PQ0BZ9)$41
MN=F&^5C\J[3SG/%*WO<H7TN>Y>='Y;2>8FQ20S;A@8X.3[4^OGG5-6GB\&VN
ME2ZE]ALY&NITA"K_ *9,-1V^7E@3PI+87![]J[SXE^)]5T36K:&PU-K!19FX
MMHEB5OMUP)440DL#GY6)PN#SGM1O;S#J_(]*HKS/X=:_KFI>)IXM6U26\@N+
M6>=(I(T40%+MX@%*J#C:O?->F4NEQ]6@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH P];\7Z5X?U&TL=2-V)[SB 0V<LH<\\912,X!./3FMEIHE7<
MTB <#)8=^E<MXVT/4-9O=$;3X/-2VGG:9BZKL#6\B*>3S\S <9ZUY;<^!?%6
MIVL;W>@W4,,8MH)+426[O*8[8Q>8H9MF W.200#D=*.@=4>]-/$F_=*@\L O
MEA\H]_2JFEZU8:SIT-[8SAH+@.8RXVE@K%2<'G&17C=YX%UN'7IWB\-7%_8Y
MMY+QKMX&FO C1AHU8/\ ,K!"Q1^ 5X//,.E> /$CZQX?BU+03;V=KMCD>,6_
M[N$^;O5W!+Y&\85?EP>>E'0#W95B,?E*$V  ; !@#MQ7/W'C#PU9M=QSW,:-
M87D5K,GD-E)I,;,<<YSU'H:XWX6/>Z5IML]Y;R7T^KWCVBW*'"Q6UK'Y:,?K
ML/U+5C>(OAMXAU'QWJ.K6T4GV2;48[D0B50)3&80CXSV#S_]\GVIV7,ET_X8
M.GF>SA;7S'51#OSM< #//.#_ #JKJ>JV&@:4]]=;EMU(&+>%I&9B< !4!))/
M%>(7OAGQ'I=OXD\0:A8?V=<VZQWEO(J0K$]RER6&T1G+ J<9?GG'2O1KS3->
M\/?":STKPS;RS:HL444IB=!(FXYF=2Q W<MCGJ:7V;C^U8W4\::#)9Z3<K??
M)K$WD68,;!I'R05VD9&""#GI4_B'Q'IOANQ6XU8S>5(VP+#;O,3QD\*#Q@$Y
M/I7FMSX(UF-]&US3[06MMICQ;-*NHUDGM8T<M(_F++M9G/S'@DY KI/%]UX@
MUSPAI/\ 96C7IAU(J^I6UO/&D\<!3)C#.5 )) )'(&:'L[=Q+?7L:MUXV\+6
ME]8V<UTA:[C26%DMV9%63_5[F PA;' ."<57/Q-\+M8S7/G7;+!*J-'_ &?-
MOY!96"[,[<*3NZ<&N5UWPWKTEW-%H_ATK::G#ISKF>,"P^S'<T3#/)Q@#;D=
M>:I+9>,9=!DBN?#.J_;]4ND;6[E+JW$EQ#M;]U$=^$0<+V."?4TWUL"Z7/7(
M;FQN=/AO(GB:UF5)8Y" %8'!4\_ABHM/U:PU*^OX;)P\]C,+>Y^7!#;0V,]Q
MAOIUK@/B5H&KZYX+TBPT/03Y*QG?:!('DM6\K$:@R': "2"5.1@$&M'X=>&[
MGP_JVMF^T<6\ETT,J7H*'S08D#)P=V0X<G(QDY[T:-L71&]H_C+0-7U:YTO3
M+K,]L6R#$R(^&VL48@!\,<''<UB:GXF\%WNL_;M2FN6NM#.Z*.2&90[EM@:.
M/ $K!OE! ."?QKDM!\%:O8^+Y+S5O#,M_ LS^87GB,9=[E9$E@4L-BJH)88&
M3V/:?5O#GB?4?&%QX@AT&YC-K)!-);7%]'+]I:*96"V[9^1=@)P=H+8XR*2W
MC_5AOK8]1TC5-/U_38-5TUUFAD#!)"A5EP<,I!&5((P0?2K326\MMN=XG@<=
M2058?R-<';Z'KL'PIUBW33XO[4U&:XN18R;'""64ML.3M+!3],US>F^$==E\
M%V?AJ]\.3/:OK(O)C/);HJ0"=24*(V!E"QPHQQ@4=;>@/17/8 MO/N $4F%V
M,, X!&<'VQCBL3Q!XPT#PQ=VUOK<[PO(C2QE;9Y%C12%+$JIV@;@,G'6N-\!
M^&=;\%7LTJZ QANK>UADC@GB'SB60.Y^;G:C*??H/;<\5^#)/%/C.P>[-S'I
M*Z=/!<O;S*A<L\9$9_BVD*>@[=13MJ@]2[;?$CPS>?;1:WD\KV:,\B):2EG5
M7V,R#;\X#<$KG%:NA:WIWB+3%U?2Q(;>4866:W>$NHY!&\ E>>#TKSSPOX3U
MZ/4D2[TG[!:Z8FI+#*TR$W1N)"4"@$D*%Y^;'-=)X0AN6\,Q^$M7TV2W-CI-
MO!<RLZLKL\95D7&0<8Y.>XH^S=?UN'6QTMS?6=I?VT<D;-+=,4$B1%@N%+?.
MPX48'&>I-,MM:TR75KC2;:=/M%I#'+(BC"HCDA<'I_">G2O%KKX9^+KCPG''
M<V N-3,\T<@^T1#]REIY$/);'./K\W.*Z'6_ $EKJNOIH'AJ 17FBQ16DT'E
MHL4B,V^/D@@L-O(&#CDT[+N&O]>MCU0-!"H0&- S%0H(&6/)'UZUCZ!XKT77
MIKBUT:4DV> ZF(Q@?.Z #('>-OTKR/5?"7B_5;Q;@^')8$EU*2\C&;9Y82TL
M9.YRQ*C:O\!SD8/!J2?PGKOASPIXEU2]MQ9W%O)!>Z?(9$?=+'=3.!A2>JR*
M,'^]CUJ5\-V&^B/<"("Q<B,EUP6X^8#M[BJUGJ-I*MT(E:".UF\EFEC,:LV%
M.5)P&'S 9'!->=^)/ 6KM\.O#VG^'TW:G9*8;@F15^2>-DN&RQQU;=^%8_BO
MP+XA;1M1T[3-&%Q:3:I+-"$$$D@3[-''$P\PX4;E8$\,, CM1LW_ %V_S!:V
M\ST765\.Z3XFL]7U<L+^Y1[:V+L[JH",[X3[H)53DXR>!6MI>J6&HZ-;:C82
M(MI<QI)&3A>& (!'8\CBN(\9^%K[5-%\*,NCC4[C3SLGA+)N3= 4W98@$!]A
M//8&N'F^%NOV^FV]O%H[K:!;8SVML\#,\WV8H[A7;9D2'EB>^1G%/:X;V\T>
MY75Y;VU_9Q30R-+<LR1R)"6"84L=S 8487OU.*CN]=TZRN[&VGN%\V_F,%N%
M^;<X4L02.!P._M7+Z]X<U.ZA\+QVD4ES_9\4R7$DLB!P6M'C4MSR2Q .,]?3
MFO/HOA=J]C'I[1^'8W\HVV8TDB^20VC)))]['RS;&)ZG:",XHVN"UL>Z-);O
M&6=XV16P22" P/\ ,&D,UM-"Y:2)XU&7RP( ]37CNA?#K5%\(#3K[2YSYNIV
M+W5K<F 1.D3?O74(W((SG=\S8!P<UFS?"[7;6P<6.CK#&X+7<4+PL;@"\9U7
M:6VL?*VD!N.,'GBBW]?(70]=C_L*P\9&.-576-2M1)P"0T41VC'8<R=N3D^E
M7-6U+3-%TNZO-2:..WM(S<2@+N*C^]M'/)_6N#T7P;=:9XB\(7EQH\MVEI83
MVTLMP83)9N7#H6PV, %U&S.,USGBCP+XDUWQAK]P=&4Q7%M=1PRJL"1S#8GD
M_,#O9LK_ !< @8QS0_\ /\"EJ]?(]J26W$:S*T:K*H(8D#<.U(3:^3DF'RUD
M]L!]W\\_K7GGBSP=<>(_#?AVTM= 2*"UAG,EB[1J+=C;.L8P&QGS"O3..M<I
M??#;Q FDFTCTJ3["NH>=]CMG@8MNM43>%=MF1(#DD@C[PHZO^NHELKGL-S=Z
M1X4T*XFD,=I964;3R)&,E0223M'/))_&K\=S#*$V2(?,7<J[ADC&>E>&WOPQ
MUZZNM;6XM;RZEDLY!;W$C0%9_P!RHCCD;=OW!ESCE00#GG-:FH> -5O]8BU/
M2]!7372.Q2V_>Q*UJJI*)0-K<8+1YQU[9YI/:X?\']#UZ-[=5_=-$%4;?E(P
M-O;\/TI[2QHC,SJJK]XD\#ZUX(_PO\1ZCI:1V.EG1@TEO:SQ-+&=R^4T=S/P
MV#N.T^K8SBMB;1-;T?X;6-EKVBM=8N_[3UEFNH5C=5F&8CN< Y3!Y.WY<9H>
M@=#U:'6["?5;S3XYOW]E%'+/D855?=M^;H?N&F6^K:;/KUUID#*;VWBCDE&W
M&5DW;<'^+[A/'M7C/AKPGJ]UX/%XFBM<Z?,+"7[%YB W4,4TS/'M)P>'4X;
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MTNZU*]!N(HK.T,@2(0B5D?,H"D;@,Y)V\A<UB)X\\5Z?J&HFSEM[J74-1S%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445CWWB[PWI=[)
M9ZGXATJSNH\;X+B]CC=<@$94L",@@_C0!L45S_\ PGW@_P#Z&S0__!E#_P#%
M4?\ "?>#_P#H;-#_ /!E#_\ %4 =!17/_P#"?>#_ /H;-#_\&4/_ ,51_P )
M]X/_ .ALT/\ \&4/_P 50!T%%<__ ,)]X/\ ^ALT/_P90_\ Q5'_  GW@_\
MZ&S0_P#P90__ !5 '045S_\ PGW@_P#Z&S0__!E#_P#%4?\ "?>#_P#H;-#_
M /!E#_\ %4 =!17/_P#"?>#_ /H;-#_\&4/_ ,51_P )]X/_ .ALT/\ \&4/
M_P 50!T%%<__ ,)]X/\ ^ALT/_P90_\ Q5'_  GW@_\ Z&S0_P#P90__ !5
M'045S_\ PGW@_P#Z&S0__!E#_P#%4?\ "?>#_P#H;-#_ /!E#_\ %4 =!17/
M_P#"?>#_ /H;-#_\&4/_ ,51_P )]X/_ .ALT/\ \&4/_P 50!T%%<__ ,)]
MX/\ ^ALT/_P90_\ Q5'_  GW@_\ Z&S0_P#P90__ !5 '045S_\ PGW@_P#Z
M&S0__!E#_P#%4?\ "?>#_P#H;-#_ /!E#_\ %4 =!17/_P#"?>#_ /H;-#_\
M&4/_ ,51_P )]X/_ .ALT/\ \&4/_P 50!T%%<__ ,)]X/\ ^ALT/_P90_\
MQ5'_  GW@_\ Z&S0_P#P90__ !5 '045S_\ PGW@_P#Z&S0__!E#_P#%4?\
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M?>#_ /H;-#_\&4/_ ,51_P )]X/_ .ALT/\ \&4/_P 50!T%%<__ ,)]X/\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/^'/\
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M%K?1G^PZ>K'Y?,**TTH'K\PC!ZC8^/O&K/B'Q?;Z)=PZ=:6EQJVL7*[H=.M
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M>1C.!Q5G87]AJMAI7B>SD\/^ Y-1-W8VMSL9DF#!X[:9T=ECB\S+H.Y"H2.
M?2%L_&\'FH-9T.Z4Y\F27394=/3<%FP_;IMZ=L\0R>#KS7(PGC76CJEMU?3K
M2W%K:2<Y&]=S.^,="^T]UH 9I\H\8^+(=8A^;0]'\Q;&3M=W+ H\R\<HB%D5
MAPQ=^P!/7TR&&*V@C@MXTBBC4(D:*%55'   Z"GT %%%% !1110 4444 5[C
M3[*\DWW=G!._E-#NEB5CY;8W)R/NG R.AP*J2>&M"ENI+F71M/>>6'R'D:U0
MLT?383CE<=NE:=5[_P _^S;G['_Q\>4WE8_O8./UI-V5QK5V,C2- T&P\2:K
M?V202ZM<2"2YE(0RPAE4!,@952$!P?<TY+;PHM\]NEOI7VF:[D#H(HRSW#1Y
M?/'WS&3GOM//6O(8;/7_ +-)-8CQ!:V]Q+;_ &VXG@O&F,HMF!.%Q(RB7LOR
M9Q_#6S=:7XK$%W%8/J<5U-J<TK7,$<D(F(T]=KD#'RF50.>,\=:NVZ?1?Y$I
MMVMU_P"">IPZ%I-MJ0U"WTRSBO!$(1<) JR!!P%W 9QCM[4V?P[HMU?37EUI
M%C-=3Q>3+-);(SR)_=)(R1[5Y;/'XQNUT.ZN;G5=/-Z9KDCR;B7[-,\X,<;I
M&> (N,.-@^;C-2ZK#XCTGP7%JME<ZFNK7.K3VTL5U=3?,DLDL,1",2%"[HV7
M  X!]Z5G\]OG>PU;Y?T_T/4AI&FB5)1I]KYD<QG1_(7*R$8+@XX8C@GK5>*Q
MT)[R:RAM+ SQ0D2PK"FY8YF+$$8Z.RDD=R,FLJZNEU3X=7G]FWFH0[89+9;M
M(I))]R$QEPJ_.W*GD<GJ*X2SFU^32+EKJUUZUTT?85D1)+IW,(GF$K1EOWHR
MNPD#YPI4'I2[K^M=!=+GJ,/AK0K>U2V@T;3XX(T,:1K;(%52P8@#'0L ?J :
MEET32IS*9],LY#.6,N^W0^9N4*V[(YRJ@'/4 #M7DOA7_A(;^\T;4Q<:Y<6Z
MO9JKR33M&\;/<"4N"=K' CR6!(^7I70^+[W6[?Q9);V8U802/:2QO;QRF%8U
M$WFY=1M7DID$C/'7%$G97\[?D-;_ "N=K'X;T.*YFN(M'L$GGD66606R!G=3
ME6)QR0>0>QYIHT_0M+U"UF6TL+2\D4VMLZQ(CL#ES&N!G'#-@>YKB?AC=:G)
MX8O;T?VG>PO96\L(OY)2\UQY.9=C2\[2VW!'RYSBN:T*SU>ZU#2KO6(-<:UM
M];1T^2^4Q![5@W$C%RHEPI;.WENBL15<MI\O;_AA)WC?U_#4]<D\.Z4;R[OH
M-/M;?4+N)HI;V*!!,P(QRV,GMU]!4FGZ+9:=X?M]%CB66R@MUMQ'*H8.@7&&
M'0Y'6O-OB,OCJ'Q5(WA4W\EE]ECGQ$9"ID),)08X&!(),?[&?>JFHV/CR#QS
M]ALKC5)-&6[@M_/\V4YCE"/))NS_  &)ESV\S'&>9BKZ='_7ZCEIKV/38/"G
MAZVDMI+?0].B>U1HX&2U0&)3G(7C@')_,^M$_A3P]=1QI<:%ILJQ%"BM:(0N
MP87''8<#T'%>86$GCC3_ !IYFK?VQ+H5O=SJWEK-(S10;GC; SN\SS57W\OO
MCB77H_%LNN>)I;2[U:)_(F^R0007)$D1B7R]C+^[5@^X\8?.[--7=OO!JSM\
MCTVZT#0I;J>_O=*L))Y83%//+;H6>/NK,1RN.QJO+:^&#8QZY+;:;]FC5KI+
MUHDVJ)%&Z0-C^(8R>]>;W=AXPM)([/2Y-;-K/?3VA9Y9G:"%9(Y4DW$YP561
M V>=P&:@U4^)HK"R:W'B"ZU*70$1T07<;6LHA)+Y'R2,S8!!^<-@BB*NK_UK
M=AU_KT/5QX<T3[,88M(L$B964!+6/ #($/&,<J OT '2JWA_PCI?A[PZ^BVT
M0GM)F=IEEC3;*7^]E%4*!VP !BO.O$H\4G5-:&F_V]]NQ<8,/G>3]F\A?*\K
M;\OF>9G[OS_>SQ5[2-)U[_A(WMI'UO[)8I?/9&>YGV,X>+R=S%L2<%\!R01G
MTI?JK_=T_KJ+HO7^G_70]!C\.Z+%=6ES%I-DD]C'Y5K(MNH:!/[J''RCV%37
M>CZ;?+<K>Z?:W ND6.X\V%6\U5SM#9'(&3C/3->)&37+;1=.CU?4M?/VJY9)
M+:%+V.<3BUD) ).YP9 I^7* @]!5R_7QGY-Z!_;_ /;/V:03&(S>3Y/V9=GE
M[?D\SS<_=^?.[/%5:[:_K^OTU"^WG_7]>>AZL=(\.SW-M8'3]-DFTM5EMX/)
M0FU4Y"LJX^0':<8QT]JFL_#NBZ<X>PTBQMF$IF#0VR*1(006R!U()&?0XK@+
MW0#IOB37DM9=<MO/T*%+>\C:[NMK!Y-_1CN897C.[DE>233AJ=]=?#VVM/L&
MNVA@N(6O?+6Z:5[4S,&,;M^].57.W[ZJ0*7]?>Q_U^%_U.[D\-:%,L"RZ-I[
MK;S&>%6M4(CD)R7 QPQ/)/K4U_H^F:K) ^IZ?:WC6S^9"UQ"KF)O5<C@UYOI
M7]M?\)0WV<>(>DV?MOG>7]D^SCR?O?+YOF>GSYW9K!_XJ3PUIMGJK-KSS[8D
M=;RXGD0O+9-D,') S<;!ST; &.E%G;3R_'_AM06KMZ_U_D>DK=>!M:U"V1AH
M]Q>S3O/!'/$@EDE0[&D56&XGY,;NX7@D"GQIX%OH-3,0T&>*XN%CU CR2LDI
M;Y5D]6W= ><^]<K/HD_AW6-,T_P];7LEU+:0VET9+0O;NBHX$ZS8Q'(A8Y!(
MR&QCO6#+H^L:UX,FT:WT66Q$<&EVOG?V<T4R2I*!("Y_UB)C?O V@,>>IHTO
M\[?C_P -_6@>?S/3=63P:NGW:ZTNB"TBN5:Z6Y$6Q)MHV[\\!]NW&><8[5J0
MZ7I+L+J"QLV,F9!*D*'=N4*6R!SE0!GN !7D&@:7KFF2Q:UXGTV^NR^JF]O(
MXK5Y"#+9[050 EE5FV<9Q^%>G^![&ZTSP)H]G?QM%<0VJ*\;=8^/NGZ#C\*+
M:._E^0=B]::!I%A>_;+'2[*VN?*6'SH;=4;RU& F0.@ ''L/2M"BBD 4444
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M_!!??_&:/^$TTO\ Y]=<_P#!!??_ !FN@HH Y_\ X332_P#GUUS_ ,$%]_\
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MFE_\^NN?^""^_P#C-=!10!S_ /PFFE_\^NN?^""^_P#C-'_"::7_ ,^NN?\
M@@OO_C-=!10!S_\ PFFE_P#/KKG_ ((+[_XS1_PFFE_\^NN?^""^_P#C-=!1
M0!S4OBO1)IH9IM.UB22!BT3MX>O28R1@E3Y/!P2..QJ7_A--+_Y]=<_\$%]_
M\9KH** .?_X332_^?77/_!!??_&:/^$TTO\ Y]=<_P#!!??_ !FN@HH Y_\
MX332_P#GUUS_ ,$%]_\ &:/^$TTO_GUUS_P07W_QFN@HH Y__A--+_Y]=<_\
M$%]_\9H_X332_P#GUUS_ ,$%]_\ &:Z"B@#G_P#A--+_ .?77/\ P07W_P 9
MH_X332_^?77/_!!??_&:Z"B@#G_^$TTO_GUUS_P07W_QFC_A--+_ .?77/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4C'"D@%L#H.]+10!YW8?&OPWJ7B2+0;:SU8ZC)/\ 9_):V4%7
M!P<_-QC!R?:NDU'QEIVFZS_9307EQ>94"*V@+DY4M_)34%EX!TBQ^(-[XNAC
M_P!-NH%C*8^5&_B<>[ */P/J:CO/ \-_XXBU^[EBFCBDCE6VDAW8=$958$G@
M@L"#CM36ROOU$]W;8GU?QYHFAWLUIJ$DRSPLJLBQ%B=T;2 C'484CZ\55N?B
M3HMI;V\TL&H;)S(IQ:G]TT;%71_[K*1R/IZTSQ-\/;?Q%X@DU8W9MYCIYM5
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MR12.L!94*2>6<D=!N( /O45QX(GO;!X;F\M(';2_[/46=H8XH\2;E*H7.
M,9_$5C7?PF>^\BYNM5A>^222=Y!:_(99)A(^%+'"XR ,DYP<]J/Z_P @_P"!
M_P $ZBR\<:/J6AW6K:<;BZMK6))9/*B);:ZAA@=\ \^F#3(_'FD/"LC+=1;O
M+^62':W[Q'=>/=8R?RJCX9^'D7AC0]8TVTO-T>I1@#]W@1-Y01B!GH6RV.V<
M56N_AE!=ZA%?/<0?:H8H(HYS;9=5CB>-@#G(#%@<?[/>B76WE_P072_G_P
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M?X<6^C>-O^$BM[LER)4:+R\;D94" G/5=IY[[O:JTYGV)5^57W+]E\0M!O\
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MP@[EOF''6IY/&NEJUGY"75TEY:?;(Y+> LJP\?,W]WKWKG8_AQJEJUR;36+
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M** "BBB@ HHHH **** "BBB@ HHHH RGU>]1(ROAW4G+KEE62VRAR1@YFZX
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MN(]LUI44778/:1_D7X_Y]3*?5[U$C*^'=2<NN659+;*')&#F;K@ \9&".<Y
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MS+?;'D G/[W=\N<' /0XSQEB:O>NDA;P[J2%%RJM);9<Y P,3=<$GG P#SG
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MC_F9IU2[%U)%_86H%$W[9O,M]LF 2,?O=WS8P,@=1G'.&#5[TP-(?#NI!E8
M1F2VW,"#DC]]C P,Y.?F& ><:M%%UV#VD?Y%^/\ F4&U&Y6>VC&CWK+,JEY
M\&V D\ALR9)'?:&'H34*:O>NDA;P[J2%%RJM);9<Y P,3=<$GG P#SG .K11
M==@52/\ (OQ_S,V35+M+6"5="U"1Y-V^%9+?=%@X&[,H7GJ-I/OB@ZI=BZDB
M_L+4"B;]LWF6^V3 )&/WN[YL8&0.HSCG&E11==@]I'^1?C_GT,H:O>F!I#X=
MU(,K ",R6VY@0<D?OL8&!G)S\PP#SB9M1N5GMHQH]ZRS*I>0/!M@)/(;,F21
MWVAAZ$U?HHNNP.I'^1?C_F92:O>NDA;P[J2%%RJM);9<Y P,3=<$GG P#SG
M+Y-4NTM8)5T+4)'DW;X5DM]T6#@;LRA>>HVD^^*TJ*+KL'M(W^!?C_F9IU2[
M%U)%_86H%$W[9O,M]LF 2,?O=WS8P,@=1G'.&#5[TP-(?#NI!E8 1F2VW,"#
MDC]]C P,Y.?F& ><:M%%UV#VD?Y%^/\ F4&U&Y6>VC&CWK+,JEY \&V D\AL
MR9)'?:&'H34*:O>NDA;P[J2%%RJM);9<Y P,3=<$GG P#SG .K11==@52/\
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MX >:2)-'1I(\;T%[,2N>F1OXS0&AT/\ PO+X=?\ 0P_^25Q_\;H_X7E\.O\
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M'_QNC_A>7PZ_Z&'_ ,DKC_XW6#_PI_P+_P! /_R;G_\ BZ/^%/\ @7_H!_\
MDW/_ /%T!H;W_"\OAU_T,/\ Y)7'_P ;H_X7E\.O^AA_\DKC_P"-U@_\*?\
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M_P FY_\ XNC_ (4_X%_Z ?\ Y-S_ /Q= :&]_P +R^'7_0P_^25Q_P#&Z/\
MA>7PZ_Z&'_R2N/\ XW6#_P *?\"_] /_ ,FY_P#XNC_A3_@7_H!_^3<__P 7
M0&AO?\+R^'7_ $,/_DE<?_&Z/^%Y?#K_ *&'_P DKC_XW6#_ ,*?\"_] /\
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M,/\ Y)7'_P ;H_X7E\.O^AA_\DKC_P"-U@_\*?\  O\ T __ ";G_P#BZ/\
MA3_@7_H!_P#DW/\ _%T!H;W_  O+X=?]##_Y)7'_ ,;H_P"%Y?#K_H8?_)*X
M_P#C=8/_  I_P+_T _\ R;G_ /BZ/^%/^!?^@'_Y-S__ != :&]_PO+X=?\
M0P_^25Q_\;H_X7E\.O\ H8?_ "2N/_C=8/\ PI_P+_T _P#R;G_^+H_X4_X%
M_P"@'_Y-S_\ Q= :&]_PO+X=?]##_P"25Q_\;KJ/#7BO1?&&FR7_ (<O/MEK
M',87D\IX\. &(PX!Z,.?>O.?^%/^!?\ H!_^3<__ ,77=^"/#>D^%]$FLM"M
M/LMO)<-*R>8[Y<JH)RQ)Z*/RH$='1110 4444 %%%% !1110 4444 8.I?\
M(0E_#^0KQ3XA6<=_\1YK9M!GUJ631]L$<)P89"^!(3G@#^M>UZE_R$)?P_D*
MP%T"W7Q8VOB67[0UI]D,?&S;N#9Z9SD>M%KM?UT&G9/^NIY]X*OO%MM=7UIJ
MFIQ&R\.0QK<6ODJSR?N2VT2>Q&,T:/XJ\7W\NG">_M,>(+2XEL@D"K]DDCR5
M!)SN!  .?7VKOM/\,V>GZIK-ZKR2MK#JT\<F"HVJ5P,#H0>^:YVT^%>GV?G"
M/5M29?(DM[16=3]DCD^^$XZG)&3Z^O--W?\ 7]=1*R.8LO'GBO4O".I>)8[B
M"&#398(7MEC1_-Q@3,3C(!R"/Q]*[?P3KMYXCDUG4))TETT7I@L J ?(@Y;/
M4Y)'7TJD_@&ST'0]970HYYOMNF_9C8Y0)(ZIM5^0,,>I.>Y-;7@G0SX<\%Z9
MIDB[9H809AQP[?,PXZX)(_"GW_K^MOQ RI?%?BU)G2/P#/(BL0KC4HAN&>O2
MH?B)H.H^(= TVXMK$736<ZW-SI3R8$Z[?F3<.I'('U.*[BL/Q/X93Q+:VZ_V
MA>:?/:R>;#/:R;2K8QR.AI=!GG-UXUM-,\&Z;%X'N7THDS/+8M:-=2QE>6!R
M<*H.>?3'3FH]0\?>*YH?M>GWUO:QV^B0ZC-$;97\QF8*P!/(SFNI?X2:2MO:
M)9ZCJ-I/"LBS7,4B[[@2??#9&.?8=*L_\*PTK[)-;_;+S;-IB::QW)D1JP8-
M]W[V1]/:C^OS_P" +^OQ7_!.0U3X@^)[AKG4],NK>SL+6ZM;5K4P!V<R+N9M
MQZ>E:-CX]U.Y^)EO80:@EYI5U=RVZHMB8T4*I/RRD_,0<9[?I4/B3X:74OB"
MSM] %V+&=H)+V1YT$*F+Y=Q3&XO@9XXR371Z;\,M/TO7H-1@U+4#%;7+W-O9
MLZF*-G&&[9_7TIJW]?(73^O,Y"/Q?XTN]3BCMM7M(X;[5I]-A5[-6,&P@A\\
M9X.,&F6?Q!\6ZSILDEA=6EO+I6G-=W9> -]J9967 _N_*O;O^&.ZMOAYIMK<
M6DR75T3:ZC+J* E>9),94\?=X^OO6:_PBTK[/##;:GJ-LHC:&Y,3J#<Q-(7*
MMQZGKZ 5.MOZ[?YE:7_KO_D;.L0V7BKX=&ZU*T26.:Q%XD;$X1_+W _AFO,H
MM(2V\#^!7T0165_?:DCM<%-X\S# ,0>N/2O:)-.@;1FTR,&*W-N;=0IY5-NW
MC/H*Q(_ MA'IF@V(N;GR]#G6>!LKF0C/#<=.>V*K2[MW0M;?)GG+_%'7I--L
M+,WL5I>^9<B>]6R,WF>6<(!&HXR>">W6MC1O%_B?Q%X@M46^M](M8=-COKV.
M6V#9 D*O@GE<@9]JVS\+;"&VA_LW5=0L;R"XEFCO(742 28W)TZ<<?6M>V\%
MV4&J37TMU=W4DVG#3I?/D#;XQ_$3C.X^M+7^O1A_7XGG-M\2=?:75]NH)=1+
MILUW;2G3_)5&5@%*9SO7KR:U+#QUXATBSU0Z[-;ZB\>C1ZI;.D(CVE\ (P'4
M98?E[U9O?A8FG:!J']F7^H:A=?V?+9VEO<2)L17.0HX&.??%:GAWX<6ECI%P
MFLW-S?W5_8I:3F>0-Y,84?NTP.@/0^PHZ:?UO_P!]?Z\O^"<3%\3/$BZ=,OV
MQ+IB;:1+S["80F]@KQ;6&&QGAO;\I_%.J:[KFL26JZC%!%I_B6WM[8&W5MK-
M]QCTSM(/'?-=DOPW@?P[=Z1?:YJE[#,$$#32@_9@ARFP8QD=#ZCTJ+_A5UI_
M9=Q;?VSJ37-Q>1WK7CNID$J @$?+[G]*?7^NZ%_7X,YF;Q#K&G^,M2T;3)+.
M'4K_ %"UMFO_ +*O_/++.5'WB3T!Z9-:7BWQ!XP\-VFBQ7M_:6JR*ZWFJ1VA
MEB\S/R*RXRH(QD@>N!Q6S>?#+3KM[F<:C?QWLLL,\=V)%,D4D:; P..<]3GJ
M?2G:A\/%U#1[73I/$6LK%%&8YOWX87*LQ8[@1C/. >P J>G]=AZ7.MM)#+9P
MR&6.8O&K>;%]Q\C[R\G@]1R:\G\0ZUJ&@>)/'%]I$JPW0ETV-7= X 9"#P:[
MOPUX<N="U+4GDNVDLI?)BL;?SF<011IMQ@\ D^GI5;5OA_IVL7&K37%U=(VJ
MR6[RA"N$,/W=N1W[YS3ZW_KH+HT<<GC?Q2+R7PTU[;-JIU=;)-1^S@*J;<D^
M7TSQ7INBQZI%H\":]-!/?J")9+=2J-SP<'VQGWKF[_X::;>SW]TE[>6]Y=7B
MWL=Q&RAK>0 @;>.G/Z#FM31/"O\ 8MY%<?VUJEX([;R#%=3[D8ERQ?&/O<X'
MH.*/Z_ /Z_$WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *V=(_P"/-O\ KH?Y"L:MG2/^/-O^NA_D* +]%%<A
MXK^*'AGP7JD>GZ]<S17$D0F41P,X*DD=1[@TAV;.D@U;3[K4KC3[:^MY;RU
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M]#O'_P"#:[_^(KZ$HH ^>_\ A3WQ9_Z'>/\ \&UW_P#$4?\ "GOBS_T.\?\
MX-KO_P"(KZ$HH ^>_P#A3WQ9_P"AWC_\&UW_ /$4?\*>^+/_ $.\?_@VN_\
MXBOH2B@#Y[_X4]\6?^AWC_\ !M=__$4?\*>^+/\ T.\?_@VN_P#XBOH2B@#Y
M[_X4]\6?^AWC_P#!M=__ !%'_"GOBS_T.\?_ (-KO_XBOH2B@#Y[_P"%/?%G
M_H=X_P#P;7?_ ,17J7PQ\-^(O"WAFXLO%NJKJE[)>-,DRW$DVV,H@"[G /56
M..G-=E10(*CDMH)FW2PQNV,99 :DHH \R\*:%<0?&SQE=W6E2QV$\4 MYI+<
MB*0A5SL8C!_"O2HX8X5(AC6,$Y(50*?11M%+L'5ON%%%% !1110 4444 <WX
MT\7CP?8V<ZZ;/J4MY=+;16]NP#,[ XQGZ8KEF^-$,KVUK8>&=4N=4DEE@FTX
M;5FA>-0S#'<8)_(\5/\ &"WFNX/"]M:W;64\VN0)'<(H9HF.0& /!(ZUQWB/
MP#<Z+XMT&RT;7+XZWJ OKJ34B566680Y ] #C'XGFDGH[_UHF5977I_F=M+\
M7=.DT'3[S2-)O]1O]0FD@CTR-0)E>/F0-U' Y[YS]<.7XOZ*+'2+^:WGAL=2
M2?,[LO[B6($M$P]3CCUR*\V\+7VE>&YO!'B>Z+6^GK'>6NHSMND\J[.<E\#C
M=QCVK/O;>YU?X:VF@6-B)+[6]6N]8MHFZQVR G..OS8('K^--Z?U_7342_K^
MOP/5K+XNV#(7UG3+C25?2SJEL9Y5/VB,$C:/]HXR!Z5T2^+K>'P"/%6IVLUE
M;BU^U- Q#2!3RHXXR>/SKS3QD-(\:>"?A_JJ0"-+C4[:Q:.([0B/E98OH#'@
M?2O4_%+Z9;>#]2.M6LD^F);,)X(8RS,F,8 '\^,=>,42T3_K^MT);K^OZV.:
ML/BE$_AG4=:UO0-2TB"SB29/.4,+E7X38PX))(X]"#5:/XOVR:'JEUJ.AWMA
MJ&EM%YVG7# 2%)" K@^G/IZ>M>77-Y=7_AG7=(\.:A=:[X9TDVM_;RS(3)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRP"@<<@"JNKLFSLCD?!^JW$?C"!9=7NK@7TNIK<V]S=M(D?E702$JK$[.#M
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M#!R>*U=5\2Z7HM];6FH3ND]R"45(7DVJ" 78J#M7+ ;FP,FELDNUOP*Z_?\
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M4PR?(6! SMQP,UGVGQ-DNTM+A-'Q9E;8WLIN/FB-Q(8X_+&W]XN1N))7Y6!
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M@Q.. -F"><XYJ/3?B7>VT-RKV4E^;1%N+V6>Z5=D0B@W&-5CY.92=I/8_-R
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M@&&#9 !SQ7;^&?#G_".QWR?:OM/VNX6;/E[-F(DCQU.?]7G/O7/V7B35-?\
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MV55W80%B3\N.2:EO/!'AZ_:X-WI_F&X>1Y?WT@W%T6-SPW&511QZ>M;9GB4
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M!;M4<M%=3*)"I!.%;: 0<'GD5OZM%I%MX@O8=?C2/PY'XAD2Y0J1"N+!!$&
MXQGI[XKU/4_&6AZ1KMOI%_=F.[N-H $3,J;SM3>P&$W$$#)&:2Q\7Z!K5U%9
M6ET+B2>6>%8S$WWX"/,!R.,;@??/%3TLOZV_*WXCZZ_UO_F>"W<&N1VUI>DR
M-%_9VEVM[%*#N$;S,T;GZ>6@_P"!5W7CNUL;OQ/XE34]0@L(EM=-=9+J,O [
MAYB$E _@/0FO3;O7M-L=<L-'N;D)?:@LC6T."2X09;GH./7K6-<?$/PL+.22
M:],D(:XCD MW;!A($H(V]MP/N#0W?\6/_@?U^!QGB65]:^ NDG1[)=.EFN+6
M.W@C8LJ,)@J[2>2I(R/8BN'ENM<U[POJ]G]GE;5O$6JQ7AM[=@I6(6_G@ L0
M, !/K]<5]!:=KFEZM]L%A.LT=A((YI-I$:MM#<,1@X!!XZ5AQ_$SPI_9EY?P
MW4YM[0KYQ2RER$8';)@+DH0I^;IQ2[_?^7^0+H>4^(=5L-=U3^T@0VNW6FZ7
M+IVP?O ^]_.QC^$+G=VKNO@PFCW7@ 6T']CSSO#&M['8P[25*8"SY)W/][)Z
M'TKJ!XW\/^3-=/+-$8(H9)?-M)$=4F<I'D%0>6'3\:KM\2?#JP7,YDO3#;2^
M0\HT^<JTGF>7M0[,.=W&%S57W5MR>S[?Y'G&EZ4UCIWAEO#%OI]G?R^(;]1)
M- 3&P07"@,$() 48'/'%9W@*/2)O%6DP:\='83:3;QQQWL1:9W+S " Y^4Y(
MSUR,5[CI?B#3-:T8ZIIMSYUHN[<VQE92OW@5(!!&.A&:IV'C70-3DL$LK\2'
M4+5[NW_=L-T2'#,<CC!['T-+U_K0;UO;^M;G*_#SPJL.F^(HKRZ:[D,TND12
MR+S';1 JB#_OHD^O'I7C^FV>LW%AK+ZNF((=&N+F)B<Y* 6@_2-J][?XF^&A
M::?<Q3WEQ#J08VK6]A-)YA4L"/E4\C:W'7 STI(_B=X;ELH[J-]0:.6X-M&!
MIMP6DD )*JNS)QM.<=,<T*Z=WVL_Z]1_YW_KY'!ZCK6FP^'/B-I$M["FH3.\
ML=L6^=T%M%E@/3@_E6]X^UG2=<^%MO=Z=?:?=6:W]I')-/\ O+=2)%W"0 C*
MCN/2NHM?'WAZZUU='2ZFCO7<1JDUK+&I<H'V;RNW=M(.W.:GUWQ9I&AZA::?
MJBW337IQ L5E+,KGGC*J1G@G'H,T-WM\OP)6B^_\3Q31WTR.Z\'_ -MOI2V*
M1WHWZI$7A=?M2X, S\IQ]S.0!GK7;_%K3;N75M%;3E;_ (G.[1+E@< 1R.K@
M_@$?\Z[>U\7:->2VT<%V2UTUPL6Z-E!,#;9<DCC!]>O:LX?$GPV\.FS07%W<
M1:ID6CP6,T@D(8@CY5."-IX/.!GI1>]OZW_IH>S;_K^D>9^'-/TN[UC["MJL
MM\+74UUZ&2,G@2@P"0'CC V^PJ+X?VVAZ?XUT(74>BVYET:QDB6Y@_?R3L'^
M:$@X#%L;B0<\5[7J&LZ;H]Y90WTJP3:G.+>#Y"?,DP2 2!QP.]4$\<^'I+:T
MN%U >5>7YTZ!C&PWS@D;>G3(Z]/>B+M_7K_F$M4_Z_K8\W^&_P!C/CV+^Q@/
MM8;4O[9,?3;]I_<[^V[KCOBO:*PM*\7:%JM[#9Z9<>9<3B5_+6%@5\M]CE^/
ME^;CG&>U;M'1 ]V%%%%( HHHH \_^(T^ER>(/#-OJ&N6VF?9[M[B=CJ,=M+'
M&8I%#C<P."WR\>]>:WMS;7>DW.E?VIH:+IEIJ,<%R-8MB+YKB3<@4;\CCKNQ
MS7JWQ'\5W_A>WTLZ;/9VYO+AXWEO(6E50L3.!A6!R2H'XUQ^C?%OQ!=:['#?
M6=F 2?.TY+>59X4%NLK2[R2, G&"N>E"Z^16J:?]=3?^%<^G0SZY8PZM::E>
MO>&=9X]0BN))X-JA6(5B1MSM/ '3UKEI/ WBU6\2WS60FD\26-V)+="BM;R>
M;F%68OALIG!XQT-:%Q\2?$VGZ3OU(Z7#/=V]E?6\X@<QV\-Q+L977?EBO7((
MSS3_  [\1_$>MZ[]BN9+&R\NU,X0:=,WVL!I<LK;L1 K&"-V<YXS3=T^;MI^
M&I*T7W/_ "-;P_/XBC\>7&H7GA*_MK74+2VM6D>X@/D&,R99@')(^8=,FJWQ
M4\#:GXNOTGTN-A+:Z7.+>4.J_OB\?[OG^\GF#TYK,\/_ !4U_4K%995T^Z4S
M6"O/!;R1K$T\@5X2&8Y8*<A@<>U=5'XF\1/\2F\,-9P"!'-XUYY3;39E<*HY
M_P!9YGRYZ8'2FTV]?/\ K\;@O=_#^OT.6M?"'B1+F'2I-)"VR7ZZJ;_SD(_X
M]?+\G;G.[?QZ8[US6G_"GQ38:;<![:6=FTF>T@A,R?NM\<;[!D]Y7E'_  $]
ML5Z?!XC\0W.OZQ=PI8?V!I,TMM-"P87#&.(/O5N1RQ"[<=,G-<A-\6M?T+4M
M$7Q''IWV35!;W;RP1./L]O,'RI^8\H5!W=QGBDGU[V_+3\ 6GR_S_P V-U'X
M<:Y+XT_MRTMF&_5<SQ^:N)(1;J$DZ_POY@]?FJ"V\-^)(_"GARR?P_X@$FDW
M8DGV:I&)6!@9#Y+^9\B X^7(X)]ZOZ-\3]<\07FBQ136.G+J<MR%9]/EG)"2
MJL:X5QMRK<L>!BMKXE>/=4\(:G:1::;39):27!2XMI)?-9710FY& C&&)W-P
M,4U=67?] MK;L2:/9:XGQ*-_;:)=:/I]U&TFHB6ZCDAN&*#8RJ#E90W#8XP.
MM8OQ!^'^L:_XMNM9TR!O,B%BD9$B@3QB1S,F">W[MN<=.*LW_P 0-<BN_%I@
MN+%!H<+R16C6,KEP(T(8S!@A^9\;0,D"EO/&WBB+3XFTZZTN]DCTZ?5IIGL9
M8%>&-E7R@C/N#$[OF/H./5;6?]=_R_R#?3O_ , PW\#>+ _B2]DLA,_B6RNQ
M+;H45K>3S<Q*S;R&RF<$8QT-9\?PR\3:9::@#;7=^\CVH1H;E4D,<%R0JHQ8
M;2(D0@]LCO6EK?Q@UZRU#41IJ:?*D08Q6CVTAECC%NLOFLX;:0"V",#]:]"T
MO4M7U#P#)J4.I6<]Z\;2P7!T^6&, =FB=]W9AG([&E\*3[?\..]W;N<7?>'_
M !)K.L/%'H-U;VVH6^GQR75[=Q.]J+>9F8L0Q+N1C!&<YYK<^+?AO5?$FDV$
M.C69NGB><R*'5<!K>1!U(ZE@/QK&E^)^KZ1H6F7FMR6;R:GHD^H0_9[&4A9@
M$,:$!F^7YCEC@=.E;7@SQAJWB3Q9>V=U=6<<%HB,;5+&7>X:*-MWG;M@^9_N
MXS@?C56=[?U_6@KVU_K8C\"^#-1\+1^*[&56>VN)%&GL7!+1"(A5]MN0O/I6
M3%\-+JW^'^FQQK>MK4S:<MVS7"[K:.)U+*AZ +R>YX'6C7/B[>:5XFU70UAM
MC=0ZK;6UH#&QWPN 9&//5>F?]H<4U_B1KW_"/ZKJ8OM/7[+J2V7DG2YSY"FX
M,8<MOQ+\JDX3G/'M23V?I^%O\]0M96_K^M"C'X.\3Z9HB1V^A->W5WI]]I=R
MS7*9$DLNY;DDMRK 9..1CI5S3/A5=I\/]0CN!,^N-%=06L,\R^4BM,7&T#@;
MPHSDGKVYK</B#Q3%XBTZT_M+2[BTN=+DU!G&G21LP3;\H#297.\=1D8Y%<W<
M?&'5[1K**XM[0-?:997$4@B;;Y\KC>A^;H4WD?[O>FKVT]/S_P""#?7Y_E_P
M!+G0O%MSXBG\16?AJZT[5;VYC-M+'>Q?Z,B(B.LZYPR.%)XR1@>M0^-/ WBS
M5/$>M:]96:S&\\[3X[12@<V_D823>7Q@N/ND9'7O78^$?&&J:YXB9+^YTF.S
MNTFDM+%"PNHTCE,88]0P.UB>F.*S?%OQ.O\ 1/%NM:196]NR6.DM/#)(I8M<
M@!]IP1\NPY^O>IVM\_Z_#\1J]]#N] O+R^T=)-1TN?2YE^3R)Y$=L #YLH2,
M'ZUA_#^6^L]-70+_ $V6VDTZ!&>9V!5VD9SM&/0 $\]Q7'V/Q0\0^(KF&WT)
M-/MYIKN.WVW4#L(W%JTDB-AP<^8A7/85UESXXE7X1'Q;#;QK=/9AT@8Y3SB=
M@7MD;S^5.6EVR8K1)'#>,_ OBO5?$NLZ]:6:S"],VGI:J5#FW\@!9-Y?&"X^
M[C(Z]Z2S\"^)/"FM-+IVD2:M;6VJ^;:()XU+0&V>-02S#A2P4Y["M'6OB]?:
M9I.@WXMH/)U+29YYV*$B&Y4!5'WON^9\OXCFMK1?&'B74/&5IH5Q9VZI)$NH
M27:Q-L-HT8PHRWW_ #"5STP.E"6G+\OZ^YO[QM]7_7]72$U;19M"^ -SH]]/
M;QW$6F&%WEG6.,2-_#O8@ ;FVC)':N4\5:MI5J(5T77=*UE;G1;C27:XUR R
M0/(P82,SORHY'&3P*T?$/Q5US1/$VL6UO!8WL%E.\*VHAD$J 0AUE:0-MV[V
MVD8'UJ?4?'7BS2HKBRO6TV.>PODAO-4^RR-;QQO$)$+(&W+DG:6S@=:-]>_Z
MZ?J/5.W;^OT,+X9KINC>+[#[9KNFW?F0W,%NBZM!)Y$S7!VA$#Y_>(1P 3GZ
MUW-YX(_MOXDWVHZJ+D::L%FT*1RA8YY8WD;#CJ=I*GMU[UFZOXO\4:9=^)76
M\TF>UTG3$OH0EH_[PR!]HW>9R!LSG'(/:LF#XF>++Z.]CL4TJ4Z;;SWSWAMY
M5CO(8PGRHI;*DEF&[)'RT[N_I_P16Z+K_P #_@%,?#CQ#(-266TDE-Y:7RVP
MFN%*6TK7)=0!G@2)CUP<YQFKEKX#U?Q5X^N]8\1Z;=Z/IVHV\B2V\5S'OP%@
M4(Y7/#;&/'H.14K?%W4&\42:4MM;QB2]B6U9XS\\+0%W!.[[RL4Z=FJ5/B3K
M=O\ "G_A+99K*]E:XMT,$=A+"(@Q7S$^9CO.&X9>/K2CIKVT^_\ X<&[OUU_
MK[B6?PIK0\2R:='HD<NE+K!U9;LS($>/[/Y8@P?FW$\=,8K$N/!/BSQ!H?\
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MM[4[0_ Z>'];DOK'6M1\B8AI;%C'Y+L(UC#'Y=V<*#UZBNIHIW=[ATL<9?\
MPPT74=9N=4GDN!=7$YF+@K\IS"<#CI^X _X&WMB!OAA$;*YLU\1ZNEK+=?:X
MH08L6\OG>;N3Y,_>]<]:[JBEL!ST'A&-;NUN[S4KV]NK>QFLO.G*;I%E8,6;
M"@9&T 8Q62_PKT2734LYI[IUCBLXXW++N0VQ;8P^7J0Y!]CVKMZ*=V!RNB^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:*"\A"EF/)  "@FL>'XG:9-JB6O]G:E%"Y\K[5-"$19_*\WR&!.X/M]L9XH
M[2BO/U^+^D3Z*=3T_3K^\A2Q%],L7EAHDWLC!LN.04Y [$5;U#XG:=I%K<3:
MOIM_9FUCMI)XW$;,BSNRK]UR.-N3ST-.S [6BN0C^(^ERO?B.WN6%C!>3LP"
MD.MLRJVTY[[@1_2H#\3+8VVIW<>AZD]CID6^XN@8MH/E+)M W[LX8#IC/>D!
MVU-2-(]WEHJ[FW-M&,GU/O6'H/BVSUS3KVY-O<V$FGN4N[>[4!XB%#9.TD$%
M2""#63;?%+0;G0]"U;;<1VNMW9M(BX4&)P2/GYX&5[9ZBC^OO#I<[2BN$M?B
MSI-S=6B?V;J*6]PD+/=%$,<!F=DC#X;(RRGD @5K>)O&2^&=1L;672+Z\6]+
M!)K<Q;5*J68'<X/"J6Z?K0!TM%<UX5\;V?BJ>:&&RO+*184N8ENU4>? ^=DJ
MX)X..AY'%90^*VEJNH-/IFHPBSMY[E"RQD7*0R>6Y3#G!W?WL4[,#NJ*Y^7Q
M6MEX1NM?U?2[W3XK92[6\OEM(R\8(V,5YSZUD+\3K-;6Z-WHVIVUW;I 5LW1
M"\SS.R1HA#$')7.<XP0:0=+G;T5Q-S\4=+L$LQJFGZC8SW=I<W"P7,2HRF $
MLG)Y)P=I&0>.:#\3+8VVIW<>AZD]CID6^XN@8MH/E+)M W[LX8#IC/>@#MJ*
MPM \66>NZ?>W!M[FPDL'*7=O=J \1"AL_*2""I!!!KG?^%O:-%I4]_?6&HV<
M40@E19D0-+!,VU)EPWW>.0>13MK8.ESOZ*YP^-M/_P"$7U?75AG>UTJ6:*0+
MM+2>4<$KS@@]LD5E+\4+67RX(-"U6347N_LAT_$0D5_+,F=QDV$;03]ZD!W%
M%<+J7Q5TS2K6=[O3K\7%O<202VH";TV0B5F^]C&TX'/)IVH_$R/2$@.I^&]7
MA:2"2Y>,>0S10H5!D.),$9<< D^U '<45Q3_ !.T_;JT\&EZC/8Z5"9);R-$
M\MF"ABF"P(.&&,@ \^E:LOBM;+PC=:_J^EWNGQ6REVMY?+:1EXP1L8KSGUH
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MM(TG*+YJQL656QR 2!D9[XJ6BBD 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_"C^R+?^_)^8_P *OT4 4/[(M_[\GYC_  H_LBW_ +\GYC_"K]% %#^R+?\
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M:HMU!X#G$;B1!(EVVUAT89Z$>M2_\7A_ZD?_ ,FZ] HH \__ .+P_P#4C_\
MDW1_Q>'_ *D?_P FZ] HH \__P"+P_\ 4C_^3='_ !>'_J1__)NO0** //\
M_B\/_4C_ /DW1_Q>'_J1_P#R;KT"B@#S_P#XO#_U(_\ Y-T?\7A_ZD?_ ,FZ
M] HH \]:+XNM(LC)X%+ID*Q%WE<]<&G?\7A_ZD?_ ,FZ] HH \__ .+P_P#4
MC_\ DW1_Q>'_ *D?_P FZ] HH \__P"+P_\ 4C_^3='_ !>'_J1__)NO0**
M//\ _B\/_4C_ /DW1_Q>'_J1_P#R;KT"B@#S_P#XO#_U(_\ Y-T?\7A_ZD?_
M ,FZ] HH \__ .+P_P#4C_\ DW1_Q>'_ *D?_P FZ] HH \__P"+P_\ 4C_^
M3='_ !>'_J1__)NO0** //\ _B\/_4C_ /DW1_Q>'_J1_P#R;KT"B@#S_P#X
MO#_U(_\ Y-T?\7A_ZD?_ ,FZ] HH \__ .+P_P#4C_\ DW1_Q>'_ *D?_P F
MZ] HH \__P"+P_\ 4C_^3='_ !>'_J1__)NO0** //\ _B\/_4C_ /DW1_Q>
M'_J1_P#R;KT"B@#S_P#XO#_U(_\ Y-T?\7A_ZD?_ ,FZ] HH \__ .+P_P#4
MC_\ DW1_Q>'_ *D?_P FZ] HH \__P"+P_\ 4C_^3='_ !>'_J1__)NO0**
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MC_\ DW1_Q>'_ *D?_P FZ] HH \__P"+P_\ 4C_^3='_ !>'_J1__)NO0**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\ A1_S.O\
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MO^A>_P#)VX_^.4 >@45Y_P#\*-^'7_0O?^3MQ_\ '*/^%&_#K_H7O_)VX_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
